DDrare: Database of Drug Development for Rare Diseases

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (11C)PE2I; (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide); (3beta, 5beta, 25R)-spirostan-3-ol; (3ß, 5ß, 25R)-spirostan-3-ol; (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol; (R)-troloxamide quinone; (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol; (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate; (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate; 0 mg tropicamide; 0.04 mg Lu AE04621; 0.08 mg Lu AE04621; 0.2 mg Lu AE04621; 0.3 mg tropicamide; 0.4 mg Lu AE04621; 0.6 mg Lu AE04621; 0.8 mg Lu AE04621; 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 00000; 000000; 009-0; 009-1; 009-2; 009-3; 009-4; 009-5; 009-A0; 009-A1; 009-A2; 009-A3; 1 mg QD to 15 mg QD PF-06649751; 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study); 1 mg tropicamide; 1. Tesofensine (NS 2330); 1.0 mg Lu AE04621; 1.0 mg rasagiline mesylate; 1.2 mg Lu AE04621; 100; 11C-PBR28; 11C-PiB; 11C-Raclopride; 11C-methylreboxetine; 125; 13N-Ammonia; 15 mg QD PF-06649751; 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD; 15O H2O; 18-FDTBZ; 18F florbetaben; 18F- DTBZ; 18F-AV-133; 18F-AV-45; 18F-DOPA; 18F-DOPA PET; 18F-DTBZ; 18F-DTBZ AV-133; 18F-Dopa; 18F-Dopamne; 18F-FDG; 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-; 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea; 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-; 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea; 2 mg perampanel; 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide; 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE; 200 mg BIA 6-512; 207-3120; 240mg Amantadine HCl ER tablets; 25 mg BIA9 1067; 25 mg Ongentys; 25330; 3 mg QD to 15 mg QD PF-06649751; 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study); 3 mg tropicamide; 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate; 3-(3,4-Dihydroxyphenyl)-L-alanine; 320mg Amantadine HCl ER tablets; 4 mg perampanel; 50 mg BIA 9 1067; 50 mg Ongentys; 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate; 6aß - apomorphine-10,11-diol hydrochloride hemihydrate; 7 mg QD to 15 mg QD PF-06649751; 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study); 7-beta-Hydroxyepiandrosterone; 7-beta-hydroxyepiandrosterone; 75; 8-OHdG; A-dopamine; AAV2-GDNF; AB1010; ABBV-0805; ABBV-951; ABT-SLV187; ACP-103; ACR325; AD-810N (zonisamide); ADS-5102; ADS-5102 (extended release amantadine HCl); ADX48621; AFFITOPE® PD01A; AFFITOPE® PD01A + Adjuvant; AFQ056; AFQ056 with L-dopa; AFQ065; AHA; AKST4290; AL; ALTROPANE®; AMANTADINE; AMANTADINE HYDROCHLORIDE; AMBROSAN 60mg Tablets; ANAVEX2-73; ANHYDROUS CARBIDOPA; AP; AP-CD/LD; AP09004; APL-130277; APO-go; APO-go®; APOKINON; APOKYN; APOMORPHINE HYDROCHLORIDE; APOMORPHINE HYDROCHLORIDE HEMIHYDRATE; APORON; AQW051; ARICEPT; AS2; ASyn Mab; AT 10; ATM FOG in PD; AV-101; AVALOX - 400 MG COMPRESSE RIVESTITE CON FILM 5 COMPRESSE IN BLISTER PP/AL; AVE8112; AVP-923; AVP-923-45; AZD3241; AZD3241 300 mg BID; AZD3241 600 mg BID; AZD3241 Alternative titration scheme with formulation 1 or 2; AZD3241 ER formulation 1; AZD3241 Extended release tablets 100 mg; AZD3241 Extended release tablets 25 mg; AZILECT; AZILECT 1 mg comprimidos; AZILECT®; Acamprosate; Accordion Pill Carbidopa/Levodopa; Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg; Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg; Accordion Pill? Carbidopa/Levodopa 50/400 mg; Accordion Pill? Carbidopa/Levodopa 50/500 mg; Accordion Pill™ Carbidopa/Levodopa; Accordion Pill™ Carbidopa/Levodopa 50/400 mg; Accordion Pill™ Carbidopa/Levodopa 50/500 mg; Acetate; Acetylcysteine; Active Investigational Treatment ENT-01; Active comparator; Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.; Active drug: pimavanserin 17mg (2 strength tablets); Adjuvant without active component; Administration of stable isotope-labelled leucine-; Agomelatine; Agomelatine or PIacebo; Alanine; Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg); Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg); Allopurinol; Altropane; Amantadin-ratiopharm 100mg; Amantadine; Amantadine 300 mg; Amantadine HCl ER; Amantadine HCl Extended Release; Amantadine HCl Extended Release Capsule; Amantadine hydrochloride; Amantadine hydrochloride (HCl); Amantadine sulfate; Ambroxol; Ambroxol hydrochloride; Ammonia; Amoxicillin; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Ampyra; Ampyra first,; Anti-Parkinson medication; Antiparkinsonian Agent(s); Aplindore; Aplindore MR tablets; Apo-go; Apo-go®; Apokyn; Apomor; Apomorp; Apomorphine; Apomorphine 0.25% (2.5mg/ml); Apomorphine HCl injection; Apomorphine Hydrocloride; Apomorphine Hydrocloride Hemihydrate; Apomorphine Nasal Powder; Apomorphine hydrochloride; Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed; Apomorphine infusion; Aricept 5 mg-Filmtabletten; Aricept 5mg-Filmtabletten; Aripiprazole; Armodafinil; Artane; Atomoxetine; Atypical Antipsychotics; Autologous mesenchymal stem cells; Avalox; Azathioprine; Azilect; Azilect 1mg; Azilect®; B-CIT and SPECT imaging; B6, B12, L-methylfolate; BAVISANT HYDROCHLORIDE MONOHYDRATE; BEN-2001; BENSERAZIDE; BENSERAZIDE HYDROCHLORIDE; BF 2.649; BF 2.649 10 mg; BF 2.649 20 mg; BF 2.649 40 mg; BF 2.649 5 mg; BF2.649; BF2.649 (Pitolisant); BF2.649 (pitolisant); BI-Sifrol®; BIA; BIA 3-202; BIA 3-202 (200 mg); BIA 6-512; BIA 6-512 100 mg; BIA 6-512 100 mg dose; BIA 6-512 200 mg dose; BIA 6-512 25 mg; BIA 6-512 25 mg dose; BIA 6-512 400 mg; BIA 6-512 50 mg dose; BIA 9-1067; BIA 9-1067 (test); BIA 9-1067 15 mg; BIA 9-1067 25 mg; BIA 9-1067 30 mg; BIA 9-1067 5 mg; BIA 9-1067 micronized; BIA 9-1067 non-micronized; BIIB014; BIIB054; BIIB094; BOTOX; BOTULINUM TOXIN TYPE A; BROMOCRIPTINE; BTRX-246040; BTX-A; BYDUREON; Balance; Band; Bavisant; Bavisant dihydrochloride monohydrate; Beam; Bee venom; Behavioral: Assessment of cognition; Behavioral: Assessment of depression; Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Behavioral: Assessment of quality of life; Behavioral: Assessment of severity of ICD (impulse control disorders); Behavioral: Assessment of severity of Parkinson Disease; Behavioral: Attention Control; Behavioral: Augmented Reality Multi-Modal Training; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Balance & Strengthening Exercises; Behavioral: Balance Training; Behavioral: Brisk walking and balance training; Behavioral: Building Better Caregivers Workshop; Behavioral: CBT and sleep hygiene; Behavioral: CO-OP treatment protocol; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: Combined balance and brisk walking training; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: Dexterity; Behavioral: Dual Task; Behavioral: ECOCAPTURE; Behavioral: Emotion Assessment; Behavioral: Exercise; Behavioral: Exercise only; Behavioral: Flexibility and strengthening exercise; Behavioral: Gait and balance; Behavioral: Healthy age-matched controls; Behavioral: ICM_APATHY_TASKS; Behavioral: Levodopa or acupuncture; Behavioral: Low-Impact Exercise Control; Behavioral: Memory; Behavioral: PAT sessions; Behavioral: Participant open-response writing; Behavioral: Participant self-assessment surveys; Behavioral: Pelvic floor muscle exercise-based behavioral therapy; Behavioral: Phonation; Behavioral: Physical Therapy; Behavioral: Resistance Training; Behavioral: Rest; Behavioral: Role of dopamine; Behavioral: Single Task; Behavioral: Strength training; Behavioral: Tai Chi; Behavioral: Traditional Multi-Modal Training; Behavioral: Upper limb exercise; Behavioral: balance training; Behavioral: exercise; Behavioral: exercise+multi-modal sensory feedback (MMSF); Behavioral: gait and balance training program; Behavioral: physical exam and UPDRS part III assessment; Behavioral: stretching; Benserazide; Benzofuran; Berachin; Best Medical Treatment; Best médical treatment; Betaquik MCT supplement; Better; Bisphosphonates; BoNT-A; Bone marrow derived mesenchymal stem cells; Botox; Botulinum Toxin; Botulinum Toxin Type A; Botulinum Toxin Type B; Botulinum Toxin Type B (Myobloc); Botulinum Toxin: Xeomin; Botulinum toxin; Botulinum toxin type A; Bromocriptine; Bromocriptine and other dopamine agonists; Bumetanide; Bumetanide white, oblong, scored tablet; Bupleurum+Ginkgo; Buspirone; Buspirone Hydrochloride; Buspirone hydrochloride; Butylphthalide; Bydureon; Bydureon 2 mg powder and solvent for prolonged-release suspension; Byetta; Byetta 5 micrograms; CABERGOLINA; CAPTURE; CARBIDOPA; CARBIDOPA (FU); CARBIDOPA ANIDRA; CARBIDOPA FU; CARBIDOPA INN; CARBIDOPA LEVODOPA; CARBIDOPA MONOHYDRATE; CARBODOPA LEVADOPA; CBD; CD; CD-LD CR; CD-LD IR; CDNF; CEP-1347; CEP-1347 10mg; CEP-1347 50mg; CEP1347; CEP1347 25mg; CERE-120; CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]); CERE-120: Adeno-Associated Virus Delivery of Neurturin; CERETEC (TM) Estabilizado; CIPRALEX; CJH1 (CLR4001); CLE; CLENBUTEROL HYDROCHLORIDE; CLOZAPINE; CO; COMTAN; COMTAN 200* 60 CPR 200 MG; COMTAN®; CP; CST-103; CST-139; CVD00118-E; CVL-751; CVN424 High Dose; CVN424 Low Dose; CVT-301; CVT-301 (Dose Level 1); CVT-301 (Dose Level 2); CVT-301 35mg; CVT-301 50mg; CVT-301 High Dose; CVT-301 Low Dose; CVT-301, LIP; CVXL-0107; CX-8998; CYMBALTA; Cabaser; Cabaseril; Cabaseril, 1,0 mg Tablette; Cabaseril, 2,0 mg Tablette; Cabergolina; Cabergoline; Caffeine; Caffeine 100-200 mg BID; Caffeine alkaloid; Calcium; Cannabidiol; Cannabidiol (CBD); Cannabis; Cannabis Oil; Cannabis, Medical; Capsaicin; Capsaicin vapor; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 200mg oral dose; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa Levodopa; Carbidopa Monohydrate; Carbidopa and Levodopa 25mg/100mg; Carbidopa and Levodopa Tablets, USP; Carbidopa and Levodopa tablets, USP; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- Levodopa; Carbidopa-4'-Monophosphate; Carbidopa-Levodopa; Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet; Carbidopa-levodopa; Carbidopa/Levodopa, immediate release; Carbidopa/Levodopa/Entacapone; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa/entacapone; Carbidopamonohydraat; Carbodopa/levadopa; Carbon; Carnosine; Carnosine supplementation; Carvedilol; Catapres ampoules; Catapressan; Ceftriaxone; Cerebral Dopamine Neurotrophic Factor; Ceretec; Champix; Chloride; Chocolate; Cipralex; Circadin; Circadin®; Citalopram; Citalopram 20mg; Clarithromycin; Clarithromycin (Not used as of 4/2020); Clarium 50 mg Retardtabletten; Clartihromycin, amoxicillin, and omeprazole; Clenbuterol; Clenbuterol HCl; Clonazepam; Clonidine; Clonidine hydrochloride; Clozapine; CoFactor; CoQ10; Cocoa; Coenzyme Q10; Coenzyme Q10 Nanodispersion (Nanoquinone); Coenzyme Q10 with vitamin E; Coenzyme q10; Cogane; Cogane™ (PYM50028); Cohort 1:Nilotinib Oral Capsules (150mg or 300mg); Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1); Combination Product: L-dopa 140 mg; Combination Product: L-dopa 35 mg; Combination Product: L-dopa 70mg; Combination Product: L-dopa 70mg/carbidopa 7mg; Combination Product: ND0612 Solution for SC infusion; Combination injection of EPO and G-CSF; Comparator: carbidopa; Comparator: levodopa; Comtan; Comtan®; ComtanÂ®; Comtess; Comtess®; Continuous Apomorphine infusion; Continuous Release Dopamine Agonists; Continuous Subcutaneous Lisuride Infusion; Continuous intrajejunal infusion of levodopa-carbidopa; Control; Controlled-release levodopa / carbidopa; Cord blood therapy; Cortef; Creatine; Cu(II)ATSM; CyberKnife; Cysteine; Cystoscopic injection of Botox into the urinary bladder; D-Serine; D-serine (~2g/day); DA-9701; DA-9805 45mg; DA-9805 90mg; DAAOI-P; DATSCAN; DC158AM; DCI; DCS; DEBRUMYL; DEFERIPRONE; DEXMEDETOMIDINA; DEXMEDETOMIDINE; DHA; DM; DM-1992; DMI; DNL151; DNL201; DNS-7801 (high dose); DNS-7801 (low-dose); DONEPEZIL; DOPS; DPA; DPA-714-PET/MRI; DUODOPA; DUODOPA®Intestinal Gel; DaTSCAN; DaTSCAN 74 MBq/ml solution for injection; DaTSCAN™; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Dacepton 5 mg/ml; Dacepton 5 mg/ml infuusioneste, liuos; Daily ingestion of Lactobacillus plantarum PS128; Darifenacin; Dark chocolate (85% cocoa); DatSCAN; Datscan; Deanol; Deanol pyroglutamate; Deferiprone; Deferiprone (Ferriprox); Deferiprone 20mg; Deferiprone 30mg; Deferiprone 600 mg delayed release tablet; Deferiprone DR; Desipramine; Desipramine (DMI); Desmopressin; Desmopressin Acetat; Desmotabs; Desmotabs® 0,2 mg Tabletten; Desmotabs® 0,2mg Tabletten; Determination of drug effects through amantadine cessation; Device: AHA Exergame System; Device: Abdominal compression; Device: ActiMyo recording; Device: Active tPCS; Device: Adaptor: Hakko Adaptor; Device: B-STN DBS; Device: Balance Training; Device: Balance Training with Nintendo Wii Fit; Device: CADD-Legacy ambulatory infusion pump; Device: CADD-Legacy® 1400 ambulatory infusion pump; Device: Carbon Fiber Ankle Foot Orthosis (AFO); Device: Clonidine (Catapressan); Device: Deep Brain Stimulation; Device: Infusion Pump: CADD-Legacy® 1400 Pump; Device: Inspiratory Muscle Training; Device: J-tube; Device: Jejunal extension tube; Device: Kinetra and Soletra (neurostimulator, Medtronic); Device: Light box ( Litebook company); Device: Light box (Litebook company); Device: MS Band 2; Device: Magnetic Resonance Imaging; Device: Massage with a spiky ball; Device: NJ-Tube: Silicon ED Tube; Device: Nebulizer; Device: OCT - TCE; Device: PEG tube; Device: Percutaneous endoscopic gastrostomy tube; Device: Renishaw Drug Delivery System; Device: Resistive respiratory loads; Device: SPECT imaging; Device: Sham tPCS; Device: SpotOn balance glasses; Device: Stimulator OFF; Device: Stimulator ON; Device: active tDCS; Device: deep brain stimulation; Device: functional Magnetic Resonance Imaging; Device: jejunal extension tube (J-tube); Device: percutaneous endoscopic gastrostomy tube (PEG tube); Device: sham compression; Device: sham tDCS; Dexdor; Dexmedetomidina; Dexmedetomidine; Dexmedetomidine Hydrochloride Infusion; Dextromethorphan; Diagnostic Test: Auto-Assessment Manikins (SAM); Diagnostic Test: Barcelona test (BT); Diagnostic Test: Beam test to predict falls; Diagnostic Test: Beck Depression Inventory-II (BDI-II); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Frontal assessment battery (FAB); Diagnostic Test: Global Deterioration Scale (GDS); Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Measurement of serum level of anti-dementia drug; Diagnostic Test: Memory alteration test (M@T); Diagnostic Test: Mini Cognitive Examination (MCE); Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Positive and Negative Affect Scale (PANAS); Diagnostic Test: Respiratory Muscle Strength; Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT); Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC); Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Different diets; Dihydroergotoxine Mesylate; Dipivefrin; Dipivefrine; Dipraglurant; Ditropan elixir; Docosahexaenoic Acid (DHA); Docosahexaenoic acid; Domperidone; Domperidone (drug); Dompéridone; Donepezil; Donepezil Sandoz; Donepezil hydrochloride; Dopamine; Dopamine Agent; Dopamine Agonists (pramipexole, ropirinole); Dopaminergic Agonist + Apomorphine; Dopaminergic Agonists; Doxepin; Doxepin and Zopiclone; Droxidopa; Droxidopa 100 MG [Northera]; Duloxetine; Duloxetine hydrochloride; Duodopa; Duodopa LD/CD 20/5 mg/mL; Duodopa gel intestinale; Duodopa intestinal gel; Duodopa intestinalgel; Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel; Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel; Dynacirc CR (Isradipine); E2007; EBIXA®; EGCG; ELC200; ELTOPRAZINE; EMD 128130; EMD128130; EN; ENA713; ENA713B; ENT-01; ENTACAPONA; ENTACAPONE; ENTACAPONE INN; EPI-589; EPI-743 200mg; EPI-743 400mg; ER CD-LD; ER tablet 100 mg AZD3241; ER tablet 25 mg AZD3241; ETHNODYNE VISIO; EXELON; EXENATIDE; Ebixa; Eliprodil; Elobixibat; Eltoprazine; Eltoprazine HCl; Eltoprazine Hydrochloride; Entacapon; Entacapona; Entacapone; Entacapone 400mg oral dose; Entacapone and carbidopa; Entecapone; Equal; Eradication of Helcobacter Pylori; Eradication therapy for H.pylori infection; Eradication therapy for Helicobacter pylori; Erythromycin; Erythropoietin; Erythropoietin human recombinant (EPOrh); Escitalopram; Escitalopram oxalate; Eszopiclone; Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below); Exametazime; Exelon; Exelon 4.6 mg/24 h transdermal patch; Exelon 9.5 mg/24 h transdermal patch; Exelon Patch; Exelon Patch (rivastigmine transdermal system); Exelon path transdermal; Exelon ®; Exenatide; Exenatide 10 micrograms; Exenatide 5 micrograms; Exenatide extended release 2mg (Bydureon); F-18 FPCIT; FB-101; FLECAINIDE ACETATE; FLORBETABEN (18F); FPF1100NW; FPFS-1169; Famotidine; Febuxostat; Ferriprox; Ferriprox 500 mg; Ferrprox (Deferiprone); Fesoterodine; Fetal porcine cells, Neurocell-PD; Filgrastim; Finamine tablets; Finasteride; Fipamezole; Fipamezole ODT; Fipamezole ODT Cohort 2; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Flecainide; Flecainide acetate; Flecainidum; Florbetapir F 18; Fludrocortisone; Flumazenil; Flutemetamol; Flutemetamol F18; Folic Acid, Vitamin B6, Vitamin B12; Folic acid; Foliglurax; Foliglurax 10 mg (treatment A); Foliglurax 30 mg (treatment B); Foscarbidopa; Foscarbidopa and Foslevodopa; Foslevodopa; G-CSF; GABAPENTIN; GABAPENTINA; GABAPENTINA KERN PHARMA; GENZ-682452; GM1 ganglioside; GM608; GOCOVRI; GPI 1485; GRF6021; GSH; GSK962040; GSK962040 (25 mg tablet); GZ/SAR402671; Gabapentin; Gabapentina; Galantamine; Ganoderma; Genetic: Optional pharmacogenetic assessment; Genz-682452-AU; Ghrelin; Ginkgo; Glial Cell Line-Derived Neurotrophic Factor (GDNF); Glial cell line-derived neurotrophic factor; Glucose; Glutathione; Glycerol; Glycerol Phenylbutyrate; Glycerol phenylbutyrate; Glycopyrrolate; Gold; Gold Nanocrystals; Grapefruit; Green Tea; Green Tea Polyphenols (EGCG/ECG); Group AD Anti-PD + Antidepressant; Group R Rasagiline; Group R+AD Rasagiline + Antidepressant; Guar gum; HB-adMSCs; HEC122505MsOH; HF0220; HP-3000 (ropinirole hydrochloride patch); HP-3000 placebo; HP-3000(ropinirole hydrochloride patch); Helicobacter pylori eradication therapy; Heptaminol; Heptaminol hydrochloride; Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.); Hericium erinaceus mycelium; Heshouwu; High Protein. T-Diet plus Range; High dose AFFITOPE® PD03A + Adjuvant; High dose ANAVEX2-73; Human Amniotic Epithelial Stem Cells; Human Stem Cells; Human neural stem cell; Hydrocortisone; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g FNA Fagron; Hydrogen; Hydrolyzed guar gum; I 123; I-123; I-123-5-IA85380; I123; IBEROGAST; IOFLUPANE (123I); IPRONIAZID; IPT803; IPX054 100 mg; IPX054 150 mg; IPX054 200 mg; IPX054 250 mg; IPX054 300 mg; IPX066; IPX066 145 mg; IPX066 145 mg LD; IPX066 195 mg; IPX066 195 mg LD; IPX066 245 mg; IPX066 245 mg LD; IPX066 95 mg; IPX066 95 mg LD; IPX066-145; IPX066-195; IPX066-245; IPX066-95; IPX203; IPX203 140 mg; IPX203 180 mg; IPX203 210 mg; IPX203 270 mg; IPX203 280 mg; IPX203 350 mg; IPX203 ER CD-LD; IR CD-LD; IR CD-LD (carbidopa-levodopa) tablets; IR LD / CD; IR LD/CD; IRL752; IRL790; IRX4204; ISC-hpNSC; ISTRADEFYLLINE; ITI-214; IV Apomorphine; IV Levodopa; IZD174; Idebenone; Immediate Release carbidopa/levodopa 10/100 mg; Immediate Release carbidopa/levodopa 25/100 mg; Immediate release carbidopa/levodopa; Impact; Incobotulinum Toxin A; IncobotulinumtoxinA; IncobotulinumtoxinA (100 Units); IncobotulinumtoxinA (75 Units); Infudopa i.v.; Infudopa s.c.; Infusions of young plasma; Inhaled VR040; Injection of Umbilical cord derived MSCs; Injection of apomorphine; Injection of normal saline; Inosine; Intracerebral microinjections; Intranasal Insulin; Intranasal glutathione - (in)GSH; Intravenous Infusion; Intravenous Levodopa; Intravenous and Oral n-acetyl cysteine; Intravesical injection of Botulinum A toxin; Ioflupane 123I (DATSCAN®); Ioflupane I 123; Ioflupane [123 I]; Ioflupane [123I]; Ipratropium; Ipratropium bromide (drug); Iproniazid; Ips-nsc cells; Isicom; Isoflurane; Isradipine; Isradipine CR 10mg; Isradipine CR 20mg; Isradipine CR 5mg; Istradefylline; Istradefylline ( KW-6002); Istradefylline (KW-6002); Istradefylline 20 mg; Istradefylline 20 mg or 40 mg; Istradefylline 40 mg; JM; JM-010; JM-010 group A; JM-010 group B; JNJ-31001074; JNJ31-31001074; JP 1730; JP-1730/F01; JP-1730/F02; JP-1730/F03; JZP-110; K0706; KDT-3594; KM-819; KW-6002; KW-6002 (istradefylline); KW-6356; KW-6356 High Dose; KW-6356 Low Dose; KW-6356 Middle Dose; KW-6356 X Dose; KW-6356 Y Dose; KW-6500; Ketone Ester Elite endurance Nutrition Drink; Ketone ester drink; Kinoquinone (proposed); L-123 Ioflupane; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA; L-DOPS; L-Dopa; L-Dopa/ MODOPAR; L-dopa; L-methylfolate; L-tyrosine; LA; LCIG; LCIG (Duodopa); LD / BE; LD+DDCI; LD-DDCI; LD/CD; LEVODOPA; LEVODOPA (DC.IT) (FU); LEVODOPA / BENSERAZIDE 200 + 50 MG; LEVODOPA DC.IT FU; LEVODOPA INN; LEVODOPA/BENZERASIDE; LEVODOPA/CARBIDOPA; LISURIDE; LODALÈS®; LUBIPROSTONE; LY03003; LY03003 ( Rotigotine, extended-release microspheres); LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection); LY03003( the name of rotigotine); LY03003(Rotigotine,extended-release microspheres); LY03009 F1; LY03009 F2; LY03009 F3; LY03009 F4; LY300164; LY3154207; Lactobacillus casei DG (Enterolactis duo®); Lactobacillus plantarum; Lactobacillus plantarum PS128; Lactose; Leptin; Leucine; Levetiracetam; Levodopa; Levodopa (L-DOPA) + Standard care; Levodopa (L-dopa); Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa / Benserazid; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg A CAP; Levodopa 125 mg A CAP; Levodopa 150 mg A CAP; Levodopa 25mg/100mg; Levodopa 75 mg A CAP; Levodopa Benserazide Madopar; Levodopa Benserazide Teva Italia; Levodopa CR (controlled release); Levodopa Cyclops; Levodopa MR; Levodopa acute challenge; Levodopa and Domperidone; Levodopa and carbidopa; Levodopa and carbidopa SC solution; Levodopa and carbidopa solution for SC administration; Levodopa and decarboxylase inhibitor; Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets; Levodopa carbidopa intestinal gel (LCIG); Levodopa dispersible; Levodopa infusion; Levodopa powder for inhalation; Levodopa tablet; Levodopa, carbidopa, ODM-104; Levodopa, carbidopa, entacapone; Levodopa, decarboxylase inhibitor and COMT inhibitor; Levodopa-4'-Monophosphate; Levodopa-Carbidopa; Levodopa-Carbidopa Intestinal Gel; Levodopa-Carbidopa Intestinal Gel (LCIG); Levodopa-Carbidopa Multilayer Extended Release Tablet; Levodopa-Carbidopa XL tablet (M); Levodopa-carbidopa; Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets; Levodopa-carbidopa Immediate Release (LC-IR) Tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa intestinal gel (LCIG); Levodopa-carbidopa-entacapone; Levodopa/Benzerazide; Levodopa/Carbidopa; Levodopa/Carbidopa (LD/CD); Levodopa/Carbidopa (Sinemet); Levodopa/Carbidopa Hydrate; Levodopa/Carbidopa Solution; Levodopa/Carbidopa(200mg/50mg); Levodopa/DDCI; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/carbidopa; Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa/entacapone; Levodopa/dopa decarboxylase inhibitor; Liatermin; Liatermin (r-metHuGDNF); Lidocaine; Lingzhi (Ganoderma); Lipuro; Liquigen MCT oil; Liraglutide; Lisparin; Lisuride; Lisuride Hydrogenmaleate; Lisuride TTS; Lisuride TTS 10cm²; Lisuride TTS 20cm²; Lisuride Transdermal System; Lithium; Lixisenatide; Local Anesthesia (lidocaine hydrochloride); Local Trade Name, 2mg; Local Trade Name, 4mg; Local Trade Name, 8mg; Lodosyn®; Lovastatin; Low dose AFFITOPE® PD03A + Adjuvant; Lu 00-800; Lu AF28996; Lu AF82422; Lubiprostone; MANTADIX; MARS; MCT; ME2125 (safinamide mesilate); MEDI1341; MEMANTINE; MEMANTINE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE; MIRAPEXIN*30CPR 0,7MG; MK0657; MOCLOBEMIDE; MODAFINIL; MODOPAR; MOTILIUM; MOXIFLOXACINA CLORIDRATO; MSC; Madopar; Madopar 125 mg, orodispersible tablet; Madopar 200+50 mg; Madopar LT; Madopar® 125; Madopar® 250; Madopar® HBS; Madopar® HBS 125; Magnesium; Magnesium oxide; Maltodextrin; Mannitol; Mantadix; Masitinib; Masitinib mesylate; Mavoglurant; Melatonin; Melatonin PR; Melatonin(Circadin®); Melevodopa; Melevodopa and decarboxylase inhibitor; Melperon; Melperone; Melperone HCl; Memantin Orion; Memantine; Memantine (drug); Memantine hydrochloride; Mesdopetam; Mesdopetam (IRL790); Mesencephalic Neuronal Precursor Cells; Mesenchymal stem cells; Mestinon; Metabolic Cofactor Supplementation; Metformin; Methylphenidate; Methylphenidate (MPD); Methylprednisolone; Mg; Mid dose ANAVEX2-73; Midazolam; Midodrine; Minocycline; Minodronic acid; Mirabegron; Mirapex; Mirapex (pramipexole); Mirapex ER; Mirapex LA; Mirapexin; Mirapexin / Sifrol; Mirapexin extended release various strengths; Mirapexin/Sifrol; MitoQ; Moclobemide; Modafinil; Modafinil 50mg; Modal; Modiodal; Monoamine oxidase B inhibitors; Motilium; Moxifloxacin; Moxifloxacin infusion; Muscimol; Mémantine; N acetyl cysteine; N-0923; N-Acetylcysteine; N-acetylcysteine; N-acetylcysteine capsule; N.a.; N04BD02; NABILONE; NACOM 100; NACOM levodopa+cardidopa; NAL; NALOXONE HYDROCHLORIDE DIHYDRATE; NBTX-001; ND0611; ND0612; ND0612 (Levodopa/Carbidopa solution); ND1421; ND1587; ND1589; ND1590; ND1702; NERIXIA*IM EV 1F 25MG; NEUPRO; NEUPRO 2 mg/24 h parche transdérmico; NEUPRO 4 mg/24 h parche transdérmico; NEUPRO 6 mg/24 h parche transdérmico; NEUPRO 8 mg/24 h parche transdérmico; NEUPRO*28CER 2MG/24H; NEUPRO*28CER 4MG/24H; NEUPRO*28CER 6MG/24H; NEUPRO*28CER 8MG/24H; NEUPRO*7CER 4MG/24H; NEUPRO*7CER 6MG/24H; NEUPRO*7CER 8MG/24H; NEUROBLOC; NICOTINAMIDE; NICOTINE; NLY01; NMDA; NPC transplantation; NR2B NMDA Antagonist CP-101,606 (traxoprodil); NS 2330; NS2330; NT 101; NTCELL Implantation; NW-1015; NW-1015E, EMD 1195686, MSC2191632B; NYX-458; Nabilone; Nabilone 0.25 mg; Nacom; Nacom 100; Nalmefene; Naloxone; Naloxone Hydrochloride Dihydrate; Naltrexone; Nardil; Nebicapone; Nelotanserin; Neridronic Acid; Neridronic acid; Neu-120; Neupro; Neupro (Reference); Neupro 2 mg/24 h transdermal patch; Neupro 2mg/24 h transdermal patch; Neupro 2mg/24h transdermal patch; Neupro 4 mg/24 h transdermal patch; Neupro 4Mg/24Hr Transdermal Patch; Neupro 4mg/24 h transdermal patch; Neupro 4mg/24h transdermal patch; Neupro 6 mg/24 h transdermal patch; Neupro 6mg/24 h transdermal patch; Neupro 6mg/24h transdermal patch; Neupro 8 mg/24 h transdermal patch; Neupro 8mg/24h transdermal patch; Neupro®; Neuraceq; NeuroEPO; Neurobloc; Neurohormonal mechanisms; Neurpro; Niacin; Niacinamide; Nicorette 10mg/ 16 h; Nicorette 15 mg/ 16 h; Nicorette 5 mg/ 16 h; Nicotinamide; Nicotinamide Riboside; Nicotinamide riboside; Nicotine; Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY); Nicotine gum; Nicotine patch; Nicotine transdermal patch; Nicotinell; Nicotinell 17,5 mg/24-Stunden-Pflaster; Nicotinell 35 mg/24-Stunden-Pflaster; Nilotinib; Nilotinib 150mg oral capsule [Tasigna]; Nilotinib 300mg oral capsule [Tasigna]; Nitrogen; Normal Saline; Northera; Nortriptyline; Nortriptyline hydrochloride; Null; OC oral solution treatment A; OC oral solution treatment B; OC oral solution treatment C; OC oral solution treatment D; ODM-101; ODM-101 105mg Carbidopa; ODM-101 65mg Carbidopa; ODM-104; ONO-2160/CD; ONO-2370; ONO-2506PO; OPC; OSU 6162 similar to (-)-OSU 6162; OSU6162 similar to (-)-OSU 6162; OTHER NERVOUS SYSTEM DRUGS; OXB-102; OXN 10 mg / 5 mg PR; OXN 20 mg / 10 mg PR; OXN 5 mg/2.5 mg PR; OXYCODONE HYDROCHLORIDE; OXYTOCIN SYNTHETIC; Omeprazole; Onabotulinumtoxin A Injection; OnabotulinumtoxinA; Ondansetron; Ondansetron 8 mg film-coated tablets; Ondansetron hydrochloride dihydrate; Ongentys; Opicapone; Opicapone (OPC); Optimal drug therapy; Optimized antiparkinsonian treatment; Oral Levodopa/Carbidopa; Oral escitalopram; Oral levodopa and carbidopa; Orally disintegrating selegiline (Zelapar); Other Parkinson's Disease treatments; Other: Balance; Other: Balance Training; Other: Balance exercise; Other: Berg Balance Scale; Other: Best Medical Treatment; Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease; Other: Control; Other: Controlled environment tests (series of tasks of everyday life); Other: Controls Primary Cervical Dystonia (Trihexyphenidyl); Other: DYT 1 Dystonia; Other: DYT 1 Dystonia (Healthy Control); Other: Data Capture; Other: Diary completion; Other: Endurance; Other: Evaluation by Investigator; Other: Event-related evoked potential using electroencephalography (EEG).; Other: Four Square Step Test; Other: Functional Reach Test; Other: Functional mobility; Other: Gait and balance group training; Other: High intensity exercise and balance training; Other: Hoehn and Yahr Scale; Other: Imitation Surgical Procedure (ISP); Other: Lower Limb Strength; Other: MIBG label with I123 or I124; Other: MP+DDCI; Other: MP-Equivalent; Other: MP-Low; Other: MRI; Other: Mobile platform exercise; Other: Motor Assessments before taking regular PD treatment; Other: Motor Assessments on regular PD treatment; Other: Multidisciplinary intensive rehabilitation treatment; Other: Music; Other: Neupro 4 mg / 24 Hr. Transdermal Patch; Other: Non-Motor Symptoms; Other: Nordic walking (only osteoporosis group); Other: Observational cohort; Other: Optional Blood-Oxygen-level Dependent functionalMRI; Other: PD exercise intervention; Other: PD vitamin + exercise; Other: Parkinson mPower mobile application; Other: Physical Function Performance Test; Other: Physical Therapy; Other: Pittsburgh Compound B [11C]-PIB; Other: Questionnaires; Other: Recommendation with regard to nutrition; Other: Rhythmic Auditory Stimulation (RAS); Other: Rhythmic Balance-Movement Training (rBMT); Other: Rotigotine; Other: Saline; Other: Screening to prevent falls; Other: Sham Surgery; Other: Sham group; Other: Smartphone-based balance exercises; Other: Specific SL-therapy; Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS; Other: Stool Sample; Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale; Other: Timed Up and Go Test; Other: Trunk Impairment Scale; Other: Unified Parkinson's Disease Rating Scale; Other: Usual care arm exercise; Other: Usual drug treatment of Parkinson's disease; Other: Voluntary cough test; Other: [11C]donepezil PET; Other: collection of CSF, blood, urine, saliva; Other: fog; Other: hemicellulose crystalline; Other: t-DCS group; Other: the timed 360° turn test; Other: tyramine; Over-encapsulated Entacapone Tablets; Over-encapsulated Modafinil; Oxaloacetate (OAA); Oxybate; Oxybuprocaine; Oxybutynin; Oxybutynin and darifenacin; Oxybutynin hydrochloride; Oxycodone; Oxycodone Hydrochloride; Oxycodone hydrochloride; Oxycodone/Naloxone Prolonged Release tablets; Oxycodone/naloxone prolonged release tablets 10 mg /5 mg; Oxycodone/naloxone prolonged release tablets 20 mg /10 mg; Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg; Oxygen; Oxytocin; P2B001; P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; PARCOPA; PAT; PBF-509; PD patients H&Y=1.5-2 Medications OFF; PD patients H&Y=1.5-2 Medications ON; PD patients H&Y=3 Medications OFF; PD patients H&Y=3 Medications ON; PD vitamin supplementation; PEG; PERGOLIDE; PET; PF-06412562; PF-06649751; PF-06649751 - 15mg; PF-06649751 - 1mg; PF-06649751 - 5mg; PF-06649751 high dose (15 mg QD); PF-06649751 low dose (1 mg QD); PF-06649751 middle dose 1 (3 mg QD); PF-06649751 middle dose 2 (7 mg QD); PF-06669571; PK-Merz; PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj; PR Oxycodone; PR001A; PRAMIPEXOLE; PRAMIPEXOLE DIHYDROCHLORIDE; PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; PRIM-DJ2727; PROPOFOL; PROSCAR*30CPR RIV 5MG; PRX002; PRX002, ELT2, anti-alpha-synuclein monoclonal antibody; PT320 2.0 mg; PT320 2.5 mg; PXT002331; PXT002331 - 20mg; PXT002331 - dose 1; PXT002331 - dose 2; PYM50028; PYRIDOSTIGMINE BROMIDE; Paracetamol; Parapres; Parcopa; Pardaprunox; Pardoprunox; Pardoprunox hydrochloride; Paroxetine; Part 1, JM-010 component Group A; Part 1, JM-010 component Group B; Part 1, JM-010 component Group C; Part 2, JM-010 combination Group A; Part 2, JM-010 combination Group B; Part 2, JM-010 component Group C; Perampanel; Pergolide; Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid; PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid; Phenlarmide Tablets; Phenylbutyrate; Piclozotan; Pilocarpine; Pimavanserin; Pimavanserin (ACP-103); Pimavanserin tartrate; Pimavanserin tartrate (ACP-103); Pioglitazone; Piribedil; Piribedil (Clarium); Pitolisant; Pittsburgh Compound B; Placebo; Plantago ovata husk; Posiphen; Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin); Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin); Pramipexol; Pramipexol Extended Release; Pramipexol Immediate Release; Pramipexole; Pramipexole 0.125 mg tablets; Pramipexole 0.5 mg tablets; Pramipexole ER; Pramipexole Extended Release; Pramipexole IR; Pramipexole Immediate Release; Pramipexole SR; Pramipexole dihydrochloride; Pramipexole dihydrochloride extended-release tablets; Pramipexole dihydrochloride monohydrate; Pramipexole dihydrochloride monohydrate extended release; Pramipexole extended release tablet; Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole); Pramipexole immediate release; Pramipexole immediate release tablet; Pramipexole or ropinirole; Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride); Prednisone; Preladenant; Preladenant 10 mg tablet; Preladenant 2 mg tablet; Preladenant 5 mg tablet; Premarin ®; Pridia (Donepezil Hydrochloride) 5mg; Pridia 10mg; Pridia 5mg; Pridopidine; Primary Cervical Dystonia (Trihexyphenidyl); Primavanserin tartrate; Prior Donepezil 5mg; Prior Donzepezil 10mg; ProSavin; Probiotic; Probiotic Capsule; Probiotics with prebiotic; Procedure: Biofluid samplings; Procedure: Blood analysis; Procedure: Cardiac monitoring; Procedure: DATscan and SPECT imaging; Procedure: Electroacupuncture; Procedure: Exergame; Procedure: Fluoroscopic swallow evaluation; Procedure: Home based balance training; Procedure: Lumbar Puncture; Procedure: MEG; Procedure: Motion Analysis; Procedure: PET/CT; Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J); Procedure: Sedation with IV propofol; Procedure: Sham Surgery; Procedure: Static, dynamic and functional balance exercises; Procedure: Static, dynamic and functional balance exercises with dual task; Procedure: Tissue samplings; Procedure: Umbilical cord blood therapy; Procedure: [123I]-IBZM imaging; Procedure: [123I]beta-CIT and SPECT imaging; Procedure: [123I]ß-CIT and SPECT imaging; Procedure: blood draw; Procedure: embryonic dopamine cell implant surgery; Procedure: physical exam and UPDRS part III assessment; Prolonged release tablet; Prolopa®; Propanoic acid; Propofol; Propofol-Lipuro; Propranolol; Propranolol HCl CF 40 mg tablet; Pyridostigmine; Pyridostigmine bromide; Quetiapine; R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride; R-metHuGDNF; RAAV-GAD; RAS; RASAGILINA MESILATO; RASAGILINE; RASAGILINE MESILATE; RASAGILINE MESYLATE; REQUIP; REQUIP 21 CPR 0,25 MG; REQUIP 21 CPR 0,5 MG; REQUIP 21 CPR 1 MG; REQUIP 21 CPR 2 MG; REQUIP*21CPR 0,25MG; REQUIP*21CPR 0,5MG; REQUIP*21CPR 1MG; REQUIP*21CPR 5MG; REQUIP*28CPR 8MG R.P.; REQUIP-LP; REQUIP-MODUTAB , 2mg; REQUIP-MODUTAB , 4mg; REQUIP-MODUTAB , 8mg; REQUIP-MODUTAB, 2mg; REQUIP-MODUTAB, 4mg; REQUIP-MODUTAB, 8mg; RIV-TDS 13.3 mg/24 h; RM-131; RO; RO7046015; ROP; ROP+L-Dopa; ROPINIROLE; ROTIGOTINA; ROTIGOTINE; ROZEREM; RQ-00000010; RVG 08740; RVG 55618; RVT-101 35 mg; Raclopride; Racol; Radiation: Fluoroscopy; Radiation: H215O PET; Radiation: PET with the tracer 11C-PE2I; Radiation: PET with the tracer 18F-DPA-714; Radiation: Radiosurgical thalamotomy; Radiation: Videofluoroscopic swallow evaluation; Radiation: [18-Fluorine] Flubatine PET Scan; Ramelteon; Rasagilin; Rasagilina; Rasagilina mesilato; Rasagilina mesilato (12 weeks); Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline Mesylate; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus Mirapex; Rasagiline mesylate with Levodopa; Rasagiline mesylate with Requip; Rasagiline tablets; ReQuip CR; ReQuip PR; Recombinant human Cerebral Dopamine Neurotrophic Factor; Recombinant-methionyl human glial cell line-derived neurotrophic factor; Reduced Glutathione; Reduced Glutathione 100mg; Reduced Glutathione 200mg; Regular Novolin R; Remifentanil; Remifentanyl; Reminyl; Reminyl Retard; Repaglinide; Requip; Requip Modutab, 2mg; Requip Modutab, 4mg; Requip Modutab, 8mg; Requip PR; Requip XL prolonged-release; Requip prolonged release; Requip-Modutab; Resistant maltodextrin; Resistant starch; Restex Tabletten; Rifampicin; Rifampin; Rifampin 300mg BID + istradefylline 40mg Day 8 only; Rifaximin; Rifaximin 550 MG; Ritalin; Rivastigmin Luye Transdermal Patches - 4.6mg/24h; Rivastigmine; Rivastigmine CF; Rivastigmine Luye Transdermal Patch- 9.5mg/24h; Rivastigmine Patch 9.5 cm2; Rivastigmine Transdermal System; Rivastigmine capsule; Rivastigmine transdermal patch; Rivastigmine transdermal system 13.3 mg/24 h; Ropinirole; Ropinirole (as hydrochloride); Ropinirole CR 2mg tablet; Ropinirole CR 8mg tablet; Ropinirole Hydrochloride; Ropinirole IR; Ropinirole IR Tablets; Ropinirole Implant; Ropinirole PR; Ropinirole PR, 2mg; Ropinirole PR/XR; Ropinirole PR/XR Tablets; Ropinirole PR/XR tablets; Ropinirole Prolonged release; Ropinirole XL; Ropinirole XL (formerly CR); Ropinirole controlled-release (REQUIP CR) for RLS; Ropinirole hydrochloride; Ropinirole hydrochloride extended-release tablet; Ropinirole hydrochloride extended-release tablet placebo; Ropinirole hydrochloride prolonged release; Ropinirole immediate release; Ropinirole monotherapy; Ropinirole oral product; Ropinirole prolonged release; Ropinirole prolonged release/extended release(PR/XR); Ropinirole/L-dopa; Rosuvastatin; Rotigotin; Rotigotina; Rotigotine; Rotigotine (Reference product PR 2.1.1); Rotigotine (Test product PR 2.3.1); Rotigotine Nasal Spray; Rotigotine TTS (Test); Rotigotine hydrochloride; Rotigotine nasal spray; Rotigotine transdermal patch; Rotigotine transdermal patch 2mg/24h(10cm2); Rotigotine transdermal patch 4mg/24h (20cm2); Rotigotine transdermal patch 6mg/24h (30cm2); Rotigotine transdermal patch 8mg/24h (40cm2); Rotigotine, extended-release microspheres; Rozerem; Rytary 145 mg; Rytary 195 mg; S 90049; S 90049 - F36; S 90049 - F38; S.c. apomorphine; S90049; SA; SAFINAMIDE; SAFINAMIDE METANSOLFONATO; SAFINAMIDE METHANESULFONATE; SAGE-217; SAGE-718; SAM; SAM-e; SAR402671, GZ402671 or GZ/SAR402671; SARIZOTAN; SCH 420814; SCH 420814 10 mg; SCH 420814 100 mg; SCH 900800; SCH420814; SELEGILINE; SEP-363856; SER-214; SIFROL; SINEMET; SINEMET 10-100; SINEMET 100 mg + 25 mg compresse; SINEMET 125; SINEMET 25-100; SINEMET 25/100; SINEMET CR; SINEMET Plus; SINEMET*50CPR 100MG+25MG; SINEMET® Plus 25 mg/100 mg Tablets; SINEMET®-Plus Tablets; SIRIO*30CPR EFF 25MG+100MG; SK&F101468; SKF-101468A; SLV308; SLV308 (mono) hydro; SLV308 (mono) hydrochlo; SLV308 (mono) hydrochlori; SLV308 (mono) hydrochloride; SLV308 (mono)hydrochloride; SLV308 hydrochloride; SLV308(mono)hydrochloride; SMILAGENIN; SND 919 CL2 Y; SND 919 CL2Y; SNN0031; SOLIGEN; SPECT; SPM 926; SPM 962; SPM962; SQJZ herbal mixtures; SR57667B; STALEVO*100CPR 100/25/200MG; STALEVO*100CPR 50/12,5/200MG; SYN115; SYN115 Tablets, 60 mg; SYN120; Safety observation; Safinamida; Safinamide; Safinamide (as add-on therapy); Safinamide + Levodopa; Safinamide Methanesulfonate; Safinamide Methanesulfonate 100mg; Safinamide Methanesulfonate 150mg; Safinamide metansolfonato (12 weeks); Safinamide methansulfonate; Safinamide, MAO-B inhibitor; Safinimide 50-100 mg/day; Sage; Sage leaf; Saline; Saline Intranasal Delivery; Saracatinib; Sarcosine; Sarcosine Capsule; Sargramostim; Sarizotan; Sarizotan HC1; Sarizotan HCl; Sarizotan Hydrochloride; Sarizotan hydrochloride; Selegiline; Selegiline HCl 5 PCH; Semaglutide; Semi continuous intra-oral administration of LD/CD; Serine; Seroquel; Sertraline; Sevoflurane; Sifol; Sifrol; Sifrol 0,088; Sifrol 0,18; Sifrol 0,35; Sifrol 0,7; Sifrol, 0,35 mg Tablette; Sifrol, 0,70 mg Tablette; Sifrol, Mirapexin; Sifrol®; Sildenafil; Silicon; Silodosin; Simvastatin; Simvastatine; Sinemet; Sinemet (carbidopa/levodopa); Sinemet (comparator); Sinemet (levodopa/carbidopa); Sinemet 125 mg; Sinemet 200mg/50mg; Sinemet 25/100; Sinemet CR; Sinemet CR 25Mg-100Mg Extended-Release Tablet; Sinemet IR; Sinemet Plus; Sinemet plus; Sinemet plus (levodopa/carbidopa); Sinemet-Plus Tablets; Sinemet®; Sinemet® 100/25; Sinemet® 100/25 mg; Sinemet® CR; Sinemet® CR 100/25; Sinemet® controlled release (Carbidopa/levodopa); Sinemet®25-100; Sirolimus; Sitagliptin; Smilagenin; Sodium Oxybate; Sodium chloride; Sodium oxybate; Solifenacin; Solifenacin Succinate (VESIcare); Solifenacin succinate (VESIcare); Solu-Cortef; Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'; Solu-cortef; Sorbitol; Soy protein; Spheramine (BAY86-5280); Spiropent; Stalevo; Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Stalevo (levodopa/carbidopa/entacapone); Stalevo 100; Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten; Stalevo 100 mg/25 mg / 200 mg; Stalevo 100/25/200 mg; Stalevo 150; Stalevo 150/37.5/200 mg; Stalevo®; Standard LD/CD; Standard of Care; Stilnoct; Strattera; Study Drug; Subcutaneous apomorphine; Subcutaneous hydrocortisone 10mg; Subjects will undergo the 123-I IBVM imaging visit; Sugar Pill; Sugar pill; Sulfate; Sumanirole; Supplementation; Supressi. T-Diet plus Range; Suvorexant; Synthetic Oxytocin; Syntocinon; Syntocinon 40 IU/ml nasal spray; TACROLIMUS TABLETS; TAK-071; TAVAPADON; TCE; TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt); TD-9855; TECHNETIUM (99MTC) EXAMETAZIME; THN02; THN102 Dosage A; THN102 Dosage B; THN102 Dosage C; TO; TOLCAPONE; TOPIRAMATE; TOZ; TOZADENANT; TRIGEL; TULOBUTEROL HYDROCHLORIDE; TVP-1012; TVP-1012 (1 mg/day) with levodopa; TVP-1012 0.5mg; TVP-1012 1mg; Tacrolimus; Tadalafil; Talampanel; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20 mg/10 mg prolonged-release tablets; Targinact 5 mg/2.5 mg prolonged-release tablets; Tasmar; Tavapadon; Tavapadon 0.25mg; Tavapadon 1mg; Tavapadon 5mg; Terazosin; Terazosin 5 MG; Tesofensine; Tigan; Tigan®; Tocovid Suprabio; Tolcapon; Tolcapone; Tolubuterol Hydrochloride; Topiramate; Topiramate (drug); Tozadenant; Tozadenant (SYN115) 120 mg BID; Tozadenant (SYN115) 180 mg BID; Tozadenant (SYN115) 240 mg BID; Tozadenant (SYN115) 60 mg BID; Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant); Transdermal flumazenil (Added 4/2020); Transdermal nicotine; Trihexyphenidyl; Trimethobenzamide; Trimethobenzamide Hydrochloride; Trivastal; Tropicamide; Tryptophan; Tryptophan (TRP) depletion; Tulobuterol; Tyramine; Tyrosine; UB-312; UCB0599; UCB7853; Ubiquinol; Urate; Ursodeoxycholic acid; Ursonorm; Usual dopaminergic per os treatment; V1512; V1512 and Entacapone; V81444; VARENICLINE; VARENICLINE TARTRATE; VIUSID/ALZER; VR040; VR040/Aspirair® inhaler; VY-AADC01; VY-AADC02; Valerian; Varenicline; Variation of behaviors of Parkinson's disease; Vehicle; Venglustat; Venglustat malate; Venlafaxine; ViNeuro; Vitamin B12; Vitamin B12 Supplementation; Vitamin B6; Vitamin D3; Vitamin D3 - high dose; Vitamin E; Vortioxetine; WD-1603; WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS; WIN-1001X; Warfarin; Water; Whey protein; White chocolate (0% cocoa); Wuling Powder; XADAGO (safinamide); XC130-A10H; XP21279; XP21279 and carbidopa (experimental); Xadago; Xeomin; Xiaoyao Pill; Yohimbine; Yohimbine HCl; Zelapar; Zoledronic Acid 5Mg/Bag 100Ml Inj; Zoledronic acid; Zolmitriptan; Zolpidem; Zolpidem Tartrate; Zolpidem first dose; Zolpidem second dose; Zonegran; Zonisamide; Zonisamide Capsules; Zopiclone; [11C]PBR28; [11C]PXT012253; [11C]SMW139; [123I] 5-IA; [123I] IBVM and SPECT imaging; [123I] mZINT injection and serial dynamic SPECT imaging; [123I]-IBVM; [123I]B-CIT; [123I]B-CIT SPECT imaging; [123I]CLINDE; [123I]MNI-420; [123I]beta CIT; [123I]beta CIT and SPECT imaging; [123I]beta-CIT; [123I]beta-CIT and SPECT imaging; [123I]ß CIT; [123I]ß CIT and SPECT imaging; [123I]ß-CIT; [123I]ß-CIT and SPECT imaging; [14C]-BIA 9-1067; [15O]H2O; [18F] CFPyPB; [18F] LBT-999; [18F] LBT-999 PET; [18F] PBR06; [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane; [18F]-FEPPA; [18F]DPA-714 PET scan; [18F]FDOPA; [18F]FDOPA PET/CT; [18F]FE-PE2I; [18F]FPEB; [18F]MK-9470; [18F]MNI-1126; [18F]MPPF; [18F]NOS; [18F]P17-059; [18F]PI-2620; [18F]T807 ([18F]MNI-777); [21CFR640.30] Plasma from 18 - 25 year old volunteer donors; [ABBV-951]; [F-18] Fluorodopa Positron Emission Tomography; [JNJ31-31001074]; [NA]; [na]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04468919 (ClinicalTrials.gov)	July 1, 2021	8/7/2020	Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit	Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit	Amyotrophic Lateral Sclerosis;Brainstem Stroke;Muscular Dystrophies;Parkinson's Disease and Parkinsonism;Multiple System Atrophy;Brain Tumor Adult;Spinal Cord Injuries;Locked-in Syndrome	Behavioral: BCI-FIT multi-modal access;Behavioral: BCI-FIT adaptive signal modeling;Behavioral: BCI-FIT active querying;Behavioral: BCI-FIT language modeling	Oregon Health and Science University	NULL	Not yet recruiting	18 Years	75 Years	All	60	N/A	United States
2	NCT03309514 (ClinicalTrials.gov)	June 2021	10/10/2017	Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease	Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease	Parkinson's Disease	Biological: Intracerebral microinjections	NeuroGeneration	NULL	Not yet recruiting	35 Years	85 Years	All	12	Phase 1;Phase 2	NULL
3	NCT04287543 (ClinicalTrials.gov)	May 2021	21/2/2020	Melatonin on Clock Genes in Parkinson's Disease	Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease	Parkinson Disease	Drug: Melatonin;Drug: Placebos	Instituto Mexicano del Seguro Social	NULL	Withdrawn	20 Years	N/A	All	0	Phase 2;Phase 3	Mexico
4	NCT04665869 (ClinicalTrials.gov)	March 15, 2021	7/12/2020	Long-term Effects of Combined Balance and Brisk Walking in Parkinson's Disease	Long-term Effects of Combined Balance and Brisk Walking on Alleviating Motor and Non-motor Symptoms in Parkinson's Disease: a Randomized Controlled Trial	Parkinson Disease	Behavioral: Combined balance and brisk walking training;Behavioral: Flexibility and strengthening exercise	The Hong Kong Polytechnic University	NULL	Not yet recruiting	30 Years	80 Years	All	70	N/A	NULL
5	NCT04322461 (ClinicalTrials.gov)	March 15, 2021	24/3/2020	Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population	Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA	Parkinson Disease;Alzheimer Disease	Dietary Supplement: Betaquik MCT supplement	Université de Sherbrooke	Nestlé	Not yet recruiting	60 Years	N/A	All	20	N/A	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04625361 (ClinicalTrials.gov)	January 1, 2021	9/11/2020	Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects	A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects	Parkinson Disease	Drug: HEC122505MsOH	Sunshine Lake Pharma Co., Ltd.	NULL	Not yet recruiting	18 Years	45 Years	All	102	Phase 1	China
7	NCT04373317 (ClinicalTrials.gov)	January 1, 2021	29/4/2020	Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis	CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)	Parkinson's Disease Psychosis	Drug: Pimavanserin;Drug: Quetiapine	VA Office of Research and Development	NULL	Not yet recruiting	40 Years	N/A	All	358	Phase 4	United States
8	NCT04491383 (ClinicalTrials.gov)	January 2021	22/7/2020	Tocotrienols in Parkinson's Disease (PD)	Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial	Neuro-Degenerative Disease;Parkinson Disease	Drug: Tocovid Suprabio;Other: Placebo	National Neuroscience Institute	Hovid Berhad	Not yet recruiting	50 Years	90 Years	All	100	Phase 2	Singapore
9	NCT04643327 (ClinicalTrials.gov)	January 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Queensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital	Not yet recruiting	N/A	N/A	All	28	Phase 2	NULL
10	NCT04497168 (ClinicalTrials.gov)	January 2021	29/7/2020	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease	Parkinson Disease	Drug: Citalopram 20mg;Drug: Placebo	University of Michigan	National Institute on Aging (NIA)	Not yet recruiting	65 Years	N/A	All	58	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT04590612 (ClinicalTrials.gov)	January 2021	17/9/2020	Improving Quality of Life in Early Parkinson's Disease	The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients	Parkinson Disease;Depression	Drug: Carbidopa -Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram	Western University, Canada	NULL	Not yet recruiting	50 Years	80 Years	All	30	N/A	NULL
12	NCT04584346 (ClinicalTrials.gov)	December 17, 2020	10/10/2020	Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)	Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)	Parkinson's Disease	Dietary Supplement: Liquigen MCT oil	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	50 Years	N/A	All	32	Phase 1	United States
13	NCT04377945 (ClinicalTrials.gov)	December 1, 2020	4/5/2020	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components	Dyskinesia, Drug-Induced	Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, Placebo Group;Drug: Part 2, JM-010 component Group C	Bukwang Pharmaceutical	NULL	Not yet recruiting	18 Years	80 Years	All	188	Phase 2	United States
14	NCT04147949 (ClinicalTrials.gov)	December 2020	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
15	NCT04346394 (ClinicalTrials.gov)	December 2020	10/3/2020	The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease	The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms	Parkinson Disease	Drug: Yohimbine HCl	Nathaniel M. Robbins	NULL	Not yet recruiting	N/A	N/A	All	22	Early Phase 1	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT04658186 (ClinicalTrials.gov)	December 2020	1/12/2020	A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease	A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease	Early-stage Parkinson's Disease	Drug: UCB0599;Drug: Placebo	UCB Biopharma SRL	NULL	Not yet recruiting	40 Years	70 Years	All	300	Phase 2	NULL
17	NCT04651153 (ClinicalTrials.gov)	December 2020	25/11/2020	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease	Parkinson's Disease	Drug: UCB7853;Other: Placebo	UCB Biopharma SRL	NULL	Not yet recruiting	18 Years	80 Years	All	64	Phase 1	NULL
18	NCT04634331 (ClinicalTrials.gov)	November 15, 2020	9/11/2020	Dual-task Augmented Reality Treatment for Parkinson's Disease	Dual-task Augmented Reality Treatment for Parkinson's Disease (DART)	Parkinson Disease	Behavioral: Augmented Reality Multi-Modal Training;Behavioral: Traditional Multi-Modal Training	The Cleveland Clinic	Michael J. Fox Foundation for Parkinson's Research	Recruiting	18 Years	N/A	All	50	Phase 2	United States
19	NCT04620382 (ClinicalTrials.gov)	November 9, 2020	27/10/2020	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients	Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease	Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	31	Early Phase 1	United States
20	NCT04506073 (ClinicalTrials.gov)	November 9, 2020	16/7/2020	Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD	Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease: Phase IIa Double-blind Randomized Placebo Controlled Trial	Parkinson's Disease	Drug: MSC+placebo;Drug: MSC;Drug: Placebo	The University of Texas Health Science Center, Houston	Michael J. Fox Foundation for Parkinson's Research	Recruiting	50 Years	79 Years	All	45	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04277247 (ClinicalTrials.gov)	November 2, 2020	10/2/2020	Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease	Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study	Dystonia Disorder;Parkinson Disease	Drug: Botulinum toxin type A;Drug: Placebo	University of Calgary	Allergan	Recruiting	30 Years	100 Years	All	40	Phase 2;Phase 3	Canada
22	NCT04386317 (ClinicalTrials.gov)	November 1, 2020	24/4/2020	Terazosin Effect on Cardiac Changes in Early Parkinson's Disease	The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease	REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson Disease	Drug: Terazosin	Cedars-Sinai Medical Center	NULL	Recruiting	25 Years	85 Years	All	15	Phase 2	United States
23	NCT03903549 (ClinicalTrials.gov)	November 1, 2020	3/4/2019	Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers	A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)	Parkinson Disease	Drug: [18F]P17-059	Five Eleven Pharma, Inc.	NULL	Not yet recruiting	45 Years	90 Years	All	26	Phase 1	United States
24	NCT04435431 (ClinicalTrials.gov)	October 29, 2020	15/6/2020	A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia	A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease	Parkinson Disease	Drug: Mesdopetam;Drug: Placebo	Integrative Research Laboratories AB	NULL	Recruiting	30 Years	79 Years	All	140	Phase 2	United States
25	NCT04542499 (ClinicalTrials.gov)	October 27, 2020	2/9/2020	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	368	Phase 3	United States;Australia;Czechia;Germany;Hungary;Poland
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	NCT03947216 (ClinicalTrials.gov)	October 23, 2020	7/5/2019	Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.	Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease	Parkinson Disease	Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring	University Hospital, Strasbourg, France	NS-PARK;EUCLID;F-CRIN	Recruiting	35 Years	75 Years	All	130	Phase 2	France
27	NCT04334317 (ClinicalTrials.gov)	October 21, 2020	30/3/2020	Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)	A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls	Parkinson's Disease	Drug: TAK-071;Drug: Placebo	Takeda	Michael J. Fox Foundation for Parkinson's Research	Recruiting	40 Years	85 Years	All	64	Phase 2	United States
28	NCT04380142 (ClinicalTrials.gov)	October 19, 2020	6/5/2020	Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease	A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients	Parkinson's Disease (PD)	Drug: ABBV-951;Drug: Placebo for Levodopa /Carbidopa (LD/CD);Drug: Levodopa /Carbidopa (LD/CD);Drug: Placebo for ABBV-951	AbbVie	NULL	Recruiting	30 Years	N/A	All	130	Phase 3	United States;Australia
29	NCT04502550 (ClinicalTrials.gov)	October 15, 2020	30/7/2020	Brain Networks and Consciousness	Subcortical-cortical Network Dynamics of Anesthesia and Consciousness	Loss of Consciousness;Parkinson Disease;Essential Tremor;Anesthesia	Drug: Propofol	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	All	48		United States
30	NCT04338997 (ClinicalTrials.gov)	October 2020	3/4/2020	PK Study in Patients With Parkinson's Disease With IZD174	An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease	Parkinson Disease	Drug: IZD174	Inflazome UK Ltd	NULL	Withdrawn	45 Years	75 Years	All	0	Phase 1	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT04593511 (ClinicalTrials.gov)	October 2020	21/9/2020	to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers	An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection	Parkinson's Disease	Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4	Luye Pharma Group Ltd.	NULL	Not yet recruiting	18 Years	65 Years	All	40	Phase 1	NULL
32	NCT03665493 (ClinicalTrials.gov)	September 30, 2020	4/9/2018	Dopamine Effect on Inhibitory Control	Dopamine Effect on Inhibitory Control	Idiopathic Parkinson's Disease	Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON	Giovanni Mirabella	NULL	Recruiting	40 Years	70 Years	All	102	N/A	Italy
33	NCT03968133 (ClinicalTrials.gov)	September 30, 2020	28/5/2019	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled Trial	Parkinson Disease;Anxiety	Dietary Supplement: Probiotic;Dietary Supplement: Placebo	University of British Columbia	The W. Garfield Weston Foundation	Not yet recruiting	40 Years	80 Years	All	72	Phase 2	Canada
34	NCT04591535 (ClinicalTrials.gov)	September 28, 2020	11/9/2020	PK Study of WD-1603 in Healthy Subjects	An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions	Parkinson Disease	Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India
35	NCT04553978 (ClinicalTrials.gov)	September 18, 2020	13/9/2020	A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions	An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions	Parkinson Disease	Drug: WD-1603	Hong Kong WD Pharmaceutical Co., Limited	NULL	Not yet recruiting	18 Years	45 Years	All	8	Phase 1	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT04387773 (ClinicalTrials.gov)	September 15, 2020	11/5/2020	Effect of GOCOVRI on Gait in Parkinson's Disease	Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease	Parkinson Disease	Drug: GOCOVRI	Oregon Health and Science University	Adamas Pharmaceuticals, Inc.	Not yet recruiting	50 Years	70 Years	All	12	Phase 4	United States
37	NCT04476017 (ClinicalTrials.gov)	September 11, 2020	15/7/2020	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)	An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment	Parkinson Disease;Cognitive Dysfunction	Drug: SAGE-718	Sage Therapeutics	NULL	Recruiting	50 Years	75 Years	All	22	Phase 2	United States
38	NCT04332276 (ClinicalTrials.gov)	September 2020	25/3/2020	Dopaminergic restauratIon by intraVEntriculaire Administration	A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?	Parkinson Disease	Drug: A-dopamine	University Hospital, Lille	InBrain Pharma	Not yet recruiting	45 Years	75 Years	All	20	Phase 1;Phase 2	NULL
39	NCT04524351 (ClinicalTrials.gov)	August 14, 2020	11/8/2020	Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)	Alzheimer Disease;Parkinson Disease	Drug: Posiphen	Annovis Bio Inc.	Parexel	Recruiting	45 Years	N/A	All	68	Phase 1;Phase 2	United States
40	NCT04513340 (ClinicalTrials.gov)	August 13, 2020	12/8/2020	WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects	AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS	Parkinson Disease	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Hong Kong WD Pharmaceutical Co., Limited	NULL	Recruiting	18 Years	45 Years	All	8	Phase 1	India
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT04449484 (ClinicalTrials.gov)	August 4, 2020	23/4/2019	Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: MEDI1341;Other: Placebo	AstraZeneca	NULL	Recruiting	40 Years	85 Years	All	36	Phase 1	United States
42	NCT04483479 (ClinicalTrials.gov)	July 30, 2020	20/7/2020	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)	A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period	Parkinson Disease;Constipation	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Recruiting	30 Years	90 Years	All	50	Phase 2	United States
43	NCT04275492 (ClinicalTrials.gov)	July 24, 2020	18/11/2019	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Parkinson's Disease	Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride);Drug: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)	First Affiliated Hospital of Zhejiang University	Hongguan biological pharmaceutical co.	Recruiting	18 Years	45 Years	All	60	N/A	China
44	NCT04630860 (ClinicalTrials.gov)	July 7, 2020	5/11/2020	A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD	A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Recruiting	18 Years	80 Years	All	30	Phase 1	China
45	NCT04193527 (ClinicalTrials.gov)	July 2020	2/12/2019	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients	A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls	Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)	Drug: DaTSCAN ™ Ioflupane (123I) Injection	GE Healthcare	PPD	Not yet recruiting	40 Years	80 Years	All	172	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT04428112 (ClinicalTrials.gov)	June 5, 2020	9/6/2020	Rural Dementia Caregiver Project	Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias	Depression;Stress, Psychological;Self Efficacy;Loneliness;Social Isolation;Health Care Utilization;Dementia;Dementia Alzheimers;Dementia of Alzheimer Type;Dementia, Vascular;Dementia Frontal;Dementia, Lewy Body;Dementia, Mixed;Dementia in Parkinsons Disease;Dementia, HIV;Dementia Frontotemporal;Dementia, Multi-Infarct	Behavioral: Building Better Caregivers Workshop;Behavioral: Attention Control	University of California, San Francisco	National Institute on Aging (NIA)	Recruiting	18 Years	N/A	All	640	N/A	United States
47	NCT04384666 (ClinicalTrials.gov)	June 2, 2020	8/5/2020	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch	Luye Pharma Group Ltd.	NULL	Completed	18 Years	45 Years	All	56	Phase 1	United States
48	NCT04414813 (ClinicalTrials.gov)	June 2020	21/5/2019	Stereotactic Transplantation of hAESCs for Parkinson's Disease	Clinical Study of Stereotactic Transplantation of Human Amniotic Epithelial Stem Cells (hAESCs) in the Treatment of Parkinson's Disease (PD)	Parkinson's Disease	Biological: Human Amniotic Epithelial Stem Cells	Shanghai East Hospital	Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China	Not yet recruiting	30 Years	70 Years	All	3	Early Phase 1	NULL
49	NCT04379050 (ClinicalTrials.gov)	May 19, 2020	1/5/2020	Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease	An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Enrolling by invitation	30 Years	N/A	All	121	Phase 3	United States;Australia;Belgium;Canada;Denmark;Italy;Japan;Netherlands;Spain;United Kingdom
50	NCT03568968 (ClinicalTrials.gov)	May 15, 2020	14/6/2018	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Drug: Placebo	Haukeland University Hospital	NULL	Recruiting	18 Years	N/A	All	400	N/A	Norway
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT04571164 (ClinicalTrials.gov)	May 11, 2020	21/9/2020	A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD	Parkinson Disease	Drug: LY03003(Rotigotine,extended-release microspheres);Drug: Placebo,extended-release microspheres	Luye Pharma Group Ltd.	Parexel	Recruiting	30 Years	N/A	All	294	Phase 3	China
52	NCT04265209 (ClinicalTrials.gov)	May 2020	6/2/2020	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor	Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.	Parkinson Disease;Essential Tremor	Drug: SPECT;Drug: PET	Zionexa	NULL	Not yet recruiting	35 Years	80 Years	All	112	Phase 3	NULL
53	NCT04459052 (ClinicalTrials.gov)	April 30, 2020	26/6/2020	FDOPA PET and Nutritional Support in Parkinson's Disease	Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson's Disease	Parkinson Disease;Idiopathic Parkinson Disease	Dietary Supplement: N acetyl cysteine;Drug: [F-18] Fluorodopa Positron Emission Tomography	Thomas Jefferson University	NULL	Active, not recruiting	30 Years	N/A	All	50	Phase 2	United States
54	NCT04182399 (ClinicalTrials.gov)	April 1, 2020	24/11/2019	Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study	Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study	Parkinson Disease	Drug: Zonisamide Capsules	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	90	N/A	Egypt
55	NCT02967250 (ClinicalTrials.gov)	April 1, 2020	13/9/2016	Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	Parkinson Disease	Drug: ursodeoxycholic acid	University of Minnesota	NULL	Not yet recruiting	18 Years	N/A	All	20	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	NCT04167540 (ClinicalTrials.gov)	April 1, 2020	7/11/2019	GDNF Gene Therapy for Parkinson's Disease	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease	Parkinson's Disease	Biological: AAV2-GDNF	Brain Neurotherapy Bio, Inc.	NULL	Recruiting	35 Years	75 Years	All	12	Phase 1	United States
57	NCT04342273 (ClinicalTrials.gov)	March 31, 2020	8/4/2020	A Through QT/QTc Study of KW-6356	A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults	Parkinson's Disease	Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	54 Years	All	128	Phase 1	Japan
58	NCT04269642 (ClinicalTrials.gov)	March 19, 2020	13/1/2020	SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease	Early Parkinson's Disease	Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg	Peptron, Inc.	NULL	Recruiting	40 Years	75 Years	All	99	Phase 2	Korea, Republic of
59	EUCTR2018-003941-41-AT (EUCTR)	05/03/2020	19/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
60	NCT04127695 (ClinicalTrials.gov)	March 3, 2020	9/10/2019	A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease	A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: ABBV-0805;Drug: Placebo ABBV-0805	AbbVie	NULL	Withdrawn	N/A	85 Years	All	0	Phase 1	United States;Puerto Rico
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT04353947 (ClinicalTrials.gov)	March 2, 2020	16/4/2020	Induction and Recognition of Emotions	Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease	Healthy Older Adults;Alzheimer's Disease;Parkinson's Disease	Diagnostic Test: Mini Cognitive Examination (MCE);Diagnostic Test: Beck Depression Inventory-II (BDI-II);Diagnostic Test: Global Deterioration Scale (GDS);Diagnostic Test: Memory alteration test (M@T);Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC);Diagnostic Test: Barcelona test (BT);Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT);Diagnostic Test: Frontal assessment battery (FAB);Diagnostic Test: Positive and Negative Affect Scale (PANAS);Diagnostic Test: Auto-Assessment Manikins (SAM)	University of Valencia	Asociación Parkinson Valencia	Recruiting	65 Years	99 Years	All	60		Spain
62	NCT04260581 (ClinicalTrials.gov)	March 1, 2020	5/2/2020	Is Long-term Use of Amantadine Effective in PD?	Is Long-term Use of Amantadine Effective in Parkinson Disease?	Parkinson Disease	Drug: Determination of drug effects through amantadine cessation	Seoul National University Hospital	NULL	Not yet recruiting	40 Years	N/A	All	32	N/A	Korea, Republic of
63	NCT04154072 (ClinicalTrials.gov)	February 27, 2020	4/11/2019	A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease	Parkinson Disease	Drug: NLY01;Drug: Vehicle	Neuraly, Inc.	NULL	Recruiting	30 Years	80 Years	All	240	Phase 2	United States;Canada
64	NCT04291859 (ClinicalTrials.gov)	February 26, 2020	28/2/2020	Lu AF28996 in Patients With Parkinson's Disease (PD)	Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease	Parkinson Disease	Drug: Lu AF28996	H. Lundbeck A/S	NULL	Recruiting	45 Years	75 Years	All	10	Phase 1	Netherlands
65	NCT04292223 (ClinicalTrials.gov)	February 10, 2020	28/2/2020	Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	Parkinson Disease Psychosis	Drug: Pimavanserin	ACADIA Pharmaceuticals Inc.	NULL	Recruiting	40 Years	N/A	All	53	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT04251585 (ClinicalTrials.gov)	February 4, 2020	28/1/2020	Intranasal Insulin in Parkinson's Disease	Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease	Parkinson Disease	Drug: Regular Novolin R;Drug: Placebo	HealthPartners Institute	NULL	Recruiting	41 Years	89 Years	All	30	Phase 2	United States
67	NCT04246437 (ClinicalTrials.gov)	February 4, 2020	25/1/2020	[18F]F-DOPA Imaging in Patients With Autonomic Failure	[18F]F-DOPA Imaging in Patients With Autonomic Failure	Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies	Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose	Daniel Claassen	NULL	Recruiting	18 Years	N/A	All	40	Phase 1	United States
68	NCT04117178 (ClinicalTrials.gov)	February 4, 2020	30/9/2019	Monitoring Anti-Dementia Drugs by Serum Levels	Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)	Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease	Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug	Zealand University Hospital	Epilepsihospitalet Filadelfia	Recruiting	18 Years	N/A	All	110	Phase 4	Denmark
69	EUCTR2018-003941-41-PT (EUCTR)	03/02/2020	21/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
70	NCT04428983 (ClinicalTrials.gov)	February 3, 2020	20/11/2019	The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease	The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease	Parkinson Disease	Dietary Supplement: Hericium erinaceus mycelium	National Cheng-Kung University Hospital	NULL	Recruiting	50 Years	79 Years	All	80	N/A	Taiwan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	NCT04322227 (ClinicalTrials.gov)	January 23, 2020	29/1/2020	Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects	Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects	Parkinson Disease;Healthy	Drug: Foliglurax 10 mg (treatment A);Drug: Foliglurax 30 mg (treatment B);Drug: Placebo (treatment C)	H. Lundbeck A/S	NULL	Terminated	50 Years	70 Years	All	6	Phase 1	France
72	NCT04305002 (ClinicalTrials.gov)	January 21, 2020	20/2/2020	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on Disease Progression in Early Parkinson's Disease	Parkinson Disease	Drug: Exenatide;Drug: Placebo	Center for Neurology, Stockholm	Karolinska Institutet	Recruiting	25 Years	80 Years	All	60	Phase 2	Sweden
73	NCT04220762 (ClinicalTrials.gov)	January 21, 2020	17/12/2019	A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients	A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study	Parkinson Disease	Drug: WIN-1001X;Drug: Placebo	Medi Help Line	NULL	Recruiting	30 Years	N/A	All	188	Phase 2	Korea, Republic of
74	NCT04232969 (ClinicalTrials.gov)	January 20, 2020	10/1/2020	Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	Parkinson's Disease	Drug: Exenatide extended release 2mg (Bydureon)	University College, London	NULL	Recruiting	25 Years	80 Years	All	200	Phase 3	United Kingdom
75	NCT04369430 (ClinicalTrials.gov)	January 16, 2020	13/4/2020	Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	Parkinson Disease	Drug: AKST4290;Drug: Placebo	Alkahest, Inc.	NULL	Recruiting	50 Years	80 Years	All	120	Phase 2	United States;Estonia;Germany;Poland;Slovakia;Hungary
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	EUCTR2019-001657-42-SK (EUCTR)	14/01/2020	01/10/2019	A study to learn how well the drug AKST4290 works and how safeAKST4290 is in people who have Parkinson's disease that are takingdopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEfficacy and Safety of AKST4290 in Subjects with Parkinson's Disease onStable Dopaminergic Treatment. - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	United States;Hungary;Estonia;Slovakia;Poland;Germany
77	NCT04295642 (ClinicalTrials.gov)	January 8, 2020	24/1/2020	A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease	A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: CVL-751	Cerevel Therapeutics, LLC	NULL	Recruiting	45 Years	75 Years	All	33	Phase 1	United States
78	NCT04223193 (ClinicalTrials.gov)	January 6, 2020	7/1/2020	Flexible-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	296	Phase 3	United States
79	NCT04127578 (ClinicalTrials.gov)	January 3, 2020	14/10/2019	Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation	Parkinson Disease	Biological: PR001A;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone	Prevail Therapeutics	NULL	Recruiting	35 Years	80 Years	All	12	Phase 1;Phase 2	United States
80	NCT04226248 (ClinicalTrials.gov)	January 2, 2020	5/12/2019	CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)	CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.	Parkinson Disease	Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System	University of Bristol	Royal United Hospitals Bath NHS Foundation Trust	Recruiting	18 Years	N/A	All	600	Phase 3	United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	NCT03808961 (ClinicalTrials.gov)	January 1, 2020	16/1/2019	Niacin for Parkinsons Disease	NAPS: Niacin for Parkinsons Disease	Parkinson's Disease	Dietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: Placebo	VA Office of Research and Development	NULL	Recruiting	35 Years	N/A	All	100	N/A	United States
82	NCT04301492 (ClinicalTrials.gov)	January 1, 2020	17/2/2020	Tolerability, Safety and Efficacy of Vortioxetine	Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study	Depression	Drug: Vortioxetine	IRCCS San Raffaele	NULL	Recruiting	30 Years	80 Years	All	20	Phase 4	Italy
83	NCT04152655 (ClinicalTrials.gov)	January 1, 2020	7/10/2019	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease	A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Idebenone;Drug: Placebo oral tablet	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	18 Years	N/A	All	180	Phase 2;Phase 3	China
84	NCT03446807 (ClinicalTrials.gov)	January 2020	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
85	NCT04218968 (ClinicalTrials.gov)	December 30, 2019	26/12/2019	Cardiac Changes in Early Parkinson's Disease: A Follow up Study	The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study	REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease	Drug: Carvedilol	Cedars-Sinai Medical Center	NULL	Enrolling by invitation	18 Years	85 Years	All	15	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	NCT03815916 (ClinicalTrials.gov)	December 19, 2019	18/1/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease	A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease	Parkinson's Disease	Drug: Gold Nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Recruiting	30 Years	80 Years	All	30	Phase 2	United States
87	NCT04164121 (ClinicalTrials.gov)	December 17, 2019	12/11/2019	A Clinical Study Trial of Phenlarmide in China	A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers	Parkinson Disease	Drug: Phenlarmide Tablets;Drug: Placebos	Yiling Pharmaceutical Inc.	NULL	Recruiting	18 Years	65 Years	All	36	Phase 1	China
88	NCT04097080 (ClinicalTrials.gov)	December 15, 2019	18/9/2019	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	Parkinson Disease	Drug: NBTX-001;Drug: Standard of Care	Nobilis Therapeutics Inc.	NULL	Recruiting	18 Years	N/A	All	60	Phase 1	Russian Federation
89	NCT04201093 (ClinicalTrials.gov)	December 13, 2019	13/12/2019	Fixed-Dose Trial in Early Parkinson's Disease (PD)	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)	Parkinson Disease	Drug: Tavapadon;Drug: Placebo	Cerevel Therapeutics, LLC	NULL	Recruiting	40 Years	80 Years	All	522	Phase 3	United States;Australia
90	NCT04183634 (ClinicalTrials.gov)	December 3, 2019	28/11/2019	An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.	An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.	Parkinson Disease	Drug: Rotigotine TTS (Test);Drug: Neupro (Reference)	Sandoz	NULL	Terminated	18 Years	80 Years	All	31	Phase 1	Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	NCT04249544 (ClinicalTrials.gov)	December 3, 2019	28/1/2020	Social Decision Making in Parkinson's Disease	Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists	Parkinson Disease	Drug: Pramipexole;Drug: Placebo	Vanderbilt University Medical Center	United States Department of Defense	Recruiting	45 Years	80 Years	All	60	Phase 1	United States
92	NCT04191577 (ClinicalTrials.gov)	December 2, 2019	30/10/2019	Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations	Parkinson Disease	Drug: CVN424 Low Dose;Drug: CVN424 High Dose;Drug: Placebo	Cerevance Beta, Inc.	NULL	Recruiting	30 Years	80 Years	All	66	Phase 2	United States
93	NCT04044131 (ClinicalTrials.gov)	December 1, 2019	17/7/2019	Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients	Alzheimer Disease;Parkinson Disease	Drug: Metabolic Cofactor Supplementation;Drug: Sorbitol	Istanbul Medipol University Hospital	ScandiBio Therapeutics AB;Alanya Alaaddin Keykubat University;Sahlgrenska University Hospital, Sweden;KTH Royal Institute of Technology	Recruiting	18 Years	N/A	All	120	Phase 2	Turkey
94	NCT03436953 (ClinicalTrials.gov)	December 2019	7/2/2018	A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease	Parkinson's Disease;Tremor	Drug: CX-8998;Drug: Placebo	Jazz Pharmaceuticals	NULL	Not yet recruiting	40 Years	80 Years	All	60	Phase 2	United States
95	NCT03924414 (ClinicalTrials.gov)	November 15, 2019	2/4/2019	Trial of Parkinson's And Zoledronic Acid	TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease	Parkinson Disease;Osteoporosis;Parkinsonism	Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo	California Pacific Medical Center Research Institute	National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation	Recruiting	60 Years	N/A	All	3500	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT04148391 (ClinicalTrials.gov)	November 14, 2019	30/10/2019	A Study to Evaluate NYX-458 in Subjects With PD-MCI	A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease	Parkinson's Disease;Mild Cognitive Impairment	Drug: Placebo Oral Capsule;Drug: NYX-458	Aptinyx	CogState Ltd.;Worldwide Clinical Trials	Active, not recruiting	50 Years	80 Years	All	135	Phase 2	United States
97	NCT04175132 (ClinicalTrials.gov)	November 12, 2019	12/11/2019	Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)	Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: foliglurax	H. Lundbeck A/S	NULL	Terminated	50 Years	70 Years	All	6	Phase 1	Sweden
98	NCT03652870 (ClinicalTrials.gov)	November 1, 2019	8/8/2018	Antidepressants Trial in Parkinson's Disease	A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease	Depression;Parkinson Disease	Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo	University College, London	London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian	Not yet recruiting	18 Years	85 Years	All	408	Phase 3	NULL
99	EUCTR2018-003941-41-DK (EUCTR)	29/10/2019	24/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Denmark;Australia;Bulgaria;Germany;New Zealand
100	NCT04164758 (ClinicalTrials.gov)	October 23, 2019	13/11/2019	Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine	Parkinson's Disease	Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine	ACADIA Pharmaceuticals Inc.	NULL	Terminated	50 Years	85 Years	All	11	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	EUCTR2019-001657-42-DE (EUCTR)	22/10/2019	11/06/2019	A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment - N/A	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE	Alkahest, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	United States;Estonia;Hungary;Slovakia;Poland;Germany
102	ChiCTR1900026956	2019-10-21	2019-10-27	Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease	Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease	Parkinson’s disease	Parkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;	The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China	NULL	Pending	40	64	Both	Parkinson’s disease group:30;Non-Parkinson’s disease group:30;	N/A	China
103	NCT04273932 (ClinicalTrials.gov)	October 17, 2019	31/10/2019	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	Parkinson Disease	Drug: Lithium	University at Buffalo	NULL	Recruiting	45 Years	80 Years	All	20	Phase 1	United States
104	NCT04157933 (ClinicalTrials.gov)	October 16, 2019	1/11/2019	Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease	A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease	Parkinson's Disease	Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover	Alexza Pharmaceuticals, Inc.	NULL	Completed	30 Years	85 Years	All	35	Phase 1	Netherlands
105	NCT04165837 (ClinicalTrials.gov)	October 14, 2019	13/11/2019	Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	Parkinson's Disease	Drug: FB-101;Drug: Placebo	1ST Biotherapeutics, Inc.	NULL	Recruiting	19 Years	55 Years	All	48	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT04146454 (ClinicalTrials.gov)	October 14, 2019	16/10/2019	Smartphone-based Wearable Telerehabilitation	A New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's Disease	Parkinson Disease	Other: Smartphone-based balance exercises	University of Houston	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Enrolling by invitation	50 Years	75 Years	All	44	N/A	United States
107	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Recruiting	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
108	NCT04575259 (ClinicalTrials.gov)	October 10, 2019	29/9/2020	OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001	Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001	Parkinson Disease Dementia	Drug: ANAVEX2-73	Anavex Life Sciences Corp.	Anavex Australia Pty Ltd.;Anavex Germany GmbH	Recruiting	50 Years	85 Years	All	120	Phase 2	Australia;Spain
109	EUCTR2018-003941-41-BG (EUCTR)	10/10/2019	26/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
110	NCT03987750 (ClinicalTrials.gov)	October 2019	12/6/2019	Safinamide for Levodopa-induced Dyskinesia (PD-LID)	A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations	Dyskinesia, Drug-Induced;Parkinson Disease	Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo	Zambon SpA	NULL	Withdrawn	30 Years	N/A	All	0	Phase 3	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	NCT03905811 (ClinicalTrials.gov)	September 24, 2019	1/4/2019	Terazosin for Parkinson's Disease	A Pilot Study of Terazosin for Parkinson's Disease	Parkinson Disease	Drug: Terazosin 5 MG;Drug: Placebo oral capsule	Jordan Schultz	University of Iowa	Enrolling by invitation	40 Years	90 Years	All	20	Phase 1;Phase 2	United States
112	NCT04477161 (ClinicalTrials.gov)	September 5, 2019	22/6/2020	Effect of Ketone Esters in Parkinson's Disease	Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.	Parkinson Disease;Ketosis	Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink;Other: Stool Sample	University of Florida	NULL	Recruiting	40 Years	75 Years	All	15	N/A	United States
113	NCT04054960 (ClinicalTrials.gov)	September 2019	9/8/2019	A Trial of tPCS on Parkinson's Disease OFF State	A Trial of tPCS on Parkinson's Disease OFF State	Parkinson Disease	Device: Active tPCS;Device: Sham tPCS;Drug: Levodopa tablet	Western University, Canada	NULL	Not yet recruiting	40 Years	80 Years	All	15	N/A	Canada
114	NCT03959540 (ClinicalTrials.gov)	September 2019	23/4/2019	Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care	Bial - Portela C S.A.	NULL	Not yet recruiting	75 Years	N/A	All	100		NULL
115	NCT04075318 (ClinicalTrials.gov)	August 29, 2019	5/8/2019	Study of UB-312 in Healthy Participants and Parkinson's Disease Patients	A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease	Parkinson Disease;Parkinsonism	Biological: UB-312;Biological: Placebo	United Neuroscience Ltd.	Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials	Active, not recruiting	40 Years	85 Years	All	62	Phase 1	Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT04006210 (ClinicalTrials.gov)	August 27, 2019	30/6/2019	A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).	A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)	Parkinson's Disease	Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg	NeuroDerm Ltd.	NULL	Recruiting	30 Years	80 Years	All	380	Phase 3	United States;Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom
117	EUCTR2018-003941-41-PL (EUCTR)	23/08/2019	03/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
118	NCT04062526 (ClinicalTrials.gov)	August 14, 2019	14/8/2019	Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT	Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)	Parkinson Disease;Healthy Volunteer	Drug: [18F]NOS	University of Pennsylvania	NULL	Recruiting	18 Years	75 Years	All	30	Early Phase 1	United States
119	EUCTR2018-003941-41-ES (EUCTR)	13/08/2019	11/06/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
120	NCT03976349 (ClinicalTrials.gov)	August 12, 2019	4/6/2019	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease	A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease	Parkinson's Disease	Drug: BIIB094;Drug: Placebo	Biogen	Ionis Pharmaceuticals, Inc.	Recruiting	35 Years	80 Years	All	82	Phase 1	United States;Canada;Israel;Norway;Spain;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	NCT04043338 (ClinicalTrials.gov)	August 11, 2019	24/7/2019	Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects	Parkinson's Disease	Drug: XC130-A10H;Drug: Placebo	Xoc Pharmaceuticals	Celerion	Recruiting	18 Years	75 Years	All	40	Phase 1	United States
122	EUCTR2018-003941-41-GB (EUCTR)	09/08/2019	16/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855	Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand
123	NCT03881371 (ClinicalTrials.gov)	August 1, 2019	18/3/2019	A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa	Parkinson Disease	Drug: Safinamide;Other: Placebo	Zambon SpA	NULL	Recruiting	18 Years	N/A	All	306	Phase 3	China
124	JPRN-UMIN000037421	2019/08/01	01/08/2019	A study on improvement of cognitive function by istradefylline for parkinson disease	An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - A study on improvement of cognitive function by istradefylline for parkinson disease	Parkinson disease	Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months. The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.	Ichinomiya Nishi Hospital	NULL	Recruiting	40years-old	85years-old	Male and Female	25	Not selected	Japan
125	EUCTR2018-003941-41-HU (EUCTR)	30/07/2019	01/08/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT04056689 (ClinicalTrials.gov)	July 23, 2019	12/8/2019	Study to Evaluate DNL151 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DNL151;Drug: Placebo	Denali Therapeutics Inc.	NULL	Active, not recruiting	30 Years	75 Years	All	34	Phase 1	United States;Belgium;Netherlands;United Kingdom
127	NCT03956979 (ClinicalTrials.gov)	July 22, 2019	17/5/2019	A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiA	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010	Dyskinesias	Drug: JM -010 group A;Drug: JM -010 group B;Drug: Placebos	Contera Pharma	Bukwang Pharmaceutical	Recruiting	18 Years	80 Years	All	81	Phase 2	Germany
128	NCT03575195 (ClinicalTrials.gov)	July 15, 2019	21/6/2018	Microbiota Intervention to Change the Response of Parkinson's Disease	Microbiota Intervention to Change the Response of Parkinson's Disease	Parkinson Disease	Drug: Rifaximin;Other: Placebo	University of California, San Francisco	Nova Southeastern University;Gateway Institute for Brain Research	Recruiting	30 Years	N/A	All	86	Phase 1;Phase 2	United States
129	EUCTR2018-003941-41-EE (EUCTR)	04/07/2019	29/05/2019	This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)	A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood	Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Theravance Biopharma Ireland Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	258	Phase 3	United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand
130	NCT03977441 (ClinicalTrials.gov)	July 2019	12/5/2019	the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease	A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease	Parkinson Disease;Depression;Sleep Disorders;Circadian Rhythm Disorders	Drug: Agomelatine or PIacebo	Second Affiliated Hospital of Soochow University	NULL	Not yet recruiting	30 Years	75 Years	All	240	Phase 4	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03938922 (ClinicalTrials.gov)	June 13, 2019	18/4/2019	A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia	A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.	Parkinson Disease;Dementia	Drug: Active Investigational Treatment ENT-01	Enterin Inc.	NULL	Active, not recruiting	30 Years	90 Years	All	40	Phase 1	United States
132	NCT03939559 (ClinicalTrials.gov)	June 10, 2019	3/5/2019	The Efficiency of Home Based Dual Task Training in Parkinson Disease	The Efficiency of Home Based Dual Task Training in Parkinson Disease	Parkinson Disease	Procedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual task	Istanbul University-Cerrahpasa	NULL	Not yet recruiting	30 Years	80 Years	All	60	N/A	NULL
133	NCT04389762 (ClinicalTrials.gov)	June 4, 2019	30/4/2020	PS128 May Improve Off Duration on Parkinson's Disease	Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	60	N/A	Taiwan
134	NCT04064294 (ClinicalTrials.gov)	June 1, 2019	19/8/2019	Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors	Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins	Parkinson Disease;Dyskinesia, Drug-Induced	Drug: Intravenous Infusion	VA Office of Research and Development	Oregon Health and Science University	Recruiting	50 Years	N/A	All	120		United States
135	JPRN-UMIN000036908	2019/05/31	31/05/2019	A dementia study by 11C-PiB, 18F-FDG PET	A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET	mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.	11C-PiB, 18F-FDG PET	Nagoya City Rehabilitation Agency	NULL	Recruiting	20years-old	Not applicable	Male and Female	150	Not applicable	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03971617 (ClinicalTrials.gov)	May 29, 2019	30/5/2019	Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease	Parkinson Disease	Drug: Hydrogen;Drug: Placebo oral tablet	Stony Brook University	NULL	Recruiting	40 Years	80 Years	All	70	Phase 2;Phase 3	United States
137	NCT03671785 (ClinicalTrials.gov)	May 15, 2019	12/9/2018	Study of the Fecal Microbiome in Patients With Parkinson's Disease	A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease	Parkinson Disease	Drug: PRIM-DJ2727;Drug: Placebo oral capsule	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Recruiting	55 Years	75 Years	All	12	Phase 1	United States
138	NCT03693872 (ClinicalTrials.gov)	May 15, 2019	1/10/2018	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals	Parkinson Disease	Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine	Rennes University Hospital	NULL	Recruiting	18 Years	N/A	All	42	N/A	France
139	NCT03552068 (ClinicalTrials.gov)	May 15, 2019	17/5/2018	Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:	Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial	Parkinson's Disease;Mpulse Control Disorders	Drug: placebo;Drug: Clonidine	Hospices Civils de Lyon	NULL	Recruiting	30 Years	80 Years	All	38	Phase 2	France
140	NCT04293159 (ClinicalTrials.gov)	May 14, 2019	19/2/2020	Effect of Probiotic on Constipation in Patients With Parkinson's Disease	Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease	Parkinson Disease;Constipation	Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)	University of Salerno	Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci	Recruiting	18 Years	75 Years	All	30	N/A	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	NCT03958708 (ClinicalTrials.gov)	May 13, 2019	14/5/2019	Modulation of Gut Microbiota by Rifaximin in PD Patients	Modulation of Gut Microbiota by Rifaximin in PD Patients	Parkinson Disease;Inflammation	Drug: Rifaximin 550 MG	Taipei Medical University Shuang Ho Hospital	NULL	Recruiting	45 Years	70 Years	All	20	Phase 1;Phase 2	Taiwan
142	NCT03970239 (ClinicalTrials.gov)	May 13, 2019	6/5/2019	Serotonin in Impulse Control Disorders in Parkinson's Disease	Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease	Parkinson Disease;Impulse Control Disorders	Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)	Hospices Civils de Lyon	NULL	Recruiting	30 Years	80 Years	All	45	N/A	France
143	NCT04566341 (ClinicalTrials.gov)	May 4, 2019	11/8/2020	Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease	Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease	Parkinson Disease;Parkinson	Device: OCT - TCE	Massachusetts General Hospital	NULL	Recruiting	40 Years	85 Years	All	20		United States
144	NCT03840837 (ClinicalTrials.gov)	May 2, 2019	11/2/2019	Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease	Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease	Parkinson Disease	Drug: Rivastigmine transdermal patch	University of Maryland, Baltimore	National Institute on Aging (NIA)	Recruiting	18 Years	N/A	All	100	Phase 4	United States
145	NCT03781167 (ClinicalTrials.gov)	April 29, 2019	18/12/2018	A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)	A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Recruiting	30 Years	N/A	All	130	Phase 3	United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03899324 (ClinicalTrials.gov)	April 26, 2019	29/3/2019	Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease	A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease	Parkinson Disease	Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet	B&A Therapeutics	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	France
147	NCT04420910 (ClinicalTrials.gov)	April 15, 2019	4/6/2020	Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease	Investigation of Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease	Parkinson Disease;Balance;Muscle Strength;Mobility;Non-motor Symptoms	Other: Non-Motor Symptoms;Other: Balance;Other: Lower Limb Strength;Other: Functional mobility	Ankara Yildirim Beyazit University	NULL	Completed	50 Years	65 Years	All	44		Turkey
148	NCT03661125 (ClinicalTrials.gov)	April 11, 2019	4/9/2018	SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.	Parkinson Disease Psychosis	Drug: Saracatinib;Drug: Placebo Oral Tablet	King's College London	AstraZeneca;King's College Hospital NHS Trust	Recruiting	40 Years	N/A	All	30	Early Phase 1	United Kingdom
149	NCT03841604 (ClinicalTrials.gov)	April 9, 2019	30/1/2019	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain	Idiopathic Parkinson Disease	Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo	Zambon SpA	NULL	Recruiting	30 Years	N/A	All	177	Phase 4	Austria;France;Germany;Italy;Spain
150	NCT03775096 (ClinicalTrials.gov)	April 4, 2019	9/12/2018	Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease	The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease	REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease	Drug: Carvedilol	Michele Tagliati, MD	NULL	Recruiting	30 Years	75 Years	All	15	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03877510 (ClinicalTrials.gov)	April 3, 2019	12/3/2019	Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations	An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations	Parkinson Disease	Drug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mg	Impax Laboratories, LLC	NULL	Enrolling by invitation	40 Years	N/A	All	300	Phase 3	United States;Czechia;France;Germany;Italy;Spain;United Kingdom
152	NCT03858270 (ClinicalTrials.gov)	April 1, 2019	2/10/2018	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine	Parkinson Disease	Drug: Memantine;Other: Placebo	Wayne State University	NULL	Recruiting	45 Years	85 Years	All	50	Phase 3	United States
153	JPRN-jRCTs051180214	29/03/2019	27/03/2019	The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease	The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease	Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy	Amyloid PET: Given the flutemetamol (3mL) intravenously FDG-PET:Given the FDG scanR (3mL) intravenously	Itoh Yoshiaki	NULL	Recruiting	Ages 20 and over	N/A	Both	100	N/A	Japan
154	NCT03922711 (ClinicalTrials.gov)	March 26, 2019	17/4/2019	A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease	A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)	Parkinson Disease	Drug: Pridopidine;Drug: Placebo	Prilenia	NULL	Terminated	30 Years	85 Years	All	23	Phase 2	United States
155	NCT04064983 (ClinicalTrials.gov)	March 14, 2019	19/8/2019	Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease	Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease	Parkinson Disease	Drug: HB-adMSCs	Hope Biosciences	NULL	No longer available	18 Years	N/A	All			United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03716570 (ClinicalTrials.gov)	March 12, 2019	22/10/2018	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease	A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease	Parkinson's Disease	Drug: BIIB054;Drug: Placebo	Biogen	NULL	Active, not recruiting	40 Years	80 Years	All	24	Phase 1	Japan
157	NCT03816020 (ClinicalTrials.gov)	March 9, 2019	7/12/2018	NAD-supplementation in Drug naïve Parkinson's Disease	NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Completed	18 Years	N/A	All	30	N/A	Norway
158	NCT03887884 (ClinicalTrials.gov)	March 5, 2019	1/3/2019	Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)	Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease	Parkinson's Disease	Drug: CVT-301;Drug: Sinemet	Acorda Therapeutics	NULL	Completed	30 Years	85 Years	All	23	Phase 1	United States
159	NCT03865121 (ClinicalTrials.gov)	March 4, 2019	26/2/2019	Pilot Trial of Transnasal Nicotine in Parkinson Disease	Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease	Parkinson Disease	Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)	El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez	Howard University	Completed	60 Years	N/A	All	6	Phase 2	Mexico
160	NCT03820037 (ClinicalTrials.gov)	March 2019	25/1/2019	Relative Bioavailability and Bioequivalence of Opicapone	A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects	Parkinson Disease	Drug: Ongentys;Drug: BIA 9-1067 (test)	Bial - Portela C S.A.	NULL	Not yet recruiting	18 Years	55 Years	All	45	Phase 1	United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT03845387 (ClinicalTrials.gov)	February 26, 2019	15/2/2019	A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: KDT-3594;Drug: Pramipexole	Kissei Pharmaceutical Co., Ltd.	NULL	Active, not recruiting	20 Years	79 Years	All	100	Phase 2	Japan
162	NCT03655236 (ClinicalTrials.gov)	February 18, 2019	18/8/2018	PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease	Early Parkinson Disease	Drug: K0706;Other: placebo	Sun Pharma Advanced Research Company Limited	NULL	Recruiting	50 Years	N/A	All	504	Phase 2	United States;Hungary;Poland;Slovakia;Spain
163	NCT03968744 (ClinicalTrials.gov)	February 18, 2019	19/4/2019	Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease	A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study	Idiopathic Parkinson's Disease (at Later Stage)	Drug: Safinamide	Alain Kaelin	Clinical Trial Unit Ente Ospedaliero Cantonale	Recruiting	18 Years	N/A	All	23	Phase 4	Switzerland
164	NCT03413384 (ClinicalTrials.gov)	February 15, 2019	8/1/2018	To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	Parkinson's Disease Dementia	Drug: Ceftriaxone;Other: Placebo	BrainX Corporation	NULL	Recruiting	50 Years	80 Years	All	106	Phase 2	Taiwan
165	NCT04510922 (ClinicalTrials.gov)	February 11, 2019	9/7/2020	Lundbeck TOMs Orthostatic Hypotension	Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study	Orthostatic Hypotension;Idiopathic Parkinson Disease	Drug: Droxidopa 100 MG [Northera]	Alberto Espay, MD, MSc	Lundbeck LLC	Recruiting	30 Years	80 Years	All	12	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03815071 (ClinicalTrials.gov)	February 1, 2019	21/1/2019	A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells	Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease	Parkinson Disease	Drug: Ips-nsc cells	Allife Medical Science and Technology Co., Ltd.	The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial People's Hospital;Beijing Hospital	Not yet recruiting	18 Years	60 Years	All	10	Early Phase 1	NULL
167	NCT03790670 (ClinicalTrials.gov)	January 30, 2019	18/12/2018	Biomarker Assessments of Leukine During Treatment of Parkinson's Disease	Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study	Parkinson Disease	Drug: sargramostim	University of Nebraska	NULL	Recruiting	35 Years	85 Years	All	10	Phase 1	United States
168	NCT03826134 (ClinicalTrials.gov)	January 17, 2019	30/1/2019	A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects	Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects	Parkinson Disease	Drug: [11C]PXT012253	H. Lundbeck A/S	NULL	Completed	20 Years	50 Years	All	7	Early Phase 1	Sweden
169	NCT04620863 (ClinicalTrials.gov)	January 15, 2019	26/10/2020	TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE	TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL	Parkinson Disease;Pisa Syndrome	Other: t-DCS group;Other: Sham group	IRCCS National Neurological Institute C. Mondino Foundation	NULL	Completed	18 Years	80 Years	All	30	N/A	Italy
170	NCT03638479 (ClinicalTrials.gov)	January 8, 2019	13/8/2018	Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders	Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders	Parkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical Parkinsonism	Other: Data Capture	Westfälische Wilhelms-Universität Münster	NULL	Recruiting	18 Years	N/A	All	500		Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	NCT03659682 (ClinicalTrials.gov)	January 2, 2019	3/9/2018	GLP1R in Parkinson's Disease	Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease	Parkinson Disease	Drug: Semaglutide	Oslo University Hospital	NULL	Not yet recruiting	40 Years	75 Years	All	120	Phase 2	NULL
172	NCT03727295 (ClinicalTrials.gov)	January 1, 2019	30/10/2018	Idebenone Treatment of Early Parkinson's Diseasesymptoms	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms	Oxidative Stress is an Important Cause of Parkinson's Disease	Drug: Idebenone/placebo	Second Affiliated Hospital of Soochow University	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	30 Years	80 Years	All	180	Phase 4	NULL
173	NCT03391882 (ClinicalTrials.gov)	December 19, 2018	2/1/2018	A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations	Motor OFF Episodes Associated With Parkinson's Disease	Drug: APL-130277;Drug: subcutaneous apomorphine	Sunovion	NULL	Recruiting	18 Years	N/A	All	106	Phase 3	Austria;France;Germany;Italy;Spain;United Kingdom
174	NCT03840005 (ClinicalTrials.gov)	December 18, 2018	11/2/2019	Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)	Parkinson's Disease	Drug: Ursonorm	Sheffield Teaching Hospitals NHS Foundation Trust	JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of Sheffield	Active, not recruiting	18 Years	75 Years	All	30	Phase 2	United Kingdom
175	NCT03781791 (ClinicalTrials.gov)	December 10, 2018	27/11/2018	Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)	Constipation;Parkinson Disease	Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment	Enterin Inc.	NULL	Active, not recruiting	30 Years	90 Years	All	152	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	NCT03710707 (ClinicalTrials.gov)	December 4, 2018	15/10/2018	Study to Evaluate DNL201 in Subjects With Parkinson's Disease	A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: DNL201;Drug: Placebo	Denali Therapeutics Inc.	NULL	Completed	30 Years	80 Years	All	29	Phase 1	United States
177	NCT03944447 (ClinicalTrials.gov)	December 1, 2018	3/5/2019	Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19	Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus	Drug: Cannabis , Medical	OMNI Medical Services, LLC	OMNI Medical Services Inc	Recruiting	7 Years	N/A	All	200000	Phase 2	United States
178	NCT03639064 (ClinicalTrials.gov)	December 2018	4/7/2018	Cannabis Oil for Pain in Parkinson's Disease	A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease	Parkinson Disease	Drug: Cannabis Oil	University Health Network, Toronto	Parkinson Society Canada	Unknown status	18 Years	N/A	All	15	Phase 2	NULL
179	NCT03942172 (ClinicalTrials.gov)	November 27, 2018	6/5/2019	Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses	Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses	Parkinson Disease	Device: SpotOn balance glasses	SpotOn Therapeutics Ltd.	NULL	Suspended	30 Years	N/A	All	50	N/A	Israel
180	NCT03822364 (ClinicalTrials.gov)	November 26, 2018	18/12/2018	Staccato Apomorphine Single and Multi Dose PK	A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5	Alexza Pharmaceuticals, Inc.	NULL	Completed	18 Years	60 Years	All	56	Phase 1	Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03823638 (ClinicalTrials.gov)	November 20, 2018	20/11/2018	Safety, Tolerability and Effects of Mannitol in Parkinson's Disease	A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease	Parkinson Disease	Dietary Supplement: Oral D-Mannitol of Placebo	Hadassah Medical Organization	NULL	Recruiting	40 Years	75 Years	All	60	Phase 2	Israel
182	NCT03713957 (ClinicalTrials.gov)	November 12, 2018	18/10/2018	A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	Parkinson Disease	Drug: GRF6021;Other: Placebo	Alkahest, Inc.	Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	85 Years	All	79	Phase 2	United States;Australia;France
183	NCT03733561 (ClinicalTrials.gov)	November 9, 2018	6/11/2018	A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers	Parkinson Disease	Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch	Luye Pharma Group Ltd.	NULL	Recruiting	18 Years	45 Years	All	40	Phase 1	United States
184	NCT03667404 (ClinicalTrials.gov)	November 6, 2018	10/9/2018	Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study	Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study	Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification	Dietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrin	Northwestern University	University of Illinois at Chicago	Recruiting	60 Years	N/A	All	30	Phase 2	United States
185	NCT03670953 (ClinicalTrials.gov)	November 6, 2018	12/9/2018	A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations	A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease (Disorder)	Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo	Impax Laboratories, LLC	NULL	Recruiting	40 Years	N/A	All	510	Phase 3	United States;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT04629404 (ClinicalTrials.gov)	November 5, 2018	5/11/2020	A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: LY03003;Drug: Placebo	Luye Pharma Group Ltd.	NULL	Completed	30 Years	N/A	All	32	Phase 1	China
187	NCT03069911 (ClinicalTrials.gov)	November 1, 2018	28/2/2017	Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Parkinson Disease;Depression	Biological: OnabotulinumtoxinA;Biological: Control	Johns Hopkins University	NULL	Terminated	18 Years	95 Years	All	3	Phase 1	United States
188	NCT03727139 (ClinicalTrials.gov)	November 1, 2018	30/10/2018	Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety	AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety	Parkinson's Disease	Drug: Rasagiline	Takeda	NULL	Active, not recruiting	N/A	N/A	All	1021		Japan
189	NCT03720418 (ClinicalTrials.gov)	October 17, 2018	16/10/2018	Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease	A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease	Parkinson Disease	Drug: OXB-102;Other: Imitation Surgical Procedure (ISP)	Axovant Sciences Ltd.	Oxford BioMedica	Recruiting	30 Years	70 Years	All	30	Phase 1;Phase 2	France;United Kingdom
190	NCT04048291 (ClinicalTrials.gov)	October 15, 2018	9/10/2018	Efficacy of Brisk Walking in Parkinson's Disease	Efficacy of Brisk Walking on Improving Balance and Gait Performance, and Functional Mobility in Parkinson's Disease - a Randomized Controlled Trial	Parkinson Disease	Behavioral: Brisk walking and balance training;Behavioral: Upper limb exercise	The Hong Kong Polytechnic University	NULL	Completed	30 Years	N/A	All	80	N/A	Hong Kong
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	NCT04451096 (ClinicalTrials.gov)	October 6, 2018	19/6/2020	Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation	Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study	Parkinson Disease;Constipation	Dietary Supplement: Probiotics with prebiotic;Dietary Supplement: Placebo	National University of Malaysia	NULL	Completed	18 Years	N/A	All	48	Phase 3	Malaysia
192	NCT03703570 (ClinicalTrials.gov)	September 29, 2018	5/10/2018	A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations	A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations	Parkinson's Disease	Drug: KW-6356;Drug: Placebo	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	80 Years	All	502	Phase 2	Japan
193	NCT03665454 (ClinicalTrials.gov)	September 24, 2018	1/8/2018	PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease	Parkinson Disease	Drug: PF-06412562;Drug: Standard of Care Placebo	Milton S. Hershey Medical Center	Pfizer	Completed	N/A	N/A	All	8	Phase 1	United States
194	NCT03582137 (ClinicalTrials.gov)	September 17, 2018	17/4/2018	A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease	Parkinson Disease	Drug: Cannabidiol;Other: Placebo	University of Colorado, Denver	Colorado Department of Public Health and Environment	Recruiting	40 Years	85 Years	All	75	Phase 2	United States
195	NCT04202757 (ClinicalTrials.gov)	September 14, 2018	21/9/2018	Intravenous Plasma Treatment for Parkinson's Disease	Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled Study	Idiopathic Parkinson Disease	Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors;Other: Saline	The Neurology Center	Carolina Longevity Institute	Completed	45 Years	90 Years	All	18	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	NCT03648905 (ClinicalTrials.gov)	September 6, 2018	24/8/2018	Clinical Laboratory Evaluation of Chronic Autonomic Failure	Clinical Laboratory Evaluation of Chronic Autonomic Failure	Parkinson's Disease;Multiple System Atrophy;Autonomic Failure	Drug: 18F-Dopa;Drug: 11C-methylreboxetine;Drug: 13N-Ammonia;Drug: 18F-Dopamne;Drug: Desipramine (DMI)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	140	Phase 1	United States
197	NCT03608371 (ClinicalTrials.gov)	August 31, 2018	9/5/2018	BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations	Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations	Parkinson Disease;Motor Disorder	Drug: BTRX-246040;Drug: Placebo	BlackThorn Therapeutics, Inc.	NULL	Completed	30 Years	76 Years	All	24	Phase 2	United States
198	NCT03229174 (ClinicalTrials.gov)	August 23, 2018	21/4/2017	Brain Perfusion & Oxygenation in Parkinson's Disease With NOH	Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo	Parkinson Disease;Neurogenic Orthostatic Hypotension	Drug: Droxidopa;Drug: Placebo	William Ondo, MD	Lundbeck LLC	Recruiting	18 Years	85 Years	All	28	Phase 4	United States
199	NCT03621046 (ClinicalTrials.gov)	August 20, 2018	6/6/2018	Use of Low-dose Zolpidem in Parkinson's Disease	A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's	Parkinson Disease	Drug: Zolpidem;Other: Placebo	Aston University	University Hospital Birmingham NHS Foundation Trust	Completed	40 Years	80 Years	All	28	Phase 2	United Kingdom
200	NCT03567447 (ClinicalTrials.gov)	August 17, 2018	21/5/2018	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Parkinson Disease;Falls Patient	Drug: Droxidopa;Other: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	H. Lundbeck A/S;Arizona State University	Recruiting	30 Years	83 Years	All	10	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	NCT03675282 (ClinicalTrials.gov)	August 14, 2018	5/9/2018	Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls	Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls	Parkinson Disease;REM Sleep Behavior Disorder;Healthy	Drug: (11C)PE2I	Weill Medical College of Cornell University	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	20 Years	100 Years	All	100	Phase 1;Phase 2	United States
202	NCT03773796 (ClinicalTrials.gov)	August 6, 2018	19/7/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy	Parkinson Disease	Drug: Nabilone 0.25 mg	Medical University Innsbruck	NULL	Recruiting	30 Years	100 Years	All	48	Phase 3	Austria
203	NCT04455555 (ClinicalTrials.gov)	August 1, 2018	28/6/2020	Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease	Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease	Parkinson's Disease	Drug: LY03003( the name of rotigotine);Other: Placebo	Peking University Third Hospital	NULL	Completed	18 Years	N/A	All	294	Phase 3	China
204	NCT03599726 (ClinicalTrials.gov)	July 30, 2018	29/6/2018	Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil	Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil	Parkinson Disease	Drug: Donepezil;Drug: Placebo	Oregon Health and Science University	Medical Research Foundation, Oregon	Completed	50 Years	90 Years	All	20	Early Phase 1	United States
205	NCT03611569 (ClinicalTrials.gov)	July 25, 2018	26/7/2018	Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease	Healthy;Parkinson Disease	Drug: Lu AF82422;Drug: Placebo	H. Lundbeck A/S	NULL	Recruiting	18 Years	80 Years	All	84	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT03587168 (ClinicalTrials.gov)	July 20, 2018	3/7/2018	The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease	The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease	Parkinson Disease	Other: the timed 360° turn test;Other: Berg Balance Scale;Other: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale	Gazi University	NULL	Completed	40 Years	N/A	All	86		Turkey
207	NCT03594656 (ClinicalTrials.gov)	July 15, 2018	11/7/2018	Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease	Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial	Parkinson Disease	Drug: Ganoderma;Drug: Placebos	Xuanwu Hospital, Beijing	NULL	Recruiting	30 Years	80 Years	All	288	Phase 3	China
208	NCT03624920 (ClinicalTrials.gov)	July 12, 2018	10/7/2018	Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness	Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness	Parkinson Disease	Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C	Theranexus	NULL	Completed	18 Years	80 Years	All	77	Phase 2	United States;Czechia;France;Germany;Hungary
209	NCT03774459 (ClinicalTrials.gov)	July 9, 2018	8/12/2018	ANAVEX2-73 Study in Parkinson's Disease Dementia	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia	Parkinsons Disease With Dementia	Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule	Anavex Life Sciences Corp.	Anavex Germany GmbH	Completed	50 Years	85 Years	All	132	Phase 2	Australia;Spain
210	NCT03146130 (ClinicalTrials.gov)	July 5, 2018	3/5/2017	Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders	Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease	Impulse Control Disorder;Parkinson	Biological: Variation of behaviors of Parkinson's disease	Centre Hospitalier Universitaire, Amiens	NULL	Unknown status	18 Years	N/A	All	70	Phase 3	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03775538 (ClinicalTrials.gov)	July 5, 2018	11/10/2018	Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002	Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases	Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System	Herantis Pharma Plc.	Renishaw plc.	Completed	35 Years	75 Years	All	15	Phase 1;Phase 2	Finland;Sweden
212	NCT03521635 (ClinicalTrials.gov)	July 3, 2018	11/4/2018	The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa	A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)	Parkinson Disease	Drug: Pramipexole SR;Drug: Pramipexole IR	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	98	Phase 4	China
213	NCT03566589 (ClinicalTrials.gov)	July 2, 2018	12/6/2018	Effects of PS128 on Parkinsonian Symptoms	Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	30	N/A	Taiwan
214	NCT03576638 (ClinicalTrials.gov)	July 2018	25/6/2018	Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients	An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease	Parkinson Disease	Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	12	Phase 2	NULL
215	NCT03562494 (ClinicalTrials.gov)	June 28, 2018	16/5/2018	VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)	A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Biological: VY-AADC02;Other: Sham (Placebo) Surgery	Neurocrine Biosciences	Voyager Therapeutics	Recruiting	40 Years	75 Years	All	85	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT03407378 (ClinicalTrials.gov)	June 26, 2018	15/1/2018	A Study to Investigate a New Treatment in Patients With Parkinson's Disease	A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease	Parkinson Disease	Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment	Tools4Patient	NULL	Completed	35 Years	N/A	All	110	Phase 1;Phase 2	United States;Belgium;France
217	NCT03439943 (ClinicalTrials.gov)	June 13, 2018	13/2/2018	Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease	Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease	Parkinson Disease	Drug: Lixisenatide;Drug: placebo	University Hospital, Toulouse	Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi	Active, not recruiting	40 Years	75 Years	All	156	Phase 2	France
218	NCT03456687 (ClinicalTrials.gov)	June 5, 2018	1/3/2018	Effects of Exenatide on Motor Function and the Brain	Effects of Exenatide on Motor Function and the Brain	Parkinson's Disease	Drug: Exenatide	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	40 Years	77 Years	All	5	Phase 1	United States
219	NCT03510572 (ClinicalTrials.gov)	June 4, 2018	17/4/2018	Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain	Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study	Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease	Drug: [18F]PI-2620	Asan Medical Center	Korea Health Industry Development Institute	Completed	40 Years	80 Years	All	20	Early Phase 1	Korea, Republic of
220	NCT03532984 (ClinicalTrials.gov)	June 1, 2018	27/4/2018	Beam Walking Across the Lifespan for Falls Prediction	Beam Walking to Assess Dynamic Balance in Health and Disease: A Protocol for the 'BEAM' Multi-center Observational Study	Aging;Parkinson Disease;Stroke;Dementia;Diagnoses Disease;Cognitive Impairment;Postural; Defect	Diagnostic Test: Beam test to predict falls	University Medical Center Groningen	Dokkyo Medical University;University of Potsdam;Somogy Megyei Kaposi Mór Teaching Hospital;University of Sao Paulo	Unknown status	20 Years	80 Years	All	432		Brazil;Germany;Hungary;Japan;Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03891069 (ClinicalTrials.gov)	June 1, 2018	18/3/2019	Feasibility of the AHA Exergame System in Parkinson's Disease Patients	Feasibility and Safety of the AHA Exergame System in Parkinson's Disease Patients: a Mixed Methods Study	Parkinson Disease	Device: AHA Exergame System	Campus Neurológico Sénior	University of Lisbon	Completed	40 Years	80 Years	All	10	N/A	Portugal
222	NCT03684122 (ClinicalTrials.gov)	June 1, 2018	23/9/2018	Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).	A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).	Parkinson Disease	Biological: Injection of Umbilical cord derived MSCs	University of Jordan	NULL	Recruiting	20 Years	75 Years	All	10	Phase 1;Phase 2	Jordan
223	NCT03589066 (ClinicalTrials.gov)	May 15, 2018	8/6/2018	Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease	An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease	Parkinson Disease	Drug: LY03003	Luye Pharma Group Ltd.	NULL	Completed	18 Years	N/A	All	24	Phase 1	United States
224	NCT03541356 (ClinicalTrials.gov)	May 8, 2018	5/4/2018	Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal	A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of DCI to L-dopa Responsive Parkinson's Disease Patients	Parkinson's Disease	Combination Product: Placebo;Combination Product: L-dopa 35 mg;Combination Product: L-dopa 70mg;Combination Product: L-dopa 140 mg;Combination Product: L-dopa 70mg /carbidopa 7mg	Impel NeuroPharma Inc.	NULL	Completed	40 Years	80 Years	All	32	Phase 2	Australia
225	NCT03587649 (ClinicalTrials.gov)	May 7, 2018	3/7/2018	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss	Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).	Alzheimer Disease;Parkinson Disease;Healthy Volunteers	Drug: [18F]MNI-1126	Invicro	NULL	Completed	18 Years	55 Years	All	12	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT04228887 (ClinicalTrials.gov)	May 4, 2018	5/8/2019	Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease	Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease	Parkinson Disease	Diagnostic Test: Respiratory Muscle Strength;Device: Balance Training;Device: Inspiratory Muscle Training	Bezmialem Vakif University	NULL	Completed	60 Years	85 Years	All	30	N/A	Turkey
227	NCT03843944 (ClinicalTrials.gov)	May 1, 2018	12/2/2019	Overnight Switch From Rasagiline To Safinamide	Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study	Parkinson Disease	Drug: Safinamide	IRCCS San Raffaele	NULL	Completed	30 Years	80 Years	All	20	Phase 4	Italy
228	NCT03230526 (ClinicalTrials.gov)	April 20, 2018	18/7/2017	Identification of a Biomarker Predictive of Evolution of Parkinson Disease	Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?	Parkinson Disease	Drug: [18F]DPA-714 PET scan	Nantes University Hospital	NULL	Recruiting	40 Years	67 Years	All	64	Phase 2	France
229	NCT03374917 (ClinicalTrials.gov)	April 18, 2018	8/12/2017	A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment	An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	30 Years	85 Years	All	20	Phase 1	United States
230	NCT03368170 (ClinicalTrials.gov)	April 12, 2018	5/12/2017	Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia	Parkinson Disease	Drug: Mesdopetam (IRL790)	Integrative Research Laboratories AB	The Clinical Trial Company	Completed	18 Years	79 Years	All	75	Phase 2	Sweden;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	EUCTR2017-002707-10-DK (EUCTR)	10/04/2018	03/11/2017	Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects	Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance	Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Memantin Orion INN or Proposed INN: MEMANTINE Product Name: Donepezil Sandoz Product Code: 25330 INN or Proposed INN: DONEPEZIL	Regional Dementia Research Centre, Dept of Neurology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	110	Phase 4	Denmark
232	NCT03827746 (ClinicalTrials.gov)	April 1, 2018	31/1/2019	The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients	The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients	Parkinson Disease;Kinesiophobia;Physical Activity;Balance;Falling	Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale	Istanbul Kültür University	Marmara University;Istanbul University-Cerrahpasa;Koç University	Completed	40 Years	85 Years	All	60		Turkey
233	NCT03648671 (ClinicalTrials.gov)	March 28, 2018	26/6/2018	Pain in Parkinson's Disease With Motor Fluctuations.	Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.	Parkinson Disease	Drug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)	Universita di Verona	Azienda Ospedaliera Universitaria Integrata Verona	Unknown status	18 Years	80 Years	All	48		Italy
234	NCT03301272 (ClinicalTrials.gov)	March 22, 2018	13/9/2017	Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease	Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study	Parkinson Disease	Drug: Onabotulinumtoxin A Injection;Other: Placebo	University of North Carolina, Chapel Hill	NULL	Completed	45 Years	80 Years	All	16	Phase 2	United States
235	NCT03457493 (ClinicalTrials.gov)	March 22, 2018	23/2/2018	TSPO-PET for Neuroinflammation in Parkinson's Disease	UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy	Parkinson Disease	Drug: DPA -714-PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	30 Years	N/A	All	20	Phase 1;Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT03482882 (ClinicalTrials.gov)	March 9, 2018	23/3/2018	Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression	An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression	Treatment of Depression in Adults With Parkinson's Disease (PD)	Drug: Pimavanserin	ACADIA Pharmaceuticals Inc.	NULL	Completed	50 Years	N/A	All	47	Phase 2	United States
237	NCT03462641 (ClinicalTrials.gov)	March 9, 2018	6/3/2018	Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm	Parkinson Disease	Drug: Flumazenil;Drug: Placebo	University of Michigan	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	50 Years	99 Years	All	30	Phase 1;Phase 2	United States
238	NCT03149809 (ClinicalTrials.gov)	March 1, 2018	9/5/2017	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Overactive Bladder;Parkinson Disease	Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy	VA Office of Research and Development	NULL	Recruiting	N/A	N/A	All	90	Phase 3	United States
239	NCT04265027 (ClinicalTrials.gov)	February 20, 2018	7/2/2020	Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)	An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.	Parkinson Disease	Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	72	Phase 1	United Kingdom
240	NCT03419806 (ClinicalTrials.gov)	February 16, 2018	10/1/2018	Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease	Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa	Parkinson Disease	Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)	Vastra Gotaland Region	The Swedish Research Council;Dizlin Medical Design AB;Göteborg University	Completed	30 Years	N/A	All	25	Phase 1	Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	NCT03882398 (ClinicalTrials.gov)	February 15, 2018	11/3/2019	Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease	Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled Trial	Parkinson Disease;Exercise;Physical Activity;Quality of Life	Other: Balance;Other: Endurance	University of Vigo	NULL	Completed	60 Years	80 Years	All	14	N/A	Spain
242	NCT03496870 (ClinicalTrials.gov)	February 8, 2018	1/3/2018	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.	A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease	Parkinson Disease	Drug: Opicapone;Drug: Carbidopa Levodopa	Neurocrine Biosciences	NULL	Completed	18 Years	85 Years	All	16	Phase 1	United States
243	NCT03189563 (ClinicalTrials.gov)	February 6, 2018	12/6/2017	Safety and Efficacy of DA-9805 for Parkinson's Disease	A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo	Dong-A ST Co., Ltd.	NULL	Completed	30 Years	79 Years	All	60	Phase 2	United States
244	NCT03329508 (ClinicalTrials.gov)	January 29, 2018	30/10/2017	A Phase 3 Study With P2B001 in Subjects With Early Parkinson's	A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.	Parkinson Disease	Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER	Pharma Two B Ltd.	NULL	Recruiting	35 Years	80 Years	All	525	Phase 3	United States;Canada;Germany;Spain
245	NCT03440112 (ClinicalTrials.gov)	January 29, 2018	26/1/2018	Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm	Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson	Parkinson Disease	Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)	Nicolaas Bohnen, MD, PhD	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	50 Years	N/A	All	30	Phase 1;Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT03531086 (ClinicalTrials.gov)	January 19, 2018	8/5/2018	Idiopathic Parkinson's Progression and Dopamine Transporter SPECT	Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Ioflupane I 123	Julie Gurwell	NULL	Active, not recruiting	40 Years	75 Years	All	12		United States
247	NCT03331848 (ClinicalTrials.gov)	January 15, 2018	1/11/2017	Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)	Parkinson Disease	Drug: Placebo oral capsule;Drug: PXT002331 - 20mg	Prexton Therapeutics	NULL	Withdrawn	35 Years	85 Years	All	0	Phase 2	NULL
248	NCT03550183 (ClinicalTrials.gov)	January 10, 2018	11/5/2018	Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease	Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells	Parkinson's Disease	Biological: mesenchymal stem cells	Hebei Newtherapy BIo-Pharma technology Co., Ltd.	NULL	Enrolling by invitation	40 Years	80 Years	All	20	Phase 1	China
249	NCT03318523 (ClinicalTrials.gov)	January 10, 2018	19/10/2017	Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: BIIB054	Biogen	NULL	Active, not recruiting	40 Years	80 Years	All	357	Phase 2	United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom
250	EUCTR2017-000087-15-DE (EUCTR)	21/12/2017	17/05/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6 -Year all-Participants-on Treatment Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Spain;Austria;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	NCT03321019 (ClinicalTrials.gov)	December 12, 2017	20/10/2017	Airway Protective Mechanisms in PD (R01)	Mechanisms of Airway Protection Dysfunction in Parkinson's Disease	Parkinson Disease	Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation	University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	45 Years	85 Years	All	260		United States
252	NCT03377322 (ClinicalTrials.gov)	December 1, 2017	7/12/2017	Trial of Probiotics for Constipation in Parkinson's Disease	A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease	Parkinson Disease	Drug: Probiotic Capsule;Drug: Placebo Capsule	University of Malaya	NULL	Completed	40 Years	85 Years	All	72	N/A	Malaysia
253	NCT03944785 (ClinicalTrials.gov)	November 30, 2017	1/5/2019	Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)	A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets	Idiopathic Parkinson Disease	Drug: XADAGO (safinamide)	US WorldMeds LLC	NULL	Completed	30 Years	80 Years	All	209		United States
254	NCT03194217 (ClinicalTrials.gov)	November 10, 2017	19/6/2017	BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness	Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).	Excessive Daytime Sleepiness;Parkinson Disease	Drug: BEN-2001;Drug: Placebo	BenevolentAI Bio	NULL	Completed	50 Years	80 Years	All	244	Phase 2	United States
255	NCT03305809 (ClinicalTrials.gov)	November 9, 2017	4/10/2017	A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Lewy Body Dementia	Drug: LY3154207;Drug: Placebo	Eli Lilly and Company	NULL	Completed	40 Years	85 Years	All	344	Phase 2	United States;Canada;Puerto Rico;China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02611167 (ClinicalTrials.gov)	November 1, 2017	11/11/2015	Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease	Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease	Parkinson's Disease	Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)	The University of Texas Health Science Center, Houston	NULL	Completed	45 Years	70 Years	All	20	Phase 1	United States
257	NCT03232996 (ClinicalTrials.gov)	November 1, 2017	24/7/2017	Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.	Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.	Parkinson Disease;Parkinson	Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease	University of Manitoba	NULL	Completed	55 Years	70 Years	All	30	N/A	Canada
258	NCT03205956 (ClinicalTrials.gov)	October 19, 2017	29/6/2017	Measuring Parkinson's Disease Progression	Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD	Parkinson's Disease	Drug: Levodopa	Kevin J. Black, MD	The Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	79 Years	All	31	Phase 1	United States
259	NCT03272165 (ClinicalTrials.gov)	October 17, 2017	29/6/2017	Single Ascending Dose Study of MEDI1341 in Healthy Volunteers	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.	Parkinson's Disease	Drug: MEDI1341;Drug: Placebo	AstraZeneca	Covance;MMS Holdings, Inc;Catalent	Recruiting	18 Years	80 Years	All	48	Phase 1	United States;United Kingdom
260	NCT03205488 (ClinicalTrials.gov)	October 16, 2017	28/6/2017	Nilotinib in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease	Parkinson Disease	Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo	Northwestern University	University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research	Completed	40 Years	79 Years	All	76	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	NCT03250117 (ClinicalTrials.gov)	October 10, 2017	11/8/2017	Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole	An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa	Parkinson Disease	Drug: Ropinirole oral product;Drug: Ropinirole Implant	Titan Pharmaceuticals	NULL	Terminated	30 Years	80 Years	All	3	Phase 1;Phase 2	United States
262	NCT04045678 (ClinicalTrials.gov)	October 10, 2017	30/7/2019	A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease	A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections	Parkinson Disease	Drug: LY03003 ( Rotigotine, extended-release microspheres);Drug: Placebo, extended-release microspheres	Luye Pharma Group Ltd.	Beijing Bozhiyin T&S Co., Ltd.	Completed	18 Years	75 Years	All	30	Phase 1	China
263	NCT03769896 (ClinicalTrials.gov)	October 3, 2017	6/12/2018	Nabilone for Non-motor Symptoms in Parkinson's Disease	Nabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal Study	Parkinson Disease	Drug: Nabilone 0.25 mg;Drug: Placebo	Medical University Innsbruck	NULL	Completed	30 Years	100 Years	All	48	Phase 2	Austria
264	NCT03257046 (ClinicalTrials.gov)	September 28, 2017	14/8/2017	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease	A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease	Parkinson Disease	Drug: ITI-214;Other: Placebo	Intra-Cellular Therapies, Inc.	NULL	Completed	50 Years	N/A	All	40	Phase 1;Phase 2	United States
265	NCT03295786 (ClinicalTrials.gov)	September 26, 2017	14/9/2017	Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease	Parkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain Diseases	Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System	Herantis Pharma Plc.	Renishaw plc.	Completed	35 Years	75 Years	All	17	Phase 1;Phase 2	Finland;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT03104725 (ClinicalTrials.gov)	September 25, 2017	4/4/2017	Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?	Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?	Parkinson Disease;Cerebrospinal Fluid	Drug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: Fluoroscopy	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	6	Phase 1	United States
267	NCT03306329 (ClinicalTrials.gov)	September 13, 2017	25/9/2017	DNS-7801 vs. Placebo in Parkinson's Disease	A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations	Parkinson's Disease	Drug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: Placebo	Dart NeuroScience, LLC	NULL	Terminated	30 Years	N/A	All	5	Phase 2	United States
268	NCT03272230 (ClinicalTrials.gov)	September 6, 2017	3/8/2017	Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System	Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease	Apathy;Frontotemporal Dementia;Parkinson Disease;Depressive Symptoms	Behavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Recruiting	40 Years	85 Years	All	135	N/A	France
269	ChiCTR-INR-17012013	2017-09-01	2017-07-17	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Parkinson‘s disease, Depression	BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;	Shanghai Tongji Hospital, Tongji University	NULL	Pending	18	80	Both	BTX-A:40;Placebo:40;		China
270	NCT03292016 (ClinicalTrials.gov)	August 22, 2017	11/9/2017	A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes	A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson Disease	Drug: APL-130277;Drug: APO-go;Drug: Apokyn	Sunovion	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	EUCTR2017-000087-15-AT (EUCTR)	17/08/2017	18/05/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab(PRX002) in Participants with Early Parkinson's Disease with A 6-Year all-Participants-on-Treatment Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Spain;Austria;Germany
272	NCT04162275 (ClinicalTrials.gov)	August 15, 2017	22/9/2019	A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China	A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects	Parkinson Disease	Drug: Finamine tablets;Drug: Placebo tablets	Yiling Pharmaceutical Inc.	NULL	Active, not recruiting	18 Years	65 Years	All	34	Phase 1	China
273	NCT03204929 (ClinicalTrials.gov)	August 14, 2017	28/6/2017	Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease	A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease	Parkinson Disease	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	30 Years	N/A	All	31	Phase 1	Australia
274	NCT03187301 (ClinicalTrials.gov)	August 3, 2017	7/6/2017	A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes	A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson's Disease;Off Episodes of Parkinson Disease	Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin	Sunovion	NULL	Completed	18 Years	N/A	All	48	Phase 2	United States;Italy
275	EUCTR2017-000087-15-FR (EUCTR)	27/07/2017	30/10/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	United States;France;Spain;Austria;Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	EUCTR2017-000087-15-ES (EUCTR)	26/07/2017	08/06/2017	A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: aSyn Mab Product Code: RO7046015 INN or Proposed INN: N/A Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	France;United States;Spain;Austria;Germany
277	NCT03178786 (ClinicalTrials.gov)	July 18, 2017	5/6/2017	Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease	Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease	Parkinson Disease	Behavioral: PAT sessions	NYU Langone Health	NULL	Recruiting	40 Years	75 Years	All	40	N/A	United States
278	NCT03412513 (ClinicalTrials.gov)	July 17, 2017	21/1/2018	Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease	Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial	Overactive Bladder;Parkinson Disease	Drug: Mirabegron;Drug: Placebo	Seoul National University Hospital	NULL	Unknown status	40 Years	80 Years	All	144	Phase 4	Korea, Republic of
279	NCT03026231 (ClinicalTrials.gov)	July 15, 2017	11/1/2017	Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients	A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease	Parkinson's Disease	Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Withdrawn	45 Years	70 Years	All	0	Phase 1;Phase 2	United States
280	NCT03555292 (ClinicalTrials.gov)	July 12, 2017	24/4/2018	11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes	Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes	Parkinson Disease	Drug: 11C-PiB	Oriental Neurosurgery Evidence-Based-Study Team	NULL	Recruiting	18 Years	N/A	All	200	Phase 2	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	EUCTR2017-000135-14-ES (EUCTR)	07/07/2017	09/06/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany
282	NCT03185481 (ClinicalTrials.gov)	July 6, 2017	9/6/2017	Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations	A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	Parkinson's Disease With Motor Fluctuations	Drug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD	Pfizer	NULL	Terminated	40 Years	87 Years	All	5	Phase 2	United States
283	NCT03162874 (ClinicalTrials.gov)	July 4, 2017	19/5/2017	Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)	Parkinson Disease	Drug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2	Prexton Therapeutics	NULL	Completed	35 Years	85 Years	All	157	Phase 2	Austria;France;Germany;Italy;Spain;United Kingdom
284	NCT04146519 (ClinicalTrials.gov)	July 1, 2017	18/10/2019	Parkinson's Disease Therapy Using Cell Technology	Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology	Transplantation:Mesenchymal Stem Cell Transplantation	Biological: Autologous mesenchymal stem cells	Belarusian Medical Academy of Post-Graduate Education	NULL	Active, not recruiting	18 Years	N/A	All	12	Phase 2	Belarus
285	NCT03288155 (ClinicalTrials.gov)	July 1, 2017	15/9/2017	Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)	A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)	Parkinson Disease;Fatigue	Dietary Supplement: Cocoa	Oxford Brookes University	European Parkinson Therapy Centre	Completed	18 Years	N/A	All	30	N/A	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT04223245 (ClinicalTrials.gov)	June 29, 2017	2/12/2019	A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease	A Comparison Of Home Exercises With Multimodal Real-time Sensory Feedback To The Same Exercise Program With No Enhanced Feedback on Walking Automaticity in People With Parkinson Disease.	Parkinson Disease	Behavioral: exercise+multi-modal sensory feedback (MMSF);Behavioral: Exercise only	Regis University	NULL	Completed	21 Years	N/A	All	26	N/A	United States
287	NCT03042416 (ClinicalTrials.gov)	June 29, 2017	1/2/2017	18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety	18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety	Congenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain Glioma	Drug: 18F-DOPA	University of Alberta	Alberta Health Services	Active, not recruiting	N/A	N/A	All	400	Phase 3	Canada
288	NCT04403399 (ClinicalTrials.gov)	June 29, 2017	21/5/2020	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3)	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3	Parkinson's Disease	Drug: Varenicline;Other: Evaluation by Investigator;Other: Placebo	University of Michigan	NULL	Completed	45 Years	N/A	All	33	Phase 2	United States
289	NCT03100149 (ClinicalTrials.gov)	June 27, 2017	29/3/2017	A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension	Parkinson's Disease	Drug: RO7046015;Drug: Placebo	Hoffmann-La Roche	Prothena Biosciences Limited	Active, not recruiting	40 Years	80 Years	All	316	Phase 2	United States;Austria;France;Germany;Spain
290	NCT03195231 (ClinicalTrials.gov)	June 25, 2017	20/6/2017	Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease	Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.	Antidepressive Agents	Drug: Wuling Powder;Drug: Placebo	Beijing Hospital	Tongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical University	Not yet recruiting	40 Years	N/A	All	120	Phase 4	NULL
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	NCT03116295 (ClinicalTrials.gov)	June 20, 2017	12/4/2017	Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone	A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects	Parkinson Disease	Drug: Opicapone (OPC)	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	56	Phase 1	Germany
292	EUCTR2017-000135-14-GB (EUCTR)	15/06/2017	17/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;United Kingdom
293	NCT03083132 (ClinicalTrials.gov)	June 13, 2017	7/3/2017	Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)	Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease	Parkinson Disease	Drug: modafinil 50mg;Drug: Placebo oral capsule	University of Arkansas	NULL	Completed	50 Years	90 Years	All	23	Early Phase 1	United States
294	NCT03973502 (ClinicalTrials.gov)	June 12, 2017	30/5/2019	Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD	Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.	Hepatitis C;Hepatitis B;Parkinson Disease	Drug: 18F-DOPA PET	National Taiwan University Hospital	NULL	Recruiting	20 Years	N/A	All	230	N/A	Taiwan
295	EUCTR2017-000135-14-DE (EUCTR)	06/06/2017	10/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;Italy;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	EUCTR2017-000135-14-IT (EUCTR)	30/05/2017	04/11/2020	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	Studio di fase IIa, multicentrico, in doppio cieco, randomizzato, controllato verso placebo, a gruppi paralleli per valutare l'efficacia, la sicurezza e la tollerabilit¿ del trattamento orale con PXT002331 (foliglurax) della durata di 28 giorni nella riduzione delle complicazioni motorie dovute alla terapia con levodopa nei pazienti affetti da malattia di Parkinson che manifestano deterioramento da fine dose e discinesia indotta da levodopa (AMBLED) - AMBLED Study	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax	PREXTON THERAPEUTICS B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	France;Spain;Austria;Germany;United Kingdom;Italy
297	EUCTR2017-000135-14-AT (EUCTR)	26/05/2017	08/03/2017	A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study	Parkinson’s Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E Product Name: foliglurax Product Code: PXT002331 INN or Proposed INN: foliglurax Other descriptive name: CVD00118-E	Prexton Therapeutics B.V.	NULL	Not Recruiting			Female: yes Male: yes	165	Phase 2	Spain;Austria;Germany;United Kingdom
298	NCT03111485 (ClinicalTrials.gov)	May 24, 2017	28/3/2017	Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease	Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease	Parkinson's Disease;Obstructive Sleep Apnea	Drug: Sinemet CR;Drug: Placebo oral capsule	McGill University Health Centre/Research Institute of the McGill University Health Centre	Weston Brain Institute	Recruiting	18 Years	N/A	All	42	Phase 4	Canada
299	NCT03033498 (ClinicalTrials.gov)	May 17, 2017	25/1/2017	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease	Parkinson's Disease (PD)	Drug: ABBV-951	AbbVie	NULL	Completed	45 Years	85 Years	All	29	Phase 1	United States
300	NCT03242499 (ClinicalTrials.gov)	May 15, 2017	1/8/2017	Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease	Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial	Parkinson Disease	Drug: Lovastatin;Drug: Placebo	National Taiwan University Hospital	NULL	Recruiting	30 Years	90 Years	All	80	Phase 2	Taiwan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	NCT03174938 (ClinicalTrials.gov)	May 15, 2017	28/5/2017	The Swedish BioFINDER 2 Study	The Swedish BioFINDER 2 Study	Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment	Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau	Skane University Hospital	Lund University	Recruiting	20 Years	100 Years	All	1505	N/A	Sweden
302	NCT03047629 (ClinicalTrials.gov)	May 11, 2017	3/2/2017	Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation	A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation	Parkinson's Disease;Constipation	Drug: ENT-01;Other: Placebo	Enterin Inc.	NULL	Completed	30 Years	86 Years	All	50	Phase 1;Phase 2	United States
303	NCT03065192 (ClinicalTrials.gov)	May 11, 2017	10/2/2017	Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease	An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa	Idiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian Disorders	Drug: VY-AADC01	Neurocrine Biosciences	Voyager Therapeutics	Active, not recruiting	40 Years	75 Years	All	16	Phase 1	United States
304	NCT02982512 (ClinicalTrials.gov)	May 1, 2017	28/11/2016	Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease	Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease	Dexmedetomidine;Deep Brain Stimulation;Parkinson Disease	Drug: Dexmedetomidine	Clinica Universidad de Navarra, Universidad de Navarra	NULL	Unknown status	18 Years	N/A	All	12	Phase 4	Spain
305	NCT02702076 (ClinicalTrials.gov)	May 2017	2/3/2016	Apomorphine in Parkinson's Disease Patients With Visual Hallucinations	Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations	Parkinson's Disease;Hallucinations, Visual	Drug: Apomorphine;Drug: Placebo	University Medical Center Groningen	NULL	Recruiting	30 Years	N/A	All	35	Phase 2	Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT03119636 (ClinicalTrials.gov)	May 2017	6/4/2017	Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease	A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease	Parkinson's Disease	Biological: NPC transplantation;Drug: Levodopa	Chinese Academy of Sciences	The First Affiliated Hospital of Zhengzhou University	Recruiting	50 Years	80 Years	All	50	Phase 1;Phase 2	China
307	NCT03425877 (ClinicalTrials.gov)	April 22, 2017	10/1/2018	Arousal Response Tool for Neurological Disease	Arousal Response Tool for Neurological Disease	Parkinson Disease;Stroke;Healthy	Device: MS Band 2;Behavioral: Emotion Assessment;Behavioral: Single Task;Behavioral: Dual Task;Behavioral: Rest	IRCCS San Camillo, Venezia, Italy	Università Politecnica delle Marche;University of Padova	Unknown status	25 Years	N/A	All	45	N/A	Italy
308	NCT03115827 (ClinicalTrials.gov)	April 18, 2017	9/3/2017	Norepinephrine-targeted Therapy for Action Control in Parkinson Disease	Norepinephrine-targeted Therapy for Action Control in Parkinson Disease	Parkinson Disease	Drug: Droxidopa;Drug: Carbidopa	Vanderbilt University Medical Center	H. Lundbeck A/S;American Academy of Neurology	Completed	18 Years	N/A	All	15	Phase 4	United States
309	NCT03128450 (ClinicalTrials.gov)	April 15, 2017	9/2/2017	A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient	A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease	Parkinson Disease	Biological: human neural stem cell	Second Affiliated Hospital of Soochow University	NULL	Enrolling by invitation	35 Years	70 Years	All	12	Phase 2;Phase 3	China
310	NCT03011476 (ClinicalTrials.gov)	April 11, 2017	27/12/2016	Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease	Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance	Parkinson Disease	Drug: Donepezil;Drug: Placebos	Kyung Hee University Hospital	NULL	Unknown status	40 Years	75 Years	All	20	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	NCT03051607 (ClinicalTrials.gov)	April 10, 2017	9/2/2017	Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off	Idiopathic Parkinson Disease	Drug: Tozadenant	Biotie Therapies Inc.	Acorda Therapeutics	Terminated	30 Years	80 Years	All	66	Phase 3	United States;Canada;United Kingdom
312	JPRN-jRCTs051180185	07/04/2017	26/03/2019	APISJ Study	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - APISJ Study	Parkinson's disease Parkinson's disease	In this research, the duration of evaluation will be 24 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by Istradefylline.	Takahashi Makio	Kyowa Kirin Co., Ltd.	Not Recruiting	>= 30age old	Not applicable	Both	30	N/A	Japan
313	NCT02953665 (ClinicalTrials.gov)	April 3, 2017	21/10/2016	Safety and Efficacy of Liraglutide in Parkinson's Disease	A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease	Parkinson Disease	Drug: Liraglutide;Drug: Placebo	Cedars-Sinai Medical Center	The Cure Parkinson's Trust;Novo Nordisk A/S	Active, not recruiting	25 Years	85 Years	All	63	Phase 2	United States
314	NCT02970019 (ClinicalTrials.gov)	March 30, 2017	18/11/2016	Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease	A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.	Parkinson Disease	Drug: K0706;Drug: Placebo	Sun Pharma Advanced Research Company Limited	NULL	Completed	18 Years	65 Years	All	60	Phase 1	United States
315	JPRN-UMIN000026492	2017/03/15	15/03/2017	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease	Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.	Parkinson's disease	In this research, the duration of evaluation will be 24 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.	Osaka Red Cross Hospital	Clinical Research Center, Wakayama Medical University	Complete: follow-up complete	30years-old	Not applicable	Male and Female	30	Not selected	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02864004 (ClinicalTrials.gov)	March 3, 2017	15/7/2016	Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)	Apomorphine Pump in Early Stage of Parkinson's Disease	Parkinson's Disease	Drug: Apomorphine;Other: Best Medical Treatment	Rennes University Hospital	NULL	Recruiting	18 Years	65 Years	All	192	Phase 3	France
317	NCT03068481 (ClinicalTrials.gov)	February 20, 2017	26/2/2017	Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease	A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease	Parkinson Disease	Drug: KDT-3594;Drug: Placebo	Kissei Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	74 Years	All	36	Phase 1	Japan
318	NCT02799381 (ClinicalTrials.gov)	February 9, 2017	10/6/2016	A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)	Parkinson's Disease (PD)	Drug: Optimized antiparkinsonian treatment;Drug: Levodopa -Carbidopa Intestinal Gel (LCIG);Device: CADD-Legacy ambulatory infusion pump;Device: Percutaneous endoscopic gastrostomy tube;Device: Jejunal extension tube	AbbVie	NULL	Completed	30 Years	N/A	All	63	Phase 3	United States;Finland;Greece;Hungary;Italy;Slovakia;Spain
319	NCT03330470 (ClinicalTrials.gov)	January 1, 2017	17/10/2017	Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease	Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease	Subjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy Volunteers	Behavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placebo	Slovak Academy of Sciences	Comenius University;University Hospital Bratislava;National Cheng Kung University	Recruiting	55 Years	80 Years	All	100	N/A	Slovakia;Taiwan
320	NCT03034564 (ClinicalTrials.gov)	January 2017	25/1/2017	A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease	Parkinson Disease;Fatigue;Parkinsonism	Drug: Northera;Drug: Placebo Oral Tablet	The Cooper Health System	NULL	Recruiting	18 Years	N/A	All	70	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT02954978 (ClinicalTrials.gov)	January 2017	1/11/2016	Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease	Parkinson Disease;Parkinsons Disease With Dementia	Drug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]	Georgetown University	NULL	Active, not recruiting	40 Years	90 Years	All	75	Phase 2	United States
322	NCT03037203 (ClinicalTrials.gov)	January 2017	23/1/2017	A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness	A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness	Excessive Sleepiness;Parkinson Disease	Drug: JZP-110;Other: Placebo	Jazz Pharmaceuticals	NULL	Completed	35 Years	80 Years	All	66	Phase 2	United States
323	NCT02969369 (ClinicalTrials.gov)	December 31, 2016	17/11/2016	A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	Parkinson Disease Psychosis	Drug: SEP-363856;Drug: Placebo capsule	Sunovion	NULL	Completed	55 Years	105 Years	All	39	Phase 2	United States
324	NCT02906020 (ClinicalTrials.gov)	December 15, 2016	14/9/2016	A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation	Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.	Parkinson's Disease	Drug: GZ/SAR402671;Drug: Placebo	Genzyme, a Sanofi Company	NULL	Active, not recruiting	18 Years	80 Years	All	270	Phase 2	United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom
325	NCT02789020 (ClinicalTrials.gov)	December 2016	20/5/2016	Image Parkinson's Disease Progression Study	Image Parkinson's Disease Progression Study	Parkinson's Disease	Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance Test	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	40 Years	77 Years	All	96	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	NCT02879136 (ClinicalTrials.gov)	December 2016	23/6/2016	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease	TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study	Parkinson's Disease, Idiopathic	Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine	Hubert Fernandez	NULL	Recruiting	18 Years	90 Years	All	42	Early Phase 1	United States
327	NCT02941822 (ClinicalTrials.gov)	December 2016	5/9/2016	Ambroxol in Disease Modification in Parkinson Disease	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease	Parkinson Disease	Drug: Ambroxol	University College, London	The Cure Parkinson's Trust	Completed	40 Years	80 Years	All	23	Phase 2	United Kingdom
328	NCT03000569 (ClinicalTrials.gov)	November 30, 2016	28/11/2016	A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease	A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease	Parkinson Disease	Drug: SAGE-217;Drug: Levodopa;Drug: Antiparkinsonian Agent(s)	Sage Therapeutics	NULL	Completed	40 Years	75 Years	All	29	Phase 2	United States
329	NCT02847442 (ClinicalTrials.gov)	November 23, 2016	21/7/2016	Efficacy and Safety of Opicapone in Clinical Practice	Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations	Parkinson's Disease With Wearing-off Motor Fluctuations	Drug: BIA 9-1067;Drug: levodopa /dopa decarboxylase inhibitor	Bial - Portela C S.A.	NULL	Completed	30 Years	N/A	All	518	Phase 4	Germany
330	NCT03007888 (ClinicalTrials.gov)	November 14, 2016	6/12/2016	A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease	A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease	Advanced Parkinson's Disease	Drug: IR CD-LD;Drug: ER CD-LD	Impax Laboratories, LLC	NULL	Completed	40 Years	100 Years	All	28	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	NCT03531060 (ClinicalTrials.gov)	November 8, 2016	10/4/2018	A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia	A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).	Parkinson Disease	Drug: IRL790;Drug: Placebo	Integrative Research Laboratories AB	NULL	Completed	50 Years	85 Years	All	15	Phase 1;Phase 2	NULL
332	NCT03022799 (ClinicalTrials.gov)	November 2016	27/12/2016	Phase I, KM-819 in Healthy Subjects for Parkinson's Disease	A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects	Parkinson's Disease	Drug: KM-819;Drug: Placebo	Kainos Medicine Inc.	NULL	Completed	19 Years	45 Years	All	88	Phase 1	Korea, Republic of
333	NCT02857244 (ClinicalTrials.gov)	November 2016	25/7/2016	A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients	A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients	Parkinson's Disease	Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil	University of Chicago	NULL	Withdrawn	18 Years	100 Years	All	0	Phase 2	United States
334	NCT02968433 (ClinicalTrials.gov)	November 2016	14/11/2016	The Stanford Parkinson's Disease Plasma Study	The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease	Parkinson Disease(PD)	Drug: Infusions of young plasma	Stanford University	NULL	Active, not recruiting	50 Years	80 Years	All	15	Phase 1	United States
335	NCT02871427 (ClinicalTrials.gov)	October 20, 2016	15/8/2016	Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder	An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder	Lewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior Disorder	Drug: Nelotanserin	Axovant Sciences Ltd.	NULL	Terminated	50 Years	N/A	All	80	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02847650 (ClinicalTrials.gov)	October 17, 2016	25/7/2016	Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON'S DISEASE	Parkinson Disease	Drug: Placebo;Drug: PF-06649751	Pfizer	NULL	Terminated	45 Years	80 Years	All	57	Phase 2	United States;France;Germany;Israel
337	NCT02728843 (ClinicalTrials.gov)	October 12, 2016	31/3/2016	Study of Parkinson's Early Stage With Deferiprone	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease	Parkinson's Disease	Drug: Deferiprone;Drug: Placebo	ApoPharma	NULL	Completed	18 Years	80 Years	All	140	Phase 2	Canada;France;Germany;United Kingdom
338	EUCTR2016-002391-27-GB (EUCTR)	07/10/2016	04/08/2016	Opicapone in clinical practice (OPTIPARK)	This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1	Parkinson's disease (PD) patients with wearing-off motor fluctuations MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550	Phase 4	Germany;United Kingdom
339	NCT02935842 (ClinicalTrials.gov)	October 1, 2016	18/8/2016	Evaluation of Intensive Language Therapy	Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial	Parkinson's Disease	Other: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT)	University Hospital, Basel, Switzerland	NULL	Completed	45 Years	80 Years	All	38	N/A	Switzerland
340	NCT02910102 (ClinicalTrials.gov)	October 2016	16/9/2016	Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia	A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia	Alzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia	Drug: RVT-101 35 mg;Drug: Placebo	Axovant Sciences Ltd.	NULL	Completed	50 Years	89 Years	All	38	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02803749 (ClinicalTrials.gov)	October 2016	14/6/2016	Buspirone in Parkinson's Disease	The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease	Parkinson Disease;Anxiety	Drug: Buspirone;Drug: Placebo	University of Rochester	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	All	21	Phase 2	United States
342	NCT02538315 (ClinicalTrials.gov)	October 2016	25/8/2015	Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients	Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients	Parkinson`s Disease	Drug: [18F]FDOPA PET/CT	University of Saskatchewan	University of Manitoba	Recruiting	18 Years	N/A	All	30	N/A	Canada
343	NCT02940912 (ClinicalTrials.gov)	October 2016	14/10/2016	Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease	Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease	Parkinson Disease	Drug: Apomorphine;Drug: Placebo	Clinique Beau Soleil	NULL	Recruiting	35 Years	90 Years	All	45	Phase 4	France
344	NCT02818777 (ClinicalTrials.gov)	October 2016	6/5/2016	A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease	A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease	Parkinson's Disease	Drug: cannabidiol	University of Colorado, Denver	Colorado Department of Public Health and Environment;GW Research Ltd	Completed	40 Years	80 Years	All	13	Phase 2	United States
345	NCT03462680 (ClinicalTrials.gov)	September 28, 2016	22/2/2018	GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures	GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures	Parkinson's Disease	Dietary Supplement: niacin;Other: placebo	VA Office of Research and Development	NULL	Completed	35 Years	N/A	All	47	N/A	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.		Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
347	NCT02688465 (ClinicalTrials.gov)	September 5, 2016	18/2/2016	Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).	Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).	Parkinson's Disease	Drug: Apomorphine	Fondation Ophtalmologique Adolphe de Rothschild	NULL	Terminated	18 Years	N/A	All	15	Phase 4	France
348	NCT02815800 (ClinicalTrials.gov)	September 2, 2016	13/6/2016	Efficacy of Ethnodyne Visio in Parkinson's Disease		Parkinson's Disease	Dietary Supplement: ETHNODYNE VISIO	University Hospital, Strasbourg, France	ETHNODYNE	Completed	40 Years	75 Years	All	24	N/A	France
349	NCT03192046 (ClinicalTrials.gov)	September 2016	13/6/2017	Bracing for Walking in Parkinson's Disease	Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD	Gait Disorders, Neurologic;Parkinson Disease	Device: Carbon Fiber Ankle Foot Orthosis (AFO)	University of Texas Southwestern Medical Center	American Orthotic and Prosthetic Association	Recruiting	30 Years	85 Years	All	16	N/A	United States
350	NCT02897063 (ClinicalTrials.gov)	September 2016	7/9/2016	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2	Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension	Drug: Droxidopa;Drug: Midodrine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	34	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	NCT02385500 (ClinicalTrials.gov)	September 2016	4/3/2015	Fesoterodine on Urgency Episodes in Parkinson's Disease Population	Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population	Urinary Bladder, Overactive;Parkinson Disease	Drug: Fesoterodine;Drug: Placebo	Sir Mortimer B. Davis - Jewish General Hospital	NULL	Terminated	50 Years	85 Years	All	5	Phase 4	Canada
352	NCT02939391 (ClinicalTrials.gov)	September 2016	17/10/2016	A Study of KW-6356 in Subjects With Early Parkinson's Disease	An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease	Parkinson's Disease	Drug: KW-6356;Drug: Placebo	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	80 Years	All	175	Phase 2	Japan
353	NCT02601586 (ClinicalTrials.gov)	September 2016	17/8/2015	Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease	Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial	Parkinson Disease	Drug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placebo	University Hospital, Toulouse	NULL	Recruiting	40 Years	75 Years	All	84	Phase 2;Phase 3	France
354	NCT02365870 (ClinicalTrials.gov)	August 2016	11/2/2015	Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment	Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment	Anxiety Disorders;Parkinson Disease	Drug: rotigotine transdermal patch;Drug: placebo	Johns Hopkins University	National Institute on Aging (NIA)	Terminated	21 Years	89 Years	All	4	Phase 4	United States
355	NCT02782481 (ClinicalTrials.gov)	August 2016	22/5/2016	A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations	A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations	Parkinson's Disease	Drug: ND0612;Drug: Placebo	NeuroDerm Ltd.	NULL	Withdrawn	30 Years	80 Years	All	0	Phase 3	Israel
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	NCT02615873 (ClinicalTrials.gov)	July 2016	23/11/2015	A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004	An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004	Parkinson's Disease	Drug: Accordion Pill™ Carbidopa/Levodopa	Intec Pharma Ltd.	NULL	Unknown status	30 Years	100 Years	All	460	Phase 3	United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom
357	NCT02452723 (ClinicalTrials.gov)	July 2016	18/5/2015	A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease	A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease	Parkinson Disease	Biological: ISC-hpNSC	Cyto Therapeutics Pty Limited	NULL	Active, not recruiting	30 Years	70 Years	All	12	Phase 1	Australia
358	NCT02382198 (ClinicalTrials.gov)	July 2016	21/1/2015	Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease	A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease	Sialorrhea;Parkinson's Disease	Drug: Glycopyrrolate;Drug: Placebo	Ottawa Hospital Research Institute	NULL	Unknown status	30 Years	N/A	All	28	Phase 2	Canada
359	NCT02642393 (ClinicalTrials.gov)	June 2016	19/12/2015	Study of Urate Elevation in Parkinson's Disease, Phase 3	A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease	Parkinson's Disease	Drug: Inosine;Drug: Placebo	Michael Alan Schwarzschild	The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)	Completed	30 Years	N/A	All	298	Phase 3	United States;Puerto Rico
360	NCT02785978 (ClinicalTrials.gov)	June 2016	11/5/2016	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers	Parkinson Disease;Healthy Volunteers	Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion	Institut de Myologie, France	NULL	Completed	18 Years	N/A	All	30	N/A	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	NCT02838797 (ClinicalTrials.gov)	June 2016	16/6/2016	RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease	RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease	Parkinson's Disease;Gastroparesis;Constipation	Drug: RQ-00000010;Drug: Placebo	Virginia Commonwealth University	Michael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.	Completed	18 Years	N/A	All	51	Phase 1	United States
362	NCT02807675 (ClinicalTrials.gov)	June 2016	17/6/2016	A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)	A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease	Parkinson's Disease	Drug: CVT-301, LIP;Other: Placebo	Acorda Therapeutics	NULL	Completed	30 Years	85 Years	All	36	Phase 1	United States
363	NCT02762591 (ClinicalTrials.gov)	May 3, 2016	3/5/2016	Expanded Access of Pimavanserin for Patients With PD Psychosis	Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis	Parkinson's Disease Psychosis	Drug: Pimavanserin tartrate	ACADIA Pharmaceuticals Inc.	NULL	Approved for marketing	40 Years	N/A	All		N/A	NULL
364	NCT02726386 (ClinicalTrials.gov)	May 2016	29/3/2016	A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion	A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease	Parkinson's Disease	Drug: ND0612	NeuroDerm Ltd.	NULL	Active, not recruiting	30 Years	N/A	All	210	Phase 2	United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain
365	NCT02812147 (ClinicalTrials.gov)	May 2016	25/5/2016	Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease	Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)	Parkinson Disease	Drug: L-DOPS;Drug: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	Arizona State University, Tempe	Active, not recruiting	30 Years	83 Years	All	20	Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	NCT02784145 (ClinicalTrials.gov)	May 2016	17/5/2016	Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease	Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease	Parkinson Disease	Dietary Supplement: Resistant starch;Other: Recommendation with regard to nutrition	Saarland University	NULL	Completed	18 Years	N/A	All	95	N/A	Germany
367	NCT02705755 (ClinicalTrials.gov)	May 2016	7/3/2016	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)	A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension	Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension	Drug: TD-9855;Drug: Placebo	Theravance Biopharma	NULL	Completed	40 Years	N/A	All	34	Phase 2	United States
368	NCT02764125 (ClinicalTrials.gov)	April 8, 2016	13/1/2016	Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)	Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off	Parkinson's Disease	Drug: Stalevo;Drug: levodopa MR	Orion Corporation, Orion Pharma	NULL	Completed	30 Years	N/A	All	84	Phase 2	Finland;Germany;Hungary;Latvia
369	NCT03034538 (ClinicalTrials.gov)	April 8, 2016	25/1/2017	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	Parkinson Disease;Parkinsonism;Dyskinesias	Drug: Zonegran	The Cooper Health System	NULL	Recruiting	18 Years	N/A	All	20	Phase 4	United States
370	NCT02775591 (ClinicalTrials.gov)	April 2016	9/5/2016	Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms	Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial	Parkinson Disease;Dyspepsia	Drug: DA-9701;Drug: DA-9701 placebo	Seoul National University Hospital	Samsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical Center	Completed	50 Years	80 Years	All	147	Phase 4	Korea, Republic of
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	NCT04470037 (ClinicalTrials.gov)	April 2016	26/5/2020	Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder	Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder	Parkinson's Disease With Dementia	Drug: DAAOI-P;Drug: Placebo	China Medical University Hospital	Ministry of Science and Technology, Taiwan	Recruiting	50 Years	90 Years	All	60	Phase 2	Taiwan
372	NCT03173781 (ClinicalTrials.gov)	April 2016	10/8/2016	Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease	Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease	Parkinson's Disease	Drug: droxidopa;Drug: Placebo	Colorado Springs Neurological Associates	H. Lundbeck A/S	Completed	18 Years	N/A	All	21	N/A	United States
373	NCT02719496 (ClinicalTrials.gov)	April 2016	15/3/2016	Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease	Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease	Gastrointestinal Disorders in Parkinson's Disease	Drug: IBEROGAST	Nantes University Hospital	NULL	Completed	30 Years	80 Years	All	45	Phase 2	France
374	NCT02729714 (ClinicalTrials.gov)	April 2016	26/1/2016	A Pilot Study of Suvorexant for Insomnia in Parkinson Disease	A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease	Insomnia	Drug: Suvorexant;Drug: Placebo	Burdick, Daniel, M.D.	Merck Sharp & Dohme Corp.	Recruiting	30 Years	80 Years	All	20	Phase 4	United States
375	NCT02462603 (ClinicalTrials.gov)	March 31, 2016	20/5/2015	Safety and Biomarker Study of EPI-589 in Parkinson's Disease	A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects	Parkinson's Disease	Drug: EPI-589	PTC Therapeutics	NULL	Completed	21 Years	75 Years	All	44	Phase 2	United States;Germany;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	NCT02787590 (ClinicalTrials.gov)	March 21, 2016	26/5/2016	Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease	Simvastatin as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity.	Parkinson Disease	Drug: Simvastatin;Drug: Matched Placebo (for Simvastatin)	University Hospital Plymouth NHS Trust	University of Plymouth	Active, not recruiting	40 Years	90 Years	All	235	Phase 2	United Kingdom
377	NCT02687542 (ClinicalTrials.gov)	March 3, 2016	29/1/2016	Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations	A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE	Parkinson Disease	Drug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)	Pfizer	NULL	Terminated	40 Years	85 Years	All	108	Phase 2	United States;Canada;France;Germany;Japan;Spain
378	NCT02994719 (ClinicalTrials.gov)	March 1, 2016	21/12/2015	Gait Analysis in Neurological Disease	Gait Pattern Analysis in Neurological Disease	Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease	Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation	Beth Israel Deaconess Medical Center	NULL	Active, not recruiting	18 Years	85 Years	All	120		United States
379	NCT02708186 (ClinicalTrials.gov)	March 2016	10/3/2016	Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)	A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)	Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease Dementia	Drug: Nelotanserin;Drug: Placebo	Axovant Sciences Ltd.	NULL	Completed	50 Years	N/A	All	34	Phase 2	United States
380	NCT02605434 (ClinicalTrials.gov)	March 2016	5/11/2015	A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients	Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients	Parkinson's Disease	Drug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- Sinemet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	420	Phase 3	United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT02668497 (ClinicalTrials.gov)	March 2016	26/1/2016	Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy	Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy	Parkinson's Disease	Drug: Botulinum Toxin Type A	Western University, Canada	NULL	Active, not recruiting	18 Years	80 Years	All	50	Phase 2	Canada
382	NCT04569656 (ClinicalTrials.gov)	February 2, 2016	24/9/2020	Treatment of Chronic Constipation in Parkinson's Disease	Pilot Study for the Evaluation of the Parameters of Activity of a Preparation of PHGG and Sodium Hyaluronate in Chronic Constipation in Patients With Parkinson's Disease	Parkinson Disease	Drug: hydrolyzed guar gum	IRCCS San Raffaele	NULL	Completed	18 Years	N/A	All	34	Phase 2	Italy
383	NCT02618941 (ClinicalTrials.gov)	February 2, 2016	25/11/2015	Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)	Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program	Parkinson's Disease	Biological: AFFITOPE® PD01A	Affiris AG	NULL	Completed	40 Years	68 Years	All	26	Phase 1	Austria
384	JPRN-UMIN000020288	2016/02/01	28/12/2015	Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.		Parkinson's disease	In this research, the duration of evaluation will be 12 weeks. Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.	Juntendo University Shizuoka Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	30	Not selected	Japan
385	NCT02641054 (ClinicalTrials.gov)	February 2016	7/12/2015	Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease	Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test	Idiopathic Parkinson Disease	Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa	CleveXel Pharma	NULL	Completed	40 Years	75 Years	All	21	Phase 2	France
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02683629 (ClinicalTrials.gov)	February 2016	8/2/2016	Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease	A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease	Parkinson's Disease	Biological: NTCELL Implantation;Other: Sham Surgery	Living Cell Technologies	Statistecol Consultants Limited	Completed	40 Years	65 Years	All	18	Phase 2	New Zealand
387	NCT02524405 (ClinicalTrials.gov)	February 2016	13/8/2015	BEAM: Brain-Eye Amyloid Memory Study	The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration	Alzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body Disease	Other: Pittsburgh Compound B [11C]-PIB	Sunnybrook Health Sciences Centre	Brain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye Institute	Recruiting	50 Years	90 Years	All	345		Canada
388	NCT02655315 (ClinicalTrials.gov)	February 2016	7/1/2016	Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease	Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone	Parkinson Disease	Drug: Deferiprone;Drug: Placebo	University Hospital, Lille	European Commission;ApoPharma	Active, not recruiting	N/A	80 Years	All	372	Phase 2	Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic
389	NCT03258294 (ClinicalTrials.gov)	January 13, 2016	20/8/2017	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease	Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial	Parkinson's Disease	Drug: Melatonin (Circadin®);Drug: Placebo Oral Tablet	KIMJisun	Kuhnil Pharmaceutical Co., Ltd.	Enrolling by invitation	55 Years	N/A	All	82	Phase 4	NULL
390	NCT02649608 (ClinicalTrials.gov)	January 2016	6/1/2016	An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients	Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease	Parkinson Disease	Drug: 0.04 mg Lu AE04621;Drug: 0.08 mg Lu AE04621;Drug: 0.2 mg Lu AE04621;Drug: 0.4 mg Lu AE04621;Drug: 0.6 mg Lu AE04621;Drug: 0.8 mg Lu AE04621;Drug: 1.0 mg Lu AE04621;Drug: 1.2 mg Lu AE04621	H. Lundbeck A/S	NULL	Completed	45 Years	75 Years	All	15	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	NCT02549573 (ClinicalTrials.gov)	January 2016	9/9/2015	Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®	Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor State	Parkinson's Disease;Motor Symptoms	Drug: APOKYN;Behavioral: Physical Therapy	US WorldMeds LLC	NULL	Terminated	18 Years	78 Years	All	13	Phase 4	United States
392	NCT02579473 (ClinicalTrials.gov)	January 2016	13/10/2015	A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214	A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration	Parkinson's Disease	Drug: SER-214	Serina Therapeutics	NULL	Active, not recruiting	40 Years	80 Years	All	20	Phase 1	United States
393	NCT02589340 (ClinicalTrials.gov)	January 2016	23/10/2015	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Parkinson's Disease;Dyskinesias;Movement Disorders	Drug: Buspirone;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Active, not recruiting	18 Years	99 Years	All	15	Phase 1	United States
394	NCT02702102 (ClinicalTrials.gov)	December 2015	3/3/2016	Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies	Imaging Inflammation in Patients With Diffuse Lewy Body Disease	Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia	Drug: 11C-PBR28	William Charles Kreisl	National Institute on Aging (NIA)	Completed	60 Years	N/A	All	5	Phase 2	United States
395	NCT02536976 (ClinicalTrials.gov)	December 2015	28/8/2015	Mirabegron in Parkinson Disease and Impaired Cognition	A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition	Parkinson Disease;Overactive Bladder;Impaired Cognition	Drug: mirabegron;Drug: Placebo	HealthPartners Institute	NULL	Completed	25 Years	80 Years	All	7	Phase 4	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	NCT02616120 (ClinicalTrials.gov)	December 2015	20/11/2015	Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease	Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease Patients	Parkinson's Disease	Drug: SQJZ herbal mixtures;Drug: Placebo	Dongzhimen Hospital, Beijing	NULL	Recruiting	18 Years	80 Years	All	240	Phase 2	China
397	NCT02610231 (ClinicalTrials.gov)	December 2015	13/11/2015	Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Istradefylline 20 mg or 40 mg	Kyowa Hakko Kirin Pharma, Inc.	Kyowa Kirin Co., Ltd.	Completed	30 Years	N/A	All	239	Phase 3	United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic
398	NCT02470780 (ClinicalTrials.gov)	December 2015	4/6/2015	Treating Bacterial Overgrowth in Parkinson's Disease	Treating Bacterial Overgrowth in Parkinson's Disease	Parkinson's Disease;Small Intestinal Bacterial Overgrowth	Drug: Rifaximin;Drug: Placebo	University of Cincinnati	NULL	Completed	18 Years	N/A	All	24	Phase 2;Phase 3	United States
399	NCT02565628 (ClinicalTrials.gov)	November 16, 2015	28/9/2015	PF-06669571 In Subjects With Idiopathic Parkinson's Disease	A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.	Idiopathic Parkinson's Disease	Drug: PF-06669571;Drug: Placebo	Pfizer	NULL	Completed	N/A	N/A	All	20	Phase 1	United States
400	JPRN-jRCTs041180070	04/11/2015	07/03/2019	Trerief Impact in PD PET Study	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS	Parkinson's disease Parkinson's disease;D010300	[1] Zonisamide treatment group Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. [2] Zonisamide non-treatment group Only levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.	Ouchi Yasuomi	NULL	Not Recruiting	Not applicable	< 80age old	Both	20	N/A	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	NCT04110678 (ClinicalTrials.gov)	November 1, 2015	18/9/2019	Tolerance to NeuroEPO in Parkinson Disease	Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial	Parkinson Disease	Drug: NeuroEPO	International Center for Neurological Restoration, Cuba	Center of Molecular Immunology, Cuba;University of Electronic Science and Technology of China	Completed	40 Years	70 Years	All	26	Phase 1;Phase 2	Cuba
402	NCT02914366 (ClinicalTrials.gov)	November 2015	8/9/2016	Ambroxol as a Treatment for Parkinson's Disease Dementia	Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia	Parkinson's Disease Dementia	Drug: Ambroxol;Other: Placebo	Lawson Health Research Institute	Weston Brain Institute;University of Western Ontario, Canada;London Health Sciences Centre	Recruiting	50 Years	N/A	All	75	Phase 2	Canada
403	NCT02271503 (ClinicalTrials.gov)	November 2015	13/10/2014	A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease	A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease	Parkinson's Disease	Drug: CD -LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mg	Impax Laboratories, LLC	NULL	Completed	40 Years	N/A	All	26	Phase 2	United States
404	NCT02758730 (ClinicalTrials.gov)	November 2015	26/4/2016	Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients	A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA	Parkinson's Disease	Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component	Affiris AG	University Hospital Tuebingen	Withdrawn	40 Years	80 Years	Both	0	Phase 1	Germany
405	NCT02577523 (ClinicalTrials.gov)	November 2015	6/10/2015	A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease	A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease	Parkinson's Disease	Drug: ND0612 (Levodopa/Carbidopa solution)	NeuroDerm Ltd.	NULL	Completed	30 Years	80 Years	All	38	Phase 2	United States;Austria;Israel;Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02632279 (ClinicalTrials.gov)	November 2015	26/11/2015	Tryptophan Depletion in PD Patients Treated With STN DBS	Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions	Parkinson's Disease	Dietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFF	Maastricht University Medical Center	Netherlands Brain Foundation	Terminated	N/A	N/A	All	7	N/A	Netherlands
407	NCT02933372 (ClinicalTrials.gov)	October 5, 2015	6/4/2016	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3	Parkinson's Disease	Drug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by Investigator	University of Michigan	NULL	Completed	45 Years	N/A	All	25	Phase 2	NULL
408	JPRN-UMIN000019524	2015/10/01	28/10/2015	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images	Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS)	Parkinson's Disease	Zonisamide treatment group: Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms. Zonisamide non-treatment group: Only Levodopa/DCI with fixed dosage and administration. Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.	Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	Not applicable	80years-old	Male and Female	20	Not applicable	Japan
409	NCT02572713 (ClinicalTrials.gov)	October 2015	7/10/2015	Systemic Synuclein Sampling Study (S4)	Systemic Synuclein Sampling Study (S4)	Parkinson's Disease	Procedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN ™	Michael J. Fox Foundation for Parkinson's Research	Indiana University;University of Iowa;Banner Health;Paracelsus Elena Klinik	Completed	40 Years	N/A	All	80	N/A	United States;Canada
410	NCT02562768 (ClinicalTrials.gov)	September 30, 2015	28/9/2015	A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease	Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease	Parkinson's Disease	Drug: LY3154207;Drug: Placebo	Eli Lilly and Company	NULL	Completed	20 Years	N/A	All	80	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT02549092 (ClinicalTrials.gov)	September 9, 2015	11/9/2015	A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)	An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study	Advanced Parkinson's Disease	Drug: ABT-SLV187	AbbVie	NULL	Active, not recruiting	30 Years	99 Years	All	89	Phase 3	United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden
412	NCT02542696 (ClinicalTrials.gov)	August 31, 2015	3/9/2015	Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)	Parkinson Disease	Drug: APL-130277	Sunovion	NULL	Recruiting	18 Years	N/A	All	226	Phase 3	United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom
413	NCT02599753 (ClinicalTrials.gov)	August 2015	1/11/2015	Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients	Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging	Parkinson's Disease	Drug: 18-FDTBZ	Chang Gung Memorial Hospital	NULL	Completed	20 Years	80 Years	All	35	Phase 2	Taiwan
414	NCT02337751 (ClinicalTrials.gov)	July 10, 2015	9/1/2015	A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants	A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa	Parkinson's Disease	Drug: TVP-1012 1mg	Takeda	NULL	Completed	30 Years	79 Years	All	198	Phase 3	Japan
415	NCT02459886 (ClinicalTrials.gov)	July 1, 2015	29/5/2015	Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease	A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease	Parkinson's Disease;Healthy	Drug: BIIB054;Drug: Placebo	Biogen	NULL	Completed	40 Years	80 Years	All	66	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	NCT02488265 (ClinicalTrials.gov)	July 1, 2015	21/5/2015	Protocol: Balance Training in Parkinson's Disease	Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease	Parkinson Disease	Other: Balance Training;Other: Screening to prevent falls	University of Sao Paulo General Hospital	NULL	Completed	50 Years	70 Years	All	150	N/A	Brazil
417	NCT02453386 (ClinicalTrials.gov)	July 2015	21/5/2015	Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)	Idiopathic Parkinson's Disease	Drug: tozadenant;Drug: placebo	Biotie Therapies Inc.	NULL	Terminated	30 Years	80 Years	All	449	Phase 3	United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04468919
(ClinicalTrials.gov)

July 1, 2021

8/7/2020

Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit

Amyotrophic Lateral Sclerosis;Brainstem Stroke;Muscular Dystrophies;Parkinson's Disease and Parkinsonism;Multiple System Atrophy;Brain Tumor Adult;Spinal Cord Injuries;Locked-in Syndrome

Behavioral: BCI-FIT multi-modal access;Behavioral: BCI-FIT adaptive signal modeling;Behavioral: BCI-FIT active querying;Behavioral: BCI-FIT language modeling

Oregon Health and Science University

NULL

Not yet recruiting

18 Years

75 Years

All

N/A

United States

NCT03309514
(ClinicalTrials.gov)

June 2021

10/10/2017

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease

Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease

Parkinson's Disease

Biological: Intracerebral microinjections

NeuroGeneration

NULL

Not yet recruiting

35 Years

85 Years

All

Phase 1;Phase 2

NULL

NCT04287543
(ClinicalTrials.gov)

May 2021

21/2/2020

Melatonin on Clock Genes in Parkinson's Disease

Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease

Parkinson Disease

Drug: Melatonin;Drug: Placebos

Instituto Mexicano del Seguro Social

NULL

Withdrawn

20 Years

N/A

All

Phase 2;Phase 3

Mexico

NCT04665869
(ClinicalTrials.gov)

March 15, 2021

7/12/2020

Long-term Effects of Combined Balance and Brisk Walking in Parkinson's Disease

Long-term Effects of Combined Balance and Brisk Walking on Alleviating Motor and Non-motor Symptoms in Parkinson's Disease: a Randomized Controlled Trial

Parkinson Disease

Behavioral: Combined balance and brisk walking training;Behavioral: Flexibility and strengthening exercise

The Hong Kong Polytechnic University

NULL

Not yet recruiting

30 Years

80 Years

All

N/A

NULL

NCT04322461
(ClinicalTrials.gov)

March 15, 2021

24/3/2020

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

Parkinson Disease;Alzheimer Disease

Dietary Supplement: Betaquik MCT supplement

Université de Sherbrooke

Nestlé

Not yet recruiting

60 Years

N/A

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04625361
(ClinicalTrials.gov)

January 1, 2021

9/11/2020

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects

A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects

Parkinson Disease

Drug: HEC122505MsOH

Sunshine Lake Pharma Co., Ltd.

NULL

Not yet recruiting

18 Years

45 Years

All

102

Phase 1

China

NCT04373317
(ClinicalTrials.gov)

January 1, 2021

29/4/2020

Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis

CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)

Parkinson's Disease Psychosis

Drug: Pimavanserin;Drug: Quetiapine

VA Office of Research and Development

NULL

Not yet recruiting

40 Years

N/A

All

358

Phase 4

United States

NCT04491383
(ClinicalTrials.gov)

January 2021

22/7/2020

Tocotrienols in Parkinson's Disease (PD)

Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial

Neuro-Degenerative Disease;Parkinson Disease

Drug: Tocovid Suprabio;Other: Placebo

National Neuroscience Institute

Hovid Berhad

Not yet recruiting

50 Years

90 Years

All

100

Phase 2

Singapore

NCT04643327
(ClinicalTrials.gov)

January 2021

18/11/2020

Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study

Parkinson Disease;Mild Cognitive Impairment;Memory Impairment

Drug: Levetiracetam;Drug: Placebo

The University of Queensland

Queensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's Hospital

Not yet recruiting

N/A

All

Phase 2

NULL

NCT04497168
(ClinicalTrials.gov)

January 2021

29/7/2020

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

Parkinson Disease

Drug: Citalopram 20mg;Drug: Placebo

University of Michigan

National Institute on Aging (NIA)

Not yet recruiting

65 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04590612
(ClinicalTrials.gov)

January 2021

17/9/2020

Improving Quality of Life in Early Parkinson's Disease

The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients

Parkinson Disease;Depression

Drug: Carbidopa -Levodopa 25 Mg-100 Mg Oral Tablet;Drug: Citalopram

Western University, Canada

NULL

Not yet recruiting

50 Years

80 Years

All

N/A

NULL

NCT04584346
(ClinicalTrials.gov)

December 17, 2020

10/10/2020

Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)

Parkinson's Disease

Dietary Supplement: Liquigen MCT oil

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Recruiting

50 Years

N/A

All

Phase 1

United States

NCT04377945
(ClinicalTrials.gov)

December 1, 2020

4/5/2020

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components

Dyskinesia, Drug-Induced

Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, Placebo Group;Drug: Part 2, JM-010 component Group C

Bukwang Pharmaceutical

NULL

Not yet recruiting

18 Years

80 Years

All

188

Phase 2

United States

NCT04147949
(ClinicalTrials.gov)

December 2020

27/10/2019

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use

Drug: AV-101;Drug: Placebo

VistaGen Therapeutics, Inc.

NULL

Not yet recruiting

30 Years

80 Years

All

Phase 2

NULL

NCT04346394
(ClinicalTrials.gov)

December 2020

10/3/2020

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms

Parkinson Disease

Drug: Yohimbine HCl

Nathaniel M. Robbins

NULL

Not yet recruiting

N/A

All

Early Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04658186
(ClinicalTrials.gov)

December 2020

1/12/2020

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

Early-stage Parkinson's Disease

Drug: UCB0599;Drug: Placebo

UCB Biopharma SRL

NULL

Not yet recruiting

40 Years

70 Years

All

300

Phase 2

NULL

NCT04651153
(ClinicalTrials.gov)

December 2020

25/11/2020

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease

Parkinson's Disease

Drug: UCB7853;Other: Placebo

UCB Biopharma SRL

NULL

Not yet recruiting

18 Years

80 Years

All

Phase 1

NULL

NCT04634331
(ClinicalTrials.gov)

November 15, 2020

9/11/2020

Dual-task Augmented Reality Treatment for Parkinson's Disease

Dual-task Augmented Reality Treatment for Parkinson's Disease (DART)

Parkinson Disease

Behavioral: Augmented Reality Multi-Modal Training;Behavioral: Traditional Multi-Modal Training

The Cleveland Clinic

Michael J. Fox Foundation for Parkinson's Research

Recruiting

18 Years

N/A

All

Phase 2

United States

NCT04620382
(ClinicalTrials.gov)

November 9, 2020

27/10/2020

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease

Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression

Vanderbilt University Medical Center

NULL

Recruiting

40 Years

80 Years

All

Early Phase 1

United States

NCT04506073
(ClinicalTrials.gov)

November 9, 2020

16/7/2020

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD

Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease: Phase IIa Double-blind Randomized Placebo Controlled Trial

Parkinson's Disease

Drug: MSC+placebo;Drug: MSC;Drug: Placebo

The University of Texas Health Science Center, Houston

Michael J. Fox Foundation for Parkinson's Research

Recruiting

50 Years

79 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04277247
(ClinicalTrials.gov)

November 2, 2020

10/2/2020

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

Botulinum Toxin A (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Control Study

Dystonia Disorder;Parkinson Disease

Drug: Botulinum toxin type A;Drug: Placebo

University of Calgary

Allergan

Recruiting

30 Years

100 Years

All

Phase 2;Phase 3

Canada

NCT04386317
(ClinicalTrials.gov)

November 1, 2020

24/4/2020

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson Disease

Drug: Terazosin

Cedars-Sinai Medical Center

NULL

Recruiting

25 Years

85 Years

All

Phase 2

United States

NCT03903549
(ClinicalTrials.gov)

November 1, 2020

3/4/2019

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)

Parkinson Disease

Drug: [18F]P17-059

Five Eleven Pharma, Inc.

NULL

Not yet recruiting

45 Years

90 Years

All

Phase 1

United States

NCT04435431
(ClinicalTrials.gov)

October 29, 2020

15/6/2020

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

Parkinson Disease

Drug: Mesdopetam;Drug: Placebo

Integrative Research Laboratories AB

NULL

Recruiting

30 Years

79 Years

All

140

Phase 2

United States

NCT04542499
(ClinicalTrials.gov)

October 27, 2020

2/9/2020

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

368

Phase 3

United States;Australia;Czechia;Germany;Hungary;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03947216
(ClinicalTrials.gov)

October 23, 2020

7/5/2019

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease

Parkinson Disease

Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring

University Hospital, Strasbourg, France

NS-PARK;EUCLID;F-CRIN

Recruiting

35 Years

75 Years

All

130

Phase 2

France

NCT04334317
(ClinicalTrials.gov)

October 21, 2020

30/3/2020

Effect of TAK-071 on Falls in Participants With Parkinson Disease (PD)

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls

Parkinson's Disease

Drug: TAK-071;Drug: Placebo

Takeda

Michael J. Fox Foundation for Parkinson's Research

Recruiting

40 Years

85 Years

All

Phase 2

United States

NCT04380142
(ClinicalTrials.gov)

October 19, 2020

6/5/2020

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Parkinson's Disease (PD)

Drug: ABBV-951;Drug: Placebo for Levodopa /Carbidopa (LD/CD);Drug: Levodopa /Carbidopa (LD/CD);Drug: Placebo for ABBV-951

AbbVie

NULL

Recruiting

30 Years

N/A

All

130

Phase 3

United States;Australia

NCT04502550
(ClinicalTrials.gov)

October 15, 2020

30/7/2020

Brain Networks and Consciousness

Subcortical-cortical Network Dynamics of Anesthesia and Consciousness

Loss of Consciousness;Parkinson Disease;Essential Tremor;Anesthesia

Drug: Propofol

University of California, Los Angeles

NULL

Recruiting

18 Years

N/A

All

United States

NCT04338997
(ClinicalTrials.gov)

October 2020

3/4/2020

PK Study in Patients With Parkinson's Disease With IZD174

An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease

Parkinson Disease

Drug: IZD174

Inflazome UK Ltd

NULL

Withdrawn

45 Years

75 Years

All

Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04593511
(ClinicalTrials.gov)

October 2020

21/9/2020

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection

Parkinson's Disease

Drug: LY03009 F1;Drug: LY03009 F2;Drug: LY03009 F3;Drug: LY03009 F4

Luye Pharma Group Ltd.

NULL

Not yet recruiting

18 Years

65 Years

All

Phase 1

NULL

NCT03665493
(ClinicalTrials.gov)

September 30, 2020

4/9/2018

Dopamine Effect on Inhibitory Control

Idiopathic Parkinson's Disease

Drug: PD patients H&Y=1.5-2 Medications ON;Drug: PD patients H&Y=1.5-2 Medications OFF;Behavioral: Healthy age-matched controls;Drug: PD patients H&Y=3 Medications OFF;Drug: PD patients H&Y=3 Medications ON

Giovanni Mirabella

NULL

Recruiting

40 Years

70 Years

All

102

N/A

Italy

NCT03968133
(ClinicalTrials.gov)

September 30, 2020

28/5/2019

Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic

Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic - a Randomized, Placebo-controlled Trial

Parkinson Disease;Anxiety

Dietary Supplement: Probiotic;Dietary Supplement: Placebo

University of British Columbia

The W. Garfield Weston Foundation

Not yet recruiting

40 Years

80 Years

All

Phase 2

Canada

NCT04591535
(ClinicalTrials.gov)

September 28, 2020

11/9/2020

PK Study of WD-1603 in Healthy Subjects

An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions

Parkinson Disease

Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Hong Kong WD Pharmaceutical Co., Limited

NULL

Recruiting

18 Years

45 Years

All

Phase 1

India

NCT04553978
(ClinicalTrials.gov)

September 18, 2020

13/9/2020

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions

Parkinson Disease

Drug: WD-1603

Hong Kong WD Pharmaceutical Co., Limited

NULL

Not yet recruiting

18 Years

45 Years

All

Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04387773
(ClinicalTrials.gov)

September 15, 2020

11/5/2020

Effect of GOCOVRI on Gait in Parkinson's Disease

Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease

Parkinson Disease

Drug: GOCOVRI

Oregon Health and Science University

Adamas Pharmaceuticals, Inc.

Not yet recruiting

50 Years

70 Years

All

Phase 4

United States

NCT04476017
(ClinicalTrials.gov)

September 11, 2020

15/7/2020

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment

Parkinson Disease;Cognitive Dysfunction

Drug: SAGE-718

Sage Therapeutics

NULL

Recruiting

50 Years

75 Years

All

Phase 2

United States

NCT04332276
(ClinicalTrials.gov)

September 2020

25/3/2020

Dopaminergic restauratIon by intraVEntriculaire Administration

A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?

Parkinson Disease

Drug: A-dopamine

University Hospital, Lille

InBrain Pharma

Not yet recruiting

45 Years

75 Years

All

Phase 1;Phase 2

NULL

NCT04524351
(ClinicalTrials.gov)

August 14, 2020

11/8/2020

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)

Alzheimer Disease;Parkinson Disease

Drug: Posiphen

Annovis Bio Inc.

Parexel

Recruiting

45 Years

N/A

All

Phase 1;Phase 2

United States

NCT04513340
(ClinicalTrials.gov)

August 13, 2020

12/8/2020

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS

Parkinson Disease

Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

Hong Kong WD Pharmaceutical Co., Limited

NULL

Recruiting

18 Years

45 Years

All

Phase 1

India

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04449484
(ClinicalTrials.gov)

August 4, 2020

23/4/2019

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: MEDI1341;Other: Placebo

AstraZeneca

NULL

Recruiting

40 Years

85 Years

All

Phase 1

United States

NCT04483479
(ClinicalTrials.gov)

July 30, 2020

20/7/2020

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover)

A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period

Parkinson Disease;Constipation

Drug: Active Investigational Treatment ENT-01

Enterin Inc.

NULL

Recruiting

30 Years

90 Years

All

Phase 2

United States

NCT04275492
(ClinicalTrials.gov)

July 24, 2020

18/11/2019

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

Parkinson's Disease

Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride);Drug: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)

First Affiliated Hospital of Zhejiang University

Hongguan biological pharmaceutical co.

Recruiting

18 Years

45 Years

All

N/A

China

NCT04630860
(ClinicalTrials.gov)

July 7, 2020

5/11/2020

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Recruiting

18 Years

80 Years

All

Phase 1

China

NCT04193527
(ClinicalTrials.gov)

July 2020

2/12/2019

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls

Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)

Drug: DaTSCAN ™ Ioflupane (123I) Injection

GE Healthcare

PPD

Not yet recruiting

40 Years

80 Years

All

172

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04428112
(ClinicalTrials.gov)

June 5, 2020

9/6/2020

Rural Dementia Caregiver Project

Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias

Depression;Stress, Psychological;Self Efficacy;Loneliness;Social Isolation;Health Care Utilization;Dementia;Dementia Alzheimers;Dementia of Alzheimer Type;Dementia, Vascular;Dementia Frontal;Dementia, Lewy Body;Dementia, Mixed;Dementia in Parkinsons Disease;Dementia, HIV;Dementia Frontotemporal;Dementia, Multi-Infarct

Behavioral: Building Better Caregivers Workshop;Behavioral: Attention Control

University of California, San Francisco

National Institute on Aging (NIA)

Recruiting

18 Years

N/A

All

640

N/A

United States

NCT04384666
(ClinicalTrials.gov)

June 2, 2020

8/5/2020

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection);Other: Neupro 4 mg / 24 Hr. Transdermal Patch

Luye Pharma Group Ltd.

NULL

Completed

18 Years

45 Years

All

Phase 1

United States

NCT04414813
(ClinicalTrials.gov)

June 2020

21/5/2019

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Clinical Study of Stereotactic Transplantation of Human Amniotic Epithelial Stem Cells (hAESCs) in the Treatment of Parkinson's Disease (PD)

Parkinson's Disease

Biological: Human Amniotic Epithelial Stem Cells

Shanghai East Hospital

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Not yet recruiting

30 Years

70 Years

All

Early Phase 1

NULL

NCT04379050
(ClinicalTrials.gov)

May 19, 2020

1/5/2020

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Enrolling by invitation

30 Years

N/A

All

121

Phase 3

United States;Australia;Belgium;Canada;Denmark;Italy;Japan;Netherlands;Spain;United Kingdom

NCT03568968
(ClinicalTrials.gov)

May 15, 2020

14/6/2018

A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease

A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study

Parkinson Disease

Dietary Supplement: Nicotinamide Riboside;Drug: Placebo

Haukeland University Hospital

NULL

Recruiting

18 Years

N/A

All

400

N/A

Norway

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04571164
(ClinicalTrials.gov)

May 11, 2020

21/9/2020

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

A Multi-centre,Randomized,Double-blind,Placebo Parallel Controlled Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

Drug: LY03003(Rotigotine,extended-release microspheres);Drug: Placebo,extended-release microspheres

Luye Pharma Group Ltd.

Parexel

Recruiting

30 Years

N/A

All

294

Phase 3

China

NCT04265209
(ClinicalTrials.gov)

May 2020

6/2/2020

[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.

Parkinson Disease;Essential Tremor

Drug: SPECT;Drug: PET

Zionexa

NULL

Not yet recruiting

35 Years

80 Years

All

112

Phase 3

NULL

NCT04459052
(ClinicalTrials.gov)

April 30, 2020

26/6/2020

FDOPA PET and Nutritional Support in Parkinson's Disease

Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Parkinson Disease;Idiopathic Parkinson Disease

Dietary Supplement: N acetyl cysteine;Drug: [F-18] Fluorodopa Positron Emission Tomography

Thomas Jefferson University

NULL

Active, not recruiting

30 Years

N/A

All

Phase 2

United States

NCT04182399
(ClinicalTrials.gov)

April 1, 2020

24/11/2019

Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study

Parkinson Disease

Drug: Zonisamide Capsules

Ain Shams University

NULL

Recruiting

18 Years

N/A

All

N/A

Egypt

NCT02967250
(ClinicalTrials.gov)

April 1, 2020

13/9/2016

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

Parkinson Disease

Drug: ursodeoxycholic acid

University of Minnesota

NULL

Not yet recruiting

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04167540
(ClinicalTrials.gov)

April 1, 2020

7/11/2019

GDNF Gene Therapy for Parkinson's Disease

Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease

Parkinson's Disease

Biological: AAV2-GDNF

Brain Neurotherapy Bio, Inc.

NULL

Recruiting

35 Years

75 Years

All

Phase 1

United States

NCT04342273
(ClinicalTrials.gov)

March 31, 2020

8/4/2020

A Through QT/QTc Study of KW-6356

A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults

Parkinson's Disease

Drug: KW-6356;Drug: Placebo;Drug: Moxifloxacin

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

54 Years

All

128

Phase 1

Japan

NCT04269642
(ClinicalTrials.gov)

March 19, 2020

13/1/2020

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease

Early Parkinson's Disease

Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg

Peptron, Inc.

NULL

Recruiting

40 Years

75 Years

All

Phase 2

Korea, Republic of

EUCTR2018-003941-41-AT
(EUCTR)

05/03/2020

19/06/2019

This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

NCT04127695
(ClinicalTrials.gov)

March 3, 2020

9/10/2019

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ABBV-0805;Drug: Placebo ABBV-0805

AbbVie

NULL

Withdrawn

N/A

85 Years

All

Phase 1

United States;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04353947
(ClinicalTrials.gov)

March 2, 2020

16/4/2020

Induction and Recognition of Emotions

Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease

Healthy Older Adults;Alzheimer's Disease;Parkinson's Disease

Diagnostic Test: Mini Cognitive Examination (MCE);Diagnostic Test: Beck Depression Inventory-II (BDI-II);Diagnostic Test: Global Deterioration Scale (GDS);Diagnostic Test: Memory alteration test (M@T);Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC);Diagnostic Test: Barcelona test (BT);Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT);Diagnostic Test: Frontal assessment battery (FAB);Diagnostic Test: Positive and Negative Affect Scale (PANAS);Diagnostic Test: Auto-Assessment Manikins (SAM)

University of Valencia

Asociación Parkinson Valencia

Recruiting

65 Years

99 Years

All

Spain

NCT04260581
(ClinicalTrials.gov)

March 1, 2020

5/2/2020

Is Long-term Use of Amantadine Effective in PD?

Is Long-term Use of Amantadine Effective in Parkinson Disease?

Parkinson Disease

Drug: Determination of drug effects through amantadine cessation

Seoul National University Hospital

NULL

Not yet recruiting

40 Years

N/A

All

N/A

Korea, Republic of

NCT04154072
(ClinicalTrials.gov)

February 27, 2020

4/11/2019

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease

Parkinson Disease

Drug: NLY01;Drug: Vehicle

Neuraly, Inc.

NULL

Recruiting

30 Years

80 Years

All

240

Phase 2

United States;Canada

NCT04291859
(ClinicalTrials.gov)

February 26, 2020

28/2/2020

Lu AF28996 in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease

Parkinson Disease

Drug: Lu AF28996

H. Lundbeck A/S

NULL

Recruiting

45 Years

75 Years

All

Phase 1

Netherlands

NCT04292223
(ClinicalTrials.gov)

February 10, 2020

28/2/2020

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

Drug: Pimavanserin

ACADIA Pharmaceuticals Inc.

NULL

Recruiting

40 Years

N/A

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04251585
(ClinicalTrials.gov)

February 4, 2020

28/1/2020

Intranasal Insulin in Parkinson's Disease

Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease

Parkinson Disease

Drug: Regular Novolin R;Drug: Placebo

HealthPartners Institute

NULL

Recruiting

41 Years

89 Years

All

Phase 2

United States

NCT04246437
(ClinicalTrials.gov)

February 4, 2020

25/1/2020

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies

Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose

Daniel Claassen

NULL

Recruiting

18 Years

N/A

All

Phase 1

United States

NCT04117178
(ClinicalTrials.gov)

February 4, 2020

30/9/2019

Monitoring Anti-Dementia Drugs by Serum Levels

Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)

Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease

Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug

Zealand University Hospital

Epilepsihospitalet Filadelfia

Recruiting

18 Years

N/A

All

110

Phase 4

Denmark

EUCTR2018-003941-41-PT
(EUCTR)

03/02/2020

21/08/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

NCT04428983
(ClinicalTrials.gov)

February 3, 2020

20/11/2019

The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease

Parkinson Disease

Dietary Supplement: Hericium erinaceus mycelium

National Cheng-Kung University Hospital

NULL

Recruiting

50 Years

79 Years

All

N/A

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04322227
(ClinicalTrials.gov)

January 23, 2020

29/1/2020

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects

Parkinson Disease;Healthy

Drug: Foliglurax 10 mg (treatment A);Drug: Foliglurax 30 mg (treatment B);Drug: Placebo (treatment C)

H. Lundbeck A/S

NULL

Terminated

50 Years

70 Years

All

Phase 1

France

NCT04305002
(ClinicalTrials.gov)

January 21, 2020

20/2/2020

Exenatide Treatment in Parkinson's Disease

Effect of Exenatide on Disease Progression in Early Parkinson's Disease

Parkinson Disease

Drug: Exenatide;Drug: Placebo

Center for Neurology, Stockholm

Karolinska Institutet

Recruiting

25 Years

80 Years

All

Phase 2

Sweden

NCT04220762
(ClinicalTrials.gov)

January 21, 2020

17/12/2019

A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients

A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study

Parkinson Disease

Drug: WIN-1001X;Drug: Placebo

Medi Help Line

NULL

Recruiting

30 Years

N/A

All

188

Phase 2

Korea, Republic of

NCT04232969
(ClinicalTrials.gov)

January 20, 2020

10/1/2020

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Parkinson's Disease

Drug: Exenatide extended release 2mg (Bydureon)

University College, London

NULL

Recruiting

25 Years

80 Years

All

200

Phase 3

United Kingdom

NCT04369430
(ClinicalTrials.gov)

January 16, 2020

13/4/2020

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

Parkinson Disease

Drug: AKST4290;Drug: Placebo

Alkahest, Inc.

NULL

Recruiting

50 Years

80 Years

All

120

Phase 2

United States;Estonia;Germany;Poland;Slovakia;Hungary

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-001657-42-SK
(EUCTR)

14/01/2020

01/10/2019

A study to learn how well the drug AKST4290 works and how safeAKST4290 is in people who have Parkinson's disease that are takingdopamine based medication.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEfficacy and Safety of AKST4290 in Subjects with Parkinson's Disease onStable Dopaminergic Treatment. - N/A

Parkinson's Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: AKST4290
Product Code: AKST4290
INN or Proposed INN: AKST4290
Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE

Alkahest, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Phase 2

United States;Hungary;Estonia;Slovakia;Poland;Germany

NCT04295642
(ClinicalTrials.gov)

January 8, 2020

24/1/2020

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: CVL-751

Cerevel Therapeutics, LLC

NULL

Recruiting

45 Years

75 Years

All

Phase 1

United States

NCT04223193
(ClinicalTrials.gov)

January 6, 2020

7/1/2020

Flexible-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

296

Phase 3

United States

NCT04127578
(ClinicalTrials.gov)

January 3, 2020

14/10/2019

Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation

Parkinson Disease

Biological: PR001A;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone

Prevail Therapeutics

NULL

Recruiting

35 Years

80 Years

All

Phase 1;Phase 2

United States

NCT04226248
(ClinicalTrials.gov)

January 2, 2020

5/12/2019

CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.

Parkinson Disease

Drug: Rivastigmine Transdermal System;Other: Placebo Transdermal System

University of Bristol

Royal United Hospitals Bath NHS Foundation Trust

Recruiting

18 Years

N/A

All

600

Phase 3

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03808961
(ClinicalTrials.gov)

January 1, 2020

16/1/2019

Niacin for Parkinsons Disease

NAPS: Niacin for Parkinsons Disease

Parkinson's Disease

Dietary Supplement: Niacin;Dietary Supplement: Niacinamide;Other: Placebo

VA Office of Research and Development

NULL

Recruiting

35 Years

N/A

All

100

N/A

United States

NCT04301492
(ClinicalTrials.gov)

January 1, 2020

17/2/2020

Tolerability, Safety and Efficacy of Vortioxetine

Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study

Depression

Drug: Vortioxetine

IRCCS San Raffaele

NULL

Recruiting

30 Years

80 Years

All

Phase 4

Italy

NCT04152655
(ClinicalTrials.gov)

January 1, 2020

7/10/2019

A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease

A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)

REM Sleep Behavior Disorder;Parkinson Disease

Drug: Idebenone;Drug: Placebo oral tablet

Second Affiliated Hospital, School of Medicine, Zhejiang University

NULL

Recruiting

18 Years

N/A

All

180

Phase 2;Phase 3

China

NCT03446807
(ClinicalTrials.gov)

January 2020

20/2/2018

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy

Drug: Droxidopa;Drug: Placebo Oral Tablet

Loma Linda University

H. Lundbeck A/S

Not yet recruiting

50 Years

N/A

All

Phase 2

United States

NCT04218968
(ClinicalTrials.gov)

December 30, 2019

26/12/2019

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study

REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease

Drug: Carvedilol

Cedars-Sinai Medical Center

NULL

Enrolling by invitation

18 Years

85 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03815916
(ClinicalTrials.gov)

December 19, 2019

18/1/2019

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease

Parkinson's Disease

Drug: Gold Nanocrystals

Clene Nanomedicine

University of Texas Southwestern Medical Center

Recruiting

30 Years

80 Years

All

Phase 2

United States

NCT04164121
(ClinicalTrials.gov)

December 17, 2019

12/11/2019

A Clinical Study Trial of Phenlarmide in China

A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose, Incremental Tolerance and Pharmacokinetics Study of Phenlarmide Tablets in Chinese Healthy Adult Volunteers

Parkinson Disease

Drug: Phenlarmide Tablets;Drug: Placebos

Yiling Pharmaceutical Inc.

NULL

Recruiting

18 Years

65 Years

All

Phase 1

China

NCT04097080
(ClinicalTrials.gov)

December 15, 2019

18/9/2019

Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Parkinson Disease

Drug: NBTX-001;Drug: Standard of Care

Nobilis Therapeutics Inc.

NULL

Recruiting

18 Years

N/A

All

Phase 1

Russian Federation

NCT04201093
(ClinicalTrials.gov)

December 13, 2019

13/12/2019

Fixed-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

Parkinson Disease

Drug: Tavapadon;Drug: Placebo

Cerevel Therapeutics, LLC

NULL

Recruiting

40 Years

80 Years

All

522

Phase 3

United States;Australia

NCT04183634
(ClinicalTrials.gov)

December 3, 2019

28/11/2019

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Parkinson Disease

Drug: Rotigotine TTS (Test);Drug: Neupro (Reference)

Sandoz

NULL

Terminated

18 Years

80 Years

All

Phase 1

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04249544
(ClinicalTrials.gov)

December 3, 2019

28/1/2020

Social Decision Making in Parkinson's Disease

Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Dopamine Agonists

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Vanderbilt University Medical Center

United States Department of Defense

Recruiting

45 Years

80 Years

All

Phase 1

United States

NCT04191577
(ClinicalTrials.gov)

December 2, 2019

30/10/2019

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

Drug: CVN424 Low Dose;Drug: CVN424 High Dose;Drug: Placebo

Cerevance Beta, Inc.

NULL

Recruiting

30 Years

80 Years

All

Phase 2

United States

NCT04044131
(ClinicalTrials.gov)

December 1, 2019

17/7/2019

Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients

Alzheimer Disease;Parkinson Disease

Drug: Metabolic Cofactor Supplementation;Drug: Sorbitol

Istanbul Medipol University Hospital

ScandiBio Therapeutics AB;Alanya Alaaddin Keykubat University;Sahlgrenska University Hospital, Sweden;KTH Royal Institute of Technology

Recruiting

18 Years

N/A

All

120

Phase 2

Turkey

NCT03436953
(ClinicalTrials.gov)

December 2019

7/2/2018

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease

Parkinson's Disease;Tremor

Drug: CX-8998;Drug: Placebo

Jazz Pharmaceuticals

NULL

Not yet recruiting

40 Years

80 Years

All

Phase 2

United States

NCT03924414
(ClinicalTrials.gov)

November 15, 2019

2/4/2019

Trial of Parkinson's And Zoledronic Acid

TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease

Parkinson Disease;Osteoporosis;Parkinsonism

Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo

California Pacific Medical Center Research Institute

National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation

Recruiting

60 Years

N/A

All

3500

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04148391
(ClinicalTrials.gov)

November 14, 2019

30/10/2019

A Study to Evaluate NYX-458 in Subjects With PD-MCI

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease;Mild Cognitive Impairment

Drug: Placebo Oral Capsule;Drug: NYX-458

Aptinyx

CogState Ltd.;Worldwide Clinical Trials

Active, not recruiting

50 Years

80 Years

All

135

Phase 2

United States

NCT04175132
(ClinicalTrials.gov)

November 12, 2019

12/11/2019

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease

Healthy;Parkinson Disease

Drug: foliglurax

H. Lundbeck A/S

NULL

Terminated

50 Years

70 Years

All

Phase 1

Sweden

NCT03652870
(ClinicalTrials.gov)

November 1, 2019

8/8/2018

Antidepressants Trial in Parkinson's Disease

A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease

Depression;Parkinson Disease

Drug: Nortriptyline;Drug: Escitalopram;Drug: Placebo

University College, London

London North West Healthcare NHS Trust;King's College London;University Hospital Plymouth NHS Trust;NHS Lothian

Not yet recruiting

18 Years

85 Years

All

408

Phase 3

NULL

EUCTR2018-003941-41-DK
(EUCTR)

29/10/2019

24/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Denmark;Australia;Bulgaria;Germany;New Zealand

100

NCT04164758
(ClinicalTrials.gov)

October 23, 2019

13/11/2019

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Parkinson's Disease

Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine

ACADIA Pharmaceuticals Inc.

NULL

Terminated

50 Years

85 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

101

EUCTR2019-001657-42-DE
(EUCTR)

22/10/2019

11/06/2019

A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment - N/A

Alkahest, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

120

Phase 2

United States;Estonia;Hungary;Slovakia;Poland;Germany

102

ChiCTR1900026956

2019-10-21

2019-10-27

Minimum alveolar concentration-awake of sevoflurane in patients with Parkinson's disease

Parkinson’s disease

Parkinson’s disease group:Sevoflurane induction;Non-Parkinson’s disease group:Sevoflurane induction;

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

NULL

Pending

Both

Parkinson’s disease group:30;Non-Parkinson’s disease group:30;

N/A

China

103

NCT04273932
(ClinicalTrials.gov)

October 17, 2019

31/10/2019

Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.

Parkinson Disease

Drug: Lithium

University at Buffalo

NULL

Recruiting

45 Years

80 Years

All

Phase 1

United States

104

NCT04157933
(ClinicalTrials.gov)

October 16, 2019

1/11/2019

Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease

Parkinson's Disease

Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug: 009-B2 (placebo --> active) crossover

Alexza Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 1

Netherlands

105

NCT04165837
(ClinicalTrials.gov)

October 14, 2019

13/11/2019

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

Drug: FB-101;Drug: Placebo

1ST Biotherapeutics, Inc.

NULL

Recruiting

19 Years

55 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

106

NCT04146454
(ClinicalTrials.gov)

October 14, 2019

16/10/2019

Smartphone-based Wearable Telerehabilitation

A New Smartphone-based Wearable Telerehabilitation System for People With Parkinson's Disease

Parkinson Disease

Other: Smartphone-based balance exercises

University of Houston

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Enrolling by invitation

50 Years

75 Years

All

N/A

United States

107

JPRN-jRCTs031190115

11/10/2019

PK & PD of coadministration of XOR inhibitor and inosine

Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine

Parkinson's disease
neurodegenerative disease

Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine

Kamatani Naoyuki

NULL

Recruiting

>= 20age old

<= 40age old

Male

Phase 1

Japan

108

NCT04575259
(ClinicalTrials.gov)

October 10, 2019

29/9/2020

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Parkinson Disease Dementia

Drug: ANAVEX2-73

Anavex Life Sciences Corp.

Anavex Australia Pty Ltd.;Anavex Germany GmbH

Recruiting

50 Years

85 Years

All

120

Phase 2

Australia;Spain

109

EUCTR2018-003941-41-BG
(EUCTR)

10/10/2019

26/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

110

NCT03987750
(ClinicalTrials.gov)

October 2019

12/6/2019

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations

Dyskinesia, Drug-Induced;Parkinson Disease

Drug: Safinamide Methanesulfonate 150mg;Drug: Safinamide Methanesulfonate 100mg;Drug: Safinamide Methanesulfonate matching placebo

Zambon SpA

NULL

Withdrawn

30 Years

N/A

All

Phase 3

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

111

NCT03905811
(ClinicalTrials.gov)

September 24, 2019

1/4/2019

Terazosin for Parkinson's Disease

A Pilot Study of Terazosin for Parkinson's Disease

Parkinson Disease

Drug: Terazosin 5 MG;Drug: Placebo oral capsule

Jordan Schultz

University of Iowa

Enrolling by invitation

40 Years

90 Years

All

Phase 1;Phase 2

United States

112

NCT04477161
(ClinicalTrials.gov)

September 5, 2019

22/6/2020

Effect of Ketone Esters in Parkinson's Disease

Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.

Parkinson Disease;Ketosis

Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink;Other: Stool Sample

University of Florida

NULL

Recruiting

40 Years

75 Years

All

N/A

United States

113

NCT04054960
(ClinicalTrials.gov)

September 2019

9/8/2019

A Trial of tPCS on Parkinson's Disease OFF State

Parkinson Disease

Device: Active tPCS;Device: Sham tPCS;Drug: Levodopa tablet

Western University, Canada

NULL

Not yet recruiting

40 Years

80 Years

All

N/A

Canada

114

NCT03959540
(ClinicalTrials.gov)

September 2019

23/4/2019

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

A Multinational, Multicentre, Prospective Non-interventional Study to Assess Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Parkinson Disease

Drug: Opicapone;Drug: Levodopa (L-DOPA) + Standard care

Bial - Portela C S.A.

NULL

Not yet recruiting

75 Years

N/A

All

100

NULL

115

NCT04075318
(ClinicalTrials.gov)

August 29, 2019

5/8/2019

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease

Parkinson Disease;Parkinsonism

Biological: UB-312;Biological: Placebo

United Neuroscience Ltd.

Centre for Human Drug Research, Netherlands;Worldwide Clinical Trials

Active, not recruiting

40 Years

85 Years

All

Phase 1

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

116

NCT04006210
(ClinicalTrials.gov)

August 27, 2019

30/6/2019

A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).

A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

Combination Product: ND0612 Solution for SC infusion;Combination Product: Placebo for SC infusion;Drug: Carbidopa and Levodopa 25mg/100mg;Drug: Placebo for Carbidopa and Levodopa 25mg/100mg

NeuroDerm Ltd.

NULL

Recruiting

30 Years

80 Years

All

380

Phase 3

United States;Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom

117

EUCTR2018-003941-41-PL
(EUCTR)

23/08/2019

03/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

118

NCT04062526
(ClinicalTrials.gov)

August 14, 2019

14/8/2019

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)

Parkinson Disease;Healthy Volunteer

Drug: [18F]NOS

University of Pennsylvania

NULL

Recruiting

18 Years

75 Years

All

Early Phase 1

United States

119

EUCTR2018-003941-41-ES
(EUCTR)

13/08/2019

11/06/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

120

NCT03976349
(ClinicalTrials.gov)

August 12, 2019

4/6/2019

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease

Parkinson's Disease

Drug: BIIB094;Drug: Placebo

Biogen

Ionis Pharmaceuticals, Inc.

Recruiting

35 Years

80 Years

All

Phase 1

United States;Canada;Israel;Norway;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

121

NCT04043338
(ClinicalTrials.gov)

August 11, 2019

24/7/2019

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects

Parkinson's Disease

Drug: XC130-A10H;Drug: Placebo

Xoc Pharmaceuticals

Celerion

Recruiting

18 Years

75 Years

All

Phase 1

United States

122

EUCTR2018-003941-41-GB
(EUCTR)

09/08/2019

16/05/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Code: TD-9855
INN or Proposed INN: ampreloxetine hydrochloride
Other descriptive name: TD-9855

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand

123

NCT03881371
(ClinicalTrials.gov)

August 1, 2019

18/3/2019

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

Drug: Safinamide;Other: Placebo

Zambon SpA

NULL

Recruiting

18 Years

N/A

All

306

Phase 3

China

124

JPRN-UMIN000037421

2019/08/01

01/08/2019

A study on improvement of cognitive function by istradefylline for parkinson disease

An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - A study on improvement of cognitive function by istradefylline for parkinson disease

Parkinson disease

Prescription istradefylline 20 mg for 1 month. If there are no side effects, We increase to 40 mg and prescribe for 2 months.
The assessments will be made in all patients participating the study, patients with MMSE scores of 26 or more, patients with MMSE score of less than 26.

Ichinomiya Nishi Hospital

NULL

Recruiting

40years-old

85years-old

Male and Female

Not selected

Japan

125

EUCTR2018-003941-41-HU
(EUCTR)

30/07/2019

01/08/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

126

NCT04056689
(ClinicalTrials.gov)

July 23, 2019

12/8/2019

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: DNL151;Drug: Placebo

Denali Therapeutics Inc.

NULL

Active, not recruiting

30 Years

75 Years

All

Phase 1

United States;Belgium;Netherlands;United Kingdom

127

NCT03956979
(ClinicalTrials.gov)

July 22, 2019

17/5/2019

A Study in Parkinson's Disease in paTients With mOderate to seveRe dyskInesiA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010

Dyskinesias

Drug: JM -010 group A;Drug: JM -010 group B;Drug: Placebos

Contera Pharma

Bukwang Pharmaceutical

Recruiting

18 Years

80 Years

All

Phase 2

Germany

128

NCT03575195
(ClinicalTrials.gov)

July 15, 2019

21/6/2018

Microbiota Intervention to Change the Response of Parkinson's Disease

Parkinson Disease

Drug: Rifaximin;Other: Placebo

University of California, San Francisco

Nova Southeastern University;Gateway Institute for Brain Research

Recruiting

30 Years

N/A

All

Phase 1;Phase 2

United States

129

EUCTR2018-003941-41-EE
(EUCTR)

04/07/2019

29/05/2019

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood

Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Theravance Biopharma Ireland Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

258

Phase 3

United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand

130

NCT03977441
(ClinicalTrials.gov)

July 2019

12/5/2019

the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease

Parkinson Disease;Depression;Sleep Disorders;Circadian Rhythm Disorders

Drug: Agomelatine or PIacebo

Second Affiliated Hospital of Soochow University

NULL

Not yet recruiting

30 Years

75 Years

All

240

Phase 4

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

131

NCT03938922
(ClinicalTrials.gov)

June 13, 2019

18/4/2019

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.

Parkinson Disease;Dementia

Drug: Active Investigational Treatment ENT-01

Enterin Inc.

NULL

Active, not recruiting

30 Years

90 Years

All

Phase 1

United States

132

NCT03939559
(ClinicalTrials.gov)

June 10, 2019

3/5/2019

The Efficiency of Home Based Dual Task Training in Parkinson Disease

Parkinson Disease

Procedure: Static, dynamic and functional balance exercises;Procedure: Static, dynamic and functional balance exercises with dual task

Istanbul University-Cerrahpasa

NULL

Not yet recruiting

30 Years

80 Years

All

N/A

NULL

133

NCT04389762
(ClinicalTrials.gov)

June 4, 2019

30/4/2020

PS128 May Improve Off Duration on Parkinson's Disease

Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study

Parkinson Disease

Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128

Professor Lu Neurological Clinic

NULL

Completed

40 Years

80 Years

All

N/A

Taiwan

134

NCT04064294
(ClinicalTrials.gov)

June 1, 2019

19/8/2019

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins

Parkinson Disease;Dyskinesia, Drug-Induced

Drug: Intravenous Infusion

VA Office of Research and Development

Oregon Health and Science University

Recruiting

50 Years

N/A

All

120

United States

135

JPRN-UMIN000036908

2019/05/31

31/05/2019

A dementia study by 11C-PiB, 18F-FDG PET

A dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET

mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.

11C-PiB, 18F-FDG PET

Nagoya City Rehabilitation Agency

NULL

Recruiting

20years-old

Not applicable

Male and Female

150

Not applicable

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

136

NCT03971617
(ClinicalTrials.gov)

May 29, 2019

30/5/2019

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson's Disease

Parkinson Disease

Drug: Hydrogen;Drug: Placebo oral tablet

Stony Brook University

NULL

Recruiting

40 Years

80 Years

All

Phase 2;Phase 3

United States

137

NCT03671785
(ClinicalTrials.gov)

May 15, 2019

12/9/2018

Study of the Fecal Microbiome in Patients With Parkinson's Disease

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease

Parkinson Disease

Drug: PRIM-DJ2727;Drug: Placebo oral capsule

The University of Texas Health Science Center, Houston

Kelsey Research Foundation

Recruiting

55 Years

75 Years

All

Phase 1

United States

138

NCT03693872
(ClinicalTrials.gov)

May 15, 2019

1/10/2018

Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

Parkinson Disease

Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine

Rennes University Hospital

NULL

Recruiting

18 Years

N/A

All

N/A

France

139

NCT03552068
(ClinicalTrials.gov)

May 15, 2019

17/5/2018

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial

Parkinson's Disease;Mpulse Control Disorders

Drug: placebo;Drug: Clonidine

Hospices Civils de Lyon

NULL

Recruiting

30 Years

80 Years

All

Phase 2

France

140

NCT04293159
(ClinicalTrials.gov)

May 14, 2019

19/2/2020

Effect of Probiotic on Constipation in Patients With Parkinson's Disease

Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease

Parkinson Disease;Constipation

Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)

University of Salerno

Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci

Recruiting

18 Years

75 Years

All

N/A

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

141

NCT03958708
(ClinicalTrials.gov)

May 13, 2019

14/5/2019

Modulation of Gut Microbiota by Rifaximin in PD Patients

Parkinson Disease;Inflammation

Drug: Rifaximin 550 MG

Taipei Medical University Shuang Ho Hospital

NULL

Recruiting

45 Years

70 Years

All

Phase 1;Phase 2

Taiwan

142

NCT03970239
(ClinicalTrials.gov)

May 13, 2019

6/5/2019

Serotonin in Impulse Control Disorders in Parkinson's Disease

Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease

Parkinson Disease;Impulse Control Disorders

Drug: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Drug: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)

Hospices Civils de Lyon

NULL

Recruiting

30 Years

80 Years

All

N/A

France

143

NCT04566341
(ClinicalTrials.gov)

May 4, 2019

11/8/2020

Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease

Parkinson Disease;Parkinson

Device: OCT - TCE

Massachusetts General Hospital

NULL

Recruiting

40 Years

85 Years

All

United States

144

NCT03840837
(ClinicalTrials.gov)

May 2, 2019

11/2/2019

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease

Parkinson Disease

Drug: Rivastigmine transdermal patch

University of Maryland, Baltimore

National Institute on Aging (NIA)

Recruiting

18 Years

N/A

All

100

Phase 4

United States

145

NCT03781167
(ClinicalTrials.gov)

April 29, 2019

18/12/2018

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Recruiting

30 Years

N/A

All

130

Phase 3

United States;Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

146

NCT03899324
(ClinicalTrials.gov)

April 26, 2019

29/3/2019

Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease

Parkinson Disease

Drug: Bumetanide white, oblong, scored tablet;Drug: Placebo white, oblong, scored tablet

B&A Therapeutics

NULL

Recruiting

40 Years

80 Years

All

Phase 2

France

147

NCT04420910
(ClinicalTrials.gov)

April 15, 2019

4/6/2020

Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease

Investigation of Non-motor Symptoms, Balance, Muscle Strength, and Functional Mobility in Patients With Parkinson's Disease

Parkinson Disease;Balance;Muscle Strength;Mobility;Non-motor Symptoms

Other: Non-Motor Symptoms;Other: Balance;Other: Lower Limb Strength;Other: Functional mobility

Ankara Yildirim Beyazit University

NULL

Completed

50 Years

65 Years

All

Turkey

148

NCT03661125
(ClinicalTrials.gov)

April 11, 2019

4/9/2018

SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.

Parkinson Disease Psychosis

Drug: Saracatinib;Drug: Placebo Oral Tablet

King's College London

AstraZeneca;King's College Hospital NHS Trust

Recruiting

40 Years

N/A

All

Early Phase 1

United Kingdom

149

NCT03841604
(ClinicalTrials.gov)

April 9, 2019

30/1/2019

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain

Idiopathic Parkinson Disease

Drug: Safinamide Methanesulfonate;Drug: Safinamide methanesulfonate matching placebo

Zambon SpA

NULL

Recruiting

30 Years

N/A

All

177

Phase 4

Austria;France;Germany;Italy;Spain

150

NCT03775096
(ClinicalTrials.gov)

April 4, 2019

9/12/2018

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

REM Sleep Behavior Disorder;Pre-motor Parkinson Disease;Symptomatic Parkinson Disease

Drug: Carvedilol

Michele Tagliati, MD

NULL

Recruiting

30 Years

75 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

151

NCT03877510
(ClinicalTrials.gov)

April 3, 2019

12/3/2019

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations

An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

Drug: IPX203 140 mg;Drug: IPX203 210 mg;Drug: IPX203 280 mg;Drug: IPX203 350 mg

Impax Laboratories, LLC

NULL

Enrolling by invitation

40 Years

N/A

All

300

Phase 3

United States;Czechia;France;Germany;Italy;Spain;United Kingdom

152

NCT03858270
(ClinicalTrials.gov)

April 1, 2019

2/10/2018

Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine

Parkinson Disease

Drug: Memantine;Other: Placebo

Wayne State University

NULL

Recruiting

45 Years

85 Years

All

Phase 3

United States

153

JPRN-jRCTs051180214

29/03/2019

27/03/2019

The usefulness of flutemetamol for diagnostic imaging of neurogenerative disease

The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease

Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy

Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously

Itoh Yoshiaki

NULL

Recruiting

Ages 20 and over

N/A

Both

100

N/A

Japan

154

NCT03922711
(ClinicalTrials.gov)

March 26, 2019

17/4/2019

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)

Parkinson Disease

Drug: Pridopidine;Drug: Placebo

Prilenia

NULL

Terminated

30 Years

85 Years

All

Phase 2

United States

155

NCT04064983
(ClinicalTrials.gov)

March 14, 2019

19/8/2019

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease

Parkinson Disease

Drug: HB-adMSCs

Hope Biosciences

NULL

No longer available

18 Years

N/A

All

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

156

NCT03716570
(ClinicalTrials.gov)

March 12, 2019

22/10/2018

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease

Parkinson's Disease

Drug: BIIB054;Drug: Placebo

Biogen

NULL

Active, not recruiting

40 Years

80 Years

All

Phase 1

Japan

157

NCT03816020
(ClinicalTrials.gov)

March 9, 2019

7/12/2018

NAD-supplementation in Drug naïve Parkinson's Disease

NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease

Parkinson Disease;Neurodegenerative Diseases

Dietary Supplement: Nicotinamide Riboside;Other: Placebo

Haukeland University Hospital

NULL

Completed

18 Years

N/A

All

N/A

Norway

158

NCT03887884
(ClinicalTrials.gov)

March 5, 2019

1/3/2019

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease

Parkinson's Disease

Drug: CVT-301;Drug: Sinemet

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

159

NCT03865121
(ClinicalTrials.gov)

March 4, 2019

26/2/2019

Pilot Trial of Transnasal Nicotine in Parkinson Disease

Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease

Parkinson Disease

Drug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

Howard University

Completed

60 Years

N/A

All

Phase 2

Mexico

160

NCT03820037
(ClinicalTrials.gov)

March 2019

25/1/2019

Relative Bioavailability and Bioequivalence of Opicapone

A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects

Parkinson Disease

Drug: Ongentys;Drug: BIA 9-1067 (test)

Bial - Portela C S.A.

NULL

Not yet recruiting

18 Years

55 Years

All

Phase 1

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

161

NCT03845387
(ClinicalTrials.gov)

February 26, 2019

15/2/2019

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Parkinson Disease

Drug: KDT-3594;Drug: Pramipexole

Kissei Pharmaceutical Co., Ltd.

NULL

Active, not recruiting

20 Years

79 Years

All

100

Phase 2

Japan

162

NCT03655236
(ClinicalTrials.gov)

February 18, 2019

18/8/2018

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Early Parkinson Disease

Drug: K0706;Other: placebo

Sun Pharma Advanced Research Company Limited

NULL

Recruiting

50 Years

N/A

All

504

Phase 2

United States;Hungary;Poland;Slovakia;Spain

163

NCT03968744
(ClinicalTrials.gov)

February 18, 2019

19/4/2019

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study

Idiopathic Parkinson's Disease (at Later Stage)

Drug: Safinamide

Alain Kaelin

Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

18 Years

N/A

All

Phase 4

Switzerland

164

NCT03413384
(ClinicalTrials.gov)

February 15, 2019

8/1/2018

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

Parkinson's Disease Dementia

Drug: Ceftriaxone;Other: Placebo

BrainX Corporation

NULL

Recruiting

50 Years

80 Years

All

106

Phase 2

Taiwan

165

NCT04510922
(ClinicalTrials.gov)

February 11, 2019

9/7/2020

Lundbeck TOMs Orthostatic Hypotension

Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study

Orthostatic Hypotension;Idiopathic Parkinson Disease

Drug: Droxidopa 100 MG [Northera]

Alberto Espay, MD, MSc

Lundbeck LLC

Recruiting

30 Years

80 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

166

NCT03815071
(ClinicalTrials.gov)

February 1, 2019

21/1/2019

A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease

Parkinson Disease

Drug: Ips-nsc cells

Allife Medical Science and Technology Co., Ltd.

The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital;Henan Provincial People's Hospital;Beijing Hospital

Not yet recruiting

18 Years

60 Years

All

Early Phase 1

NULL

167

NCT03790670
(ClinicalTrials.gov)

January 30, 2019

18/12/2018

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

Safety, Tolerability and Biomarker Assessments of Leukine (Sargramostim) During Extended Timed Treatment for Parkinson's Disease: A Phase I Pilot Study

Parkinson Disease

Drug: sargramostim

University of Nebraska

NULL

Recruiting

35 Years

85 Years

All

Phase 1

United States

168

NCT03826134
(ClinicalTrials.gov)

January 17, 2019

30/1/2019

A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects

Parkinson Disease

Drug: [11C]PXT012253

H. Lundbeck A/S

NULL

Completed

20 Years

50 Years

All

Early Phase 1

Sweden

169

NCT04620863
(ClinicalTrials.gov)

January 15, 2019

26/10/2020

TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE

TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL

Parkinson Disease;Pisa Syndrome

Other: t-DCS group;Other: Sham group

IRCCS National Neurological Institute C. Mondino Foundation

NULL

Completed

18 Years

80 Years

All

N/A

Italy

170

NCT03638479
(ClinicalTrials.gov)

January 8, 2019

13/8/2018

Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders

Parkinson Disease;Essential Tremor;Movement Disorders;Parkinson's Syndrome;Atypical Parkinsonism

Other: Data Capture

Westfälische Wilhelms-Universität Münster

NULL

Recruiting

18 Years

N/A

All

500

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

171

NCT03659682
(ClinicalTrials.gov)

January 2, 2019

3/9/2018

GLP1R in Parkinson's Disease

Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson's Disease

Parkinson Disease

Drug: Semaglutide

Oslo University Hospital

NULL

Not yet recruiting

40 Years

75 Years

All

120

Phase 2

NULL

172

NCT03727295
(ClinicalTrials.gov)

January 1, 2019

30/10/2018

Idebenone Treatment of Early Parkinson's Diseasesymptoms

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms

Oxidative Stress is an Important Cause of Parkinson's Disease

Drug: Idebenone/placebo

Second Affiliated Hospital of Soochow University

Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

30 Years

80 Years

All

180

Phase 4

NULL

173

NCT03391882
(ClinicalTrials.gov)

December 19, 2018

2/1/2018

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations

Motor OFF Episodes Associated With Parkinson's Disease

Drug: APL-130277;Drug: subcutaneous apomorphine

Sunovion

NULL

Recruiting

18 Years

N/A

All

106

Phase 3

Austria;France;Germany;Italy;Spain;United Kingdom

174

NCT03840005
(ClinicalTrials.gov)

December 18, 2018

11/2/2019

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)

Parkinson's Disease

Drug: Ursonorm

Sheffield Teaching Hospitals NHS Foundation Trust

JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of Sheffield

Active, not recruiting

18 Years

75 Years

All

Phase 2

United Kingdom

175

NCT03781791
(ClinicalTrials.gov)

December 10, 2018

27/11/2018

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)

Constipation;Parkinson Disease

Drug: Active Investigational Treatment ENT-01;Drug: Placebo Treatment

Enterin Inc.

NULL

Active, not recruiting

30 Years

90 Years

All

152

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

176

NCT03710707
(ClinicalTrials.gov)

December 4, 2018

15/10/2018

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: DNL201;Drug: Placebo

Denali Therapeutics Inc.

NULL

Completed

30 Years

80 Years

All

Phase 1

United States

177

NCT03944447
(ClinicalTrials.gov)

December 1, 2018

3/5/2019

Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus

Drug: Cannabis , Medical

OMNI Medical Services, LLC

OMNI Medical Services Inc

Recruiting

7 Years

N/A

All

200000

Phase 2

United States

178

NCT03639064
(ClinicalTrials.gov)

December 2018

4/7/2018

Cannabis Oil for Pain in Parkinson's Disease

A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease

Parkinson Disease

Drug: Cannabis Oil

University Health Network, Toronto

Parkinson Society Canada

Unknown status

18 Years

N/A

All

Phase 2

NULL

179

NCT03942172
(ClinicalTrials.gov)

November 27, 2018

6/5/2019

Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses

Parkinson Disease

Device: SpotOn balance glasses

SpotOn Therapeutics Ltd.

NULL

Suspended

30 Years

N/A

All

N/A

Israel

180

NCT03822364
(ClinicalTrials.gov)

November 26, 2018

18/12/2018

Staccato Apomorphine Single and Multi Dose PK

A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5

Alexza Pharmaceuticals, Inc.

NULL

Completed

18 Years

60 Years

All

Phase 1

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

181

NCT03823638
(ClinicalTrials.gov)

November 20, 2018

20/11/2018

Safety, Tolerability and Effects of Mannitol in Parkinson's Disease

A Phase II Single Center, Randomized, Double Blind and Placebo Controlled Study Assessing the Safety, Tolerability and Effects of Progressively Increased Dose of Oral Mannitol in Parkinson's Disease

Parkinson Disease

Dietary Supplement: Oral D-Mannitol of Placebo

Hadassah Medical Organization

NULL

Recruiting

40 Years

75 Years

All

Phase 2

Israel

182

NCT03713957
(ClinicalTrials.gov)

November 12, 2018

18/10/2018

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Parkinson Disease

Drug: GRF6021;Other: Placebo

Alkahest, Inc.

Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

85 Years

All

Phase 2

United States;Australia;France

183

NCT03733561
(ClinicalTrials.gov)

November 9, 2018

6/11/2018

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

Drug: LY03003;Drug: Neupro 4Mg/24Hr Transdermal Patch

Luye Pharma Group Ltd.

NULL

Recruiting

18 Years

45 Years

All

Phase 1

United States

184

NCT03667404
(ClinicalTrials.gov)

November 6, 2018

10/9/2018

Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study

Gut Microbial Remodeling With Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study

Parkinson Disease;Intestinal Bacteria Flora Disturbance;Dietary Modification

Dietary Supplement: Resistant maltodextrin;Dietary Supplement: maltodextrin

Northwestern University

University of Illinois at Chicago

Recruiting

60 Years

N/A

All

Phase 2

United States

185

NCT03670953
(ClinicalTrials.gov)

November 6, 2018

12/9/2018

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease (Disorder)

Drug: IR CD-LD;Drug: IPX203 ER CD-LD;Other: IPX203 placebo;Other: IR CD-LD placebo

Impax Laboratories, LLC

NULL

Recruiting

40 Years

N/A

All

510

Phase 3

United States;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

186

NCT04629404
(ClinicalTrials.gov)

November 5, 2018

5/11/2020

A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease

Parkinson Disease

Drug: LY03003;Drug: Placebo

Luye Pharma Group Ltd.

NULL

Completed

30 Years

N/A

All

Phase 1

China

187

NCT03069911
(ClinicalTrials.gov)

November 1, 2018

28/2/2017

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Parkinson Disease;Depression

Biological: OnabotulinumtoxinA;Biological: Control

Johns Hopkins University

NULL

Terminated

18 Years

95 Years

All

Phase 1

United States

188

NCT03727139
(ClinicalTrials.gov)

November 1, 2018

30/10/2018

Rasagiline Tablets Special Drug Use-Results Survey Survey on Long-term Safety

AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety

Parkinson's Disease

Drug: Rasagiline

Takeda

NULL

Active, not recruiting

N/A

All

1021

Japan

189

NCT03720418
(ClinicalTrials.gov)

October 17, 2018

16/10/2018

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease

Parkinson Disease

Drug: OXB-102;Other: Imitation Surgical Procedure (ISP)

Axovant Sciences Ltd.

Oxford BioMedica

Recruiting

30 Years

70 Years

All

Phase 1;Phase 2

France;United Kingdom

190

NCT04048291
(ClinicalTrials.gov)

October 15, 2018

9/10/2018

Efficacy of Brisk Walking in Parkinson's Disease

Efficacy of Brisk Walking on Improving Balance and Gait Performance, and Functional Mobility in Parkinson's Disease - a Randomized Controlled Trial

Parkinson Disease

Behavioral: Brisk walking and balance training;Behavioral: Upper limb exercise

The Hong Kong Polytechnic University

NULL

Completed

30 Years

N/A

All

N/A

Hong Kong

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

191

NCT04451096
(ClinicalTrials.gov)

October 6, 2018

19/6/2020

Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation

Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study

Parkinson Disease;Constipation

Dietary Supplement: Probiotics with prebiotic;Dietary Supplement: Placebo

National University of Malaysia

NULL

Completed

18 Years

N/A

All

Phase 3

Malaysia

192

NCT03703570
(ClinicalTrials.gov)

September 29, 2018

5/10/2018

A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations

Parkinson's Disease

Drug: KW-6356;Drug: Placebo

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

80 Years

All

502

Phase 2

Japan

193

NCT03665454
(ClinicalTrials.gov)

September 24, 2018

1/8/2018

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

Parkinson Disease

Drug: PF-06412562;Drug: Standard of Care Placebo

Milton S. Hershey Medical Center

Pfizer

Completed

N/A

All

Phase 1

United States

194

NCT03582137
(ClinicalTrials.gov)

September 17, 2018

17/4/2018

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease

Parkinson Disease

Drug: Cannabidiol;Other: Placebo

University of Colorado, Denver

Colorado Department of Public Health and Environment

Recruiting

40 Years

85 Years

All

Phase 2

United States

195

NCT04202757
(ClinicalTrials.gov)

September 14, 2018

21/9/2018

Intravenous Plasma Treatment for Parkinson's Disease

Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease - Randomized Controlled Study

Idiopathic Parkinson Disease

Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors;Other: Saline

The Neurology Center

Carolina Longevity Institute

Completed

45 Years

90 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

196

NCT03648905
(ClinicalTrials.gov)

September 6, 2018

24/8/2018

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Parkinson's Disease;Multiple System Atrophy;Autonomic Failure

Drug: 18F-Dopa;Drug: 11C-methylreboxetine;Drug: 13N-Ammonia;Drug: 18F-Dopamne;Drug: Desipramine (DMI)

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Recruiting

18 Years

N/A

All

140

Phase 1

United States

197

NCT03608371
(ClinicalTrials.gov)

August 31, 2018

9/5/2018

BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations

Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations

Parkinson Disease;Motor Disorder

Drug: BTRX-246040;Drug: Placebo

BlackThorn Therapeutics, Inc.

NULL

Completed

30 Years

76 Years

All

Phase 2

United States

198

NCT03229174
(ClinicalTrials.gov)

August 23, 2018

21/4/2017

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo

Parkinson Disease;Neurogenic Orthostatic Hypotension

Drug: Droxidopa;Drug: Placebo

William Ondo, MD

Lundbeck LLC

Recruiting

18 Years

85 Years

All

Phase 4

United States

199

NCT03621046
(ClinicalTrials.gov)

August 20, 2018

6/6/2018

Use of Low-dose Zolpidem in Parkinson's Disease

A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's

Parkinson Disease

Drug: Zolpidem;Other: Placebo

Aston University

University Hospital Birmingham NHS Foundation Trust

Completed

40 Years

80 Years

All

Phase 2

United Kingdom

200

NCT03567447
(ClinicalTrials.gov)

August 17, 2018

21/5/2018

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

Parkinson Disease;Falls Patient

Drug: Droxidopa;Other: Placebo

St. Joseph's Hospital and Medical Center, Phoenix

H. Lundbeck A/S;Arizona State University

Recruiting

30 Years

83 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

201

NCT03675282
(ClinicalTrials.gov)

August 14, 2018

5/9/2018

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls

Parkinson Disease;REM Sleep Behavior Disorder;Healthy

Drug: (11C)PE2I

Weill Medical College of Cornell University

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

20 Years

100 Years

All

100

Phase 1;Phase 2

United States

202

NCT03773796
(ClinicalTrials.gov)

August 6, 2018

19/7/2018

Nabilone for Non-motor Symptoms in Parkinson's Disease

Nabilone for Non-motor Symptoms in Parkinson's Disease: An Open-label Study to Evaluate Long-term Safety and Efficacy

Parkinson Disease

Drug: Nabilone 0.25 mg

Medical University Innsbruck

NULL

Recruiting

30 Years

100 Years

All

Phase 3

Austria

203

NCT04455555
(ClinicalTrials.gov)

August 1, 2018

28/6/2020

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

Parkinson's Disease

Drug: LY03003( the name of rotigotine);Other: Placebo

Peking University Third Hospital

NULL

Completed

18 Years

N/A

All

294

Phase 3

China

204

NCT03599726
(ClinicalTrials.gov)

July 30, 2018

29/6/2018

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

Parkinson Disease

Drug: Donepezil;Drug: Placebo

Oregon Health and Science University

Medical Research Foundation, Oregon

Completed

50 Years

90 Years

All

Early Phase 1

United States

205

NCT03611569
(ClinicalTrials.gov)

July 25, 2018

26/7/2018

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Healthy;Parkinson Disease

Drug: Lu AF82422;Drug: Placebo

H. Lundbeck A/S

NULL

Recruiting

18 Years

80 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

206

NCT03587168
(ClinicalTrials.gov)

July 20, 2018

3/7/2018

The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Parkinson's Disease

Parkinson Disease

Other: the timed 360° turn test;Other: Berg Balance Scale;Other: Four Square Step Test;Other: Functional Reach Test;Other: Trunk Impairment Scale;Other: Timed Up and Go Test;Other: Hoehn and Yahr Scale;Other: Unified Parkinson's Disease Rating Scale

Gazi University

NULL

Completed

40 Years

N/A

All

Turkey

207

NCT03594656
(ClinicalTrials.gov)

July 15, 2018

11/7/2018

Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease

Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Parkinson Disease

Drug: Ganoderma;Drug: Placebos

Xuanwu Hospital, Beijing

NULL

Recruiting

30 Years

80 Years

All

288

Phase 3

China

208

NCT03624920
(ClinicalTrials.gov)

July 12, 2018

10/7/2018

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Parkinson Disease

Drug: THN102 Dosage A;Drug: THN102 Dosage B;Drug: THN102 Dosage C

Theranexus

NULL

Completed

18 Years

80 Years

All

Phase 2

United States;Czechia;France;Germany;Hungary

209

NCT03774459
(ClinicalTrials.gov)

July 9, 2018

8/12/2018

ANAVEX2-73 Study in Parkinson's Disease Dementia

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia

Parkinsons Disease With Dementia

Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule

Anavex Life Sciences Corp.

Anavex Germany GmbH

Completed

50 Years

85 Years

All

132

Phase 2

Australia;Spain

210

NCT03146130
(ClinicalTrials.gov)

July 5, 2018

3/5/2017

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease

Impulse Control Disorder;Parkinson

Biological: Variation of behaviors of Parkinson's disease

Centre Hospitalier Universitaire, Amiens

NULL

Unknown status

18 Years

N/A

All

Phase 3

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

211

NCT03775538
(ClinicalTrials.gov)

July 5, 2018

11/10/2018

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002

Parkinson Disease;Movement Disorders;Neuro-Degenerative Disease;Nervous System Diseases;Brain Diseases

Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System

Herantis Pharma Plc.

Renishaw plc.

Completed

35 Years

75 Years

All

Phase 1;Phase 2

Finland;Sweden

212

NCT03521635
(ClinicalTrials.gov)

July 3, 2018

11/4/2018

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)

Parkinson Disease

Drug: Pramipexole SR;Drug: Pramipexole IR

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

Phase 4

China

213

NCT03566589
(ClinicalTrials.gov)

July 2, 2018

12/6/2018

Effects of PS128 on Parkinsonian Symptoms

Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study

Parkinson Disease

Dietary Supplement: Lactobacillus plantarum PS128

Professor Lu Neurological Clinic

NULL

Completed

40 Years

80 Years

All

N/A

Taiwan

214

NCT03576638
(ClinicalTrials.gov)

July 2018

25/6/2018

Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients

An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson Disease

Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet

Intec Pharma Ltd.

NULL

Unknown status

30 Years

N/A

All

Phase 2

NULL

215

NCT03562494
(ClinicalTrials.gov)

June 28, 2018

16/5/2018

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Biological: VY-AADC02;Other: Sham (Placebo) Surgery

Neurocrine Biosciences

Voyager Therapeutics

Recruiting

40 Years

75 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

216

NCT03407378
(ClinicalTrials.gov)

June 26, 2018

15/1/2018

A Study to Investigate a New Treatment in Patients With Parkinson's Disease

A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease

Parkinson Disease

Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment

Tools4Patient

NULL

Completed

35 Years

N/A

All

110

Phase 1;Phase 2

United States;Belgium;France

217

NCT03439943
(ClinicalTrials.gov)

June 13, 2018

13/2/2018

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease

Parkinson Disease

Drug: Lixisenatide;Drug: placebo

University Hospital, Toulouse

Cure Parkinson;Réseau NS-Park;EUCLID;Sanofi

Active, not recruiting

40 Years

75 Years

All

156

Phase 2

France

218

NCT03456687
(ClinicalTrials.gov)

June 5, 2018

1/3/2018

Effects of Exenatide on Motor Function and the Brain

Parkinson's Disease

Drug: Exenatide

University of Florida

National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

40 Years

77 Years

All

Phase 1

United States

219

NCT03510572
(ClinicalTrials.gov)

June 4, 2018

17/4/2018

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study

Healthy Volunteer;Alzheimer Disease;Frontotemporal Dementia;Parkinson Disease

Drug: [18F]PI-2620

Asan Medical Center

Korea Health Industry Development Institute

Completed

40 Years

80 Years

All

Early Phase 1

Korea, Republic of

220

NCT03532984
(ClinicalTrials.gov)

June 1, 2018

27/4/2018

Beam Walking Across the Lifespan for Falls Prediction

Beam Walking to Assess Dynamic Balance in Health and Disease: A Protocol for the 'BEAM' Multi-center Observational Study

Aging;Parkinson Disease;Stroke;Dementia;Diagnoses Disease;Cognitive Impairment;Postural; Defect

Diagnostic Test: Beam test to predict falls

University Medical Center Groningen

Dokkyo Medical University;University of Potsdam;Somogy Megyei Kaposi Mór Teaching Hospital;University of Sao Paulo

Unknown status

20 Years

80 Years

All

432

Brazil;Germany;Hungary;Japan;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

221

NCT03891069
(ClinicalTrials.gov)

June 1, 2018

18/3/2019

Feasibility of the AHA Exergame System in Parkinson's Disease Patients

Feasibility and Safety of the AHA Exergame System in Parkinson's Disease Patients: a Mixed Methods Study

Parkinson Disease

Device: AHA Exergame System

Campus Neurológico Sénior

University of Lisbon

Completed

40 Years

80 Years

All

N/A

Portugal

222

NCT03684122
(ClinicalTrials.gov)

June 1, 2018

23/9/2018

Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).

A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).

Parkinson Disease

Biological: Injection of Umbilical cord derived MSCs

University of Jordan

NULL

Recruiting

20 Years

75 Years

All

Phase 1;Phase 2

Jordan

223

NCT03589066
(ClinicalTrials.gov)

May 15, 2018

8/6/2018

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

An Open-label, Randomized, Parallel-group Trial to Evaluate the Pharmacokinetics of Two Formulations of LY03003 After a Single Intramuscular Injection Administered to Patients With Parkinson's Disease

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Completed

18 Years

N/A

All

Phase 1

United States

224

NCT03541356
(ClinicalTrials.gov)

May 8, 2018

5/4/2018

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of DCI to L-dopa Responsive Parkinson's Disease Patients

Parkinson's Disease

Combination Product: Placebo;Combination Product: L-dopa 35 mg;Combination Product: L-dopa 70mg;Combination Product: L-dopa 140 mg;Combination Product: L-dopa 70mg /carbidopa 7mg

Impel NeuroPharma Inc.

NULL

Completed

40 Years

80 Years

All

Phase 2

Australia

225

NCT03587649
(ClinicalTrials.gov)

May 7, 2018

3/7/2018

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).

Alzheimer Disease;Parkinson Disease;Healthy Volunteers

Drug: [18F]MNI-1126

Invicro

NULL

Completed

18 Years

55 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

226

NCT04228887
(ClinicalTrials.gov)

May 4, 2018

5/8/2019

Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease

Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease

Parkinson Disease

Diagnostic Test: Respiratory Muscle Strength;Device: Balance Training;Device: Inspiratory Muscle Training

Bezmialem Vakif University

NULL

Completed

60 Years

85 Years

All

N/A

Turkey

227

NCT03843944
(ClinicalTrials.gov)

May 1, 2018

12/2/2019

Overnight Switch From Rasagiline To Safinamide

Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study

Parkinson Disease

Drug: Safinamide

IRCCS San Raffaele

NULL

Completed

30 Years

80 Years

All

Phase 4

Italy

228

NCT03230526
(ClinicalTrials.gov)

April 20, 2018

18/7/2017

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?

Parkinson Disease

Drug: [18F]DPA-714 PET scan

Nantes University Hospital

NULL

Recruiting

40 Years

67 Years

All

Phase 2

France

229

NCT03374917
(ClinicalTrials.gov)

April 18, 2018

8/12/2017

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

230

NCT03368170
(ClinicalTrials.gov)

April 12, 2018

5/12/2017

Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Parkinson Disease

Drug: Mesdopetam (IRL790)

Integrative Research Laboratories AB

The Clinical Trial Company

Completed

18 Years

79 Years

All

Phase 2

Sweden;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

231

EUCTR2017-002707-10-DK
(EUCTR)

10/04/2018

03/11/2017

Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects

Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance

Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies
MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Memantin Orion
INN or Proposed INN: MEMANTINE
Product Name: Donepezil Sandoz
Product Code: 25330
INN or Proposed INN: DONEPEZIL

Regional Dementia Research Centre, Dept of Neurology

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

110

Phase 4

Denmark

232

NCT03827746
(ClinicalTrials.gov)

April 1, 2018

31/1/2019

The Effect of Kinesiophobia on Physical Activity, Balance and Falling in Parkinson's Disease Patients

Parkinson Disease;Kinesiophobia;Physical Activity;Balance;Falling

Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale

Istanbul Kültür University

Marmara University;Istanbul University-Cerrahpasa;Koç University

Completed

40 Years

85 Years

All

Turkey

233

NCT03648671
(ClinicalTrials.gov)

March 28, 2018

26/6/2018

Pain in Parkinson's Disease With Motor Fluctuations.

Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.

Parkinson Disease

Drug: safinamide metansolfonato (12 weeks);Drug: rasagilina mesilato (12 weeks)

Universita di Verona

Azienda Ospedaliera Universitaria Integrata Verona

Unknown status

18 Years

80 Years

All

Italy

234

NCT03301272
(ClinicalTrials.gov)

March 22, 2018

13/9/2017

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study

Parkinson Disease

Drug: Onabotulinumtoxin A Injection;Other: Placebo

University of North Carolina, Chapel Hill

NULL

Completed

45 Years

80 Years

All

Phase 2

United States

235

NCT03457493
(ClinicalTrials.gov)

March 22, 2018

23/2/2018

TSPO-PET for Neuroinflammation in Parkinson's Disease

UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy

Parkinson Disease

Drug: DPA -714-PET/MRI

University of Alabama at Birmingham

NULL

Recruiting

30 Years

N/A

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

236

NCT03482882
(ClinicalTrials.gov)

March 9, 2018

23/3/2018

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

Drug: Pimavanserin

ACADIA Pharmaceuticals Inc.

NULL

Completed

50 Years

N/A

All

Phase 2

United States

237

NCT03462641
(ClinicalTrials.gov)

March 9, 2018

6/3/2018

Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm

Parkinson Disease

Drug: Flumazenil;Drug: Placebo

University of Michigan

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

50 Years

99 Years

All

Phase 1;Phase 2

United States

238

NCT03149809
(ClinicalTrials.gov)

March 1, 2018

9/5/2017

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Overactive Bladder;Parkinson Disease

Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy

VA Office of Research and Development

NULL

Recruiting

N/A

All

Phase 3

United States

239

NCT04265027
(ClinicalTrials.gov)

February 20, 2018

7/2/2020

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.

Parkinson Disease

Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

All

Phase 1

United Kingdom

240

NCT03419806
(ClinicalTrials.gov)

February 16, 2018

10/1/2018

Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease

Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa

Parkinson Disease

Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa)

Vastra Gotaland Region

The Swedish Research Council;Dizlin Medical Design AB;Göteborg University

Completed

30 Years

N/A

All

Phase 1

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

241

NCT03882398
(ClinicalTrials.gov)

February 15, 2018

11/3/2019

Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease

Effects of a High-intensity Progressive-cycle Program on Quality of Life and Motor Symptomatology in Parkinson's Disease Population: a Pilot Randomized Controlled Trial

Parkinson Disease;Exercise;Physical Activity;Quality of Life

Other: Balance;Other: Endurance

University of Vigo

NULL

Completed

60 Years

80 Years

All

N/A

Spain

242

NCT03496870
(ClinicalTrials.gov)

February 8, 2018

1/3/2018

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease

Parkinson Disease

Drug: Opicapone;Drug: Carbidopa Levodopa

Neurocrine Biosciences

NULL

Completed

18 Years

85 Years

All

Phase 1

United States

243

NCT03189563
(ClinicalTrials.gov)

February 6, 2018

12/6/2017

Safety and Efficacy of DA-9805 for Parkinson's Disease

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: DA-9805 45mg;Drug: DA-9805 90mg;Other: Placebo

Dong-A ST Co., Ltd.

NULL

Completed

30 Years

79 Years

All

Phase 2

United States

244

NCT03329508
(ClinicalTrials.gov)

January 29, 2018

30/10/2017

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Parkinson Disease

Drug: P2B001;Drug: Rasagiline;Drug: Pramipexole;Drug: Pramipexole ER

Pharma Two B Ltd.

NULL

Recruiting

35 Years

80 Years

All

525

Phase 3

United States;Canada;Germany;Spain

245

NCT03440112
(ClinicalTrials.gov)

January 29, 2018

26/1/2018

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson

Parkinson Disease

Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020)

Nicolaas Bohnen, MD, PhD

National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

50 Years

N/A

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

246

NCT03531086
(ClinicalTrials.gov)

January 19, 2018

8/5/2018

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Ioflupane I 123

Julie Gurwell

NULL

Active, not recruiting

40 Years

75 Years

All

United States

247

NCT03331848
(ClinicalTrials.gov)

January 15, 2018

1/11/2017

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

Parkinson Disease

Drug: Placebo oral capsule;Drug: PXT002331 - 20mg

Prexton Therapeutics

NULL

Withdrawn

35 Years

85 Years

All

Phase 2

NULL

248

NCT03550183
(ClinicalTrials.gov)

January 10, 2018

11/5/2018

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease

Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells

Parkinson's Disease

Biological: mesenchymal stem cells

Hebei Newtherapy BIo-Pharma technology Co., Ltd.

NULL

Enrolling by invitation

40 Years

80 Years

All

Phase 1

China

249

NCT03318523
(ClinicalTrials.gov)

January 10, 2018

19/10/2017

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: BIIB054

Biogen

NULL

Active, not recruiting

40 Years

80 Years

All

357

Phase 2

United States;Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom

250

EUCTR2017-000087-15-DE
(EUCTR)

21/12/2017

17/05/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants with Early Parkinson’s Disease with a 6 -Year all-Participants-on Treatment Extension (Pasadena)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED EXTENSION (PASADENA)

Parkinson’s disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

United States;France;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

251

NCT03321019
(ClinicalTrials.gov)

December 12, 2017

20/10/2017

Airway Protective Mechanisms in PD (R01)

Mechanisms of Airway Protection Dysfunction in Parkinson's Disease

Parkinson Disease

Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation

University of Florida

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Recruiting

45 Years

85 Years

All

260

United States

252

NCT03377322
(ClinicalTrials.gov)

December 1, 2017

7/12/2017

Trial of Probiotics for Constipation in Parkinson's Disease

A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease

Parkinson Disease

Drug: Probiotic Capsule;Drug: Placebo Capsule

University of Malaya

NULL

Completed

40 Years

85 Years

All

N/A

Malaysia

253

NCT03944785
(ClinicalTrials.gov)

November 30, 2017

1/5/2019

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets

Idiopathic Parkinson Disease

Drug: XADAGO (safinamide)

US WorldMeds LLC

NULL

Completed

30 Years

80 Years

All

209

United States

254

NCT03194217
(ClinicalTrials.gov)

November 10, 2017

19/6/2017

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).

Excessive Daytime Sleepiness;Parkinson Disease

Drug: BEN-2001;Drug: Placebo

BenevolentAI Bio

NULL

Completed

50 Years

80 Years

All

244

Phase 2

United States

255

NCT03305809
(ClinicalTrials.gov)

November 9, 2017

4/10/2017

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Lewy Body Dementia

Drug: LY3154207;Drug: Placebo

Eli Lilly and Company

NULL

Completed

40 Years

85 Years

All

344

Phase 2

United States;Canada;Puerto Rico;China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

256

NCT02611167
(ClinicalTrials.gov)

November 1, 2017

11/11/2015

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

Parkinson's Disease

Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg);Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)

The University of Texas Health Science Center, Houston

NULL

Completed

45 Years

70 Years

All

Phase 1

United States

257

NCT03232996
(ClinicalTrials.gov)

November 1, 2017

24/7/2017

Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.

Parkinson Disease;Parkinson

Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease

University of Manitoba

NULL

Completed

55 Years

70 Years

All

N/A

Canada

258

NCT03205956
(ClinicalTrials.gov)

October 19, 2017

29/6/2017

Measuring Parkinson's Disease Progression

Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD

Parkinson's Disease

Drug: Levodopa

Kevin J. Black, MD

The Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

79 Years

All

Phase 1

United States

259

NCT03272165
(ClinicalTrials.gov)

October 17, 2017

29/6/2017

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.

Parkinson's Disease

Drug: MEDI1341;Drug: Placebo

AstraZeneca

Covance;MMS Holdings, Inc;Catalent

Recruiting

18 Years

80 Years

All

Phase 1

United States;United Kingdom

260

NCT03205488
(ClinicalTrials.gov)

October 16, 2017

28/6/2017

Nilotinib in Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease

Parkinson Disease

Drug: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg);Drug: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1);Drug: Placebo

Northwestern University

University of Rochester;University of Iowa;Michael J. Fox Foundation for Parkinson's Research

Completed

40 Years

79 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

261

NCT03250117
(ClinicalTrials.gov)

October 10, 2017

11/8/2017

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa

Parkinson Disease

Drug: Ropinirole oral product;Drug: Ropinirole Implant

Titan Pharmaceuticals

NULL

Terminated

30 Years

80 Years

All

Phase 1;Phase 2

United States

262

NCT04045678
(ClinicalTrials.gov)

October 10, 2017

30/7/2019

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: LY03003 ( Rotigotine, extended-release microspheres);Drug: Placebo, extended-release microspheres

Luye Pharma Group Ltd.

Beijing Bozhiyin T&S Co., Ltd.

Completed

18 Years

75 Years

All

Phase 1

China

263

NCT03769896
(ClinicalTrials.gov)

October 3, 2017

6/12/2018

Nabilone for Non-motor Symptoms in Parkinson's Disease

Nabilone for Non-motor Symptoms in Parkinson's Disease: A Randomized Placebo-controlled, Double-blind, Parallel-group, Enriched Enrolment Randomized Withdrawal Study

Parkinson Disease

Drug: Nabilone 0.25 mg;Drug: Placebo

Medical University Innsbruck

NULL

Completed

30 Years

100 Years

All

Phase 2

Austria

264

NCT03257046
(ClinicalTrials.gov)

September 28, 2017

14/8/2017

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease

Parkinson Disease

Drug: ITI-214;Other: Placebo

Intra-Cellular Therapies, Inc.

NULL

Completed

50 Years

N/A

All

Phase 1;Phase 2

United States

265

NCT03295786
(ClinicalTrials.gov)

September 26, 2017

14/9/2017

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease

Parkinson Disease;Movement Disorders;Neurodegenerative Diseases;Nervous System Diseases;Brain Diseases

Drug: Cerebral Dopamine Neurotrophic Factor;Device: Renishaw Drug Delivery System

Herantis Pharma Plc.

Renishaw plc.

Completed

35 Years

75 Years

All

Phase 1;Phase 2

Finland;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

266

NCT03104725
(ClinicalTrials.gov)

September 25, 2017

4/4/2017

Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?

Parkinson Disease;Cerebrospinal Fluid

Drug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: Fluoroscopy

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

18 Years

N/A

All

Phase 1

United States

267

NCT03306329
(ClinicalTrials.gov)

September 13, 2017

25/9/2017

DNS-7801 vs. Placebo in Parkinson's Disease

A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations

Parkinson's Disease

Drug: DNS-7801 (low-dose);Drug: DNS-7801 (high dose);Drug: Placebo

Dart NeuroScience, LLC

NULL

Terminated

30 Years

N/A

All

Phase 2

United States

268

NCT03272230
(ClinicalTrials.gov)

September 6, 2017

3/8/2017

Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System

Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease

Apathy;Frontotemporal Dementia;Parkinson Disease;Depressive Symptoms

Behavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease

Institut National de la Santé Et de la Recherche Médicale, France

NULL

Recruiting

40 Years

85 Years

All

135

N/A

France

269

ChiCTR-INR-17012013

2017-09-01

2017-07-17

Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease

Parkinson‘s disease, Depression

BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;

Shanghai Tongji Hospital, Tongji University

NULL

Pending

Both

BTX-A:40;Placebo:40;

China

270

NCT03292016
(ClinicalTrials.gov)

August 22, 2017

11/9/2017

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease

Drug: APL-130277;Drug: APO-go;Drug: Apokyn

Sunovion

NULL

Completed

18 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

271

EUCTR2017-000087-15-AT
(EUCTR)

17/08/2017

18/05/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab(PRX002) in Participants with Early Parkinson's Disease with A 6-Year all-Participants-on-Treatment Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

France;United States;Spain;Austria;Germany

272

NCT04162275
(ClinicalTrials.gov)

August 15, 2017

22/9/2019

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects

Parkinson Disease

Drug: Finamine tablets;Drug: Placebo tablets

Yiling Pharmaceutical Inc.

NULL

Active, not recruiting

18 Years

65 Years

All

Phase 1

China

273

NCT03204929
(ClinicalTrials.gov)

August 14, 2017

28/6/2017

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease

Parkinson Disease

Drug: Cu(II)ATSM

Collaborative Medicinal Development Pty Limited

NULL

Completed

30 Years

N/A

All

Phase 1

Australia

274

NCT03187301
(ClinicalTrials.gov)

August 3, 2017

7/6/2017

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes

A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson's Disease;Off Episodes of Parkinson Disease

Drug: APL-130277;Drug: Placebo;Drug: Moxifloxacin

Sunovion

NULL

Completed

18 Years

N/A

All

Phase 2

United States;Italy

275

EUCTR2017-000087-15-FR
(EUCTR)

27/07/2017

30/10/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

United States;France;Spain;Austria;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

276

EUCTR2017-000087-15-ES
(EUCTR)

26/07/2017

08/06/2017

A Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with A 52-Week Blinded Extension (Pasadena)

Product Name: aSyn Mab
Product Code: RO7046015
INN or Proposed INN: N/A
Other descriptive name: PRX002, ELT2, anti-alpha-synuclein monoclonal antibody

F. Hoffmann-La Roche Ltd

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

300

Phase 2

France;United States;Spain;Austria;Germany

277

NCT03178786
(ClinicalTrials.gov)

July 18, 2017

5/6/2017

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

Parkinson Disease

Behavioral: PAT sessions

NYU Langone Health

NULL

Recruiting

40 Years

75 Years

All

N/A

United States

278

NCT03412513
(ClinicalTrials.gov)

July 17, 2017

21/1/2018

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial

Overactive Bladder;Parkinson Disease

Drug: Mirabegron;Drug: Placebo

Seoul National University Hospital

NULL

Unknown status

40 Years

80 Years

All

144

Phase 4

Korea, Republic of

279

NCT03026231
(ClinicalTrials.gov)

July 15, 2017

11/1/2017

Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients

A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease

Parkinson's Disease

Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)

The University of Texas Health Science Center, Houston

Kelsey Research Foundation

Withdrawn

45 Years

70 Years

All

Phase 1;Phase 2

United States

280

NCT03555292
(ClinicalTrials.gov)

July 12, 2017

24/4/2018

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Parkinson Disease

Drug: 11C-PiB

Oriental Neurosurgery Evidence-Based-Study Team

NULL

Recruiting

18 Years

N/A

All

200

Phase 2

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

281

EUCTR2017-000135-14-ES
(EUCTR)

07/07/2017

09/06/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED) - AMBLED Study

Parkinson’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E
Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E

Prexton Therapeutics B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany

282

NCT03185481
(ClinicalTrials.gov)

July 6, 2017

9/6/2017

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Parkinson's Disease With Motor Fluctuations

Drug: 1 mg QD to 15 mg QD PF-06649751;Drug: 3 mg QD to 15 mg QD PF-06649751;Drug: 7 mg QD to 15 mg QD PF-06649751;Drug: 15 mg QD PF-06649751;Drug: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study);Drug: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study);Drug: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

Pfizer

NULL

Terminated

40 Years

87 Years

All

Phase 2

United States

283

NCT03162874
(ClinicalTrials.gov)

July 4, 2017

19/5/2017

Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)

Parkinson Disease

Drug: Placebo oral capsule;Drug: PXT002331 - dose 1;Drug: PXT002331 - dose 2

Prexton Therapeutics

NULL

Completed

35 Years

85 Years

All

157

Phase 2

Austria;France;Germany;Italy;Spain;United Kingdom

284

NCT04146519
(ClinicalTrials.gov)

July 1, 2017

18/10/2019

Parkinson's Disease Therapy Using Cell Technology

Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology

Transplantation:Mesenchymal Stem Cell Transplantation

Biological: Autologous mesenchymal stem cells

Belarusian Medical Academy of Post-Graduate Education

NULL

Active, not recruiting

18 Years

N/A

All

Phase 2

Belarus

285

NCT03288155
(ClinicalTrials.gov)

July 1, 2017

15/9/2017

Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)

A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)

Parkinson Disease;Fatigue

Dietary Supplement: Cocoa

Oxford Brookes University

European Parkinson Therapy Centre

Completed

18 Years

N/A

All

N/A

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

286

NCT04223245
(ClinicalTrials.gov)

June 29, 2017

2/12/2019

A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease

A Comparison Of Home Exercises With Multimodal Real-time Sensory Feedback To The Same Exercise Program With No Enhanced Feedback on Walking Automaticity in People With Parkinson Disease.

Parkinson Disease

Behavioral: exercise+multi-modal sensory feedback (MMSF);Behavioral: Exercise only

Regis University

NULL

Completed

21 Years

N/A

All

N/A

United States

287

NCT03042416
(ClinicalTrials.gov)

June 29, 2017

1/2/2017

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Congenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain Glioma

Drug: 18F-DOPA

University of Alberta

Alberta Health Services

Active, not recruiting

N/A

All

400

Phase 3

Canada

288

NCT04403399
(ClinicalTrials.gov)

June 29, 2017

21/5/2020

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3)

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3

Parkinson's Disease

Drug: Varenicline;Other: Evaluation by Investigator;Other: Placebo

University of Michigan

NULL

Completed

45 Years

N/A

All

Phase 2

United States

289

NCT03100149
(ClinicalTrials.gov)

June 27, 2017

29/3/2017

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension

Parkinson's Disease

Drug: RO7046015;Drug: Placebo

Hoffmann-La Roche

Prothena Biosciences Limited

Active, not recruiting

40 Years

80 Years

All

316

Phase 2

United States;Austria;France;Germany;Spain

290

NCT03195231
(ClinicalTrials.gov)

June 25, 2017

20/6/2017

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.

Antidepressive Agents

Drug: Wuling Powder;Drug: Placebo

Beijing Hospital

Tongji Hospital;Shanghai Tong Ren Hospital;The First Hospital of Hebei Medical University

Not yet recruiting

40 Years

N/A

All

120

Phase 4

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

291

NCT03116295
(ClinicalTrials.gov)

June 20, 2017

12/4/2017

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects

Parkinson Disease

Drug: Opicapone (OPC)

Bial - Portela C S.A.

NULL

Completed

18 Years

55 Years

All

Phase 1

Germany

292

EUCTR2017-000135-14-GB
(EUCTR)

15/06/2017

17/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;United Kingdom

293

NCT03083132
(ClinicalTrials.gov)

June 13, 2017

7/3/2017

Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)

Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease

Parkinson Disease

Drug: modafinil 50mg;Drug: Placebo oral capsule

University of Arkansas

NULL

Completed

50 Years

90 Years

All

Early Phase 1

United States

294

NCT03973502
(ClinicalTrials.gov)

June 12, 2017

30/5/2019

Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD

Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.

Hepatitis C;Hepatitis B;Parkinson Disease

Drug: 18F-DOPA PET

National Taiwan University Hospital

NULL

Recruiting

20 Years

N/A

All

230

N/A

Taiwan

295

EUCTR2017-000135-14-DE
(EUCTR)

06/06/2017

10/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

296

EUCTR2017-000135-14-IT
(EUCTR)

30/05/2017

04/11/2020

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Studio di fase IIa, multicentrico, in doppio cieco, randomizzato, controllato verso placebo, a gruppi paralleli per valutare l'efficacia, la sicurezza e la tollerabilit¿ del trattamento orale con PXT002331 (foliglurax) della durata di 28 giorni nella riduzione delle complicazioni motorie dovute alla terapia con levodopa nei pazienti affetti da malattia di Parkinson che manifestano deterioramento da fine dose e discinesia indotta da levodopa (AMBLED) - AMBLED Study

Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax
Other descriptive name: CVD00118-E
Product Name: foliglurax
Product Code: PXT002331
INN or Proposed INN: foliglurax

PREXTON THERAPEUTICS B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

France;Spain;Austria;Germany;United Kingdom;Italy

297

EUCTR2017-000135-14-AT
(EUCTR)

26/05/2017

08/03/2017

A study to look at how safe, well tolerated, and what effect on the body, study drug PXT002331 has in patients with Parkinson's Disease who are already taking the drug Levodopa

Prexton Therapeutics B.V.

NULL

Not Recruiting

Female: yes
Male: yes

165

Phase 2

Spain;Austria;Germany;United Kingdom

298

NCT03111485
(ClinicalTrials.gov)

May 24, 2017

28/3/2017

Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease

Parkinson's Disease;Obstructive Sleep Apnea

Drug: Sinemet CR;Drug: Placebo oral capsule

McGill University Health Centre/Research Institute of the McGill University Health Centre

Weston Brain Institute

Recruiting

18 Years

N/A

All

Phase 4

Canada

299

NCT03033498
(ClinicalTrials.gov)

May 17, 2017

25/1/2017

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Parkinson's Disease (PD)

Drug: ABBV-951

AbbVie

NULL

Completed

45 Years

85 Years

All

Phase 1

United States

300

NCT03242499
(ClinicalTrials.gov)

May 15, 2017

1/8/2017

Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease

Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial

Parkinson Disease

Drug: Lovastatin;Drug: Placebo

National Taiwan University Hospital

NULL

Recruiting

30 Years

90 Years

All

Phase 2

Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

301

NCT03174938
(ClinicalTrials.gov)

May 15, 2017

28/5/2017

The Swedish BioFINDER 2 Study

Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment

Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau

Skane University Hospital

Lund University

Recruiting

20 Years

100 Years

All

1505

N/A

Sweden

302

NCT03047629
(ClinicalTrials.gov)

May 11, 2017

3/2/2017

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation

Parkinson's Disease;Constipation

Drug: ENT-01;Other: Placebo

Enterin Inc.

NULL

Completed

30 Years

86 Years

All

Phase 1;Phase 2

United States

303

NCT03065192
(ClinicalTrials.gov)

May 11, 2017

10/2/2017

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa

Idiopathic Parkinson's Disease;Parkinson's Disease;Basal Ganglia Disease;Brain Diseases;Central Nervous System Diseases;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Parkinsonian Disorders

Drug: VY-AADC01

Neurocrine Biosciences

Voyager Therapeutics

Active, not recruiting

40 Years

75 Years

All

Phase 1

United States

304

NCT02982512
(ClinicalTrials.gov)

May 1, 2017

28/11/2016

Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease

Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease

Dexmedetomidine;Deep Brain Stimulation;Parkinson Disease

Drug: Dexmedetomidine

Clinica Universidad de Navarra, Universidad de Navarra

NULL

Unknown status

18 Years

N/A

All

Phase 4

Spain

305

NCT02702076
(ClinicalTrials.gov)

May 2017

2/3/2016

Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations

Parkinson's Disease;Hallucinations, Visual

Drug: Apomorphine;Drug: Placebo

University Medical Center Groningen

NULL

Recruiting

30 Years

N/A

All

Phase 2

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

306

NCT03119636
(ClinicalTrials.gov)

May 2017

6/4/2017

Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease

Parkinson's Disease

Biological: NPC transplantation;Drug: Levodopa

Chinese Academy of Sciences

The First Affiliated Hospital of Zhengzhou University

Recruiting

50 Years

80 Years

All

Phase 1;Phase 2

China

307

NCT03425877
(ClinicalTrials.gov)

April 22, 2017

10/1/2018

Arousal Response Tool for Neurological Disease

Parkinson Disease;Stroke;Healthy

Device: MS Band 2;Behavioral: Emotion Assessment;Behavioral: Single Task;Behavioral: Dual Task;Behavioral: Rest

IRCCS San Camillo, Venezia, Italy

Università Politecnica delle Marche;University of Padova

Unknown status

25 Years

N/A

All

N/A

Italy

308

NCT03115827
(ClinicalTrials.gov)

April 18, 2017

9/3/2017

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Parkinson Disease

Drug: Droxidopa;Drug: Carbidopa

Vanderbilt University Medical Center

H. Lundbeck A/S;American Academy of Neurology

Completed

18 Years

N/A

All

Phase 4

United States

309

NCT03128450
(ClinicalTrials.gov)

April 15, 2017

9/2/2017

A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient

A Single Arm, Open-Label,Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease

Parkinson Disease

Biological: human neural stem cell

Second Affiliated Hospital of Soochow University

NULL

Enrolling by invitation

35 Years

70 Years

All

Phase 2;Phase 3

China

310

NCT03011476
(ClinicalTrials.gov)

April 11, 2017

27/12/2016

Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease

Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance

Parkinson Disease

Drug: Donepezil;Drug: Placebos

Kyung Hee University Hospital

NULL

Unknown status

40 Years

75 Years

All

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

311

NCT03051607
(ClinicalTrials.gov)

April 10, 2017

9/2/2017

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off

Idiopathic Parkinson Disease

Drug: Tozadenant

Biotie Therapies Inc.

Acorda Therapeutics

Terminated

30 Years

80 Years

All

Phase 3

United States;Canada;United Kingdom

312

JPRN-jRCTs051180185

07/04/2017

26/03/2019

APISJ Study

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - APISJ Study

Parkinson's disease
Parkinson's disease

In this research, the duration of evaluation will be 24 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by Istradefylline.

Takahashi Makio

Kyowa Kirin Co., Ltd.

Not Recruiting

>= 30age old

Not applicable

Both

N/A

Japan

313

NCT02953665
(ClinicalTrials.gov)

April 3, 2017

21/10/2016

Safety and Efficacy of Liraglutide in Parkinson's Disease

A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease

Parkinson Disease

Drug: Liraglutide;Drug: Placebo

Cedars-Sinai Medical Center

The Cure Parkinson's Trust;Novo Nordisk A/S

Active, not recruiting

25 Years

85 Years

All

Phase 2

United States

314

NCT02970019
(ClinicalTrials.gov)

March 30, 2017

18/11/2016

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.

Parkinson Disease

Drug: K0706;Drug: Placebo

Sun Pharma Advanced Research Company Limited

NULL

Completed

18 Years

65 Years

All

Phase 1

United States

315

JPRN-UMIN000026492

2017/03/15

15/03/2017

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease

Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease - Intervention Study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease.

Parkinson's disease

Osaka Red Cross Hospital

Clinical Research Center, Wakayama Medical University

Complete: follow-up complete

30years-old

Not applicable

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

316

NCT02864004
(ClinicalTrials.gov)

March 3, 2017

15/7/2016

Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

Apomorphine Pump in Early Stage of Parkinson's Disease

Parkinson's Disease

Drug: Apomorphine;Other: Best Medical Treatment

Rennes University Hospital

NULL

Recruiting

18 Years

65 Years

All

192

Phase 3

France

317

NCT03068481
(ClinicalTrials.gov)

February 20, 2017

26/2/2017

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

Parkinson Disease

Drug: KDT-3594;Drug: Placebo

Kissei Pharmaceutical Co., Ltd.

NULL

Completed

20 Years

74 Years

All

Phase 1

Japan

318

NCT02799381
(ClinicalTrials.gov)

February 9, 2017

10/6/2016

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)

Parkinson's Disease (PD)

Drug: Optimized antiparkinsonian treatment;Drug: Levodopa -Carbidopa Intestinal Gel (LCIG);Device: CADD-Legacy ambulatory infusion pump;Device: Percutaneous endoscopic gastrostomy tube;Device: Jejunal extension tube

AbbVie

NULL

Completed

30 Years

N/A

All

Phase 3

United States;Finland;Greece;Hungary;Italy;Slovakia;Spain

319

NCT03330470
(ClinicalTrials.gov)

January 1, 2017

17/10/2017

Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

Subjective Cognitive Impairment;Mild Cognitive Impairment;Parkinson Disease;Healthy Volunteers

Behavioral: exercise;Dietary Supplement: carnosine supplementation;Behavioral: stretching;Dietary Supplement: supplementation with placebo

Slovak Academy of Sciences

Comenius University;University Hospital Bratislava;National Cheng Kung University

Recruiting

55 Years

80 Years

All

100

N/A

Slovakia;Taiwan

320

NCT03034564
(ClinicalTrials.gov)

January 2017

25/1/2017

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

Parkinson Disease;Fatigue;Parkinsonism

Drug: Northera;Drug: Placebo Oral Tablet

The Cooper Health System

NULL

Recruiting

18 Years

N/A

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

321

NCT02954978
(ClinicalTrials.gov)

January 2017

1/11/2016

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Parkinson Disease;Parkinsons Disease With Dementia

Drug: Placebo Oral Capsule;Drug: Nilotinib 150mg oral capsule [Tasigna];Drug: Nilotinib 300mg oral capsule [Tasigna]

Georgetown University

NULL

Active, not recruiting

40 Years

90 Years

All

Phase 2

United States

322

NCT03037203
(ClinicalTrials.gov)

January 2017

23/1/2017

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Excessive Sleepiness;Parkinson Disease

Drug: JZP-110;Other: Placebo

Jazz Pharmaceuticals

NULL

Completed

35 Years

80 Years

All

Phase 2

United States

323

NCT02969369
(ClinicalTrials.gov)

December 31, 2016

17/11/2016

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

Drug: SEP-363856;Drug: Placebo capsule

Sunovion

NULL

Completed

55 Years

105 Years

All

Phase 2

United States

324

NCT02906020
(ClinicalTrials.gov)

December 15, 2016

14/9/2016

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.

Parkinson's Disease

Drug: GZ/SAR402671;Drug: Placebo

Genzyme, a Sanofi Company

NULL

Active, not recruiting

18 Years

80 Years

All

270

Phase 2

United States;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom

325

NCT02789020
(ClinicalTrials.gov)

December 2016

20/5/2016

Image Parkinson's Disease Progression Study

Parkinson's Disease

Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance Test

University of Florida

National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

40 Years

77 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

326

NCT02879136
(ClinicalTrials.gov)

December 2016

23/6/2016

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study

Parkinson's Disease, Idiopathic

Drug: Methylphenidate;Other: Physical Therapy;Drug: Atomoxetine

Hubert Fernandez

NULL

Recruiting

18 Years

90 Years

All

Early Phase 1

United States

327

NCT02941822
(ClinicalTrials.gov)

December 2016

5/9/2016

Ambroxol in Disease Modification in Parkinson Disease

A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease

Parkinson Disease

Drug: Ambroxol

University College, London

The Cure Parkinson's Trust

Completed

40 Years

80 Years

All

Phase 2

United Kingdom

328

NCT03000569
(ClinicalTrials.gov)

November 30, 2016

28/11/2016

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease

Parkinson Disease

Drug: SAGE-217;Drug: Levodopa;Drug: Antiparkinsonian Agent(s)

Sage Therapeutics

NULL

Completed

40 Years

75 Years

All

Phase 2

United States

329

NCT02847442
(ClinicalTrials.gov)

November 23, 2016

21/7/2016

Efficacy and Safety of Opicapone in Clinical Practice

Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations

Parkinson's Disease With Wearing-off Motor Fluctuations

Drug: BIA 9-1067;Drug: levodopa /dopa decarboxylase inhibitor

Bial - Portela C S.A.

NULL

Completed

30 Years

N/A

All

518

Phase 4

Germany

330

NCT03007888
(ClinicalTrials.gov)

November 14, 2016

6/12/2016

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: IR CD-LD;Drug: ER CD-LD

Impax Laboratories, LLC

NULL

Completed

40 Years

100 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

331

NCT03531060
(ClinicalTrials.gov)

November 8, 2016

10/4/2018

A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).

Parkinson Disease

Drug: IRL790;Drug: Placebo

Integrative Research Laboratories AB

NULL

Completed

50 Years

85 Years

All

Phase 1;Phase 2

NULL

332

NCT03022799
(ClinicalTrials.gov)

November 2016

27/12/2016

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects

Parkinson's Disease

Drug: KM-819;Drug: Placebo

Kainos Medicine Inc.

NULL

Completed

19 Years

45 Years

All

Phase 1

Korea, Republic of

333

NCT02857244
(ClinicalTrials.gov)

November 2016

25/7/2016

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

Parkinson's Disease

Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil

University of Chicago

NULL

Withdrawn

18 Years

100 Years

All

Phase 2

United States

334

NCT02968433
(ClinicalTrials.gov)

November 2016

14/11/2016

The Stanford Parkinson's Disease Plasma Study

The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease

Parkinson Disease(PD)

Drug: Infusions of young plasma

Stanford University

NULL

Active, not recruiting

50 Years

80 Years

All

Phase 1

United States

335

NCT02871427
(ClinicalTrials.gov)

October 20, 2016

15/8/2016

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Lewy Body Dementia;Dementia With Lewy Bodies;Parkinson's Disease Dementia;Visual Hallucinations;REM Sleep Behavior Disorder

Drug: Nelotanserin

Axovant Sciences Ltd.

NULL

Terminated

50 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

336

NCT02847650
(ClinicalTrials.gov)

October 17, 2016

25/7/2016

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON'S DISEASE

Parkinson Disease

Drug: Placebo;Drug: PF-06649751

Pfizer

NULL

Terminated

45 Years

80 Years

All

Phase 2

United States;France;Germany;Israel

337

NCT02728843
(ClinicalTrials.gov)

October 12, 2016

31/3/2016

Study of Parkinson's Early Stage With Deferiprone

A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Deferiprone;Drug: Placebo

ApoPharma

NULL

Completed

18 Years

80 Years

All

140

Phase 2

Canada;France;Germany;United Kingdom

338

EUCTR2016-002391-27-GB
(EUCTR)

07/10/2016

04/08/2016

Opicapone in clinical practice (OPTIPARK)

This action will amend the information submitted in this data field for all relevant applications. Please refer to the guidance under the Amendment tab and consider whether further notification to review bodies is required. - Opicapone in clinical practice (OPTIPARK)_V1

Parkinson's disease (PD) patients with wearing-off motor fluctuations
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Phase 4

Germany;United Kingdom

339

NCT02935842
(ClinicalTrials.gov)

October 1, 2016

18/8/2016

Evaluation of Intensive Language Therapy

Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial

Parkinson's Disease

Other: Specific SL-therapy;Other: Rhythmic Balance-Movement Training (rBMT)

University Hospital, Basel, Switzerland

NULL

Completed

45 Years

80 Years

All

N/A

Switzerland

340

NCT02910102
(ClinicalTrials.gov)

October 2016

16/9/2016

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Alzheimer's Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia

Drug: RVT-101 35 mg;Drug: Placebo

Axovant Sciences Ltd.

NULL

Completed

50 Years

89 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

341

NCT02803749
(ClinicalTrials.gov)

October 2016

14/6/2016

Buspirone in Parkinson's Disease

The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease

Parkinson Disease;Anxiety

Drug: Buspirone;Drug: Placebo

University of Rochester

Michael J. Fox Foundation for Parkinson's Research

Completed

18 Years

N/A

All

Phase 2

United States

342

NCT02538315
(ClinicalTrials.gov)

October 2016

25/8/2015

Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients

Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients

Parkinson`s Disease

Drug: [18F]FDOPA PET/CT

University of Saskatchewan

University of Manitoba

Recruiting

18 Years

N/A

All

N/A

Canada

343

NCT02940912
(ClinicalTrials.gov)

October 2016

14/10/2016

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Parkinson Disease

Drug: Apomorphine;Drug: Placebo

Clinique Beau Soleil

NULL

Recruiting

35 Years

90 Years

All

Phase 4

France

344

NCT02818777
(ClinicalTrials.gov)

October 2016

6/5/2016

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease

Parkinson's Disease

Drug: cannabidiol

University of Colorado, Denver

Colorado Department of Public Health and Environment;GW Research Ltd

Completed

40 Years

80 Years

All

Phase 2

United States

345

NCT03462680
(ClinicalTrials.gov)

September 28, 2016

22/2/2018

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

Parkinson's Disease

Dietary Supplement: niacin;Other: placebo

VA Office of Research and Development

NULL

Completed

35 Years

N/A

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

346

JPRN-UMIN000024312

2016/09/20

25/05/2017

Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.

Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis

Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks

Tsukuba International Clinical Pharmacology Clinic

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Not selected

Japan

347

NCT02688465
(ClinicalTrials.gov)

September 5, 2016

18/2/2016

Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).

Parkinson's Disease

Drug: Apomorphine

Fondation Ophtalmologique Adolphe de Rothschild

NULL

Terminated

18 Years

N/A

All

Phase 4

France

348

NCT02815800
(ClinicalTrials.gov)

September 2, 2016

13/6/2016

Efficacy of Ethnodyne Visio in Parkinson's Disease

Parkinson's Disease

Dietary Supplement: ETHNODYNE VISIO

University Hospital, Strasbourg, France

ETHNODYNE

Completed

40 Years

75 Years

All

N/A

France

349

NCT03192046
(ClinicalTrials.gov)

September 2016

13/6/2017

Bracing for Walking in Parkinson's Disease

Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD

Gait Disorders, Neurologic;Parkinson Disease

Device: Carbon Fiber Ankle Foot Orthosis (AFO)

University of Texas Southwestern Medical Center

American Orthotic and Prosthetic Association

Recruiting

30 Years

85 Years

All

N/A

United States

350

NCT02897063
(ClinicalTrials.gov)

September 2016

7/9/2016

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension

Drug: Droxidopa;Drug: Midodrine;Drug: Placebo

Vanderbilt University Medical Center

NULL

Recruiting

40 Years

80 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

351

NCT02385500
(ClinicalTrials.gov)

September 2016

4/3/2015

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Urinary Bladder, Overactive;Parkinson Disease

Drug: Fesoterodine;Drug: Placebo

Sir Mortimer B. Davis - Jewish General Hospital

NULL

Terminated

50 Years

85 Years

All

Phase 4

Canada

352

NCT02939391
(ClinicalTrials.gov)

September 2016

17/10/2016

A Study of KW-6356 in Subjects With Early Parkinson's Disease

An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease

Parkinson's Disease

Drug: KW-6356;Drug: Placebo

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

80 Years

All

175

Phase 2

Japan

353

NCT02601586
(ClinicalTrials.gov)

September 2016

17/8/2015

Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease

Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial

Parkinson Disease

Drug: PR Oxycodone;Drug: Levodopa;Drug: Oxycodone Placebo;Drug: Levodopa placebo

University Hospital, Toulouse

NULL

Recruiting

40 Years

75 Years

All

Phase 2;Phase 3

France

354

NCT02365870
(ClinicalTrials.gov)

August 2016

11/2/2015

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

Anxiety Disorders;Parkinson Disease

Drug: rotigotine transdermal patch;Drug: placebo

Johns Hopkins University

National Institute on Aging (NIA)

Terminated

21 Years

89 Years

All

Phase 4

United States

355

NCT02782481
(ClinicalTrials.gov)

August 2016

22/5/2016

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Parkinson's Disease

Drug: ND0612;Drug: Placebo

NeuroDerm Ltd.

NULL

Withdrawn

30 Years

80 Years

All

Phase 3

Israel

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

356

NCT02615873
(ClinicalTrials.gov)

July 2016

23/11/2015

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004

Parkinson's Disease

Drug: Accordion Pill™ Carbidopa/Levodopa

Intec Pharma Ltd.

NULL

Unknown status

30 Years

100 Years

All

460

Phase 3

United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom

357

NCT02452723
(ClinicalTrials.gov)

July 2016

18/5/2015

A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease

A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Parkinson Disease

Biological: ISC-hpNSC

Cyto Therapeutics Pty Limited

NULL

Active, not recruiting

30 Years

70 Years

All

Phase 1

Australia

358

NCT02382198
(ClinicalTrials.gov)

July 2016

21/1/2015

Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease

A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease

Sialorrhea;Parkinson's Disease

Drug: Glycopyrrolate;Drug: Placebo

Ottawa Hospital Research Institute

NULL

Unknown status

30 Years

N/A

All

Phase 2

Canada

359

NCT02642393
(ClinicalTrials.gov)

June 2016

19/12/2015

Study of Urate Elevation in Parkinson's Disease, Phase 3

A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease

Parkinson's Disease

Drug: Inosine;Drug: Placebo

Michael Alan Schwarzschild

The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

All

298

Phase 3

United States;Puerto Rico

360

NCT02785978
(ClinicalTrials.gov)

June 2016

11/5/2016

Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers

Parkinson Disease;Healthy Volunteers

Drug: Levodopa acute challenge;Other: Controlled environment tests (series of tasks of everyday life);Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS;Device: ActiMyo recording;Other: Diary completion

Institut de Myologie, France

NULL

Completed

18 Years

N/A

All

N/A

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

361

NCT02838797
(ClinicalTrials.gov)

June 2016

16/6/2016

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

Parkinson's Disease;Gastroparesis;Constipation

Drug: RQ-00000010;Drug: Placebo

Virginia Commonwealth University

Michael J. Fox Foundation for Parkinson's Research;RaQualia Pharma Inc.

Completed

18 Years

N/A

All

Phase 1

United States

362

NCT02807675
(ClinicalTrials.gov)

June 2016

17/6/2016

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease

Parkinson's Disease

Drug: CVT-301, LIP;Other: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

Phase 1

United States

363

NCT02762591
(ClinicalTrials.gov)

May 3, 2016

3/5/2016

Expanded Access of Pimavanserin for Patients With PD Psychosis

Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate

ACADIA Pharmaceuticals Inc.

NULL

Approved for marketing

40 Years

N/A

All

N/A

NULL

364

NCT02726386
(ClinicalTrials.gov)

May 2016

29/3/2016

A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

Drug: ND0612

NeuroDerm Ltd.

NULL

Active, not recruiting

30 Years

N/A

All

210

Phase 2

United States;Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain

365

NCT02812147
(ClinicalTrials.gov)

May 2016

25/5/2016

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)

Parkinson Disease

Drug: L-DOPS;Drug: Placebo

St. Joseph's Hospital and Medical Center, Phoenix

Arizona State University, Tempe

Active, not recruiting

30 Years

83 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

366

NCT02784145
(ClinicalTrials.gov)

May 2016

17/5/2016

Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease

Parkinson Disease

Dietary Supplement: Resistant starch;Other: Recommendation with regard to nutrition

Saarland University

NULL

Completed

18 Years

N/A

All

N/A

Germany

367

NCT02705755
(ClinicalTrials.gov)

May 2016

7/3/2016

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension

Drug: TD-9855;Drug: Placebo

Theravance Biopharma

NULL

Completed

40 Years

N/A

All

Phase 2

United States

368

NCT02764125
(ClinicalTrials.gov)

April 8, 2016

13/1/2016

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off

Parkinson's Disease

Drug: Stalevo;Drug: levodopa MR

Orion Corporation, Orion Pharma

NULL

Completed

30 Years

N/A

All

Phase 2

Finland;Germany;Hungary;Latvia

369

NCT03034538
(ClinicalTrials.gov)

April 8, 2016

25/1/2017

An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease

Parkinson Disease;Parkinsonism;Dyskinesias

Drug: Zonegran

The Cooper Health System

NULL

Recruiting

18 Years

N/A

All

Phase 4

United States

370

NCT02775591
(ClinicalTrials.gov)

April 2016

9/5/2016

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial

Parkinson Disease;Dyspepsia

Drug: DA-9701;Drug: DA-9701 placebo

Seoul National University Hospital

Samsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical Center

Completed

50 Years

80 Years

All

147

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

371

NCT04470037
(ClinicalTrials.gov)

April 2016

26/5/2020

Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

Parkinson's Disease With Dementia

Drug: DAAOI-P;Drug: Placebo

China Medical University Hospital

Ministry of Science and Technology, Taiwan

Recruiting

50 Years

90 Years

All

Phase 2

Taiwan

372

NCT03173781
(ClinicalTrials.gov)

April 2016

10/8/2016

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

Parkinson's Disease

Drug: droxidopa;Drug: Placebo

Colorado Springs Neurological Associates

H. Lundbeck A/S

Completed

18 Years

N/A

All

N/A

United States

373

NCT02719496
(ClinicalTrials.gov)

April 2016

15/3/2016

Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease

Gastrointestinal Disorders in Parkinson's Disease

Drug: IBEROGAST

Nantes University Hospital

NULL

Completed

30 Years

80 Years

All

Phase 2

France

374

NCT02729714
(ClinicalTrials.gov)

April 2016

26/1/2016

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Insomnia

Drug: Suvorexant;Drug: Placebo

Burdick, Daniel, M.D.

Merck Sharp & Dohme Corp.

Recruiting

30 Years

80 Years

All

Phase 4

United States

375

NCT02462603
(ClinicalTrials.gov)

March 31, 2016

20/5/2015

Safety and Biomarker Study of EPI-589 in Parkinson's Disease

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects

Parkinson's Disease

Drug: EPI-589

PTC Therapeutics

NULL

Completed

21 Years

75 Years

All

Phase 2

United States;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

376

NCT02787590
(ClinicalTrials.gov)

March 21, 2016

26/5/2016

Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease

Simvastatin as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity.

Parkinson Disease

Drug: Simvastatin;Drug: Matched Placebo (for Simvastatin)

University Hospital Plymouth NHS Trust

University of Plymouth

Active, not recruiting

40 Years

90 Years

All

235

Phase 2

United Kingdom

377

NCT02687542
(ClinicalTrials.gov)

March 3, 2016

29/1/2016

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

Parkinson Disease

Drug: Placebo;Drug: PF-06649751 low dose (1 mg QD);Drug: PF-06649751 middle dose 1 (3 mg QD);Drug: PF-06649751 middle dose 2 (7 mg QD);Drug: PF-06649751 high dose (15 mg QD)

Pfizer

NULL

Terminated

40 Years

85 Years

All

108

Phase 2

United States;Canada;France;Germany;Japan;Spain

378

NCT02994719
(ClinicalTrials.gov)

March 1, 2016

21/12/2015

Gait Analysis in Neurological Disease

Gait Pattern Analysis in Neurological Disease

Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease

Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation

Beth Israel Deaconess Medical Center

NULL

Active, not recruiting

18 Years

85 Years

All

120

United States

379

NCT02708186
(ClinicalTrials.gov)

March 2016

10/3/2016

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)

Dementia With Lewy Bodies;REM Sleep Behavior Disorder;Parkinson's Disease Dementia

Drug: Nelotanserin;Drug: Placebo

Axovant Sciences Ltd.

NULL

Completed

50 Years

N/A

All

Phase 2

United States

380

NCT02605434
(ClinicalTrials.gov)

March 2016

5/11/2015

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients

Parkinson's Disease

Drug: Accordion Pill™ Carbidopa/Levodopa;Drug: Sinemet®;Drug: Placebo -AP-CD/LD;Drug: Placebo- Sinemet

Intec Pharma Ltd.

NULL

Unknown status

30 Years

N/A

All

420

Phase 3

United States;Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;Hungary

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

381

NCT02668497
(ClinicalTrials.gov)

March 2016

26/1/2016

Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy

Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy

Parkinson's Disease

Drug: Botulinum Toxin Type A

Western University, Canada

NULL

Active, not recruiting

18 Years

80 Years

All

Phase 2

Canada

382

NCT04569656
(ClinicalTrials.gov)

February 2, 2016

24/9/2020

Treatment of Chronic Constipation in Parkinson's Disease

Pilot Study for the Evaluation of the Parameters of Activity of a Preparation of PHGG and Sodium Hyaluronate in Chronic Constipation in Patients With Parkinson's Disease

Parkinson Disease

Drug: hydrolyzed guar gum

IRCCS San Raffaele

NULL

Completed

18 Years

N/A

All

Phase 2

Italy

383

NCT02618941
(ClinicalTrials.gov)

February 2, 2016

25/11/2015

Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program

Parkinson's Disease

Biological: AFFITOPE® PD01A

Affiris AG

NULL

Completed

40 Years

68 Years

All

Phase 1

Austria

384

JPRN-UMIN000020288

2016/02/01

28/12/2015

Intervention Study of Istradefylline for the Treatment of Gait Disorders in Patients with Parkinson's Disease.

Parkinson's disease

In this research, the duration of evaluation will be 12 weeks.
Treatment with istradefylline will be started at a dose of 20 mg administered once daily. The dose of istradefylline will be increased to 40 mg once daily if the patient has no tolerability issues and still has motor symptoms at Week 4. After the Week 4, the dose will be allowed to be reduced to 20 mg once daily, if the patient exhibits any tolerability issues such as the occurrence of adverse drug reactions caused by istradefylline.

Juntendo University Shizuoka Hospital

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not selected

Japan

385

NCT02641054
(ClinicalTrials.gov)

February 2016

7/12/2015

Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test

Idiopathic Parkinson Disease

Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa

CleveXel Pharma

NULL

Completed

40 Years

75 Years

All

Phase 2

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

386

NCT02683629
(ClinicalTrials.gov)

February 2016

8/2/2016

Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

Parkinson's Disease

Biological: NTCELL Implantation;Other: Sham Surgery

Living Cell Technologies

Statistecol Consultants Limited

Completed

40 Years

65 Years

All

Phase 2

New Zealand

387

NCT02524405
(ClinicalTrials.gov)

February 2016

13/8/2015

BEAM: Brain-Eye Amyloid Memory Study

The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration

Alzheimer's Disease;Mild Cognitive Impairment;Vascular Cognitive Impairment;Parkinson's Disease;Lewy Body Disease

Other: Pittsburgh Compound B [11C]-PIB

Sunnybrook Health Sciences Centre

Brain Canada;Weston Brain Institute;GE Healthcare;University Health Network, Toronto;Centre for Addiction and Mental Health;Baycrest;St. Michael's Hospital, Toronto;Kensington Eye Institute

Recruiting

50 Years

90 Years

All

345

Canada

388

NCT02655315
(ClinicalTrials.gov)

February 2016

7/1/2016

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

Parkinson Disease

Drug: Deferiprone;Drug: Placebo

University Hospital, Lille

European Commission;ApoPharma

Active, not recruiting

N/A

80 Years

All

372

Phase 2

Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic

389

NCT03258294
(ClinicalTrials.gov)

January 13, 2016

20/8/2017

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial

Parkinson's Disease

Drug: Melatonin (Circadin®);Drug: Placebo Oral Tablet

KIMJisun

Kuhnil Pharmaceutical Co., Ltd.

Enrolling by invitation

55 Years

N/A

All

Phase 4

NULL

390

NCT02649608
(ClinicalTrials.gov)

January 2016

6/1/2016

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease

Parkinson Disease

Drug: 0.04 mg Lu AE04621;Drug: 0.08 mg Lu AE04621;Drug: 0.2 mg Lu AE04621;Drug: 0.4 mg Lu AE04621;Drug: 0.6 mg Lu AE04621;Drug: 0.8 mg Lu AE04621;Drug: 1.0 mg Lu AE04621;Drug: 1.2 mg Lu AE04621

H. Lundbeck A/S

NULL

Completed

45 Years

75 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

391

NCT02549573
(ClinicalTrials.gov)

January 2016

9/9/2015

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor State

Parkinson's Disease;Motor Symptoms

Drug: APOKYN;Behavioral: Physical Therapy

US WorldMeds LLC

NULL

Terminated

18 Years

78 Years

All

Phase 4

United States

392

NCT02579473
(ClinicalTrials.gov)

January 2016

13/10/2015

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration

Parkinson's Disease

Drug: SER-214

Serina Therapeutics

NULL

Active, not recruiting

40 Years

80 Years

All

Phase 1

United States

393

NCT02589340
(ClinicalTrials.gov)

January 2016

23/10/2015

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Parkinson's Disease;Dyskinesias;Movement Disorders

Drug: Buspirone;Drug: Placebo

Oregon Health and Science University

Portland VA Medical Center

Active, not recruiting

18 Years

99 Years

All

Phase 1

United States

394

NCT02702102
(ClinicalTrials.gov)

December 2015

3/3/2016

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Imaging Inflammation in Patients With Diffuse Lewy Body Disease

Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia

Drug: 11C-PBR28

William Charles Kreisl

National Institute on Aging (NIA)

Completed

60 Years

N/A

All

Phase 2

United States

395

NCT02536976
(ClinicalTrials.gov)

December 2015

28/8/2015

Mirabegron in Parkinson Disease and Impaired Cognition

A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition

Parkinson Disease;Overactive Bladder;Impaired Cognition

Drug: mirabegron;Drug: Placebo

HealthPartners Institute

NULL

Completed

25 Years

80 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

396

NCT02616120
(ClinicalTrials.gov)

December 2015

20/11/2015

Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease

Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease Patients

Parkinson's Disease

Drug: SQJZ herbal mixtures;Drug: Placebo

Dongzhimen Hospital, Beijing

NULL

Recruiting

18 Years

80 Years

All

240

Phase 2

China

397

NCT02610231
(ClinicalTrials.gov)

December 2015

13/11/2015

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Istradefylline 20 mg or 40 mg

Kyowa Hakko Kirin Pharma, Inc.

Kyowa Kirin Co., Ltd.

Completed

30 Years

N/A

All

239

Phase 3

United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic

398

NCT02470780
(ClinicalTrials.gov)

December 2015

4/6/2015

Treating Bacterial Overgrowth in Parkinson's Disease

Parkinson's Disease;Small Intestinal Bacterial Overgrowth

Drug: Rifaximin;Drug: Placebo

University of Cincinnati

NULL

Completed

18 Years

N/A

All

Phase 2;Phase 3

United States

399

NCT02565628
(ClinicalTrials.gov)

November 16, 2015

28/9/2015

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.

Idiopathic Parkinson's Disease

Drug: PF-06669571;Drug: Placebo

Pfizer

NULL

Completed

N/A

All

Phase 1

United States

400

JPRN-jRCTs041180070

04/11/2015

07/03/2019

Trerief Impact in PD PET Study

Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS

Parkinson's disease
Parkinson's disease;D010300

[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.

Ouchi Yasuomi

NULL

Not Recruiting

Not applicable

< 80age old

Both

N/A

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

401

NCT04110678
(ClinicalTrials.gov)

November 1, 2015

18/9/2019

Tolerance to NeuroEPO in Parkinson Disease

Nasal Administration of the NeuroEPO in Parkinson Disease: Short-term Tolerance Physician Lead Trial

Parkinson Disease

Drug: NeuroEPO

International Center for Neurological Restoration, Cuba

Center of Molecular Immunology, Cuba;University of Electronic Science and Technology of China

Completed

40 Years

70 Years

All

Phase 1;Phase 2

Cuba

402

NCT02914366
(ClinicalTrials.gov)

November 2015

8/9/2016

Ambroxol as a Treatment for Parkinson's Disease Dementia

Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia

Parkinson's Disease Dementia

Drug: Ambroxol;Other: Placebo

Lawson Health Research Institute

Weston Brain Institute;University of Western Ontario, Canada;London Health Sciences Centre

Recruiting

50 Years

N/A

All

Phase 2

Canada

403

NCT02271503
(ClinicalTrials.gov)

November 2015

13/10/2014

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

Drug: CD -LD IR;Drug: IPX203 180 mg;Drug: IPX203 270 mg;Drug: Rytary 195 mg;Drug: Rytary 145 mg

Impax Laboratories, LLC

NULL

Completed

40 Years

N/A

All

Phase 2

United States

404

NCT02758730
(ClinicalTrials.gov)

November 2015

26/4/2016

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA

Parkinson's Disease

Biological: AFFITOPE® PD01A + Adjuvant;Biological: Adjuvant without active component

Affiris AG

University Hospital Tuebingen

Withdrawn

40 Years

80 Years

Both

Phase 1

Germany

405

NCT02577523
(ClinicalTrials.gov)

November 2015

6/10/2015

A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

Drug: ND0612 (Levodopa/Carbidopa solution)

NeuroDerm Ltd.

NULL

Completed

30 Years

80 Years

All

Phase 2

United States;Austria;Israel;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

406

NCT02632279
(ClinicalTrials.gov)

November 2015

26/11/2015

Tryptophan Depletion in PD Patients Treated With STN DBS

Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions

Parkinson's Disease

Dietary Supplement: Tryptophan (TRP) depletion;Dietary Supplement: Placebo;Device: Stimulator ON;Device: Stimulator OFF

Maastricht University Medical Center

Netherlands Brain Foundation

Terminated

N/A

All

N/A

Netherlands

407

NCT02933372
(ClinicalTrials.gov)

October 5, 2015

6/4/2016

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3

Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3

Parkinson's Disease

Drug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by Investigator

University of Michigan

NULL

Completed

45 Years

N/A

All

Phase 2

NULL

408

JPRN-UMIN000019524

2015/10/01

28/10/2015

Parkinson's Disease

Zonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.

Hamamatsu University School of Medicine

NULL

Complete: follow-up complete

Not applicable

80years-old

Male and Female

Not applicable

Japan

409

NCT02572713
(ClinicalTrials.gov)

October 2015

7/10/2015

Systemic Synuclein Sampling Study (S4)

Parkinson's Disease

Procedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN ™

Michael J. Fox Foundation for Parkinson's Research

Indiana University;University of Iowa;Banner Health;Paracelsus Elena Klinik

Completed

40 Years

N/A

All

N/A

United States;Canada

410

NCT02562768
(ClinicalTrials.gov)

September 30, 2015

28/9/2015

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease

Parkinson's Disease

Drug: LY3154207;Drug: Placebo

Eli Lilly and Company

NULL

Completed

20 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

411

NCT02549092
(ClinicalTrials.gov)

September 9, 2015

11/9/2015

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study

Advanced Parkinson's Disease

Drug: ABT-SLV187

AbbVie

NULL

Active, not recruiting

30 Years

99 Years

All

Phase 3

United States;Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden

412

NCT02542696
(ClinicalTrials.gov)

August 31, 2015

3/9/2015

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease

Drug: APL-130277

Sunovion

NULL

Recruiting

18 Years

N/A

All

226

Phase 3

United States;Austria;Canada;France;Germany;Italy;Spain;United Kingdom

413

NCT02599753
(ClinicalTrials.gov)

August 2015

1/11/2015

Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients

Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging

Parkinson's Disease

Drug: 18-FDTBZ

Chang Gung Memorial Hospital

NULL

Completed

20 Years

80 Years

All

Phase 2

Taiwan

414

NCT02337751
(ClinicalTrials.gov)

July 10, 2015

9/1/2015

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Parkinson's Disease

Drug: TVP-1012 1mg

Takeda

NULL

Completed

30 Years

79 Years

All

198

Phase 3

Japan

415

NCT02459886
(ClinicalTrials.gov)

July 1, 2015

29/5/2015

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease

Parkinson's Disease;Healthy

Drug: BIIB054;Drug: Placebo

Biogen

NULL

Completed

40 Years

80 Years

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

416

NCT02488265
(ClinicalTrials.gov)

July 1, 2015

21/5/2015

Protocol: Balance Training in Parkinson's Disease

Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease

Parkinson Disease

Other: Balance Training;Other: Screening to prevent falls

University of Sao Paulo General Hospital

NULL

Completed

50 Years

70 Years

All

150

N/A

Brazil

417

NCT02453386
(ClinicalTrials.gov)

July 2015

21/5/2015

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)

Idiopathic Parkinson's Disease

Drug: tozadenant;Drug: placebo

Biotie Therapies Inc.

NULL

Terminated

30 Years

80 Years

All

449

Phase 3

United States;Austria;Canada;Czechia;Germany;Italy;Spain;Czech Republic

418

NCT02469090
(ClinicalTrials.gov)

June 18, 2015

9/6/2015

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)

Parkinson Disease, Off Episodes

Drug: APL-130277;Drug: Placebo

Sunovion

NULL

Completed

18 Years

N/A

All

141

Phase 3

United States;Canada;United Kingdom

419

NCT02230930
(ClinicalTrials.gov)

June 2015

29/8/2014

Treatment of Apomorphine-induced Skin Reactions: a Pilot Study

Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions

Parkinson's Disease;Apomorphine-induced Skin Reactions

Drug: Apomorphine 0.25% (2.5mg/ml);Device: Massage with a spiky ball;Drug: Hydrocortisone cream 1%;Drug: Subcutaneous hydrocortisone 10mg

University Medical Center Groningen

NULL

Recruiting

30 Years

N/A

All

Phase 2

Netherlands

420

NCT02769793
(ClinicalTrials.gov)

June 2015

9/5/2016

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON

Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial

Parkinson Disease

Drug: Levodopa dispersible;Drug: Levodopa

Seoul National University Hospital

SMG-SNU Boramae Medical Center;Samsung Medical Center

Unknown status

31 Years

80 Years

All

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

421

NCT02450786
(ClinicalTrials.gov)

June 2015

14/5/2015

Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)

Parkinson's Disease

Drug: Donepezil

Yonsei University

NULL

Active, not recruiting

40 Years

N/A

All

Phase 2

Korea, Republic of

422

JPRN-jRCTs061180028

11/05/2015

26/02/2019

Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine

Parkinson's disease;D010300

Ando Rina

NULL

Complete

20 years old

None

Both

Phase 2

Japan

423

NCT02604914
(ClinicalTrials.gov)

May 2015

3/11/2015

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel

Parkinson's Disease

Drug: ND0612;Drug: LCIG

NeuroDerm Ltd.

Quotient Clinical

Completed

30 Years

65 Years

All

Phase 1

United Kingdom

424

NCT02452125
(ClinicalTrials.gov)

May 2015

20/5/2015

The Effects of Nicotine Chewing Gum in Parkinson's Disease

The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease

Low Blood Pressure;Parkinsons Disease

Dietary Supplement: Nicotine gum

New York Institute of Technology

NULL

Completed

N/A

All

N/A

United States

425

NCT02448914
(ClinicalTrials.gov)

May 2015

12/5/2015

A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease

Parkinson's Disease

Drug: TRIGEL;Drug: Duodopa

LobSor Pharmaceuticals AB

TFS Trial Form Support

Completed

30 Years

N/A

All

Phase 1

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

426

NCT02390089
(ClinicalTrials.gov)

April 2015

19/2/2015

Cough According to Stimulus Type in PD

Airway Protection Deficits According to Stimulus Type in Parkinson's Disease

Parkinson's Disease

Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer

University of Florida

National Institute on Deafness and Other Communication Disorders (NIDCD)

Completed

50 Years

80 Years

All

158

Phase 1

United States

427

NCT02242487
(ClinicalTrials.gov)

March 2015

15/9/2014

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Idiopathic Parkinson's Disease

Drug: CVT-301

Acorda Therapeutics

NULL

Completed

30 Years

86 Years

All

325

Phase 3

United States;Canada;Czechia;Poland;Spain;Czech Republic

428

NCT02352363
(ClinicalTrials.gov)

March 2015

26/1/2015

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Idiopathic Parkinson's Disease

Drug: CVT-301;Other: Observational cohort

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

408

Phase 3

United States;Austria;Belgium;Czechia;France;Germany;Hungary;Israel;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;Czech Republic;Italy

429

NCT02696603
(ClinicalTrials.gov)

March 2015

23/2/2016

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

Parkinson Disease;Neurodegenerative Diseases;Movement Disorders;Central Nervous System Diseases;Brain Diseases;Basal Ganglia Diseases;Parkinsonian Disorders

Behavioral: Participant self-assessment surveys;Behavioral: Phonation;Behavioral: Gait and balance;Behavioral: Memory;Behavioral: Dexterity;Behavioral: Participant open-response writing;Other: Parkinson mPower mobile application

Sage Bionetworks

Robert Wood Johnson Foundation

Recruiting

18 Years

N/A

All

20000

N/A

United States

430

NCT02373072
(ClinicalTrials.gov)

March 2015

20/2/2015

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson Disease

Drug: PF-06649751;Drug: Trimethobenzamide Hydrochloride;Drug: Placebo

Pfizer

NULL

Completed

N/A

All

Phase 1

United States;Belgium

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

431

NCT02393027
(ClinicalTrials.gov)

March 2015

6/3/2015

Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999

Idiopathic Parkinson Disease

Drug: [18F] LBT-999 PET

University Hospital, Tours

NULL

Terminated

45 Years

75 Years

All

Early Phase 1

France

432

NCT02337725
(ClinicalTrials.gov)

February 7, 2015

9/1/2015

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Parkinson's Disease

Drug: TVP-1012;Drug: Placebo

Takeda

NULL

Completed

30 Years

80 Years

All

244

Phase 3

Japan

433

NCT02337764
(ClinicalTrials.gov)

February 3, 2015

9/1/2015

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients

Parkinson's Disease

Drug: TVP-1012 1mg

Takeda

NULL

Completed

30 Years

79 Years

All

222

Phase 3

Japan

434

NCT02339064
(ClinicalTrials.gov)

February 2015

31/3/2014

Infusion of Apomorphine: Long-term Safety Study

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Idiopathic Parkinson's Disease

Drug: apomorphine infusion

US WorldMeds LLC

NULL

Active, not recruiting

30 Years

N/A

All

Phase 3

United States

435

NCT02337738
(ClinicalTrials.gov)

January 27, 2015

9/1/2015

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off

Parkinson's Disease

Drug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: Placebo

Takeda

NULL

Completed

30 Years

79 Years

All

404

Phase 2;Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

436

NCT02258152
(ClinicalTrials.gov)

December 22, 2014

3/10/2014

SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Parkinson's Disease Dementia (PDD)

Drug: SYN120;Drug: Placebo

Biotie Therapies Inc.

Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda Therapeutics

Completed

50 Years

N/A

All

Phase 2

United States

437

NCT02480803
(ClinicalTrials.gov)

December 2014

4/5/2015

INfusion VErsus STimulation in Parkinson's Disease

Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation

Parkinson's Disease

Drug: Continuous intrajejunal infusion of levodopa-carbidopa;Device: deep brain stimulation

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

18 Years

N/A

All

Phase 4

Netherlands

438

NCT03116308
(ClinicalTrials.gov)

November 21, 2014

12/4/2017

Effect of Food on Opicapone

Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects

Parkinson Disease

Drug: Opicapone (OPC)

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

439

NCT02278588
(ClinicalTrials.gov)

November 2014

28/10/2014

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

Parkinson's Disease

Drug: Rasagiline

Thomas Guttuso

NULL

Completed

N/A

All

United States

440

NCT02240030
(ClinicalTrials.gov)

November 2014

11/9/2014

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)

Idiopathic Parkinson's Disease

Drug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

85 Years

All

351

Phase 3

United States;Canada;Czechia;Poland;Spain;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

441

NCT02168842
(ClinicalTrials.gov)

November 2014

18/6/2014

Efficacy of Isradipine in Early Parkinson Disease

Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease

Parkinson Disease

Drug: Isradipine;Drug: Placebo (for Isradipine)

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research;The Parkinson Study Group

Completed

30 Years

N/A

All

336

Phase 3

United States;Canada

442

NCT02274766
(ClinicalTrials.gov)

October 2014

22/10/2014

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Dyskinesia;Levodopa-Induced Dyskinesia (LID);Parkinson's Disease (PD)

Drug: ADS-5102;Other: Placebo

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 3

United States;Austria;France;Germany;Spain

443

NCT02183519
(ClinicalTrials.gov)

October 2014

2/7/2014

Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease

Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease

Cough;Parkinson's Disease

Drug: Capsaicin;Other: Voluntary cough test

University of Florida

NULL

Completed

55 Years

85 Years

All

Phase 1;Phase 2

United States

444

NCT02224664
(ClinicalTrials.gov)

October 2014

15/8/2014

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease

A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations

Parkinson`s Disease

Drug: PF-06649751

Pfizer

NULL

Completed

30 Years

80 Years

All

Phase 1

United States;Belgium

445

JPRN-UMIN000016893

2014/09/22

01/04/2015

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.

A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine.

PD patients

The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.
The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule.

Ehime University HospitalDept. of Clinical pharmacology and Neurology

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

446

NCT02236260
(ClinicalTrials.gov)

September 3, 2014

29/8/2014

Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation

Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.

Parkinson's Disease

Procedure: Electroacupuncture;Drug: Local Anesthesia (lidocaine hydrochloride)

Nantes University Hospital

NULL

Completed

18 Years

74 Years

All

N/A

France

447

NCT02212678
(ClinicalTrials.gov)

September 2014

4/8/2014

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

Parkinson Disease

Drug: N-acetylcysteine capsule

University of Minnesota

Parkinson's Disease Society of the United Kingdom

Completed

18 Years

N/A

All

Phase 2

United States

448

NCT02230904
(ClinicalTrials.gov)

September 2014

29/8/2014

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine (Test product PR 2.3.1);Drug: Rotigotine (Reference product PR 2.1.1)

UCB BIOSCIENCES GmbH

Pharmaceutical Health Sciences;Bracket Global

Completed

18 Years

N/A

All

Phase 1

Germany

449

NCT03151460
(ClinicalTrials.gov)

September 2014

9/5/2017

Dopaminergic Modulation of Declarative Memory

Parkinson's Disease

Drug: Dopamine Agent

I.R.C.C.S. Fondazione Santa Lucia

NULL

Completed

N/A

All

Phase 4

Italy

450

NCT02228590
(ClinicalTrials.gov)

August 31, 2014

26/8/2014

A Study to Examine APL-130277 in Patients With Parkinson's Disease

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Parkinson's Disease

Drug: APL-130277

Sunovion

NULL

Completed

18 Years

80 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

451

NCT02153645
(ClinicalTrials.gov)

August 18, 2014

30/5/2014

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Parkinson's Disease;Levodopa Induced Dyskinesias (LID)

Drug: 240mg Amantadine HCl ER tablets;Drug: Placebo tablets;Drug: 320mg Amantadine HCl ER tablets

Osmotica Pharmaceutical US LLC

NULL

Terminated

30 Years

85 Years

All

Phase 3

United States;Canada;France;Germany;Spain

452

NCT02236065
(ClinicalTrials.gov)

August 2014

8/9/2014

Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders

A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders

Brain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's Disease

Procedure: Umbilical cord blood therapy;Biological: Filgrastim

MinYoung Kim, M.D.

NULL

Completed

19 Years

75 Years

All

N/A

Korea, Republic of

453

NCT02096601
(ClinicalTrials.gov)

August 2014

18/3/2014

A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD

Parkinson's Disease

Drug: Levodopa and carbidopa SC solution;Drug: Oral levodopa and carbidopa

NeuroDerm Ltd.

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

80 Years

All

Phase 1;Phase 2

United States;Israel

454

NCT02153632
(ClinicalTrials.gov)

July 30, 2014

30/5/2014

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Parkinson's Disease;Levodopa Induced Dyskinesia (LID)

Drug: amantadine HCl ER;Drug: Placebo

Osmotica Pharmaceutical US LLC

NULL

Terminated

30 Years

85 Years

All

135

Phase 3

United States;Canada;France;Germany;Spain

455

NCT02202551
(ClinicalTrials.gov)

July 2014

25/7/2014

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease (PD)

Drug: ADS-5102

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

223

Phase 3

United States;Austria;Canada;France;Germany;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

456

NCT02206620
(ClinicalTrials.gov)

July 2014

29/7/2014

Effects of Cholinergic Augmentation on Measures of Balance and Gait

Parkinson's Disease

Drug: Donepezil

Oregon Health and Science University

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

United States

457

NCT02780895
(ClinicalTrials.gov)

May 2014

12/5/2016

Parkinsonian Brain Repair Using Human Stem Cells

Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease

Idiopathic Parkinson Disease

Drug: Human Stem Cells

Celavie Bioscences, LLC

Hospital Angeles del Pedregal

Active, not recruiting

18 Years

75 Years

Both

Phase 1

Mexico

458

NCT02046447
(ClinicalTrials.gov)

May 2014

23/1/2014

Neuroimaging of Dystonia

Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida

Primary Cervical Dystonia;DYT 1 Dystonia

Drug: Primary Cervical Dystonia (Trihexyphenidyl);Other: Controls Primary Cervical Dystonia (Trihexyphenidyl);Other: DYT 1 Dystonia (Healthy Control);Other: DYT 1 Dystonia

University of Florida

Bachmann Strauss Dystonia & Parkinson Foundation, Inc.

Completed

7 Years

70 Years

All

N/A

United States

459

NCT02136914
(ClinicalTrials.gov)

May 2014

9/5/2014

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

Dyskinesia;Levodopa Induced Dyskinesia (LID);Parkinson's Disease

Drug: ADS-5102;Other: Placebo

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

126

Phase 3

United States;Canada

460

NCT03314597
(ClinicalTrials.gov)

April 2, 2014

15/10/2017

Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD)

Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.

Parkinson's Disease;Rehabilitation

Other: Balance exercise;Other: Mobile platform exercise

University of Pavia

Fondazione Salvatore Maugeri

Completed

50 Years

85 Years

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

461

NCT01738178
(ClinicalTrials.gov)

April 2014

28/11/2012

Caffeine as a Therapy for Parkinson's Disease

Caffeine as a Therapeutic Agent in Parkinson's Disease

Parkinson's Disease

Drug: Caffeine;Drug: Placebo

McGill University Health Center

Pontifícia Universidade Católica do Paraná;University of Calgary;University of Newfoundland and Eastern Health;University Health Network, Toronto;UBC Hospital;Movement Disorder Clinic - Deer Lodge Centre;The Ottawa Hospital

Completed

45 Years

75 Years

All

119

Phase 3

Brazil;Canada

462

NCT02111122
(ClinicalTrials.gov)

April 2014

8/4/2014

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Sleep-wake Disturbances in Motor-phase Parkinson's Disease

Drug: Sodium Oxybate;Drug: Placebo

Christian Baumann

NULL

Completed

18 Years

90 Years

All

Phase 2

Switzerland

463

NCT02091739
(ClinicalTrials.gov)

April 2014

18/3/2014

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Chronic Troublesome Sialorrhea;Parkinson's Disease;Post-stroke;Traumatic Brain Injury

Drug: IncobotulinumtoxinA (100 Units);Drug: IncobotulinumtoxinA (75 Units);Drug: Placebo

Merz Pharmaceuticals GmbH

NULL

Completed

18 Years

80 Years

All

184

Phase 3

Germany;Poland;United States

464

NCT02082249
(ClinicalTrials.gov)

March 10, 2014

14/2/2014

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Advanced Parkinson's Disease

Drug: ABT-SLV187

AbbVie

NULL

Completed

30 Years

99 Years

All

Phase 3

Japan;Korea, Republic of;Taiwan

465

NCT02006121
(ClinicalTrials.gov)

March 3, 2014

22/11/2013

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

Multicentre,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment

Parkinson's Disease

Drug: Apomorphine hydrochloride;Drug: Placebo

Britannia Pharmaceuticals Ltd.

NULL

Completed

30 Years

N/A

All

107

Phase 3

Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

466

NCT02445651
(ClinicalTrials.gov)

March 2014

23/1/2015

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Parkinson Disease;Idiopathic Parkinson Disease

Dietary Supplement: Intravenous and Oral n-acetyl cysteine

Thomas Jefferson University

NULL

Active, not recruiting

30 Years

80 Years

All

N/A

United States

467

NCT02092181
(ClinicalTrials.gov)

March 2014

7/3/2014

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)

Parkinsons Disease

Drug: Mirabegron;Drug: Placebo

Daniel Burdick, MD

Astellas Pharma US, Inc.

Completed

30 Years

85 Years

All

Phase 4

United States

468

NCT02305017
(ClinicalTrials.gov)

March 2014

28/11/2014

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Parkinson's Disease

Drug: BIA 9-1067;Drug: Paracetamol

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

469

NCT02064166
(ClinicalTrials.gov)

February 2014

13/2/2014

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy

Parkinson Disease;Multiple System Atrophy

Drug: Intranasal Insulin

Peter Novak

NULL

Completed

18 Years

N/A

All

Phase 2

United States

470

NCT02305316
(ClinicalTrials.gov)

February 2014

28/11/2014

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers

Parkinson Disease

Drug: BIA 9-1067 non-micronized;Drug: BIA 9-1067 micronized

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

471

NCT02103894
(ClinicalTrials.gov)

February 2014

12/2/2014

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

Alzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;Tauopathies

Drug: [18F]T807 ([18F]MNI-777)

Molecular NeuroImaging

Institute for Neurodegenerative Disorders

Completed

18 Years

85 Years

Both

Phase 1

United States

472

NCT02046434
(ClinicalTrials.gov)

January 2014

23/1/2014

Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain

Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain

Parkinson's Disease

Drug: Glycerol Phenylbutyrate

University of Colorado, Denver

NULL

Active, not recruiting

21 Years

80 Years

All

Phase 1

United States

473

NCT01968460
(ClinicalTrials.gov)

December 2013

15/10/2013

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Parkinson's Disease

Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),;Drug: Placebo;Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),

Pharma Two B Ltd.

NULL

Completed

35 Years

75 Years

All

149

Phase 2;Phase 3

United States;Israel

474

NCT02108704
(ClinicalTrials.gov)

December 2013

4/4/2014

Helicobacter Pylori Eradication Study in Parkinson's Disease

Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial

Parkinson's Disease;Helicobacter Pylori Infection

Drug: Helicobacter pylori eradication therapy;Drug: Placebo

University of Malaya

NULL

Completed

18 Years

N/A

All

N/A

Malaysia

475

NCT02018406
(ClinicalTrials.gov)

December 2013

30/10/2013

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

Neurological Diseases;Ischemic Stroke;Hemorrhagic Stroke;Cerebral Palsy;Atypical Parkinson Disease

Drug: Combination injection of EPO and G-CSF;Drug: Injection of normal saline

Yonsei University

NULL

Active, not recruiting

20 Years

N/A

All

Phase 1;Phase 2

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

476

NCT04044547
(ClinicalTrials.gov)

November 22, 2013

30/7/2019

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Parkinson Disease

Drug: Rotigotine , extended-release microspheres;Drug: Placebo, extended-release microspheres

Luye Pharma Group Ltd.

Beijing Bozhiyin T&S Co., Ltd.

Completed

18 Years

75 Years

All

Phase 1

NULL

477

NCT01856738
(ClinicalTrials.gov)

November 2013

14/5/2013

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.

Parkinson's Disease

Drug: Rivastigmine;Drug: Placebo (for rivastigmine)

VU University Medical Center

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Atrium Medical Center;University Medical Center Groningen;Leiden University Medical Center;University Medical Center Nijmegen;International Parkinson Fonds Germany GmbH;ZonMw: The Netherlands Organisation for Health Research and Development

Terminated

40 Years

N/A

All

Phase 4

Netherlands

478

NCT01927055
(ClinicalTrials.gov)

November 2013

16/8/2013

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

Symptomatic Neurogenic Orthostatic Hypotension;Parkinson's Disease;Multiple Systems Atrophy;Pure Autonomic Failure;Dopamine Beta Hydroxylase Deficiency

Drug: Droxidopa;Drug: Placebo

Chelsea Therapeutics

NULL

Terminated

18 Years

N/A

All

Phase 3

United States

479

NCT01973543
(ClinicalTrials.gov)

October 2013

25/10/2013

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Parkinson's Disease

Biological: VY-AADC01

Neurocrine Biosciences

University of California, San Francisco;Veristat, Inc.;Feinstein Institute for Medical Research;Oregon Health and Science University;Voyager Therapeutics

Completed

40 Years

70 Years

All

Phase 1

United States

480

NCT01968031
(ClinicalTrials.gov)

October 2013

18/10/2013

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: Placebo

Kyowa Hakko Kirin Pharma, Inc.

Kyowa Kirin Co., Ltd.

Completed

30 Years

N/A

All

613

Phase 3

United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

481

NCT01960842
(ClinicalTrials.gov)

October 2013

9/10/2013

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie

NULL

Completed

30 Years

N/A

All

Phase 3

Japan;Korea, Republic of;Taiwan

482

NCT01882010
(ClinicalTrials.gov)

September 2013

13/6/2013

Leukine (Sargramostim) for Parkinson's Disease

Parkinson's Disease

Procedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion Analysis

Howard Gendelman, MD

Sanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience Alliance

Completed

35 Years

85 Years

Both

Phase 1

United States

483

NCT01929317
(ClinicalTrials.gov)

August 28, 2013

22/8/2013

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.

Parkinson Disease

Drug: Ropinirole CR 2mg tablet;Drug: Ropinirole CR 8mg tablet;Drug: Ropinirole CR matching Placebo tablet

GlaxoSmithKline

NULL

Terminated

20 Years

N/A

All

Phase 3

Japan

484

JPRN-UMIN000011111

2013/07/16

15/07/2013

Spinal blood flow and metabolism in neurological diseases

motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy

PET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not applicable

Japan

485

NCT01767129
(ClinicalTrials.gov)

July 2013

9/1/2013

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.

Dyskinesia;Parkinson's Disease

Drug: AVP-923-45;Drug: Placebo

Avanir Pharmaceuticals

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

80 Years

All

Phase 2

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

486

NCT01850381
(ClinicalTrials.gov)

June 2013

7/5/2013

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease

Parkinson's Disease

Drug: GM608;Drug: Placebo Comparator

Genervon Biopharmaceuticals, LLC

Columbia University

Completed

30 Years

N/A

All

Phase 2

United States

487

NCT02263235
(ClinicalTrials.gov)

June 2013

18/9/2014

In Vivo Alzheimer Proteomics

Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease

Probable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brain Trauma;Acute Hydrocephaly

Biological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urine, saliva

University Hospital, Montpellier

Assistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic Energy Agency

Recruiting

55 Years

85 Years

Both

110

N/A

France

488

JPRN-UMIN000010752

2013/05/17

17/05/2013

A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia.

Parkinson's disease

donepezil

Kansai Medical University

NULL

Complete: follow-up complete

Not applicable

Male and Female

Not selected

Japan

489

NCT03022201
(ClinicalTrials.gov)

May 2013

23/11/2016

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial

Parkinson's Disease,Idiopathic

Drug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701

Seoul National University Hospital

NULL

Completed

20 Years

80 Years

All

Phase 4

Korea, Republic of

490

NCT02473562
(ClinicalTrials.gov)

May 2013

12/6/2015

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study

Parkinson's Disease

Drug: Varenicline;Drug: Placebo (for varenicline)

VU University Medical Center

Centre for Human Drug Research, Netherlands

Terminated

N/A

All

Phase 4

Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

491

NCT01851850
(ClinicalTrials.gov)

May 2013

1/5/2013

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Parkinson Disease

Drug: Opicapone

Rabin Medical Center

NULL

Completed

30 Years

80 Years

All

Phase 3

Israel

492

NCT02005029
(ClinicalTrials.gov)

April 2013

18/9/2013

Erythromycin in Parkinson's Disease

Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics

Parkinson's Disease;Levodopa

Drug: Erythromycin;Drug: placebo

Virginia Commonwealth University

NULL

Completed

18 Years

80 Years

All

N/A

United States

493

NCT01777555
(ClinicalTrials.gov)

April 2013

23/1/2013

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

Idiopathic Parkinson's Disease

Drug: CVT-301;Drug: Placebo

Acorda Therapeutics

NULL

Completed

30 Years

80 Years

All

Phase 2

United States;Italy;Serbia;United Kingdom

494

NCT04627155
(ClinicalTrials.gov)

March 15, 2013

5/11/2020

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Human Tolerance and Kinetics of LY03003 By Single Intramuscular Injection

Parkinson Disease

Drug: LY03003

Luye Pharma Group Ltd.

NULL

Completed

18 Years

45 Years

All

Phase 1

NULL

495

NCT01789047
(ClinicalTrials.gov)

March 2013

7/2/2013

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

Idiopathic Parkinson's Disease;Drug Induced Dyskinesia

Drug: Topiramate;Drug: Placebo;Drug: Amantadine

Rush University Medical Center

Michael J. Fox Foundation for Parkinson's Research

Terminated

30 Years

90 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

496

NCT01736176
(ClinicalTrials.gov)

March 2013

27/11/2012

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: Levodopa -Carbidopa Intestinal Gel;Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J);Drug: Levodopa -carbidopa Immediate Release (LC-IR) Tablets

AbbVie (prior sponsor, Abbott)

NULL

Completed

30 Years

N/A

All

Phase 3

United States

497

NCT02059733
(ClinicalTrials.gov)

February 2013

7/2/2014

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism

Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET

Parkinson's Disease

Drug: 18F-DTBZ

Chang Gung Memorial Hospital

NULL

Completed

20 Years

80 Years

All

Phase 2

Taiwan

498

NCT01782222
(ClinicalTrials.gov)

February 2013

30/1/2013

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood

Idiopathic Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB BIOSCIENCES GmbH

NULL

Completed

18 Years

N/A

All

122

Phase 4

United States;Austria;Hungary;Poland;Slovakia;Slovenia;Spain

499

NCT03651856
(ClinicalTrials.gov)

January 2013

2/7/2018

Atomoxetine for Freezing of Gait in Parkinson's Disease

A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease

Parkinson's Disease;Freezing of Gait

Drug: ATM FOG in PD

Medical University of South Carolina

NULL

Completed

18 Years

80 Years

All

Phase 3

United States

500

NCT01014858
(ClinicalTrials.gov)

January 2013

16/11/2009

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease

Parkinson's Disease

Drug: Donepezil

Newcastle-upon-Tyne Hospitals NHS Trust

University of Newcastle Upon-Tyne;University of Cambridge;University of Manchester;University of Birmingham;Bangor University;London School of Economics and Political Science;University College, London;Lancashire Care NHS Foundation Trust;Newcastle University;King's College London

Terminated

18 Years

N/A

All

Phase 3

United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

501

NCT01741701
(ClinicalTrials.gov)

December 2012

1/12/2012

A Pilot Study of Oxaloacetate in Subjects With Treated PD

A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)

Parkinson's Disease

Drug: Oxaloacetate (OAA);Drug: Placebo

University of Kansas Medical Center

Terra Biological LLC

Completed

30 Years

N/A

All

Phase 2;Phase 3

United States

502

NCT01770145
(ClinicalTrials.gov)

December 2012

7/1/2013

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Parkinson's Disease;Motor Symptoms;Akinesia;Hypomobility;Delayed Levodopa Onset

Drug: APOKYN;Drug: L-dopa;Drug: Trimethobenzamide

US WorldMeds LLC

NULL

Completed

18 Years

N/A

All

127

Phase 4

United States

503

NCT01744496
(ClinicalTrials.gov)

November 2012

5/12/2012

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Advanced Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB BIOSCIENCES GmbH

NULL

Completed

18 Years

N/A

All

Phase 4

United States;Germany;Poland;Slovakia;Hungary;Korea, Republic of

504

NCT01723228
(ClinicalTrials.gov)

November 2012

5/11/2012

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Teva Branded Pharmaceutical Products, R&D Inc.

NULL

Completed

45 Years

80 Years

All

170

Phase 4

United States

505

NCT01721460
(ClinicalTrials.gov)

November 2012

30/10/2012

Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus

Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery

Parkinson's Disease;Deep Brain Stimulation Surgery

Drug: Dexmedetomidine

University of Wisconsin, Madison

NULL

Completed

18 Years

85 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

506

NCT01738191
(ClinicalTrials.gov)

November 2012

28/11/2012

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

Parkinson's Disease;Cognitive Impairment

Drug: Atomoxetine;Drug: Placebo

Medical University of South Carolina

Michael J. Fox Foundation for Parkinson's Research

Completed

35 Years

75 Years

All

Phase 2

United States

507

NCT01683253
(ClinicalTrials.gov)

November 2012

7/9/2012

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy

Impulse Control Disorder

Drug: Levodopa /Carbidopa(200mg/50mg);Drug: Dopaminergic Agonists

Sandoz

NULL

Completed

30 Years

80 Years

All

150

Phase 4

NULL

508

NCT03652363
(ClinicalTrials.gov)

October 25, 2012

21/8/2018

GDNF in ideopathicParkinsons Disease

A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease

Idiopathic Parkinson Disease

Drug: glial cell line-derived neurotrophic factor

North Bristol NHS Trust

NULL

Completed

35 Years

75 Years

All

Phase 2

NULL

509

NCT01563913
(ClinicalTrials.gov)

October 2012

16/3/2012

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids

Parkinson's Disease

Drug: Docosahexaenoic Acid (DHA);Drug: Placebo

VA Office of Research and Development

Oregon Health and Science University

Completed

21 Years

99 Years

All

Phase 1

United States

510

NCT01796483
(ClinicalTrials.gov)

October 2012

13/2/2013

EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PD

Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson

Parkinson Disease

Device: Clonidine (Catapressan);Device: Placebo 90 minutes before EEG

Hospices Civils de Lyon

NULL

Completed

40 Years

70 Years

All

N/A

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

511

NCT01723904
(ClinicalTrials.gov)

October 2012

6/11/2012

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B

Advanced Parkinson's Disease

Drug: Rotigotine

UCB BIOSCIENCES GmbH

Otsuka Pharmaceutical Co., Ltd.

Completed

30 Years

80 Years

All

Phase 3

Australia;Korea, Republic of;Malaysia;Singapore;Taiwan

512

NCT01711866
(ClinicalTrials.gov)

September 2012

18/10/2012

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4

Advanced Idiopathic Parkinson's Disease

Drug: Rotigotine

UCB BIOSCIENCES GmbH

Otsuka Pharmaceutical Co., Ltd.

Completed

30 Years

80 Years

All

Phase 4

United States;Korea, Republic of;Malaysia;Singapore;Taiwan

513

NCT01684475
(ClinicalTrials.gov)

September 2012

11/9/2012

A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE

Parkinson's Disease

Drug: CJH1 (CLR4001)

Alexandra Marine and General Hospital

NULL

Recruiting

40 Years

85 Years

Both

Phase 1;Phase 2

Canada

514

NCT01662791
(ClinicalTrials.gov)

September 2012

7/8/2012

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth

Parkinson's Disease

Drug: Rifaximin

Mayo Clinic

NULL

Completed

18 Years

N/A

All

Phase 3

United States

515

NCT02419313
(ClinicalTrials.gov)

August 2012

27/1/2014

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach

Parkinson;Tremor

Drug: incobotulinumtoxinA;Drug: Saline

Yale University

NULL

Completed

18 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

516

NCT01646268
(ClinicalTrials.gov)

July 2012

18/7/2012

Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease

IDIOPATHIC PARKINSON'S DISEASE

Drug: Rotigotine;Drug: Placebo Patch

UCB Pharma

NULL

Completed

30 Years

N/A

All

249

Phase 3

China

517

NCT01491022
(ClinicalTrials.gov)

July 2012

8/12/2011

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

Parkinson's Disease

Drug: Ampyra first, then Placebo;Drug: placebo first, then Ampyra

University of Miami

Acorda Therapeutics

Completed

45 Years

80 Years

All

Phase 1;Phase 2

United States

518

NCT01398748
(ClinicalTrials.gov)

July 2012

19/7/2011

Intranasal Glutathione in Parkinson's Disease

A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease

Parkinson's Disease (PD)

Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery

Bastyr University

National Center for Complementary and Integrative Health (NCCIH)

Completed

21 Years

100 Years

All

Phase 1

United States

519

NCT01602549
(ClinicalTrials.gov)

July 2012

17/5/2012

A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

Gastroparesis

Drug: GSK962040 (25 mg tablet);Drug: Placebo

GlaxoSmithKline

NULL

Completed

40 Years

80 Years

All

Phase 2

Australia;Germany;Sweden;United Kingdom

520

NCT01646255
(ClinicalTrials.gov)

July 2012

18/7/2012

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa

Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo Patch;Drug: L-dopa

UCB Pharma

UCB Trading (Shanghai) Co. Ltd.

Completed

30 Years

N/A

All

346

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

521

NCT02786667
(ClinicalTrials.gov)

June 2012

18/5/2016

Non Motors Aspects in De Novo Parkinson's Disease

Non Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects.

Parkinson Disease;Apathy

Drug: Rotigotine;Drug: Placebo

University Hospital, Grenoble

NULL

Active, not recruiting

30 Years

72 Years

All

199

Phase 3

France

522

NCT01993680
(ClinicalTrials.gov)

June 2012

27/4/2012

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease

Autonomic Disturbances in Parkinson's Disease

Drug: Pyridostigmine bromide;Drug: fludrocortisone

Christian Baumann

NULL

Completed

50 Years

80 Years

All

Phase 2

Switzerland

523

JPRN-UMIN000007896

2012/05/01

07/05/2012

Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes

Parkinson's disease and other parkinsonian syndromes

The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.
The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug.

Kansai Medical University

NULL

Recruiting

Not applicable

Male and Female

100

Not selected

Japan

524

NCT01617135
(ClinicalTrials.gov)

May 2012

7/5/2012

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes

A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations (Off Episodes)

Idiopathic Parkinson's Disease

Drug: CVT-301;Drug: Placebo;Drug: Sinemet (carbidopa/levodopa)

Acorda Therapeutics

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

Israel;Serbia;United Kingdom

525

NCT01494532
(ClinicalTrials.gov)

April 2, 2012

1/12/2011

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease

Parkinson Disease

Drug: ropinirole /L-dopa;Drug: placebo/L-dopa

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

352

Phase 4

United States;Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

526

NCT01550484
(ClinicalTrials.gov)

April 2012

6/3/2012

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis

Parkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's Disease

Drug: 18F-AV-133

Avid Radiopharmaceuticals

NULL

Completed

40 Years

N/A

All

170

Phase 2;Phase 3

United States;Australia

527

NCT01491529
(ClinicalTrials.gov)

April 2012

12/12/2011

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents

Drug: AFQ056;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

30 Years

80 Years

All

154

Phase 2

United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey

528

NCT01556165
(ClinicalTrials.gov)

April 2012

13/3/2012

Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Parkinson's Disease

Drug: rasagiline;Drug: placebo

H. Lundbeck A/S

NULL

Completed

35 Years

N/A

All

130

Phase 3

China

529

NCT01523301
(ClinicalTrials.gov)

April 2012

27/1/2012

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB Korea Co., Ltd.

NULL

Completed

20 Years

N/A

All

380

Phase 4

Korea, Republic of

530

NCT01653132
(ClinicalTrials.gov)

March 2012

25/7/2012

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Sialorrhea

Drug: Incobotulinum Toxin A;Drug: Placebo

Beth Israel Deaconess Medical Center

NULL

Completed

18 Years

90 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

531

NCT01565395
(ClinicalTrials.gov)

March 2012

26/3/2012

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Parkinson Disease;Amyotrophic Lateral Sclerosis

Drug: Incobotulinum Toxin A;Drug: placebo

Beth Israel Deaconess Medical Center

Merz Pharmaceuticals

Withdrawn

20 Years

80 Years

All

Phase 2

United States

532

NCT01491932
(ClinicalTrials.gov)

March 2012

1/12/2011

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Dyskinesias;Parkinson Disease;Movement Disorders;Parkinsonian Disorders;Anti-Dyskinesia Agents

Drug: AFQ056

Novartis Pharmaceuticals

NULL

Completed

N/A

All

129

Phase 2

United States;Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey

533

NCT01519882
(ClinicalTrials.gov)

March 2012

24/1/2012

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.

Advanced Idiopathic Parkinson's Disease

Other: Placebo;Other: Rotigotine

UCB Pharma SA

NULL

Terminated

18 Years

N/A

All

Phase 4

United Kingdom

534

NCT03061513
(ClinicalTrials.gov)

February 28, 2012

13/2/2017

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

Parkinson Disease

Drug: Ubiquinol;Dietary Supplement: Placebo

Weill Medical College of Cornell University

NULL

Completed

40 Years

75 Years

All

Phase 2

NULL

535

NCT01673724
(ClinicalTrials.gov)

February 2012

23/8/2012

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study

Parkinson's Disease

Drug: pramipexole;Drug: Bromocriptine

Sandoz

NULL

Completed

30 Years

N/A

All

121

Phase 4

Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

536

NCT01539837
(ClinicalTrials.gov)

February 2012

22/2/2012

A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease

Parkinson's Disease

Drug: Deferiprone 20mg;Drug: Placebo;Drug: Deferiprone 30mg

Imperial College London

NULL

Completed

50 Years

75 Years

All

Phase 2

United Kingdom

537

NCT01525641
(ClinicalTrials.gov)

February 2012

1/2/2012

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Drug: Mirapex LA

Boehringer Ingelheim

NULL

Completed

N/A

All

615

N/A

Japan

538

NCT01485172
(ClinicalTrials.gov)

January 31, 2012

1/12/2011

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease

Parkinson Disease

Drug: ropinirole monotherapy;Drug: placebo monotherapy

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

186

Phase 4

United States;Estonia;Korea, Republic of;Russian Federation;Slovakia;Poland

539

NCT01470027
(ClinicalTrials.gov)

January 2012

4/11/2011

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

Parkinson Disease

Drug: N-acetylcysteine;Drug: Placebo

Weill Medical College of Cornell University

National Institute on Aging (NIA)

Completed

50 Years

75 Years

All

Phase 1;Phase 2

United States

540

NCT01536015
(ClinicalTrials.gov)

January 2012

15/2/2012

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Advanced Parkinson's Disease

Drug: Rotigotine;Drug: Placebo

UCB Pharma

NULL

Terminated

30 Years

N/A

All

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

541

NCT01515410
(ClinicalTrials.gov)

January 2012

11/1/2012

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations

Parkinson's Disease;Motor Fluctuations

Drug: DM -1992;Drug: Sinemet IR

Depomed

NULL

Completed

30 Years

N/A

All

Phase 2

United States

542

NCT01479530
(ClinicalTrials.gov)

December 2011

22/11/2011

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Parkinson's Disease

Drug: Placebo;Drug: Azilect ®

H. Lundbeck A/S

NULL

Completed

30 Years

N/A

All

321

Phase 3

China

543

NCT01470859
(ClinicalTrials.gov)

December 2011

9/11/2011

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: pramipexole;Drug: Sinemet CR

Huashan Hospital

Boehringer Ingelheim

Completed

30 Years

75 Years

All

N/A

China

544

NCT01519271
(ClinicalTrials.gov)

December 2011

10/1/2012

Mild Cognitive Impairment in Parkinson's Disease

A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease

Parkinson's Disease;Mild Cognitive Impairment

Drug: Exelon Patch (rivastigmine transdermal system);Drug: Placebo Patches

University of Pennsylvania

NULL

Completed

40 Years

85 Years

All

Phase 4

United States

545

NCT02302144
(ClinicalTrials.gov)

December 2011

24/11/2014

A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease

Parkinson Disease

Behavioral: Balance & Strengthening Exercises

Boston University Charles River Campus

NULL

Completed

18 Years

N/A

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

546

NCT01457807
(ClinicalTrials.gov)

November 2011

10/10/2011

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers

Parkinson's Disease

Drug: AZD3241 ER formulation 1;Drug: Placebo;Drug: AZD3241 Alternative titration scheme with formulation 1 or 2

AstraZeneca

NULL

Completed

30 Years

65 Years

Both

Phase 1

United Kingdom

547

NCT01556100
(ClinicalTrials.gov)

November 2011

6/3/2012

Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression

Parkinson Disease

Drug: 18F-DTBZ AV-133

Chang Gung Memorial Hospital

NULL

Completed

20 Years

N/A

All

Phase 2

NULL

548

NCT02427646
(ClinicalTrials.gov)

October 2011

22/4/2015

Kinematic-guided BoNT-A Treatment for ET and PD Tremor

Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease

Tremor

Drug: BoNT-A

Western University, Canada

NULL

Active, not recruiting

18 Years

80 Years

All

Phase 2

NULL

549

NCT01479127
(ClinicalTrials.gov)

October 2011

26/9/2011

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Drug: ABT-SLV187;Drug: Oral Levodopa/Carbidopa;Device: Infusion Pump: CADD-Legacy® 1400 Pump;Device: NJ-Tube: Silicon ED Tube;Device: Adaptor: Hakko Adaptor

AbbVie (prior sponsor, Abbott)

Abbott Japan Co.,Ltd

Completed

30 Years

99 Years

All

Phase 2

Japan

550

NCT01474421
(ClinicalTrials.gov)

September 15, 2011

5/10/2011

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias

Dyskinesias;Drug-induced

Drug: AQW051;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

30 Years

85 Years

All

Phase 2

United States;France;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

551

NCT01545856
(ClinicalTrials.gov)

September 2011

2/2/2012

Cardiovascular Events in Parkinson's Disease Patients

Background Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact Database

Cardiovascular Event;Parkinson Disease

Drug: levodopa

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

N/A

NULL

552

NCT02170376
(ClinicalTrials.gov)

September 2011

19/6/2014

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa /carbidopa

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

553

EUCTR2010-020299-42-DE
(EUCTR)

30/08/2011

26/04/2011

A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.

A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD

Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed
MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE
Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE

Philipps-University Marburg

NULL

Not Recruiting

Female: yes
Male: yes

160

Phase 2

United States;Germany

554

NCT01411137
(ClinicalTrials.gov)

August 2011

4/8/2011

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD

Parkinson's Disease

Drug: IPX066

Impax Laboratories, LLC

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 3

United States

555

NCT01461109
(ClinicalTrials.gov)

August 2011

27/9/2011

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects

Parkinson Disease;Alzheimer Disease

Drug: [18F] CFPyPB

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

90 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

556

NCT01427517
(ClinicalTrials.gov)

July 2011

30/8/2011

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

Parkinson's Disease;Gaucher's Disease

Drug: N-acetylcysteine

University of Minnesota

Rare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

18 Years

N/A

All

Phase 1

United States

557

NCT01397422
(ClinicalTrials.gov)

July 2011

18/7/2011

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Dyskinesia;Levodopa Induced Dyskinesia;Parkinson's Disease

Drug: ADS-5102 (extended release amantadine HCl)

Adamas Pharmaceuticals, Inc.

NULL

Completed

30 Years

85 Years

All

Phase 2;Phase 3

United States

558

NCT01652534
(ClinicalTrials.gov)

June 2011

15/8/2011

Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease

Parkinson's Disease

Drug: Amantadine;Drug: Placebo

Northwestern University

NULL

Terminated

18 Years

85 Years

All

Phase 3

United States

559

NCT01528592
(ClinicalTrials.gov)

June 2011

31/1/2012

PharmacoMRI of Parkinson Disease

A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease

Parkinson's Disease

Drug: Carbidopa -Levodopa

Northwestern University

NULL

Completed

30 Years

N/A

All

N/A

United States

560

NCT01504178
(ClinicalTrials.gov)

May 2011

30/12/2011

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Parkinson's Disease

Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-Dopa

University Hospital, Toulouse

French Parkinson Association

Completed

30 Years

70 Years

All

Phase 3

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

561

NCT01361009
(ClinicalTrials.gov)

May 2011

23/5/2011

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance

Parkinson Disease

Drug: pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

75 Years

All

2017

N/A

China

562

NCT01119131
(ClinicalTrials.gov)

May 2011

23/4/2010

Effects of Vitamin D in Parkinson's Disease (PD)

The Effects of Vitamin D on Balance in Persons With PD

Parkinson Disease;Accidental Falls

Drug: Vitamin D3;Dietary Supplement: calcium;Other: Placebo

VA Office of Research and Development

Oregon Health and Science University

Completed

50 Years

99 Years

All

101

Phase 2

United States

563

NCT01856439
(ClinicalTrials.gov)

May 2011

14/5/2013

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.

Parkinson's Disease

Drug: ProSavin

Axovant Sciences Ltd.

Oxford BioMedica

Active, not recruiting

N/A

All

Phase 1;Phase 2

France;United Kingdom

564

NCT01520987
(ClinicalTrials.gov)

May 2011

26/1/2012

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

65 Years

All

105

Phase 1

United States

565

NCT01323855
(ClinicalTrials.gov)

March 28, 2011

24/3/2011

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment

Parkinson Disease

Drug: Preladenant

Merck Sharp & Dohme Corp.

NULL

Completed

18 Years

75 Years

All

Phase 1

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

566

NCT01568073
(ClinicalTrials.gov)

March 2011

29/3/2012

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study

Parkinson's Disease

Drug: BIA 9-1067;Drug: Entacapone;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: Benserazide

Bial - Portela C S.A.

NULL

Completed

30 Years

83 Years

All

600

Phase 3

Portugal;Austria

567

NCT01283594
(ClinicalTrials.gov)

March 2011

24/1/2011

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off

Parkinson's Disease

Drug: Tozadenant (SYN115) 60 mg BID;Drug: Placebo;Drug: Levodopa (L-dopa);Drug: Tozadenant (SYN115) 120 mg BID;Drug: Tozadenant (SYN115) 180 mg BID;Drug: Tozadenant (SYN115) 240 mg BID

Biotie Therapies Inc.

NULL

Completed

30 Years

80 Years

All

420

Phase 2;Phase 3

United States;Argentina;Canada;Chile;Romania;Ukraine

568

NCT01330290
(ClinicalTrials.gov)

March 2011

18/3/2011

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support

Idiopathic Parkinson's Disease

Drug: Neupro ®

UCB Pharma

NULL

Completed

18 Years

N/A

All

148

N/A

Germany

569

NCT01264861
(ClinicalTrials.gov)

March 2011

20/12/2010

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients

Parkinson Disease

Drug: Safinamide

Newron

NULL

Terminated

40 Years

80 Years

All

Phase 2

United States

570

NCT01227655
(ClinicalTrials.gov)

March 2011

22/10/2010

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.

Parkinson's Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa;Drug: Benserazide

Bial - Portela C S.A.

NULL

Completed

30 Years

83 Years

All

427

Phase 3

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

571

NCT01280123
(ClinicalTrials.gov)

March 2011

3/12/2010

Pioglitazone in Early Parkinson's Disease

A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease

Parkinson's Disease

Drug: Pioglitazone;Drug: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

210

Phase 2

United States

572

NCT01294800
(ClinicalTrials.gov)

February 25, 2011

10/2/2011

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)

Parkinson's Disease

Drug: Preladenant;Drug: Placebo tablet to match Preladenant

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

450

Phase 2

Japan

573

NCT01300819
(ClinicalTrials.gov)

February 2011

18/2/2011

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Other: Placebo;Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

All

349

Phase 4

Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland

574

NCT02880033
(ClinicalTrials.gov)

February 2011

3/8/2016

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Parkinson's Disease;Amyotrophic Lateral Sclerosis;Oxidative Stress;Iron Overload

Drug: deferiprone;Drug: placebo

University Hospital, Lille

NULL

Completed

18 Years

80 Years

All

N/A

France

575

EUCTR2010-021860-13-ES
(EUCTR)

24/01/2011

27/10/2010

EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED, PLACEBO- AND ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL STUDY.EFICACIA Y SEGURIDAD DE BIA 9-1067 EN PACIENTES CON ENFERMEDAD DE PARKINSON IDIOPÁTICA CON FENÓMENO DE 'WEARING OFF' TRATADOS CON LEVODOPA Y UN INHIBIDOR DE DOPA DESCAROBOXILASA (IDDC): ENSAYO CLÍNICO MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO Y ACTIVO, DE GRUPOS PARALELOS - BIPARK STUDY I

Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations.Adjunto a levodopa/inhibidor dopa descarboxilasa para pacientes con enfermedad de Parkinson y fluctuaciones motoras de fin de dosis
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Trade Name: Comtan®
Product Name: Over-encapsulated Entacapone Tablets
Product Code: Over-encapsulated Entacapone Tablets
INN or Proposed INN: ENTACAPONE
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067
Product Name: BIA 9-1067
Product Code: BIA 9-1067
INN or Proposed INN: BIA 9-1067
Other descriptive name: BIA 9-1067

BIAL - Portela & Ca, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

550

Portugal;Czech Republic;Hungary;Slovakia;Spain;Romania;Lithuania;Austria;Bulgaria;Germany;Latvia;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

576

NCT01268891
(ClinicalTrials.gov)

January 2011

30/12/2010

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea

Parkinson's Disease

Drug: Placebo;Drug: Azilect ®

H. Lundbeck A/S

NULL

Completed

30 Years

N/A

All

132

Phase 3

Korea, Republic of

577

NCT01340885
(ClinicalTrials.gov)

January 2011

19/4/2011

Cognitive Decline in Non-demented PD

Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study

Parkinson's Disease

Drug: Strattera;Drug: Exelon;Other: Placebo

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

18 Years

N/A

All

Phase 4

United States

578

NCT01341080
(ClinicalTrials.gov)

December 28, 2010

21/4/2011

Varenicline for Gait and Balance Impairment in Parkinson Disease

Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease

Parkinson Disease

Drug: Varenicline;Drug: Sugar pill

Rush University Medical Center

NULL

Completed

40 Years

90 Years

All

Phase 2

United States

579

EUCTR2010-020109-34-ES
(EUCTR)

29/11/2010

23/09/2010

Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo.A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.

Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopática
MedDRA version: 12.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamida
Product Code: NW-1015
Other descriptive name: Safinamida

Merck Serono S.A. - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

100

Phase 2

Spain;Italy

580

NCT01227265
(ClinicalTrials.gov)

November 19, 2010

22/10/2010

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.

Parkinson Disease;Idiopathic Parkinson Disease;Idiopathic Parkinson's Disease

Drug: Preladenant;Drug: Placebo

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

476

Phase 3

Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

581

NCT01215227
(ClinicalTrials.gov)

November 18, 2010

4/10/2010

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)

Parkinson Disease;Idiopathic Parkinson Disease

Drug: Preladenant;Drug: Rasagiline;Drug: Placebo to preladenant;Drug: Placebo to rasagiline

Merck Sharp & Dohme Corp.

NULL

Terminated

30 Years

85 Years

All

839

Phase 3

Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States

582

NCT01270711
(ClinicalTrials.gov)

November 2010

9/12/2010

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Parkinson's Disease;Hyperprolactinemia

Drug: Study Drug

Pfizer

NULL

Completed

N/A

All

22014

N/A

NULL

583

NCT01192529
(ClinicalTrials.gov)

October 2010

30/8/2010

Evaluation of a Diet in Patients With Senile Dementia

Clinical Evaluation of an Specific Diet for People With Dementia Disease

Alzheimer's Disease;Parkinson's Disease;Senile Dementia

Dietary Supplement: Supressi. T-Diet plus Range;Dietary Supplement: High Protein. T-Diet plus Range

Vegenat, S.A.

NULL

Recruiting

70 Years

N/A

Both

184

N/A

Spain

584

NCT01173731
(ClinicalTrials.gov)

October 2010

28/7/2010

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Parkinson Disease;Dyskinesia, Drug-Induced;Levodopa

Drug: AFQ056

Novartis Pharmaceuticals

NULL

Completed

N/A

All

Phase 2

United States;Australia;Canada;France;Germany;Italy;Finland;Spain

585

NCT01536574
(ClinicalTrials.gov)

September 2, 2010

19/1/2012

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Parkinson Disease

Drug: Requip PR

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

295

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

586

NCT01191944
(ClinicalTrials.gov)

August 2010

30/8/2010

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa

Parkinson Disease

Drug: pramipexole immediate release tablet;Drug: pramipexole extended release tablet

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

475

Phase 3

China

587

NCT01785628
(ClinicalTrials.gov)

August 2010

24/6/2011

The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease

Parkinson's Disease With Dementia

Dietary Supplement: Sarcosine Capsule;Dietary Supplement: Placebo Capsule

China Medical University Hospital

National Science Council, Taiwan

Completed

N/A

All

N/A

Taiwan

588

NCT01190735
(ClinicalTrials.gov)

August 2010

26/8/2010

Caffeine for Motor Manifestations of Parkinson's Disease

Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.

Parkinson's Disease

Drug: Caffeine alkaloid

Ron Postuma

Canadian Institutes of Health Research (CIHR)

Completed

18 Years

N/A

Both

Phase 2

Canada

589

NCT01155466
(ClinicalTrials.gov)

July 14, 2010

30/6/2010

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)

Parkinson Disease

Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Placebo to Preladenant Tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo to Rasagiline capsule

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

85 Years

All

778

Phase 3

Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States

590

NCT01155479
(ClinicalTrials.gov)

July 6, 2010

30/6/2010

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)

A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease

Parkinson Disease

Drug: Preladenant 2 mg tablet;Drug: Preladenant 5 mg tablet;Drug: Preladenant 10 mg tablet;Drug: Rasagiline 1 mg capsule;Drug: Placebo for Rasagiline 1 mg capsule;Drug: Placebo for Preladenant

Merck Sharp & Dohme Corp.

NULL

Terminated

30 Years

85 Years

All

1022

Phase 3

Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

591

NCT01174004
(ClinicalTrials.gov)

July 2010

30/7/2010

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: pimavanserin tartrate;Drug: placebo

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

199

Phase 3

United States;Canada

592

NCT01435915
(ClinicalTrials.gov)

June 28, 2010

1/9/2011

Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects

A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects

Parkinson Disease

Drug: Ropinirole

GlaxoSmithKline

NULL

Completed

18 Years

45 Years

All

Phase 1

China

593

NCT01176240
(ClinicalTrials.gov)

June 2010

30/7/2010

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Orthostatic Hypotension;Parkinson's Disease

Drug: Droxidopa;Other: Placebo

Chelsea Therapeutics

NULL

Completed

18 Years

N/A

All

225

Phase 3

United States

594

NCT01227681
(ClinicalTrials.gov)

June 2010

22/10/2010

Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

Parkinson Disease

Drug: G-CSF;Drug: Placebo

Buddhist Tzu Chi General Hospital

NULL

Terminated

40 Years

65 Years

All

Phase 2

Taiwan

595

NCT01141023
(ClinicalTrials.gov)

June 2010

8/6/2010

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

The Parkinson's Progression Markers Initiative (PPMI)

Parkinson Disease

Drug: DaTscan

Ken Marek, MD

Institute for Neurodegenerative Disorders

Active, not recruiting

30 Years

N/A

All

1100

Phase 2

United States;Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

596

NCT01130493
(ClinicalTrials.gov)

May 2010

24/5/2010

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease

Parkinson's Disease

Drug: IPX066;Drug: CLE

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

110

Phase 3

United States;France;Germany;Italy

597

NCT00988117
(ClinicalTrials.gov)

April 2010

29/9/2009

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)

Parkinsons Disease With Dementia;Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems

Drug: Rivastigmine Patch 9.5 cm2

University of California, San Francisco

Novartis

Completed

55 Years

N/A

All

Phase 4

United States

598

NCT01484990
(ClinicalTrials.gov)

April 2010

28/7/2011

A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Drug: Levodopa -Carbidopa

AbbVie

Quintiles, Inc.

Completed

30 Years

99 Years

All

Phase 1

Germany;Sweden

599

NCT01055379
(ClinicalTrials.gov)

March 2010

22/1/2010

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study

Depressive Symptoms;Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Lundbeck Italia S.p.A.

Teva Pharmaceutical Industries

Completed

40 Years

80 Years

All

121

Phase 4

Italy

600

NCT01097421
(ClinicalTrials.gov)

March 2010

25/3/2010

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease

Parkinson Disease

Drug: Pramipexole Extended Release

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

329

N/A

Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

601

NCT01096186
(ClinicalTrials.gov)

March 2010

25/3/2010

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: IPX066 95 mg;Drug: IPX066 145 mg;Drug: IPX066 195 mg;Drug: IPX066 245 mg

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

617

Phase 3

United States;Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine

602

NCT01503944
(ClinicalTrials.gov)

March 2010

14/7/2010

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers

Dementia With Lewy Bodies;Alzheimer's Disease;Parkinson's Disease

Drug: 18F-AV-133;Drug: 18F-AV-45

Avid Radiopharmaceuticals

NULL

Completed

50 Years

N/A

Both

Phase 1;Phase 2

United States

603

NCT02101190
(ClinicalTrials.gov)

March 2010

20/1/2012

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

18 Years

65 Years

All

Phase 1

France;Russian Federation

604

NCT01092065
(ClinicalTrials.gov)

March 2010

22/3/2010

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia

Parkinson's Disease

Drug: AFQ056 with L-dopa;Drug: Placebo

Novartis

NULL

Completed

30 Years

80 Years

All

Phase 2

United States

605

NCT01154166
(ClinicalTrials.gov)

February 15, 2010

29/6/2010

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Parkinson Disease

Drug: ReQuip PR;Drug: Placebo

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

347

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

606

EUCTR2009-016360-37-SE
(EUCTR)

06/02/2010

04/12/2009

TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY

Parkinsons disease is complicated by dyskinesias and dystonia. Due stabilizing properties, we believe (-)-OSU6162 may alleviate dyskinesias, without causing parkinsonism. Aim: To evaluate in a double-blind cross over pilot study whether OSU6162 attenuates dyskinesias without worsening parkinsonism in PD patients with motor complications using clinical examination and patient diaries.

Björn Holmberg

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Sweden

607

NCT02169414
(ClinicalTrials.gov)

February 2010

24/1/2012

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Parkinson's Disease (PD)

Drug: BIA 9-1067 5 mg;Drug: BIA 9-1067 25 mg;Drug: levodopa /carbidopa 100/25;Drug: Placebo;Drug: levodopa /benserazide 100/25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

608

NCT01568047
(ClinicalTrials.gov)

February 2010

29/3/2012

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon)

Parkinson's Disease

Drug: Placebo;Drug: BIA 9-1067;Drug: Levodopa /Carbidopa;Drug: Levodopa /Benzerazide

Bial - Portela C S.A.

NULL

Completed

30 Years

N/A

All

Phase 2

Romania;Ukraine

609

NCT01018264
(ClinicalTrials.gov)

January 2010

19/11/2009

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Overactive Bladder in Parkinson's Disease

Drug: solifenacin succinate (VESIcare);Drug: placebo

University of South Florida

NULL

Completed

40 Years

80 Years

All

Phase 4

United States

610

NCT01071395
(ClinicalTrials.gov)

January 2010

17/2/2010

Validation of Dyskinesia Rating Scales

Parkinson's Disease

Drug: Amantadine;Drug: Placebo

Rush University Medical Center

Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

90 Years

All

Phase 4

United States;Austria;Canada;France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

611

NCT01417598
(ClinicalTrials.gov)

January 2010

15/8/2011

BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity

Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study.

Elderly;Parkinsons Disease;Osteoporosis

Other: Gait and balance group training;Other: Nordic walking (only osteoporosis group)

Karolinska Institutet

The Swedish Research Council

Active, not recruiting

60 Years

N/A

All

200

N/A

Sweden

612

NCT01058291
(ClinicalTrials.gov)

January 2010

27/1/2010

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500

Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)

Parkinson's Disease

Drug: KW-6500;Drug: KW-6500 Placebo

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

613

NCT01063621
(ClinicalTrials.gov)

January 2010

4/2/2010

Extended Long-Term Safety Study of KW-6500

Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)

Parkinson's Disease

Drug: KW-6500

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

614

NCT01049984
(ClinicalTrials.gov)

December 2009

13/1/2010

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

Teva Neuroscience, Inc.

H. Lundbeck A/S

Completed

30 Years

N/A

All

328

Phase 4

United States

615

NCT00660387
(ClinicalTrials.gov)

December 2009

15/4/2008

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations

Advanced Parkinson's Disease

Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo Gel;Drug: Levodopa -carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

616

NCT01168596
(ClinicalTrials.gov)

December 2009

19/2/2010

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)

Parkinson's Disease

Drug: Rasagiline;Drug: Placebo

University of Florida

NULL

Completed

40 Years

85 Years

All

Phase 4

United States

617

NCT00660673
(ClinicalTrials.gov)

November 13, 2009

15/4/2008

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD

Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Active, not recruiting

30 Years

99 Years

All

262

Phase 3

United States;Australia;Canada;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;Czech Republic

618

EUCTR2009-013885-14-ES
(EUCTR)

12/11/2009

23/09/2009

A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-label extension phase.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de 12 semanas de duración para evaluar la eficacia y seguridad de BF2.649 en la somnolencia diurna excesiva de la enfermedad de Parkinson, seguido de una fase de extensión abierta de 38 semanas.

Excessive daytime sleepiness in Parkinson?s DiseaseSomnolencia diurna excesiva en la enfermedad de Parkinson.
MedDRA version: 12.0;Level: LLT;Classification code 10015595;Term: Excessive daytime sleepiness
MedDRA version: 12.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism

Product Name: Pitolisant
Product Code: BF2.649
INN or Proposed INN: Pitolisant

BIOPROJET

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

246

France;Spain

619

NCT01519284
(ClinicalTrials.gov)

November 2009

23/1/2012

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067 5 mg;Drug: Entacapone;Drug: Placebo;Drug: levodopa /carbidopa;Drug: BIA 9-1067 15 mg;Drug: BIA 9-1067 30 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

620

NCT01532128
(ClinicalTrials.gov)

November 2009

23/1/2012

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects

Parkinson Disease

Drug: rasagiline;Drug: BIA 9-1067

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

621

NCT01532141
(ClinicalTrials.gov)

November 2009

23/1/2012

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Rasagiline

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

France

622

NCT01052831
(ClinicalTrials.gov)

November 2009

15/1/2010

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease

Impulse Control Disorder;Parkinson Disease

Drug: Naltrexone;Drug: Placebo

University of Pennsylvania

Michael J. Fox Foundation for Parkinson's Research

Completed

18 Years

85 Years

All

Phase 4

United States

623

NCT01028209
(ClinicalTrials.gov)

November 2009

8/12/2009

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Alzheimer Disease;Parkinson Disease;Multiple Sclerosis

Drug: [18F] PBR06

Institute for Neurodegenerative Disorders

NULL

Terminated

18 Years

N/A

All

Phase 1

United States

624

NCT00985517
(ClinicalTrials.gov)

October 29, 2009

25/9/2009

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;Procedure: Sham Surgery

Sangamo Therapeutics

NULL

Completed

35 Years

70 Years

All

Phase 1;Phase 2

United States

625

NCT01631825
(ClinicalTrials.gov)

October 2009

25/6/2012

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

321

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

626

NCT01371682
(ClinicalTrials.gov)

September 18, 2009

10/6/2010

A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda

An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda

Parkinson Disease

Drug: Ropinirole XL

GlaxoSmithKline

NULL

Completed

18 Years

50 Years

All

Phase 1

Belgium

627

NCT00986414
(ClinicalTrials.gov)

September 2009

29/9/2009

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Parkinson Disease;Dyskinesias

Drug: AFQ056;Drug: Placebo

Novartis

NULL

Completed

30 Years

80 Years

All

260

Phase 2

Australia;Canada;Finland;France;Germany;Italy;Japan;Spain

628

NCT00986245
(ClinicalTrials.gov)

September 2009

24/9/2009

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease

Parkinson Disease

Drug: Ropinirole Prolonged release

Seoul National University Hospital

NULL

Completed

30 Years

80 Years

All

Phase 4

Korea, Republic of

629

NCT00794313
(ClinicalTrials.gov)

September 2009

19/11/2008

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Parkinson's Disease

Drug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar Pill

Oregon Health and Science University

NULL

Terminated

21 Years

N/A

All

N/A

United States

630

NCT00974974
(ClinicalTrials.gov)

September 2009

10/9/2009

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease

Parkinson's Disease

Drug: IPX066;Drug: IR CD-LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

471

Phase 3

United States;Canada;France;Germany;Poland;Romania;Spain;Ukraine

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

631

NCT03316365
(ClinicalTrials.gov)

August 2009

16/10/2017

Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease

Continuous Rhythmic Auditory Stimulation;Intermittent Rhythmic Auditory Stimulation

Other: Rhythmic Auditory Stimulation (RAS)

University of Toronto

Poudre Valley Health System Fort Collins CO;Colorado State University

Completed

18 Years

N/A

All

N/A

NULL

632

NCT00970333
(ClinicalTrials.gov)

August 2009

31/8/2009

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Alzheimer Disease;Parkinson Disease;Multiple Sclerosis

Drug: [18F]-FEPPA

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

N/A

Both

Phase 1

United States

633

NCT00955604
(ClinicalTrials.gov)

July 2009

6/8/2009

Azilect + Antidepressant Chart Review

Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review

Serotonin Syndrome

Drug: Group R+AD Rasagiline + Antidepressant;Drug: Group R Rasagiline;Drug: Group AD Anti-PD + Antidepressant

Teva Pharmaceutical Industries

NULL

Completed

N/A

All

1500

N/A

United States

634

NCT00955318
(ClinicalTrials.gov)

July 2009

7/8/2009

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease

Parkinson's Disease

Drug: KW-6500

Kyowa Hakko Kirin Co., Ltd

NULL

Completed

20 Years

N/A

All

Phase 3

Japan

635

NCT00970229
(ClinicalTrials.gov)

July 2009

31/8/2009

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls

Parkinson Disease;Huntington Disease

Drug: [123I]MNI-420

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

636

NCT00909545
(ClinicalTrials.gov)

July 2009

26/5/2009

Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease

Parkinson Disease

Drug: Isradipine CR 5mg;Drug: Isradipine CR 10mg;Drug: Isradipine CR 20mg;Drug: Placebo

Northwestern University

Michael J. Fox Foundation for Parkinson's Research;Northwestern University Dixon Fund;The Parkinson Study Group

Completed

30 Years

N/A

All

Phase 2

United States;Canada

637

EUCTR2008-004146-88-ES
(EUCTR)

16/06/2009

16/04/2009

A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist.Ensayo de extensión de fase III, doble ciego y controlado con placebo para investigar la eficacia y la seguridad a largo plazo de la safinamida en dosis bajas (50 mg/día) y altas (100 mg/días), como tratamiento añadido en sujetos con enfermedad de Parkinson idiopática temprana que reciben una dosis estable de un único agonista dopaminérgico - Safinamide in early PD patients treated with a single dopamine agonist. Extension Trial to 27918

Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono SA - Geneva

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

498

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

638

NCT00921128
(ClinicalTrials.gov)

June 2, 2009

13/6/2009

Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease

Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease

Parkinson's Disease

Drug: Muscimol

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Withdrawn

18 Years

N/A

All

Phase 1

United States

639

NCT01536366
(ClinicalTrials.gov)

June 2009

23/1/2012

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers

Parkinson Disease

Drug: BIA 9-1067;Drug: Repaglinide

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

640

NCT01628926
(ClinicalTrials.gov)

June 2009

24/6/2012

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962;Drug: Ropinirole;Drug: Placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

420

Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

641

NCT00669461
(ClinicalTrials.gov)

June 2009

28/4/2008

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Constipation;Parkinson's Disease

Drug: Lubiprostone

University of Arkansas

Takeda

Terminated

50 Years

85 Years

All

N/A

United States

642

NCT00833690
(ClinicalTrials.gov)

June 2009

27/1/2009

Safety of Urate Elevation in Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease

Parkinson Disease

Drug: Placebo;Drug: inosine

The Parkinson Study Group

Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's Research

Completed

30 Years

N/A

All

Phase 2

United States

643

NCT02169440
(ClinicalTrials.gov)

June 2009

24/1/2012

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

Parkinson's Disease (PD)

Drug: BIA 9-1067;Drug: Warfarin

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

644

NCT00360568
(ClinicalTrials.gov)

June 2009

3/8/2006

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Dyskinesias;Parkinson's Disease;Severe Motor Fluctuations

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;Germany;New Zealand

645

NCT00845000
(ClinicalTrials.gov)

April 21, 2009

13/2/2009

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients

Parkinson Disease

Drug: SCH 420814 10 mg;Drug: SCH 420814 100 mg;Drug: Placebo;Drug: Levodopa;Drug: Carbidopa

Merck Sharp & Dohme Corp.

Oregon Health and Science University

Completed

18 Years

N/A

All

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

646

NCT01568034
(ClinicalTrials.gov)

April 2009

29/3/2012

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor

Parkinson's Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa /Carbidopa;Drug: Levodopa /Benzerazide

Bial - Portela C S.A.

NULL

Completed

30 Years

75 Years

All

Phase 2

Portugal;Romania;Ukraine

647

NCT00880620
(ClinicalTrials.gov)

April 2009

3/4/2009

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: IPX066 95 mg LD;Drug: IPX066 145 mg LD;Drug: IPX066 195 mg LD;Drug: IPX066 245 mg LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

381

Phase 3

United States;Canada;Estonia;Latvia;Lithuania;Romania;Ukraine

648

NCT00865579
(ClinicalTrials.gov)

April 2009

10/3/2009

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Drug: Safinamide

Newron

NULL

Terminated

30 Years

N/A

All

964

Phase 3

Romania

649

NCT00940914
(ClinicalTrials.gov)

March 2009

16/7/2009

Dopaminergic Loss and Pain in Parkinson's Disease

Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain

Parkinson's Disease;Pain

Drug: ioflupane 123I (DATSCAN®)

University Hospital, Toulouse

NULL

Completed

30 Years

70 Years

All

Phase 2

France

650

NCT01399905
(ClinicalTrials.gov)

March 2009

21/7/2011

High and Low Dose Carbidopa Treatment of Parkinson's Disease

A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.

Parkinson's Disease

Drug: carbidopa

Oregon Health and Science University

NULL

Completed

35 Years

85 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

651

NCT00823836
(ClinicalTrials.gov)

March 2009

15/1/2009

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Drug: ropinirole PR/XR;Drug: ropinirole IR

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

302

Phase 3

Japan

652

NCT00870974
(ClinicalTrials.gov)

March 2009

26/3/2009

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions

Parkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive Impairment

Drug: [18F]FPEB

Institute for Neurodegenerative Disorders

NULL

Completed

18 Years

85 Years

All

Phase 1

United States

653

NCT01533077
(ClinicalTrials.gov)

March 2009

24/1/2012

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Sinemet® 100/25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Canada

654

NCT00758368
(ClinicalTrials.gov)

March 2009

23/9/2008

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia

Parkinson's Disease

Drug: Apomorphine

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Withdrawn

21 Years

N/A

All

Phase 2

United States

655

NCT01533116
(ClinicalTrials.gov)

March 2009

24/1/2012

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Parkinson Disease

Drug: BIA 9-1067;Drug: Placebo;Drug: levodopa /carbidopa;Drug: levodopa /benserazide

Bial - Portela C S.A.

NULL

Completed

25 Years

45 Years

All

Phase 1

Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

656

NCT01421719
(ClinicalTrials.gov)

February 2009

19/8/2011

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy

Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse Reaction

Drug: Cystoscopic injection of Botox into the urinary bladder

Stanford University

Allergan

Completed

50 Years

85 Years

All

Phase 4

United States

657

NCT00908076
(ClinicalTrials.gov)

February 2009

21/5/2009

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease

Parkinson's Disease

Drug: LUBIPROSTONE

Baylor College of Medicine

University of South Florida

Completed

18 Years

85 Years

All

Phase 4

United States

658

NCT01039090
(ClinicalTrials.gov)

February 2009

22/12/2009

Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease

Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study

Parkinsons's Disease

Drug: Continuous Apomorphine infusion;Drug: Usual dopaminergic per os treatment

Rennes University Hospital

NULL

Completed

18 Years

N/A

All

Phase 3

France

659

NCT00857532
(ClinicalTrials.gov)

January 2009

5/3/2009

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

A Phase 2 Trial of Florbetapir F18 PET Imaging of ß-amyloid in Parkinson's Disease Patients With Cognitive Impairment

Parkinson's Disease

Drug: florbetapir F 18

Avid Radiopharmaceuticals

National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)

Completed

60 Years

N/A

All

Phase 2

United States

660

NCT00357994
(ClinicalTrials.gov)

January 2009

27/7/2006

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

Drug: Levodopa carbidopa intestinal gel (LCIG);Drug: Placebo gel;Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets;Drug: Placebo (PBO) oral capsules;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

Phase 3

United States;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

661

NCT00740714
(ClinicalTrials.gov)

December 2008

22/8/2008

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

Effects of Coenzyme Q10 in Parkinson Disease - Phase III

Parkinson Disease

Drug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin E

Weill Medical College of Cornell University

National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester

Terminated

30 Years

N/A

All

600

Phase 3

United States;Canada

662

EUCTR2007-006721-27-GB
(EUCTR)

11/11/2008

25/02/2009

A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease.

idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: CERE-120
Product Code: CERE-120

Ceregene Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom

663

NCT00869791
(ClinicalTrials.gov)

November 2008

24/3/2009

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Parkinson's Disease

Drug: IPX066;Drug: IR CD-LD

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

664

EUCTR2007-006721-27-AT
(EUCTR)

20/10/2008

15/09/2008

idiopathic Parkinson's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: CERE-120
Product Code: CERE-120

Ceregene Inc.

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Austria;United Kingdom

665

EUCTR2008-003225-16-FI
(EUCTR)

10/09/2008

30/05/2008

Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla

Vaikeahoitoinen Parkinsonin tauti potilailla, joille on aiemmin asetettu aivostimulaattori, tai on päädytty päivittäisten oireiden vuoksi aloittamaan Duodopa-infuusio.
MedDRA version: 9.1;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS

Trade Name: Duodopa

Organisation name was not entered

NULL

Not Recruiting

Female: yes
Male: yes

Finland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

666

NCT01010802
(ClinicalTrials.gov)

August 2008

8/11/2009

Safety Study of Erythropoietin (EPO) in Parkinson's Disease

Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)

Parkinson Disease

Drug: Erythropoietin human recombinant (EPOrh)

International Center for Neurological Restoration, Cuba

Centro de Immunologia Molecular, Cuba

Completed

45 Years

75 Years

All

Phase 1

Cuba

667

NCT00753636
(ClinicalTrials.gov)

April 2008

13/9/2008

Parkinson's Disease Isradipine Safety Study

Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II

Parkinson's Disease

Drug: Dynacirc CR (Isradipine)

Northwestern University

Northwestern Memorial Hospital

Completed

30 Years

75 Years

All

Phase 2

United States

668

NCT00651183
(ClinicalTrials.gov)

April 2008

31/3/2008

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Drug: Pramipexole immediate release

Boehringer Ingelheim

NULL

Completed

18 Years

N/A

All

286

Austria

669

NCT00605553
(ClinicalTrials.gov)

April 2008

15/1/2008

Study to Evaluate SYN115 in Parkinson's Disease

A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease

Parkinson's Disease

Drug: Placebo;Drug: Tozadenant

Biotie Therapies Inc.

NULL

Completed

40 Years

75 Years

All

Phase 2

United States

670

NCT00761137
(ClinicalTrials.gov)

March 2008

25/9/2008

Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients

A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients

Sialorrhea Secondary to Parkinson's Disease

Drug: 0.3 mg tropicamide;Drug: 1 mg tropicamide;Drug: 3 mg tropicamide;Drug: 0 mg tropicamide

NeuroHealing Pharmaceuticals Inc.

Michael J. Fox Foundation for Parkinson's Research

Completed

50 Years

80 Years

All

Phase 2

Argentina

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

671

NCT00607451
(ClinicalTrials.gov)

March 2008

22/1/2008

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia

Levodopa-induced Dyskinesia

Drug: Neu-120

Neurim Pharmaceuticals Ltd.

NULL

Terminated

30 Years

80 Years

All

Phase 1;Phase 2

Israel

672

NCT00658567
(ClinicalTrials.gov)

March 2008

10/4/2008

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

123

Phase 3

United States;Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden

673

NCT00642356
(ClinicalTrials.gov)

March 2008

19/3/2008

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Parkinson's Disease

Drug: Carbidopa /levodopa/entacapone;Drug: Immediate release carbidopa/levodopa

Novartis

NULL

Terminated

30 Years

85 Years

All

Phase 4

United States

674

EUCTR2007-002964-90-ES
(EUCTR)

18/01/2008

30/11/2007

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receivingconcomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.Ensayo fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de un rango de dosis de 50 - 100 mg/día de safinamida, como terapia añadida, en pacientes con enfermedad de Parkinson idiopática con fluctuaciones motoras tratados con una dosis estable de levodopa y que podrían estar recibiendo tratamiento concomitante con dosis estables de un agonista de la dopamina, un anticolinérgico y/o amantadina. - Safinamide in IPD with motor fluctuations, as add-on to levodopa

Ideopathic Parkinson's Disease Enfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1121

Phase 3

Hungary;Finland;Czech Republic;United Kingdom;Germany;Netherlands;Belgium;Estonia;France;Spain;Austria

675

EUCTR2007-002963-28-ES
(EUCTR)

17/01/2008

16/11/2007

A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s Disease treated with a stable dose of a single dopamine agonist.Ensayo en fase III aleatorizado, doble ciego y controlado con placebo, para determinar la eficacia y la seguridad de una dosis baja (50 mg/día) y una alta (100 mg/día) de safinamida, como terapia añadida en pacientes con enfermedad de Parkinson idiopática precoz tratados con una dosis estable de un único agonista de la dopamina. - Safinamide in early IPD, as add-on to dopamine agonist

Idiopathic Parkinson's DiseaseEnfermedad de Parkinson Idiopática
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide
Product Name: Safinamide
Product Code: NW-1015
INN or Proposed INN: Safinamide

Merck Serono International S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

1036

Phase 3

Portugal;Finland;Germany;Czech Republic;Bulgaria;Spain;Italy;Poland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

676

NCT00601523
(ClinicalTrials.gov)

January 2008

15/1/2008

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

Drug: Placebo;Drug: Pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

511

Phase 3

United States;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;Argentina

677

NCT00335153
(ClinicalTrials.gov)

January 2008

8/6/2006

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications

Advanced Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel;Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: PEG tube;Device: J-tube

AbbVie (prior sponsor, Abbott)

Quintiles, Inc.

Completed

30 Years

N/A

All

354

Phase 3

United States;Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;Greece

678

NCT00623103
(ClinicalTrials.gov)

January 2008

14/2/2008

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Parkinson's Disease Dementia

Drug: Rivastigmine capsule;Drug: Rivastigmine transdermal patch

Novartis

NULL

Completed

50 Years

85 Years

All

583

Phase 3

United States;Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom

679

NCT00612872
(ClinicalTrials.gov)

January 2008

16/1/2008

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects

Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis

Drug: [123I]CLINDE

Institute for Neurodegenerative Disorders

NULL

Terminated

30 Years

50 Years

All

Phase 1

United States

680

NCT01628965
(ClinicalTrials.gov)

January 2008

25/6/2012

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

143

Phase 2;Phase 3

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

681

NCT00526630
(ClinicalTrials.gov)

December 2007

5/9/2007

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study

Parkinson's Disease;Gait Impairment

Drug: Methylphenidate (MPD);Drug: Placebo

University of Cincinnati

Michael J. Fox Foundation for Parkinson's Research

Completed

35 Years

85 Years

All

Phase 4

United States

682

NCT00584025
(ClinicalTrials.gov)

December 2007

21/12/2007

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

Parkinson's Disease

Drug: levetiracetam;Drug: Placebo

University of South Florida

NULL

Withdrawn

30 Years

80 Years

All

Phase 4

United States

683

NCT00577460
(ClinicalTrials.gov)

December 2007

19/12/2007

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

32 Years

N/A

All

391

Phase 3

Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom

684

NCT00537017
(ClinicalTrials.gov)

November 23, 2007

27/9/2007

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)

Parkinson Disease;Neurodegenerative Diseases;Central Nervous System Diseases;Movement Disorders;Brain Diseases

Drug: Preladenant;Drug: L-dopa;Drug: Other Parkinson's Disease treatments

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

N/A

All

140

Phase 2

Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States

685

NCT00610103
(ClinicalTrials.gov)

November 2007

22/1/2008

Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy

A Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's Disease

Parkinson's Disease

Drug: apomorphine hydrochloride

Kyowa Kirin Co., Ltd.

NULL

Completed

20 Years

N/A

All

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

686

NCT00560508
(ClinicalTrials.gov)

November 2007

16/11/2007

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER

Parkinson Disease

Drug: Pramipexole Immediate Release;Drug: Pramipexole Extended Release

Boehringer Ingelheim

NULL

Completed

1 Year

N/A

All

112

Phase 2;Phase 3

Japan

687

EUCTR2005-005791-32-SE
(EUCTR)

04/10/2007

30/07/2007

Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.

HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this mechanism has the potential to reduce disease progression in a wide range of disorders of the nervous system, e.g. Alzheimer's and Parkinson's disease, and brain damage due to acute stroke and head injury. It may also apply to the protection of peripheral tissues, such as the heart and/or kidney.
MedDRA version: 9.1;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes)

Product Name: HF0220
Product Code: HF0220
Other descriptive name: 7-beta-hydroxyepiandrosterone

Hunter-Fleming Ltd

NULL

Not Recruiting

Female: yes
Male: yes

United Kingdom;Sweden

688

NCT00558025
(ClinicalTrials.gov)

October 2007

12/11/2007

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR

Parkinson Disease

Drug: Pramipexole Extended Release;Drug: Pramipexole Immediate Release

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

156

Phase 3

France;Germany;Netherlands

689

NCT00566462
(ClinicalTrials.gov)

October 2007

29/11/2007

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Parkinson's Disease

Drug: perampanel;Drug: placebo

Eisai Inc.

NULL

Terminated

30 Years

N/A

All

Phase 2

United States

690

NCT00547911
(ClinicalTrials.gov)

October 2007

19/10/2007

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone

Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases

Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Terminated

18 Years

N/A

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

691

NCT00594464
(ClinicalTrials.gov)

September 2007

21/12/2007

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

An Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

80 Years

All

Phase 4

Germany

692

NCT00537485
(ClinicalTrials.gov)

September 2007

27/9/2007

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Early Parkinson's Disease

Drug: SPM 962;Drug: placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

180

Phase 2;Phase 3

Japan

693

NCT00522379
(ClinicalTrials.gov)

July 2007

28/8/2007

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB Pharma

NULL

Completed

30 Years

N/A

All

514

Phase 3

United States;Chile;India;Mexico;Peru

694

NCT00505622
(ClinicalTrials.gov)

July 2007

9/7/2007

Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

Drug: Perampanel

Eisai Limited

NULL

Terminated

30 Years

N/A

All

328

Phase 3

France

695

NCT00550238
(ClinicalTrials.gov)

July 2007

26/10/2007

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

459

Phase 3

United States;Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

696

NCT00593606
(ClinicalTrials.gov)

July 2007

21/12/2007

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

18 Years

N/A

All

124

Phase 3

NULL

697

NCT00515437
(ClinicalTrials.gov)

July 2007

10/8/2007

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Drooling

Biological: Botulinum Toxin Type B (Myobloc);Biological: Matched placebo to Myobloc

Solstice Neurosciences

NULL

Completed

18 Years

85 Years

All

Phase 2

United States

698

NCT00519532
(ClinicalTrials.gov)

July 2007

21/8/2007

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Terminated

18 Years

N/A

All

Phase 3

United States;Australia;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;Austria

699

NCT00485069
(ClinicalTrials.gov)

June 2007

11/6/2007

REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -

Parkinson Disease;Parkinson's Disease

Drug: ROP;Drug: ROP +L-Dopa

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

123

Phase 4

Japan

700

NCT00571285
(ClinicalTrials.gov)

June 2007

7/12/2007

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

Parkinson's Disease

Dietary Supplement: Vitamin D3;Dietary Supplement: Vitamin D3 - high dose;Dietary Supplement: Placebo

Emory University

NULL

Terminated

18 Years

89 Years

All

Phase 4

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

701

NCT00477672
(ClinicalTrials.gov)

June 2007

22/5/2007

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Parkinson's Disease Psychosis

Drug: Pimavanserin tartrate (ACP-103);Drug: Placebo

ACADIA Pharmaceuticals Inc.

NULL

Completed

40 Years

N/A

All

298

Phase 3

United States;Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom

702

EUCTR2007-000074-23-ES
(EUCTR)

29/05/2007

02/03/2010

A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).Estudio aleatorizado, doble ciego, doble simulación, controlado con placebo de tres grupos paralelos que compara la eficacia, la seguridad y la tolerabilidad de pramipexol ER frente a placebo y frente a pramipexol IR administrados por vía oral durante una fase de mantenimiento de 26 semanas de duración en pacientes con enfermedad de Parkinson (EP) avanzada tratados con L-Dopa+.

Pacientes varones o mujeres, diagnosticados de enfermedad de Parkinson idiopática, al menos dos años antes, con 30 años o más de edad en el momento del diagnóstico, con un estadío entre 2 y 4 en la escala modificada de Hoehn y Yahr en el periodo on.Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Product Name: Pramipexole ER
Product Code: SND 919 CL2Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

516

Phase 1

Hungary;United Kingdom;Spain;Italy;Austria;Sweden

703

EUCTR2006-006752-35-ES
(EUCTR)

27/05/2007

27/03/2007

RECOVER: EVALUACIÓN ALEATORIZADA DE LA COBERTURA 24 HORAS: EFICACIA DE ROTIGOTINA. ESTUDIO DE FASE 3B, MULTICÉNTRICO, MULTINACIONAL, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE 2 BRAZOS PARA EVALUAR EL EFECTO DE LA ADMINISTRACIÓN TRANSDÉRMICA 24 HORAS DE ROTIGOTINA SOBRE EL CONTROL DE LA FUNCIÓN MOTORA A PRIMERA HORA DE LA MAÑANA, LA CALIDAD DEL SUEÑO, LOS SÍNTOMAS NOCTURNOS Y LOS SÍNTOMAS NO MOTORES EN SUJETOS CON ENFERMEDAD DE PARKINSON IDIOPÁTICA.(RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINEPHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCTION, SLEEP QUALITY, NOCTURNAL SYMPTOMS, AND NON-MOTOR SYMPTOMS IN SUBJECTS WITH IDIOPATHIC PARKINSON’S DISEASE) - Recover

Enfermedad de Parkinson(Parkinson's disease)
MedDRA version: 9.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Trade Name: Neupro 2mg/24 h transdermal patch
Product Code: ND1587
INN or Proposed INN: Rotigotine
Trade Name: Neupro 4mg/24 h transdermal patch
Product Code: ND1589
INN or Proposed INN: Rotigotine
Trade Name: Neupro 6mg/24 h transdermal patch
Product Code: ND1590
INN or Proposed INN: Rotigotine
Trade Name: Neupro 8 mg/24 h transdermal patch
Product Code: ND1702
INN or Proposed INN: Rotigotine

Schwarz Biosciences GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

400

Phase 3B

Hungary;Finland;Spain;Austria;Germany;United Kingdom;Italy

704

NCT00477802
(ClinicalTrials.gov)

May 2007

22/5/2007

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study

Parkinson Disease

Biological: Botulinum Toxin Type A;Biological: Placebo

University of Cincinnati

Allergan

Terminated

35 Years

75 Years

Both

Phase 4

United States

705

NCT00479401
(ClinicalTrials.gov)

May 2007

25/5/2007

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

Early Parkinson Disease (Early PD)

Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

539

Phase 3

United States;Argentina;Austria;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;Brazil

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

706

NCT00474058
(ClinicalTrials.gov)

May 2007

14/5/2007

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Drug: Rotigotine;Other: Placebo

UCB Pharma

NULL

Completed

18 Years

N/A

All

287

Phase 3

United States;Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom

707

NCT00489255
(ClinicalTrials.gov)

May 2007

20/6/2007

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo

Parkinson's Disease

Drug: Tigan ®;Drug: Placebo

Ipsen

INC Research Limited

Completed

18 Years

N/A

All

117

Phase 4

United States

708

EUCTR2006-000577-29-DE
(EUCTR)

27/04/2007

12/10/2006

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products who Continue toExperience Persistent Motor Fluctuations

Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: DUODOPA®Intestinal Gel
INN or Proposed INN: Levodopa
Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
Trade Name: Sinemet®25-100
INN or Proposed INN: Levodopa
Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA
INN or Proposed INN: Carbidopa Monohydrate
Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate

Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)

NULL

Not Recruiting

Female: yes
Male: yes

United States;Germany

709

EUCTR2007-000307-15-IT
(EUCTR)

24/04/2007

23/08/2007

Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.

Psicosi associata al morbo di Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's

Product Name: Melperon
INN or Proposed INN: melperon

OVATION PHARMACEUTICALS INC

NULL

Not Recruiting

Female: yes
Male: yes

Italy

710

NCT00434304
(ClinicalTrials.gov)

April 9, 2007

9/2/2007

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -

Parkinson Disease

Drug: Ropinirole prolonged release/extended release(PR/XR)

GlaxoSmithKline

NULL

Completed

20 Years

N/A

All

Phase 2

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

711

NCT00466167
(ClinicalTrials.gov)

April 2007

25/4/2007

Pivotal Study in Advanced Parkinsons Disease Patients

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).

Parkinson Disease

Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

32 Years

N/A

All

517

Phase 3

Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom

712

NCT00438607
(ClinicalTrials.gov)

April 2007

20/2/2007

Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa

Parkinson's Disease

Drug: BIIB014;Drug: Placebo

Biogen Idec

NULL

Completed

30 Years

N/A

Both

Phase 2

India;Israel;United Kingdom

713

NCT00437125
(ClinicalTrials.gov)

March 2007

16/2/2007

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease

Major Depressive Disorder;Idiopathic Parkinson Disease

Drug: Duloxetine hydrochloride

Eli Lilly and Company

NULL

Completed

30 Years

75 Years

All

151

Phase 4

Italy

714

NCT00443872
(ClinicalTrials.gov)

March 2007

3/3/2007

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications

Parkinson's Disease

Drug: orally disintegrating selegiline (Zelapar)

Parkinson's Disease and Movement Disorder Center of Boca Raton

Valeant Pharmaceuticals International, Inc.

Completed

30 Years

90 Years

All

Phase 4

United States

715

NCT00449865
(ClinicalTrials.gov)

March 2007

20/3/2007

NET-PD LS-1 Creatine in Parkinson's Disease

A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)

Parkinson's Disease

Drug: creatine;Other: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Terminated

N/A

All

1741

Phase 3

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

716

NCT00480701
(ClinicalTrials.gov)

February 2007

30/5/2007

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease

Alzheimer Disease;Parkinson Disease

Drug: [123I]-IBVM

Institute for Neurodegenerative Disorders

NULL

Completed

50 Years

N/A

Both

Phase 2

United States

717

NCT00427011
(ClinicalTrials.gov)

February 2007

24/1/2007

A Study of E2007 In Patients With Parkinson's Disease

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Terminated

18 Years

N/A

All

Phase 2

United States

718

EUCTR2006-003490-27-GB
(EUCTR)

19/12/2006

29/09/2006

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa

Parkinson's disease
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease

BIOGEN IDEC LTD

NULL

Not Recruiting

Female: yes
Male: yes

137

Phase 2

United Kingdom

719

NCT01631812
(ClinicalTrials.gov)

December 2006

25/6/2012

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

N/A

All

130

Phase 2

Japan

720

NCT00406029
(ClinicalTrials.gov)

November 20, 2006

30/11/2006

Dyskinesia in Parkinson's Disease (Study P04501)

A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Parkinson Disease;Movement Disorders;Central Nervous System Diseases;Neurodegenerative Diseases;Brain Diseases

Drug: Preladenant;Drug: Placebo;Drug: L-dopa;Drug: Other Parkinson's Disease treatments

Merck Sharp & Dohme Corp.

NULL

Completed

30 Years

N/A

All

253

Phase 2

Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

721

EUCTR2006-001793-24-PT
(EUCTR)

07/11/2006

31/07/2006

A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE - not available

Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (wearing-off) phenomenon although currently treated with levodopa/DDCI.
MedDRA version: 7;Level: LLT;Classification code 10061536

Product Name: Nebicapone
Product Code: BIA 3-202
Trade Name: COMTAN®
Product Name: Entacapone
INN or Proposed INN: Entacapone
Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Nebicapone
Product Code: BIA 3-202

BIAL - Portela & Cª, SA

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Austria

722

NCT00397228
(ClinicalTrials.gov)

November 2006

6/11/2006

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Parkinson Disease

Drug: ALTROPANE ®

Molecular NeuroImaging

Institute for Neurodegenerative Disorders

Completed

30 Years

N/A

Both

Phase 2

United States

723

NCT00360308
(ClinicalTrials.gov)

November 2006

2/8/2006

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: Placebo;Drug: E2007

Eisai Limited

NULL

Terminated

30 Years

N/A

All

723

Phase 3

France

724

NCT00387075
(ClinicalTrials.gov)

November 2006

10/10/2006

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease

Parkinson Disease

Procedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CIT

Institute for Neurodegenerative Disorders

United States Department of Defense;Molecular NeuroImaging

Active, not recruiting

50 Years

N/A

All

3000

Phase 2

United States

725

NCT00404170
(ClinicalTrials.gov)

November 2006

22/11/2006

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort

Parkinson Disease

Drug: B-CIT and SPECT imaging

Institute for Neurodegenerative Disorders

United States Department of Defense

Completed

30 Years

N/A

All

396

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

726

NCT00402233
(ClinicalTrials.gov)

November 2006

19/11/2006

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)

Parkinson Disease

Drug: Pramipexole;Drug: Placebo

Boehringer Ingelheim

NULL

Completed

31 Years

N/A

All

312

Phase 4

United States

727

NCT00400634
(ClinicalTrials.gov)

November 2006

15/11/2006

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]);Procedure: Sham Surgery

Ceregene

NULL

Completed

35 Years

75 Years

All

Phase 2

United States

728

NCT00391898
(ClinicalTrials.gov)

October 2006

24/10/2006

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa

Parkinson's Disease

Drug: Levodopa /carbidopa /entacapone;Drug: Levodopa /carbidopa

Novartis

NULL

Completed

30 Years

80 Years

All

Phase 4

Spain

729

NCT00399477
(ClinicalTrials.gov)

October 2006

10/11/2006

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)

Parkinson's Disease

Drug: rasagiline mesylate;Drug: Rasagiline mesylate plus Mirapex;Drug: Rasagiline mesylate with Levodopa;Drug: Rasagiline mesylate with Requip

Teva Neuroscience, Inc.

NULL

Completed

30 Years

N/A

Both

200

Phase 4

United States

730

NCT03103399
(ClinicalTrials.gov)

September 26, 2006

28/3/2017

Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon

A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide

Parkinson Disease

Drug: Comtan®;Drug: Nebicapone;Drug: Levodopa /DDCI;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

30 Years

80 Years

All

254

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

731

EUCTR2005-001006-12-CZ
(EUCTR)

06/09/2006

24/08/2006

Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSO

Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.
MedDRA version: 9.1;Level: LLT;Classification code 10034006;Term: Parkinson's disease aggravated

Product Name: Lisparin
INN or Proposed INN: Lisuride Hydrogenmaleate
Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea

Axxonis Pharma GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Germany;Czech Republic;Italy;Austria

732

NCT01628848
(ClinicalTrials.gov)

August 2006

24/6/2012

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Parkinson's Disease

Drug: SPM 962;Drug: Placebo

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

174

Phase 2

Japan

733

NCT00368108
(ClinicalTrials.gov)

August 2006

22/8/2006

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Drug: 2 mg perampanel;Drug: 4 mg perampanel;Drug: placebo comparator

Eisai Inc.

NULL

Completed

30 Years

N/A

All

752

Phase 3

United States;Canada

734

EUCTR2006-001793-24-AT
(EUCTR)

31/07/2006

24/07/2006

Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Entacapone
INN or Proposed INN: Entacapone
Product Name: Nebicapone
Product Code: BIA 3-202
Product Name: Nebicapone
Product Code: BIA 3-202

BIAL - Portela & Cª, SA

NULL

Not Recruiting

Female: yes
Male: yes

250

Portugal;Austria

735

EUCTR2006-000391-32-NL
(EUCTR)

18/07/2006

10/05/2006

A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Active, Efficacy, safety and Tolerability Assessment of APO Nasal Powder (2 and 4 mg) in the Alleviation of Acute Episodes of Motor Symptoms Associated with PD, Followed by Period 2 Comprising a 36-Week Open, Active Treatment, Safety Assessment of APO Nasal Powder (2 and 4 mg), in Subjects with PD. - Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Subjects with Parkinson's Disease

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

130

Germany;United Kingdom;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

736

NCT03097211
(ClinicalTrials.gov)

July 17, 2006

27/3/2017

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Nebicapone

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

737

EUCTR2006-000680-28-ES
(EUCTR)

07/07/2006

22/05/2006

Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Parkinson y wearing-off”A 3-months, multicenter, double-blind, randomized study to evaluate the efficacy of levodopa/carbidopa/entacapone vs. levodopa/carbidopa in Parkinson's disease patients with 'wearing-off' - DERBI

Enfermedad de Parkinson (Parkinson Disease)

Trade Name: Stalevo 100
Product Name: Stalevo (levodopa/carbidopa/entacapona)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: ENTACAPONA
Trade Name: Sinemet plus
Product Name: Sinemet plus (levodopa/carbidopa)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
Trade Name: Stalevo 150
Product Name: Stalevo (levodopa/carbidopa/entacapona)
INN or Proposed INN: LEVODOPA
INN or Proposed INN: CARBIDOPA
INN or Proposed INN: ENTACAPONA

NOVARTIS FARMACEUTICA, S.A

NULL

Not Recruiting

Female: yes
Male: yes

200

Spain

738

EUCTR2006-000391-32-DE
(EUCTR)

04/07/2006

27/04/2006

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

130

United Kingdom;Germany;Netherlands

739

NCT00346827
(ClinicalTrials.gov)

July 2006

29/6/2006

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods.

Parkinson's Disease

Drug: Apomorphine Nasal Powder

Britannia Pharmaceuticals Ltd.

NULL

Completed

18 Years

85 Years

All

Phase 2;Phase 3

NULL

740

NCT00354133
(ClinicalTrials.gov)

July 2006

19/7/2006

Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease

The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)

Parkinson Disease

Device: Kinetra and Soletra (neurostimulator, Medtronic);Drug: Best Medical Treatment

German Parkinson Study Group (GPS)

University Hospital Schleswig-Holstein;Assistance Publique - Hôpitaux de Paris;KKS Netzwerk

Active, not recruiting

18 Years

60 Years

All

251

Phase 4

France;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

741

NCT00331149
(ClinicalTrials.gov)

June 20, 2006

26/5/2006

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.

Parkinson Disease

Drug: Ropinirole prolonged release;Drug: ropinirole immediate release

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

343

Phase 3

Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic

742

EUCTR2006-000391-32-GB
(EUCTR)

06/06/2006

21/04/2006

Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease

Product Name: Apomorphine Nasal Powder
Other descriptive name: 6aß - apomorphine-10,11-diol hydrochloride hemihydrate

Britannia Pharmaceuticals Limited

NULL

Not Recruiting

Female: yes
Male: yes

130

Phase 3

Netherlands;Germany;United Kingdom

743

EUCTR2005-004949-34-ES
(EUCTR)

29/05/2006

21/04/2006

A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start Study

Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536

Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España, S.A.

NULL

Not Recruiting

Female: yes
Male: yes

500

Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden

744

NCT00324896
(ClinicalTrials.gov)

May 2006

9/5/2006

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

Parkinson's Disease;Insomnia

Drug: eszopiclone;Other: placebo

University of Medicine and Dentistry of New Jersey

Sunovion

Completed

35 Years

85 Years

All

Phase 3

United States

745

NCT00321854
(ClinicalTrials.gov)

May 2006

3/5/2006

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.

Parkinson Disease

Drug: pramipexole

Boehringer Ingelheim

NULL

Completed

30 Years

79 Years

All

535

Phase 4

United States;Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

746

NCT03094156
(ClinicalTrials.gov)

April 26, 2006

23/3/2017

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Drug: Placebo;Drug: BIA 6-512;Drug: Madopar® 250;Drug: Comtan®

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

747

EUCTR2005-005791-32-GB
(EUCTR)

24/04/2006

17/02/2006

Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.

Hunter-Fleming Ltd

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

United Kingdom;Sweden

748

EUCTR2005-001006-12-AT
(EUCTR)

02/04/2006

28/02/2006

Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.

Product Name: Lisparin
INN or Proposed INN: Lisuride Hydrogenmaleate
Other descriptive name: 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Trade Name: Sifrol, 0,35 mg Tablette
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Trade Name: Sifrol, 0,70 mg Tablette
Product Name: Pramipexol
INN or Proposed INN: Pramipexol
Other descriptive name: (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Trade Name: Cabaseril, 1,0 mg Tablette
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Trade Name: Cabaseril, 2,0 mg Tablette
Product Name: Cabergoline
INN or Proposed INN: Cabergoline
Other descriptive name: 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-

Axxonis Pharma GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Germany;Czech Republic;Italy;Austria

749

NCT00467597
(ClinicalTrials.gov)

April 2006

27/4/2007

Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)

Dyskinesias;Movement Disorders;Parkinson Disease

Drug: Levodopa (delivered intravenously)

VA Office of Research and Development

Oregon Health and Science University

Completed

21 Years

N/A

All

N/A

United States

750

NCT00294554
(ClinicalTrials.gov)

April 2006

21/2/2006

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Parkinson's Disease;Cognitive Impairment;Dementia

Drug: Memantine;Drug: Placebo Oral Tablet

Johns Hopkins University

Forest Laboratories

Completed

50 Years

N/A

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

751

EUCTR2005-001006-12-DE
(EUCTR)

09/03/2006

05/09/2006

Axxonis Pharma GmbH

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Czech Republic;Germany;Italy;Austria

752

NCT00141518
(ClinicalTrials.gov)

March 2006

30/8/2005

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia

Advanced Idiopathic Parkinson's Disease

Drug: Levodopa -carbidopa intestinal gel (LCIG);Device: CADD-Legacy® 1400 ambulatory infusion pump;Device: percutaneous endoscopic gastrostomy tube (PEG tube);Device: jejunal extension tube (J-tube)

AbbVie (prior sponsor, Abbott)

NULL

Completed

18 Years

99 Years

All

Phase 4

Norway;Sweden

753

NCT00282152
(ClinicalTrials.gov)

March 2006

23/1/2006

Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)

Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease

Parkinson's Disease

Device: B-STN DBS;Drug: Optimal drug therapy

Vanderbilt University Medical Center

NULL

Completed

50 Years

75 Years

All

N/A

United States

754

NCT00297778
(ClinicalTrials.gov)

March 2006

28/2/2006

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms

Parkinson Disease;Depression

Drug: Pramipexole;Other: Placebo

Boehringer Ingelheim

NULL

Completed

30 Years

80 Years

All

296

Phase 4

Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom

755

EUCTR2005-003788-22-ES
(EUCTR)

09/02/2006

28/12/2005

A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.Estudio aleatorizado, doble ciego, controlado con placebo sobre la eficacia de pramipexol y placebo administrados por vía oral durante una fase de tratamiento de 12 semanas en pacientes con Parkinson con función motora estable y síntomas depresivos

Trade Name: Mirapexin / Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Mirapexin/Sifrol
Product Name: Sifol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole

Boehringer Ingelheim España S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

318

Phase 1

Finland;Germany;United Kingdom;Spain;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

756

NCT00296192
(ClinicalTrials.gov)

February 2006

22/2/2006

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of OFF Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease

Parkinson's Disease

Drug: Rotigotine nasal spray;Other: Placebo

UCB Pharma

NULL

Completed

30 Years

N/A

All

Phase 2

Germany

757

NCT03095105
(ClinicalTrials.gov)

January 24, 2006

23/3/2017

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Drug: 200 mg BIA 6-512

Bial - Portela C S.A.

NULL

Completed

18 Years

N/A

All

Phase 1

Germany

758

NCT00292227
(ClinicalTrials.gov)

January 2006

14/2/2006

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.

Parkinson's Disease

Drug: Rotigotine;Other: Placebo;Drug: Moxifloxacin infusion;Other: Placebo infusion

UCB Pharma

NULL

Completed

18 Years

N/A

All

130

Phase 1

South Africa

759

NCT00275275
(ClinicalTrials.gov)

January 2006

9/1/2006

Pramipexole Conversion to Ropinirole Controlled Release (CR)

An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.

Parkinson Disease

Drug: Requip PR;Drug: Mirapex

Rajesh Pahwa, MD

GlaxoSmithKline

Completed

18 Years

N/A

All

Phase 3

United States

760

NCT00279825
(ClinicalTrials.gov)

January 2006

18/1/2006

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: CD -LD IR;Drug: CD -LD CR;Drug: IPX054 200 mg Placebo;Drug: IPX054 250 mg Placebo;Drug: CD -LD IR Placebo;Drug: CD -LD CR Placebo

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

761

NCT00253084
(ClinicalTrials.gov)

November 2005

11/11/2005

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease

Parkinson's Disease

Drug: IPX054 200 mg;Drug: CD -LD IR;Drug: IPX054 Placebo;Drug: CD -LD IR Placebo

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 2

United States

762

NCT00256204
(ClinicalTrials.gov)

November 2005

16/11/2005

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects

Parkinson's Disease

Drug: Rasagiline Mesylate;Other: Placebo

Teva Pharmaceutical Industries

NULL

Completed

30 Years

80 Years

All

1174

Phase 3

Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States

763

NCT00239564
(ClinicalTrials.gov)

October 2005

13/10/2005

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: IPX054 100 mg;Drug: IPX054 150 mg;Drug: IPX054 200 mg;Drug: IPX054 250 mg;Drug: IPX054 300 mg

Impax Laboratories, LLC

NULL

Completed

30 Years

N/A

All

Phase 1;Phase 2

United States

764

NCT00472355
(ClinicalTrials.gov)

October 2005

10/5/2007

Low Dose Apomorphine and Parkinsonism

Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?

Parkinson's Disease

Drug: apomorphine

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Withdrawn

35 Years

85 Years

All

Phase 2

United States

765

NCT00912808
(ClinicalTrials.gov)

October 2005

2/6/2009

Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease

A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's

Parkinson's Disease

Drug: Donepezil;Drug: Sugar Pill (placebo)

Oregon Health and Science University

NULL

Completed

21 Years

N/A

All

N/A

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

766

NCT00199381
(ClinicalTrials.gov)

October 2005

12/9/2005

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.

Parkinson's Disease

Drug: Istradefylline

Kyowa Kirin Pharmaceutical Development, Inc.

NULL

Terminated

30 Years

N/A

All

504

Phase 3

United States

767

NCT00165789
(ClinicalTrials.gov)

September 2005

12/9/2005

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

Drug: E2007

Eisai Inc.

NULL

Completed

18 Years

N/A

All

Phase 2

United States

768

NCT00134966
(ClinicalTrials.gov)

August 2005

23/8/2005

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa

Parkinson's Disease

Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Novartis

NULL

Completed

30 Years

80 Years

All

493

Phase 3

United States;Canada;Czechia;Israel;Italy;Poland;Portugal;Turkey;Czech Republic

769

NCT00125138
(ClinicalTrials.gov)

July 2005

27/7/2005

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease;Psychotic Disorders

Drug: Melperone HCl;Drug: Placebo

Lundbeck LLC

NULL

Completed

N/A

All

Phase 2

United States;India;Italy

770

NCT00143026
(ClinicalTrials.gov)

July 2005

31/8/2005

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.

Parkinson's Disease

Drug: carbidopa , levodopa, entacapone

Novartis

NULL

Completed

30 Years

N/A

All

184

Phase 4

Australia;Philippines;Taiwan;Thailand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

771

NCT00086190
(ClinicalTrials.gov)

June 2005

28/6/2004

Study of Antidepressants in Parkinson's Disease

Parkinson Disease;Depression

Drug: paroxetine;Drug: venlafaxine;Other: placebo

University of Rochester

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

30 Years

N/A

All

115

Phase 3

United States;Canada;Puerto Rico

772

NCT03095092
(ClinicalTrials.gov)

May 23, 2005

23/3/2017

Effect of Food on BIA 6-512 (Trans-resveratrol)

The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects

Parkinson Disease

Drug: BIA 6-512 400 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

773

NCT03093389
(ClinicalTrials.gov)

May 11, 2005

22/3/2017

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers

Parkinson Disease

Drug: BIA 6-512;Drug: Placebo

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

774

NCT00505687
(ClinicalTrials.gov)

February 2005

20/7/2007

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

186

Phase 3

United States;Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom

775

NCT00286949
(ClinicalTrials.gov)

January 6, 2005

3/2/2006

Treatment of Executive Dysfunction in Parkinson's Disease

Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study

Parkinson's Disease

Drug: Atomoxetine

Johns Hopkins University

Eli Lilly and Company

Completed

21 Years

65 Years

All

N/A

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

776

NCT00219284
(ClinicalTrials.gov)

January 2005

30/6/2005

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off

Parkinson's Disease With End of Dose Wearing Off

Drug: Carbidopa /levodopa/entacapone

Novartis Pharmaceuticals

NULL

Completed

30 Years

85 Years

All

359

Phase 4

United States;Puerto Rico

777

NCT01634243
(ClinicalTrials.gov)

January 2005

27/6/2012

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Drug: SPM 962

Otsuka Pharmaceutical Co., Ltd.

NULL

Completed

30 Years

79 Years

All

Phase 2

Japan

778

NCT00144300
(ClinicalTrials.gov)

January 2005

2/9/2005

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients

Parkinson Disease

Drug: Mirapex;Drug: Requip

Boehringer Ingelheim

NULL

Completed

30 Years

N/A

All

246

Phase 4

United States

779

NCT01518309
(ClinicalTrials.gov)

November 17, 2004

16/12/2008

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients

Parkinson's Disease Psychosis

Drug: pimavanserin tartrate (ACP-103)

ACADIA Pharmaceuticals Inc.

NULL

Completed

N/A

All

Phase 2

United States

780

NCT03091868
(ClinicalTrials.gov)

November 3, 2004

21/3/2017

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg

Parkinson Disease

Drug: Placebo oral capsule;Drug: Sinemet® 100/25;Drug: Comtan®;Drug: BIA 6-512 25 mg;Drug: BIA 6-512 100 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

781

NCT01634360
(ClinicalTrials.gov)

November 2004

3/7/2012

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With Wearing Off Motor Fluctuations and on Period Dyskinesias

Parkinson's Disease

Drug: Perampanel

Eisai Inc.

NULL

Terminated

N/A

All

185

Phase 2

NULL

782

NCT00296946
(ClinicalTrials.gov)

November 2004

23/2/2006

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease

Parkinson's Disease

Drug: ipratropium bromide (drug)

University Health Network, Toronto

Parkinson's Disease Foundation

Completed

30 Years

N/A

All

Phase 2

Canada

783

NCT00105508
(ClinicalTrials.gov)

September 30, 2004

15/3/2005

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan;Drug: Placebo

EMD Serono

NULL

Completed

30 Years

N/A

All

506

Phase 3

United States

784

NCT00099268
(ClinicalTrials.gov)

September 2004

10/12/2004

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

Parkinson's Disease

Drug: Carbidopa /levodopa/entacapone;Drug: Immediate release carbidopa/levodopa

Novartis Pharmaceuticals

Orion Corporation, Orion Pharma

Completed

30 Years

70 Years

All

747

Phase 3

United States;Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom

785

NCT00105521
(ClinicalTrials.gov)

September 2004

15/3/2005

Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan HC1

EMD Serono

NULL

Completed

30 Years

N/A

All

594

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

786

NCT00089622
(ClinicalTrials.gov)

August 4, 2004

6/8/2004

Lisuride Patch to Treat Parkinson's Disease

Transcutaneous Lisuride Therapy of Parkinson's Disease

Parkinson Disease

Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

40 Years

80 Years

All

Phase 2

United States

787

NCT00501969
(ClinicalTrials.gov)

August 2004

16/7/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa

Advanced Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

395

Phase 3

Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom

788

NCT00304161
(ClinicalTrials.gov)

July 2004

15/3/2006

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

Depression Diagnosis and Treatment in Parkinson Disease

Depressive Disorder;Parkinson Disease

Drug: Atomoxetine;Drug: Placebo

University of Pennsylvania

National Institute of Mental Health (NIMH)

Completed

30 Years

79 Years

All

Phase 4

United States

789

NCT00359723
(ClinicalTrials.gov)

July 2004

31/7/2006

Methylphenidate and Parkinson's Disease

Subacute Trial of Methylphenidate in Parkinson's Disease

Parkinson's Disease

Drug: methylphenidate

Oregon Health and Science University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

21 Years

N/A

All

Phase 2

United States

790

NCT00086294
(ClinicalTrials.gov)

June 25, 2004

29/6/2004

ACP-103 to Treat Parkinson's Disease

5HT2A/C Serotonin Blockade in Parkinson's Disease

Parkinson's Disease;Dyskinesias

Drug: Intravenous Levodopa;Drug: ACP-103

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

30 Years

80 Years

All

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

791

NCT03091543
(ClinicalTrials.gov)

May 4, 2004

21/3/2017

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg

Parkinson Disease

Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

All

Phase 1

Portugal

792

NCT00674310
(ClinicalTrials.gov)

February 2004

5/5/2008

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Parkinson's Disease;Restless Leg Syndrome

Drug: Ropinirole Hydrochloride

Roxane Laboratories

NULL

Completed

18 Years

45 Years

All

N/A

NULL

793

NCT00673088
(ClinicalTrials.gov)

February 2004

5/5/2008

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Parkinson's Disease;Restless Leg Syndrome

Drug: Ropinirole Hydrochloride

Roxane Laboratories

NULL

Completed

18 Years

45 Years

All

N/A

NULL

794

NCT00632736
(ClinicalTrials.gov)

February 2004

4/3/2008

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169

Parkinson Disease;Parkinson's Disease

Drug: Ropinirole XL (formerly CR)

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

419

Phase 3

United States;Belgium;Czech Republic;France;Hungary;Italy;Poland;Spain;United Kingdom;Germany;Philippines

795

NCT00363727
(ClinicalTrials.gov)

December 2003

7/8/2006

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.

Parkinson's Disease;Parkinson Disease;Dyskinesias

Drug: ropinirole controlled-release (REQUIP CR) for RLS

GlaxoSmithKline

NULL

Completed

30 Years

70 Years

All

209

Phase 3

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

796

NCT00615472
(ClinicalTrials.gov)

October 2003

9/1/2008

Intravenous Versus Inhalational Anesthesia in Parkinson's Disease

Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease

Parkinson's Disease

Drug: Isoflurane;Drug: Remifentanil;Drug: Propofol

Columbia University

NULL

Terminated

18 Years

N/A

All

N/A

United States

797

NCT00070941
(ClinicalTrials.gov)

July 2003

9/10/2003

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

SAM-e Treatment of Depression in Parkinson's Disease.

Parkinson's Disease;Depression

Drug: SAM -e;Drug: oral escitalopram;Drug: placebo

New York University School of Medicine

National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS)

Completed

30 Years

80 Years

All

Phase 2;Phase 3

United States

798

NCT00381472
(ClinicalTrials.gov)

June 2003

26/9/2006

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa

Parkinson Disease

Drug: Ropinirole

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

393

Phase 3

United States;Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain

799

NCT00062738
(ClinicalTrials.gov)

June 2003

12/6/2003

Treatment of Depression in Parkinson's Disease Trial

Treatment of Depression in Patients With Parkinson's Disease

Parkinson Disease;Depression

Drug: paroxetine;Drug: Nortriptyline;Other: placebo

Rutgers, The State University of New Jersey

GlaxoSmithKline

Completed

35 Years

80 Years

All

Phase 2

United States

800

NCT00237263
(ClinicalTrials.gov)

February 2003

7/10/2005

An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off

Parkinson's Disease

Drug: Entacapone

Novartis

NULL

Completed

20 Years

N/A

All

285

Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

801

NCT00056524
(ClinicalTrials.gov)

February 2003

15/3/2003

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.

Alzheimer's Disease;Stroke;Parkinson's Disease;Traumatic Brain Injury

Drug: AVP-923

Avanir Pharmaceuticals

NULL

Completed

18 Years

80 Years

Both

600

Phase 3

United States

802

NCT00599196
(ClinicalTrials.gov)

August 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

Early Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

30 Years

N/A

All

381

Phase 3

Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom

803

NCT00594386
(ClinicalTrials.gov)

August 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.

Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

258

Phase 3

United States;Canada

804

NCT00314288
(ClinicalTrials.gov)

July 2002

12/4/2006

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Parkinson's Disease;Dyskinesia

Drug: Sarizotan HCl

EMD Serono

NULL

Completed

30 Years

N/A

All

360

Phase 2

United States;Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom

805

NCT00594165
(ClinicalTrials.gov)

June 2002

24/12/2007

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

Early-Stage Parkinson's Disease

Drug: Rotigotine

UCB Pharma

NULL

Completed

31 Years

N/A

All

217

Phase 3

United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

806

NCT00040209
(ClinicalTrials.gov)

June 2002

21/6/2002

JP-1730 to Treat Parkinson's Disease

Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease

Parkinson Disease

Drug: JP 1730;Drug: IV Levodopa;Drug: IV Apomorphine

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

N/A

Both

Phase 2

United States

807

NCT00650104
(ClinicalTrials.gov)

May 2002

27/3/2008

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164

Parkinson Disease

Drug: Ropinirole XL (formerly CR)

GlaxoSmithKline

NULL

Completed

30 Years

N/A

All

Phase 3

United States;Belgium;France;Netherlands;Norway

808

NCT02162979
(ClinicalTrials.gov)

February 2002

26/12/2007

Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Parkinson's Disease

Drug: sildenafil;Drug: Placebo

Loma Linda University

NULL

Terminated

18 Years

80 Years

All

Phase 2

United States

809

NCT00070928
(ClinicalTrials.gov)

September 2000

9/10/2003

Valerian to Improve Sleep in Patients With Parkinson's Disease

Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease

Insomnia;Parkinson's Disease

Drug: valerian

National Center for Complementary and Integrative Health (NCCIH)

NULL

Completed

30 Years

80 Years

Both

Phase 2

United States

810

NCT00134784
(ClinicalTrials.gov)

April 2000

23/8/2005

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease

Parkinson Disease

Drug: [123I]B-CIT SPECT imaging

Institute for Neurodegenerative Disorders

United States Department of Defense

Completed

22 Years

N/A

All

142

Phase 2

NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

811

NCT00037830
(ClinicalTrials.gov)

November 1999

22/5/2002

GM1 Ganglioside Effects on Parkinson's Disease

The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication

Parkinson Disease

Drug: GM1 ganglioside;Drug: Placebo

Thomas Jefferson University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

39 Years

85 Years

All

Phase 2

United States

812

NCT00132626
(ClinicalTrials.gov)

September 1992

18/8/2005

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism

Parkinson's Disease;Parkinsonian Syndrome

Drug: [123I]ß-CIT and SPECT imaging

Institute for Neurodegenerative Disorders

Molecular NeuroImaging;National Institutes of Health (NIH)

Completed

35 Years

N/A

All

500

Phase 2

NULL